



National Comprehensive
Cancer Network®

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)

Melanoma: Cutaneous

Version 3.2023 — October 27, 2023

NCCN.org

NCCN Guidelines for Patients® available at www.nccn.org/patients

Continue



***Susan M. Swetter, MD/Chair** ☐
Stanford Cancer Institute

Douglas Johnson, MD †/Vice-Chair
Vanderbilt-Ingram Cancer Center

***John A. Thompson, MD** ‡ †/
Immediate Past Vice-Chair
Fred Hutchinson Cancer Center

Mark R. Albertini, MD †
University of Wisconsin
Carbone Cancer Center

Christopher A. Barker, MD §
Memorial Sloan Kettering Cancer Center

Sarah Bateni, MD, MAS ¶
O'Neal Comprehensive Cancer Center
at UAB

Joel Baumgartner, MD ¶
UC San Diego Moores Cancer Center

Shailender Bhatia, MD †
Fred Hutchinson Cancer Center

Christopher Bichakjian, MD ☐
University of Michigan Rogel Cancer Center

Genevieve Boland, MD, PhD ¶
Massachusetts General Hospital
Cancer Center

Sunandana Chandra, MD, MS †
Robert H. Lurie Comprehensive Cancer
Center of Northwestern University

Bartosz Chmielowski, MD, PhD ‡ †
UCLA Jonsson
Comprehensive Cancer Center

Dominick DiMaio, MD ≠
Fred & Pamela Buffett Cancer Center

Roxana Dronca, MD †
Mayo Clinic Cancer Center

Ryan C. Fields, MD ¶
Siteman Cancer Center at Barnes-
Jewish Hospital and Washington
University School of Medicine

Martin D. Fleming, MD ¶
The University of Tennessee
Health Science Center

Anjela Galan, MD ≠
Yale Cancer Center/
Smilow Cancer Hospital

Samantha Guild ¥
AIM at Melanoma

John Hynstrom, MD ¶
Huntsman Cancer Institute
at the University of Utah

Giorgos Karakousis, MD ¶
Abramson Cancer Center at the
University of Pennsylvania

Kari Kendra, MD, PhD †
The Ohio State University
Comprehensive Cancer Center -
James Cancer Hospital and
Solove Research Institute

Maija Kiuru, MD, PhD ☐
UC Davis Comprehensive Cancer Center

Julie R. Lange, MD, ScM ¶
The Sidney Kimmel Comprehensive
Cancer Center at Johns Hopkins

Ryan Lanning, MD, PhD §
University of Colorado Cancer Center

Theodore Logan, MD, FACP †
Indiana University Melvin and Bren Simon
Comprehensive Cancer Center

Daniel Olson, MD †
The UChicago Medicine Comprehensive Cancer Center

Anthony J. Olszanski, MD, RPh †
Fox Chase Cancer Center

Patrick A. Ott, MD, PhD † ‡ †
Dana-Farber/Brigham and Women's Cancer Center

Merrick I. Ross, MD ¶
The University of Texas
MD Anderson Cancer Center

Luke Rothermel, MD, MPH ¶
Case Comprehensive Cancer Center/University
Hospitals Seidman Cancer
Center and Cleveland Clinic Taussig
Cancer Institute

April K. Salama, MD †
Duke Cancer Institute

Rohit Sharma, MD ¶
UT Southwestern Simmons
Comprehensive Cancer Center

Joseph Skitzki, MD ¶
Roswell Park Comprehensive Cancer Center

Emily Smith, MD ≠ ☐
University of Michigan Rogel Cancer Center

Katy Tsai, MD †
UCSF Helen Diller Family
Comprehensive Cancer Center

Evan Wuthrick, MD §
Moffitt Cancer Center

Yan Xing, MD, PhD
City of Hope National Medical Center

NCCN
Sara Espinosa, PhD
Nicole McMillian, MS

Continue

| | |
|----------------------------------|-----------------------------------|
| ☐ Dermatology | ¥ Patient advocacy |
| ‡ Hematology/Hematology oncology | § Radiotherapy/Radiation oncology |
| † Internal medicine | ¶ Surgery/Surgical oncology |
| † Medical oncology | * Writing committee member |
| ≠ Pathology | |



[NCCN Melanoma Panel Members](#)
[Summary of the Guidelines Updates](#)

[Clinical Presentation and Preliminary Workup \(ME-1\)](#)

[Stage 0 \(in situ\), Stage IA, IB \(ME-2\)](#)

[Stage IB, Stage II \(ME-3\)](#)

[Stage IIIB Microscopic Satellites \(ME-4\)](#)

[Stage III \(Sentinel Node Positive\) \(ME-5\)](#)

[Stage III \(Clinically Positive Node\[s\]\) \(ME-6\)](#)

[Stage III \(Clinical Satellite/In-Transit\) \(ME-7\)](#)

[Stage IV Metastatic \(ME-8\)](#)

[Follow-up \(ME-9 and ME-10\)](#)

[Common Follow-up Recommendations for All Patients \(ME-11\)](#)

[True Scar Recurrence \(Persistent Disease\) \(ME-12\)](#)

[Local Satellite/In-Transit Recurrence \(ME-13\)](#)

[Nodal Recurrence \(ME-14\)](#)

[Distant Metastatic Disease \(ME-16\)](#)

[Systemic Therapy for Metastatic or Unresectable Disease \(MELSYS-1\)](#)

[Risk Factors for Development of Single or Multiple Primary Melanomas \(ME-A\)](#)

[Principles of Biopsy and Pathology \(ME-B\)](#)

[Principles of Molecular Testing \(ME-C\)](#)

[Principles of Imaging \(ME-D\)](#)

[Principles of Surgical Margins for Wide Excision of Primary Melanoma \(ME-E\)](#)

[Principles of Sentinel Lymph Node Biopsy \(SLNB\) \(ME-F\)](#)

[Principles of Completion/Therapeutic Lymph Node Dissection \(ME-G\)](#)

[Principles of Radiation Therapy \(ME-H\)](#)

[Systemic Therapy Considerations \(ME-I\)](#)

[Management of Toxicities Associated with Targeted Therapy \(ME-J\)](#)

[Principles of Brain Metastases Management \(ME-K\)](#)

[Staging \(ST-1\)](#)

[Abbreviations \(ABBR-1\)](#)

Clinical Trials: NCCN believes that the best management for any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

Find an NCCN Member Institution:
<https://www.nccn.org/home/member-institutions>.

NCCN Categories of Evidence and Consensus: All recommendations are category 2A unless otherwise indicated.

See [NCCN Categories of Evidence and Consensus](#).

NCCN Categories of Preference: All recommendations are considered appropriate.

See [NCCN Categories of Preference](#).

The NCCN Guidelines® are a statement of evidence and consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network® (NCCN®) makes no representations or warranties of any kind regarding their content, use or application and disclaims any responsibility for their application or use in any way. The NCCN Guidelines are copyrighted by National Comprehensive Cancer Network®. All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN. ©2023.

**Updates to Version 3.2023 of the NCCN Guidelines for Melanoma: Cutaneous from Version 2.2023 include:****[ME-3](#)**

- Adjuvant Treatment: Nivolumab (category 1) added as a treatment option for patients with completely resected pathological stage IIB or IIC cutaneous melanoma.

[ME-3A](#)

- Footnote z revised: "Pathologic staging (with SLNB) is strongly recommended for stage IIB and IIC melanoma prior to consideration of adjuvant pembrolizumab *or* nivolumab—to enhance risk/benefit patient discussions and optimize local/regional disease control.
- Footnote aa revised: Adjuvant pembrolizumab *is and* nivolumab *are* active in reducing relapse events for resected stage IIB and IIC melanoma. However, longer follow-up is needed to evaluate the impact of adjuvant pembrolizumab *or* nivolumab on OS. Clinicians considering adjuvant pembrolizumab *or* nivolumab therapy for stages IIB or IIC disease should have a detailed discussion with the patient to weigh the pros and cons of treatment benefit versus toxicity. Factors to be considered, ~~in addition to stage,~~ include patient's age, performance status, personal/family history of autoimmune disease, and tolerance for risk of *lifelong immunotoxicities*.

Updates to Version 2.2023 of the NCCN Guidelines for Melanoma: Cutaneous from Version 1.2023 include:**[ME-2](#)**

- Footnote n revised: If a patient's risk of a positive sentinel lymph node (SLN) is <5%, NCCN does not recommend SLNB. This would include clinical stage IA, T1a melanoma with (Breslow depth of <0.8 mm, ~~without ulceration~~ *nonulcerated*) ~~without~~ *without* or other adverse features, unless there is significant uncertainty about the adequacy of microstaging (*due to positive deep margins or limited sampling of a larger lesion*). If a patient's risk of a positive SLNB is 5%–10%, NCCN recommends discussing and considering SLNB. This would include clinical stage IB, T1b melanoma (Breslow depth <0.8 mm with ulceration or 0.8–1 mm with or without ulceration), or T1a lesions with Breslow depth <0.8 mm ~~and with other adverse features (eg, mitotic index ≥2/mm² [particularly in the setting of young age], lymphovascular invasion, combination of these factors) ≥0.5 mm and other adverse features (age ≤42 years, head/neck location, lymphovascular invasion, and/or mitotic index ≥2/mm²), with additive increased risk when multiple adverse features are present [Shannon AB, et al. J Am Acad Dermatol 2023;88:52-59]. Readily available, no-cost risk calculators (eg, melanomarisks.org.au; https://www.mskcc.org/nomograms/melanoma/sentinel_lymph_node_metastasis) may aid clinicians in discussion of risk versus benefit of SLNB in these scenarios.~~

[ME-2A](#) and [ME-3A](#)

- Footnote o revised: *Currently, there is insufficient evidence to support incorporation of current GEP tests into melanoma care.* The use of GEP testing according to specific AJCC-8 melanoma stage (before or after SLNB) requires further prospective investigation in large, contemporary data sets of unselected patients. Prognostic GEP testing tests to differentiate melanomas at low versus high risk for metastasis should not replace pathologic staging procedures *and are not recommended outside of the context of a clinical study or trial.* Moreover, since there is a low probability of metastasis in stage I melanoma and a higher proportion of false-positive results *using these tests*, GEP testing should not guide clinical decision-making in this subgroup. On an individual basis, the likelihood of a positive SLNB may be informed by the use of multivariable nomograms/risk calculators. ~~and~~ *Ongoing prospective investigation will further inform the use of GEP tests for SLNB risk prediction.* [See Principles of Molecular Testing \(ME-C\).](#)

[ME-6A](#), [ME-14A](#), [ME-15A](#)

• Footnote tt revised:

- ▶ Second paragraph: "...to study pathologic response after neoadjuvant treatment and its effect on RFS. ~~Recent presented data from aA randomized phase II phase 2 trial of 313 patients (naïve to prior immunotherapy) showed an event-free survival (EFS) benefit (hazard ratio, 0.59) at 2 years of 72% (95% confidence interval [CI], 64 to 80) for neoadjuvant pembrolizumab for 3 cycles followed by surgery and adjuvant pembrolizumab compared to with 49% (95% CI, 41 to 59) in the up-front surgery and adjuvant therapy group. At present..."~~
- ▶ Reference updated: Patel SP, et al. Ann Oncol 2022; 33(suppl_7):S808–S869. Patel SP, et al. N Engl J Med 2023; 388:813-823.

**Continued
UPDATES**

**Updates to Version 2.2023 of the NCCN Guidelines for Melanoma: Cutaneous from Version 1.2023 include:****ME-C Principles of Molecular Testing****1 of 8**

• Prognostic testing section revised

- ▶ ~~Despite commercially available GEP tests are being marketed as being able to classify risk stratify cutaneous melanomas into separate categories based on risk of metastasis. However, it remains unclear whether these current GEP platforms do not provide clinically actionable prognostic information when combined or compared with known clinicopathologic factors (eg, sex, age, primary tumor location, thickness, ulceration, mitotic rate, lymphovascular invasion, microsatellites, and/or SLNB status) or multivariable nomograms/risk calculators that incorporate patient sex, age, tumor location and thickness, ulceration, mitotic rate, lymphovascular invasion, microsatellites, and/or SLNB status. Furthermore, the impact clinical utility of these tests on to inform treatment recommendations and predict patient outcomes has not been established.~~ Various studies of prognostic GEP testing tests suggest its their role as an independent predictor of worse outcome;. However, GEP is though not superior to Breslow thickness, ulceration, or SLN status and; it remains unclear whether available GEP tests are reliably predictive of outcome across the risk spectrum of cutaneous melanoma. Prospective Validation studies on prospectively collected, independent cohorts (similar to those performed in breast cancer) are required necessary to more accurately define: the clinical utility of molecular prognostic GEP testing as an adjunct to traditional AJCC staging or as part of the multidisciplinary decision-making process; to its role in guiding guide surveillance imaging, SLNB, and adjuvant therapy.
- ▶ Existing and emerging GEP tests and other prognostic molecular techniques (ie, circulating tumor DNA testing tests) should be prospectively compared with to determine their clinical utility, including with no-cost, contemporary multivariable phenotypic SLNB risk prediction models (eg, melanomarisk.org.au or https://www.mskcc.org/nomograms/melanoma/sentinel_lymph_node_metastasis).

ME-F Principles of Sentinel Lymph Node Biopsy (SLNB)**1 of 3**

- 1st arrow sub-bullet revised: "...NCCN does not generally recommend SLNB for these patients unless there is significant uncertainty about the adequacy of microstaging (eg, positive deep margins or limited sampling of a larger lesion)."
- 2nd arrow sub-bullet revised: For patients with clinical stage IB, T1b melanoma (Breslow depth <0.8 mm with ulceration or 0.8–1 mm with or without ulceration), or T1a lesions with Breslow depth <0.8 mm and with other adverse features (eg, mitotic index >2/mm² [particularly in the setting of young age], lymphovascular invasion, or a combination of these factors) ≥0.5 mm and other adverse features (age ≤42 years, head/neck location, lymphovascular invasion, and/or mitotic index ≥2/mm²), the probability of a positive SLNB is 5-10%, with additive increased risk when multiple adverse features are present.; the probability of a positive SLNB is 5%–10%. NCCN recommends discussing..."
- 5th arrow sub-bullet revised: "...SLNB eligibility. Readily available, no-cost risk calculators (eg, melanomarisk.org.au; https://www.mskcc.org/nomograms/melanoma/sentinel_lymph_node_metastasis) may aid clinicians in discussion of risk versus benefit of SLNB."

**Updates to Version 1.2023 of the NCCN Guidelines for Melanoma: Cutaneous from Version 3.2022 include:****[ME-1A](#)**

- Footnote c revised: "...rebiopsy may be appropriate, *along with relevant/ further immunohistochemistry (IHC) and potential molecular testing...*"
- Footnote removed from this page: "The use of gene expression profiling (GEP) testing according to specific AJCC-8 melanoma stage (before or after SLNB) requires further prospective investigation in large, contemporary data sets of unselected patients. Prognostic GEP testing to differentiate melanomas at low versus high risk for metastasis should not replace pathologic staging procedures. Moreover, since there is a low probability of metastasis in stage I (T1) melanoma and a higher proportion of false-positive results, GEP testing should not guide clinical decision-making in this subgroup. On an individual basis, the likelihood of a positive SLNB may be informed by the use of optimized multivariable nomograms/risk calculators and ongoing investigation of GEP tests. See Principles of Molecular Testing (ME-C)." The footnote remains on page ME-2A.

[ME-2](#)

- Footnote n revised: "... with other adverse features (eg, mitotic index ≥ 2 $\geq 2/\text{mm}^2$ [particularly in the setting of young age]..."

[ME-2A](#)

- Footnote o revised: "...stage I (T1) melanoma and a higher proportion of false-positive results, GEP testing should not guide clinical decision-making in this subgroup. On an individual basis, the likelihood of a positive SLNB may be informed by the use of optimized multivariable..."
- Footnote r revised: "... patient preference, or other factors (*such as advanced age and/or poor functional status*)."
- Footnote s revised: SLNB is an important staging tool. While SLNB itself has not been shown to improve disease-specific survival (DSS), *it is associated with improved regional nodal disease control (Crystal JS, et al. JAMA Surg 2022;157:835-842)*. A positive SLNB would upstage a patient to stage III. Adjuvant therapy has been shown to *mainly* improve relapse-free survival (RFS) and OS (over overall survival [OS]) in selected *patients with high-risk stage III disease patients*. (Also for ME-3A)

[ME-3](#)

- Stage IB (T2a) or II (T2b or higher)
 - ▶ Workup;
 - ◇ 2nd bullet revised: *Routine Baseline* imaging/lab tests not recommended *unless needed for surgical planning*
 - ◇ 3rd bullet revised: Imaging ~~only~~ to evaluate specific signs or symptoms
 - ▶ Adjuvant Treatment revised: Pembrolizumab for pathologically Staged IIB or IIC (*category 1*)

[ME-3A](#)

- Footnote y is new: For stage IIB/IIC patients being considered for adjuvant therapy, pretreatment imaging is appropriate.
- Footnote z revised: "Pathologic staging (with SLNB) *is strongly recommended* for stage IIB and IIC melanoma ~~is strongly preferred~~ prior ~~to the recommendation~~ *consideration* of adjuvant pembrolizumab..."

**Updates to Version 1.2023 of the NCCN Guidelines for Melanoma: Cutaneous from Version 3.2022 include:**[ME-4](#)

- Workup revised for 1st and 2nd pathways
 - ▶ 3rd bullet: Imaging *for baseline staging or* to evaluate specific signs or symptoms
 - ▶ The following bullet was removed and combined with recommendation in 3rd bullet noted above: "Recommend imaging for baseline staging."
- Adjuvant Treatment
 - ▶ Microscopic satellites in biopsy specimen from primary lesion after wide excision without SLNB or with SLNB and negative sentinel nodes:
 - ◊ *Adjuvant PD-1 immunotherapy: Nivolumab and Pembrolizumab* were added as options.
 - ▶ Microscopic satellites in wide excision specimen and negative sentinel nodes or SLNB not performed:
 - ◊ *Adjuvant PD-1 immunotherapy: Nivolumab and Pembrolizumab* were added as options.

[ME-5](#)

- Primary Treatment for "Stage IIIA (sentinel node positive)" and "Stage IIIB/C/D (sentinel node positive)" revised: ~~Nodal basin ultrasound (US) surveillance (generally preferred) Observation without additional nodal surgery, and with mandatory radiographic nodal surveillance (preferred).~~

[ME-5A](#)

- Footnote gg revised: "...*BRAF*-directed therapy may be an option. [See Principles of Molecular Testing \(ME-C\)](#). Consider broader genomic profiling if the test results might guide further treatment decisions or eligibility for participation in a clinical trial."
- Footnote ii revised: *Nodal US surveillance is preferred if institutional expertise is available.* Alternative imaging modalities (eg, CT, MRI), ~~may be used are acceptable for head and neck melanoma.~~
- Footnote jj revised: "... it would be appropriate for the frequency of clinical exam and US/*imaging* surveillance to be..."
- Footnote kk revised: "Nodal basin US/*imaging* surveillance may not..."

[ME-6](#)

- Primary Treatment for Stage III (clinically positive node[s]); Resectable nodal disease: Revised, "~~Consider~~ Neoadjuvant therapy, preferably in the context of a clinical trial."

[ME-6A](#)

- Footnote tt revised on ME-6A, ME-14A, and ME-15A:
 - ▶ ~~In patients with gross resectable nodal disease at very high risk of recurrence after complete resection, at high risk of perioperative morbidity due to extent of resection or underlying comorbidities, or if achieving gross complete resection of nodal disease is uncertain, recommend multidisciplinary tumor board review to consider neoadjuvant systemic therapy, preferably in the context of a clinical trial. Patients with extensive clinically evident nodal or in-transit disease are at high risk for metastatic progression and have increased risks of perioperative morbidity.~~ Multiple early clinical trials have investigated neoadjuvant therapy, including single/combination checkpoint inhibitors, BRAF/MEK inhibitors, and intralesional therapies either alone or in combination with checkpoint inhibitors (see references below). Clinical trials have also been designed to study pathologic response after neoadjuvant treatment and its effect on RFS. *Recent presented data from a randomized phase II trial of 313 patients (naïve to prior immunotherapy) showed an event-free survival (EFS) benefit (hazard ratio, 0.59) for neoadjuvant pembrolizumab for 3 cycles followed by surgery and adjuvant pembrolizumab compared to up-front surgery and adjuvant therapy.* At present, there is no consensus regarding the recommended agents to use, duration of neoadjuvant therapy, extent of subsequent surgery, or how pathologic response to neoadjuvant therapy might impact the choice of adjuvant therapy outside the context of a prospective study.
 - ▶ New bulleted reference added: Amaria RN, et al. *Nature* 2022;611:155-160.
 - ▶ Bulleted references were updated.

[ME-7A](#)

- Footnote yy revised: ~~Intra~~Lymphatic metastases can be characterized as clinically, *radiologically*, or pathologically detectable satellite metastases (*dermal and/or visible or microscopic cutaneous and/or subcutaneous intralymphatic* metastases occurring within 2 cm ~~of~~ from the primary melanoma), or in-transit metastases (~~regional cutaneous and/or subcutaneous metastases~~ identified at a distance *between* ~~≥~~ 2 cm from the primary melanoma *and the regional nodal basin*). The 2-cm cutoff is consistent with AJCC staging definitions, *but* satellite and in-transit *lymphatic* metastases are biologically and prognostically similar.

**Updates to Version 1.2023 of the NCCN Guidelines for Melanoma: Cutaneous from Version 3.2022 include:****[ME-11](#) Common Follow-up Recommendations for All Patients**

- 1st arrow sub-bullet revised: "Pre-diagnostic clinical modalities (ie, *dermoscopy*, total-body photography and sequential digital dermoscopy), *noninvasive imaging* and other *imaging* technologies (eg, reflectance confocal microscopy, electrical impedance spectroscopy) may ~~enhance early detection aid in surveillance for~~ *new primary melanoma, particularly in patients with high mole count...*"
- 2nd arrow sub-bullet revised: "*For melanocytic neoplasms that are clinically/dermoscopically suspicious for melanoma*, pre-diagnostic noninvasive..."
- 2nd bullet revised: "Provide patient education..."
- 3rd bullet revised: "*Clinicians are encouraged to recommend avoidance of behaviors that may increase the risk of future (new primary) melanomas. This includes patient education...*"
- 6th bullet revised: "... This information can guide recommendations for surveillance and early detection in ~~the patient and his/her appropriate patients and their relatives.~~"
 - ▶ 2nd arrow sub-bullet revised: "Multigene panel testing that includes *CDKN2A* is ~~also~~ recommended for patients with..."
- Bullet and corresponding sub-bullets regarding Regional lymph node US in patients with a positive SLNB who did not undergo CLND were removed from this page because these recommendations are also in the Principles of Imaging (ME-D).

[ME-14](#)

- Disease limited to nodal recurrence; No previous lymph node dissection; Resectable; Treatment of Recurrence revised: ~~Consider~~ Neoadjuvant therapy, preferably in the context of a clinical trial

[ME-15](#)

- Disease limited to nodal recurrence; Previous lymph node dissection; Resectable; Treatment of Recurrence revised: ~~Consider~~ Neoadjuvant therapy, preferably in the context of a clinical trial

[ME-16](#)

- Distant metastatic disease; Oligometastatic pathway
 - ▶ Treatment of Metastatic Disease; Metastasis-directed therapy: *T-VEC/Intralesional therapy (for accessible lesions)* added as an option.
 - ▶ No evidence of disease; Adjuvant Treatment
 - ◇ Systemic therapy options; Preferred regimens
 - Pembrolizumab changed from category 2A to category 1.
 - Nivolumab/ipilimumab changed from category 2B to category 2A and moved from "Other recommended regimens" to "Preferred regimens."
- Distant metastatic disease; Widely disseminated pathway; Options; 2nd bullet revised: " For *limited* extracranial lesions:..."

[ME-16A](#)

- Footnote removed: Although patients with resected stage IV disease were not included in the phase III prospective randomized trial testing adjuvant pembrolizumab, it is included as an option here because all available evidence suggests that pembrolizumab and nivolumab have highly similar efficacy and safety in patients with melanoma.

**Updates to Version 1.2023 of the NCCN Guidelines for Melanoma: Cutaneous from Version 3.2022 include:**[MELSYS](#) Systemic Therapy for Metastatic or Unresectable Disease

- General: The placement of this section was moved up in the Guidelines to follow the the recommendations for Distant Metastatic disease on ME-16. Previously it was placed after the Principles of Radiation and the page designation was ME-I.

[1 of 7](#)

• First-line Therapy

▶ Preferred regimens

- ◊ Combination checkpoint blockades listed as *preferred*.
 - Nivolumab and relatlimab-rmbw changed from category 2A to category 1.

▶ Other recommended regimens

- ◊ The following regimens moved from Preferred Regimens to Other Recommended Regimens:
 - Combination targeted therapy if *BRAF* V600-activating mutation
 - Dabrafenib/trametinib (category 1)
 - Vemurafenib/cobimetinib (category 1)
 - Encorafenib/binimetinib (category 1)
- ◊ The following regimen was removed as a first-line therapy option:
 - Combination targeted therapy and immunotherapy if *BRAF* V600-activating mutation present: Vemurafenib/cobimetinib + atezolizumab

- 3rd column revised: Disease progression, or ~~Maximum clinical benefit from intolerance, and/or projected risk of progression with BRAF-targeted therapy~~

• Second-line or Subsequent Therapy

▶ Preferred regimens

- ◊ Nivolumab and relatlimab-rmbw added as an option.
- ◊ Revised: Pembrolizumab/low-dose ipilimumab *for progression following* anti-PD-1 therapy

▶ Useful in certain circumstances; Regimens revised or added as follows:

- ◊ For activating mutations of *KIT*
 - *KIT inhibitor therapy* (eg, imatinib, dasatinib, nilotinib, ripretinib)
- ◊ For *ROS1* fusions
 - Crizotinib, entrectinib
- ◊ For *BRAF* fusions and non-V600 mutations
 - Trametinib
- ◊ Combination therapy
 - Pembrolizumab/lenvatinib changed from category 2B to category 2A

- ◊ *Combination BRAF/MEK + PD(L)-1 checkpoint inhibitors* (eg, dabrafenib/trametinib + pembrolizumab or vemurafenib/cobimetinib + atezolizumab)

[1A of 7](#)

- Footnote c revised: ~~The choice of a treatment is based on evaluation of the individual patient. The order of listed systemic therapies in a given section does not reflect order of preference. The choice of a treatment is based on evaluation of the individual patient to include patient characteristics, disease presentation, health system resources/experience, and patient preference.~~
- Footnote d is new: Considerations for using combination nivolumab/ipilimumab or nivolumab and relatlimab-rmbw versus PD-1 monotherapy include: patient willingness to take on a higher risk of treatment-related toxicities (immune-related adverse events [irAEs]); absence of comorbidities or autoimmune processes that would elevate the risk of irAEs; and patient social support and preparedness to work with medical team to handle toxicities.
- Footnote g revised: Nivolumab/ipilimumab combination therapy is associated with improved overall response rate (ORR), PFS, and OS compared with single-agent ipilimumab, at the expense of significantly increased toxicity *in previously untreated patients with unresectable stage III or IV melanoma. While that study was not powered to compare nivolumab plus ipilimumab and nivolumab alone, improved OS with the combination support a meaningful survival benefit of the combination compared with nivolumab monotherapy. Compared to nivolumab, the impact of nivolumab/ipilimumab combination therapy on OS is not known. The phase III trial of nivolumab/ipilimumab or nivolumab monotherapy versus ipilimumab monotherapy was conducted in previously untreated patients with unresectable stage III or IV melanoma. Relative indications for combination nivolumab/ipilimumab in comparison to PD-1 monotherapy include: patient willingness to take on high risk of treatment-related toxicities (immune-related adverse events [irAEs]); absence of comorbidities or autoimmune processes that would elevate the risk of irAEs; and patient social support and anticipated compliance with medical team to handle toxicities.*

**Updates to Version 1.2023 of the NCCN Guidelines for Melanoma: Cutaneous from Version 3.2022 include:**[1A of 7](#)

- Footnote h is new: Nivolumab/ipilimumab has demonstrated clinically meaningful intracranial activity.
- Footnote i is new: Appropriateness of single agent depends on patient fitness/frailty, comorbidities, low-volume disease, autoimmune disease history, and other factors.
- Footnote n is new: High-volume symptomatic disease *BRAF*+ patients may benefit from BRAF/MEK inhibition, as opposed to combination immunotherapy. Otherwise ipilimumab/nivolumab is preferred first-line over BRAF/MEK therapy due to OS benefit.
- Footnote p revised: For patients who experience progression of melanoma during or shortly after *adjuvant* or first-line therapy, consider second-line agents if not used first line and if from a different class. For patients who progressed on single-agent anti-PD-1 checkpoint immunotherapy, ~~anti-PD-1/ipilimumab combination therapy or ipilimumab monotherapy is a~~ *anti-PD-1/ipilimumab or BRAF/MEK inhibitor combination therapy or ipilimumab monotherapy* are reasonable treatment options. For patients who experience disease control (CR, PR, or SD) and have no residual toxicity, but subsequently experience disease progression/relapse >3 months after treatment discontinuation, re-induction with the same agent or same class of agents may be considered.
- Footnote q is new: The combination nivolumab and relatlimab-rmbw is associated with higher progression-free survival (PFS) but more frequent and more severe toxicity than nivolumab alone.
- Footnote s is new: Case reports and preclinical data have suggested that BRAF + MEK inhibition may be an option for certain non-V600 *BRAF* mutations, including *BRAF* L597 mutations.
- Footnote t revised: In patients who were previously untreated or ~~had prior failure of~~ *whose disease progressed despite* immunotherapy, binimetinib was associated with a response rate of 15%, and demonstrated a modest improvement in PFS with no improvement in OS compared with single-agent dacarbazine.
- Footnote removed: In a randomized, double-blind, placebo-controlled, phase 3 trial, the addition of atezolizumab to vemurafenib and cobimetinib was associated with longer median PFS and longer duration of response; however, the triplet induced more toxicity than the vemurafenib/cobimetinib doublet. Until mature OS data are published, it is not clear that the triplet regimen is preferred over sequential BRAF/MEK inhibitor therapy followed by PD-L1 or PD-1 inhibition.

[3 of 7](#) to [7 of 7](#) References

- References were updated.

[ME-A](#) Risk Factors for Development of Single or Multiple Primary Melanomas

- 2nd bullet revised: ~~Older >60~~ *Age >50 years*
- 3rd bullet; 1st arrow sub-bullet: ~~Atypical moles/dysplastic nevi nevus-pattern~~
- 5th bullet; 1st arrow sub-bullet: "... (eg, *CDKN2a*, *CDK4*, *MC1R*, *BRGA2*, *BAP1*.."
- 6th bullet; 3rd arrow sub bullet: ~~Intermittent, intense sun exposure (for truncal/extremity melanomas, often observed with associated increased nevus count)~~
- 6th bullet; 4th arrow sub-bullet: ~~Chronic sun exposure (for head/neck/arm melanomas, often associated with lower nevus count)~~

**Updates to Version 1.2023 of the NCCN Guidelines for Melanoma: Cutaneous from Version 3.2022 include:****[ME-B](#) Principles of Biopsy of a Suspicious Pigmented Lesion****[1 of 3](#)**

- 1st bullet revised: "... (elliptical, punch, or saucerization/deep shave *removal*)..."
- 3rd bullet revised: "... acceptable *and may be preferred* in certain anatomic areas (eg, palm/sole, digit, face, ear) or for very large lesions. Multiple "scouting" biopsies may help guide management for very large lesions. Superficial/*tangential* shave biopsy..."
- New bullet added: Appropriate biopsy of the nail matrix should be performed for suspected subungual melanoma and requires expertise in biopsy of the nail apparatus.

[2 of 3](#)

- 1st bullet revised: "...in melanocytic neoplasms. *Appropriate immunohistochemical stains may aid in histopathologic diagnosis.*"
- 2nd bullet revised: "Consider the use of molecular testing for histologically equivocal lesions, *as well as expert dermatopathology review.*" Previously, this was also the last bullet in this section.
- 6th bullet revised: ~~Encourage consistent~~ Synoptic reporting of additional prognostic criteria, *including containing the following information is strongly recommended for optimal patient care:*
 - ▶ 1st arrow sub-bullet: Presence of macroscopic satellite lesions in the gross tumor specimen, *if clinically evident.*
 - ▶ 4th arrow sub-bullet; New diamond sub-bullet added: Notation of LM/high CSD subtype may affect surgical or other treatment approaches.
 - ▶ 6th arrow sub-bullet revised: Neurotropism (*including peri-tumoral or intratumoral*)/perineural invasion.

[2A of 3](#)

- Footnote d revised: "... specific lymphatic marker such as D2–40 may assist in ~~distinction.~~ *differentiating lymphovascular invasion from microsatellites.*"

[ME-C](#) Principles of Molecular Testing

- General: Title revised for all pages: **Emerging Molecular Technologies for Cutaneous Melanoma Diagnosis and Prognostication**

[1 of 8](#)

- 2nd bullet; Prognostic Testing
 - ▶ 2nd arrow sub-bullet revised: "... not superior to Breslow thickness, *ulceration*, or SLN status..."
 - ▶ 3rd arrow sub-bullet revised: Existing and emerging GEP tests and other prognostic molecular techniques (ie, ~~et~~*ctDNA circulating tumor DNA* testing) should be compared with ~~optimized~~ contemporary multivariable phenotypic models (eg, melanomarisk.org.au or https://www.mskcc.org/nomograms/melanoma/sentinel_lymph_node_metastasis) and the ~~AJCC 8th Edition melanoma decision-tree analysis in development.~~

[3 of 8](#)

- 2nd bullet revised: Other uncommon mutations *genetic drivers* detected by NGS panel.
 - ▶ New arrow sub-bullet and diamond sub-bullets added:
 - ◊ Fusion-directed therapy for *NTRK*, *ROS1*, *ALK*, or *BRAF* fusions
 - ◊ Case reports or limited clinical trial data have suggested activity (larotrectinib or entrectinib for *NTRK* fusions, crizotinib or entrectinib for *ROS1* fusions, or trametinib for *BRAF* fusions, and crizotinib for *ALK* fusions).
- 3rd bullet; Methods of mutation testing
 - ▶ 1st arrow sub-bullet; 2nd diamond sub-bullet revised: "~~KIT IHC testing may be used as a screening tool for assessment of KIT status in acral lentiginous or mucosal melanoma.~~ Due to the wide range of different KIT mutations and lack of widespread use of this test *KIT IHC testing, confirmatory...*"
 - ▶ 2nd arrow sub-bullet; 1st diamond sub-bullet revised: Molecular testing *may be performed* on tumor tissue ~~is preferred, or if not available, but may be performed~~ on peripheral blood (liquid biopsy) ~~if tumor tissue is not available.~~ *Given the possibility of a false negative, a negative liquid biopsy should prompt tissue testing.*

**Updates to Version 1.2023 of the NCCN Guidelines for Melanoma: Cutaneous from Version 3.2022 include:****[ME-D](#) Principles of Imaging****[2 of 5](#)**

- Workup (Baseline); Stage 0, IA, IB, II
 - ▶ 3rd bulle; 1st arrow sub-bullet revised: ~~Routine~~ *Baseline* cross-sectional imaging with or without brain imaging is not recommended *unless needed for surgical planning*.

[4 of 5](#)

- Follow-up (surveillance for recurrence in patients with NED); 2nd bullet revised: "... compared with similar treatment in those ~~with~~ *who underwent surveillance imaging but had* symptomatic recurrence."

[ME-E](#) Principles of Surgical Margins for Wide Excision of Primary Melanoma

- 1st bullet is new: There are no randomized trials to inform peripheral surgical margins or depth of wide excision for MIS. Depth of excision into the subcutaneous fat may be adequate and considered in anatomic locations where excision to fascia would cause significant morbidity.
- 2nd bullet revised: "*For invasive melanoma, wide local excision involves removal of all tissue to the level of the fascia, which...*"
- 6th bullet is new: In the setting of an adequate biopsy, digit-sparing surgery may be an option for subungual MIS and select thin tumors (<0.8 mm), although further investigation is needed.
- Footnote a revised: "For large and/or poorly defined MIS, LM/*high CSD* or acral lentiginous subtypes, or LM melanoma with a minimally invasive (T1a) component, ~~(also referred to as high CSD melanoma)~~ surgical margins >0.5 cm may be necessary, and techniques for comprehensive histologic evaluation of margins (ie, complete circumferential peripheral and deep margin assessment) should be considered. If MMS is performed, use of frozen section melanocytic immunohistochemistry IHC stains may assist in accurate interpretation of histologic margins *and has been associated with lower local recurrence rates....*"
- References were updated.

[ME-F](#) Principles of Sentinel Lymph Node Biopsy (SLNB)**[1 of 3](#)**

- General Principles
 - ▶ 1st bullet revised: SLNB is a surgical procedure developed to accurately stage patients with cutaneous melanoma through pathologic assessment of the regional nodal basin(s) and to provide prognostic information for patients with clinical stage I/II melanoma (no clinical or radiographic evidence of nodal disease). *There are emerging data that pathologic assessment of the index node carries strong prognostic significance. Discussion regarding relevant risks and benefits of SLNB should occur with the appropriate health care provider(s).*
 - ▶ 2nd bullet revised: In patients with clinical stage I/II melanoma, SLN status is ~~the~~ *a strongest* predictor of survival *and provides improved regional nodal disease control, with or without subsequent CLND.*
 - ▶ 5th bullet revised: NCCN makes recommendations on when to perform SLNB based on the likelihood that a patient will have a positive SLNB, *taking patient factors into account regarding appropriateness of the staging procedure.*
 - ▶ 6th bullet; 4th arrow sub-bullet: "... (eg, pursue surveillance nodal basin US, undergo CLND, consider adjuvant therapy, *and/or* change follow-up schedules)..."
 - ▶ 7th bullet revised: "... after a prior wide excision, rotational flap, or skin graft closure of a primary melanoma, it may be considered *selectively* in this setting, *particularly for non-head and neck primary melanomas.*"
 - ▶ Last bullet revised: "... SLNB may be considered, *if it will affect the decision for adjuvant therapy.*"

[2 of 3](#)

- Principles of Surgery
 - ▶ 2nd bullet revised: "... with a fine-gauge needle at the site of the primary lesion. ~~Massage of the primary lesion is not usually necessary.~~"
 - ▶ 4th bullet revised: "... SLN count and/or are blue in color. *Elevated nodal basin counts above the 10% threshold indicate the need for further nodal exploration.*"

**Updates to Version 1.2023 of the NCCN Guidelines for Melanoma: Cutaneous from Version 3.2022 include:****[ME-F](#) Principles of Sentinel Lymph Node Biopsy (SLNB)**
[3 of 3](#)

- Principles of Pathology
 - ▶ 1st bullet revised: SLN(s) ~~should~~ *are usually not be sent for frozen section analysis, but there are certain scenarios where this may be appropriate, such as unexpected findings at the time of SLNB that would affect immediate subsequent care.*
 - 5th bullet revised: "... Additional H&E levels and IHC stains may be useful to confirm morphologic features of melanoma."

[ME-G](#) Principles Of Completion/Therapeutic Lymph Node Dissection

- Adequacy of Regional Lymph Node Dissection
 - ▶ 5th bullet revised: ~~Additionally,~~ In the groin, the presence of clinically positive inguinofemoral nodes, ≥3 microscopically positive (subclinical) inguinofemoral nodes, or a positive Cloquet's node may increase the likelihood of occult external iliac or obturator microscopic nodal disease. ~~the survival benefit of elective lymphadenectomy for clinically/radiographically uninvolved pelvic nodal basins is unclear in the context of modern imaging and/or adjuvant therapies. However, there is no known survival benefit of prophylactic lymphadenectomy for clinically/radiographically uninvolved pelvic nodal basins. This decision should be made jointly by a multidisciplinary team, given the advances in modern imaging and adjuvant therapies.~~
 - ▶ New bullet added: Clinical trials are evaluating neoadjuvant response-directed treatment after resection of the index node, using pathologic complete or near complete response to inform subsequent surgical and adjuvant decision-making.
 - ▶ 7th bullet revised: "...symptoms of lymphedema and, if possible available and necessary, followed and treated by..."
- References added
 - ▶ Schermers B, Franke V, Rozeman EA, et al. Surgical removal of the index node marked using magnetic seed localization to assess response to neoadjuvant immunotherapy in patients with stage III melanoma. Br J Surg 2019;106:519-522.
 - ▶ Rozeman EA, Hoefsmit EP, Reijers ILM, et al. Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma. Nat Med 2021;27:256-263.

[ME-H](#) Principles of Radiation Therapy
[1 of 7](#)

- Primary Disease; Definitive Therapy
 - ▶ 2nd arrow sub-bullet; 3rd diamond sub-bullet revised: 35 Gy in 5 fractions over 1 week for fields <3 cm *in diameter.*

[3 of 7](#)

- Palliative whole brain RT (WBRT), Revised: Only consider for palliative purposes when SRS/SRT is not feasible in patients with good performance status for whom ~~effective systemic therapy has failed~~ *disease has progressed* (See ME-L).

[ME-I](#) Systemic Therapy Considerations
[2 of 4](#)

- Considerations for Patients with CNS Disease;
 - ▶ 2nd bullet revised: "... combination therapy with anti-PD-1 *nivolumab/ipilimumab (nivolumab 1 mg/kg and ipilimumab 3 mg/kg)* is preferred in comparison..."
 - ▶ 4th bullet revised: "... for symptom control, *management comprehensive care* by a multidisciplinary team, including..."
- Considerations for Adjuvant Treatment; Last bullet revised: "... The results showed a ~~statistically significant and clinically meaningful improvement in RFS with nivolumab + ipilimumab compared to placebo, and a large separation in RFS curves in favor of nivolumab + ipilimumab in comparison to nivolumab monotherapy that both active regimens significantly improved RFS. Overall survival (OS) was significantly improved for patients who received nivolumab + ipilimumab compared to placebo.~~
- Reference updated.

**Updates to Version 1.2023 of the NCCN Guidelines for Melanoma: Cutaneous from Version 3.2022 include:****[ME-I](#) Systemic Therapy Considerations****[3 of 4](#)**

- Recommendations for Patients Who Progress on Systemic Therapy
 - ▶ **BRAF** V600-activating mutation present
 - ◇ 1st arrow sub-bullet; New diamond sub-bullet added: Pembrolizumab/lenvatinib after progression on anti-PD(L)-1.
 - ◇ 2nd arrow sub-bullet; 1st diamond sub-bullet; New dashed sub-bullet added: Pembrolizumab/lenvatinib after progression on anti-PD(L)-1
 - ◇ 2nd arrow sub-bullet; 3rd diamond sub-bullet added: T-VEC monotherapy (for low burden of disease and injectable lesions.
 - ◇ 3rd arrow sub-bullet revised: "...rechallenge with BRAF/MEK inhibitors after other **intervening** therapies. The optimal..."
 - ◇ 4th arrow sub-bullet; 2nd diamond sub-bullet revised: T-VEC **monotherapy** (for low burden of disease and injectable lesions)
 - ▶ **BRAF** V600-activating mutation **not** present:
 - ◇ 1st arrow sub-bullet revised: " For patients with progression on **anti-PD-1 monotherapy immune therapy**, consider..."
 - New diamond sub-bullet added: Pembrolizumab/lenvatinib after progression on anti-PD-1/PD-L1.

[ME-J](#) Management Of Toxicities Associated With Targeted Therapy

- Targeted Therapy (BRAF or combined BRAF/MEK inhibitors)
 - ▶ Dermatologic; 2nd arrow sub-bullet revised: " Severe **and life-threatening** skin toxicity..."
 - ▶ Pyrexia bullet revised: "... The pyrexia is episodic, ~~and onset is often 2 to 4 weeks following the start of therapy~~ with a median duration of 9 days, **and onset is often 2–4 weeks following the start of therapy.** Pyrexia..."
 - ▶ New reference added: Maloney NJ, Rana J, Yang JJ, et al. Clinical features of drug-induced hypersensitivity syndrome to BRAF inhibitors with and without previous immune checkpoint inhibition: a review. Support Care Cancer 2022;30:2839-2851.

[ME-K](#) Principles of Brain Metastases Management**[2 of 5](#)**

- Brain-Directed Therapy; Management of symptoms
 - ▶ 4th arrow sub-bullet; New diamond sub-bullet added: The risks of anti-vascular endothelial growth factor (VEGF) in the setting of melanoma metastases with hemorrhage should be weighed against perceived benefit.




NCCN Guidelines Version 3.2023

Melanoma: Cutaneous

CLINICAL PRESENTATION

- Suspicious skin lesion
- Assessment of melanoma-related risk factors^a

→ Biopsy^b



PATHOLOGY REPORT^{b,e}

- Breslow thickness^f
- Ulceration status (present or absent)
- Dermal mitotic rate (#/mm²)^g
- Assess deep and peripheral margin status^h
- Microsatellitosis^{i,j,k} (present or absent)
- Pure desmoplasia^l if present
- Lymphovascular/angiolympathic invasionⁱ
- Neurotropism/perineural invasion^m

PRELIMINARY WORKUP

- H&P with attention to locoregional area, draining lymph nodes
- Complete skin exam

CLINICAL STAGE

- [Stage 0 in situ \(ME-2\)](#)
- [Stage IA, Stage IB \(ME-2\)](#)
- [Stage IB, Stage II \(ME-3\)](#)
- [Stage III \(ME-5\) and \(ME-7\)](#)
- [Stage IV Metastatic \(ME-8\)](#)

[See Footnotes on ME-1A](#)

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

**FOOTNOTES FOR CLINICAL PRESENTATION, PATHOLOGY REPORT, AND PRELIMINARY WORKUP**

^a [See Risk Factors for Single or Multiple Primary Melanomas \(ME-A\).](#)

^b [See Principles of Biopsy and Pathology \(ME-B\).](#)

^c If diagnostic biopsy is inadequate for treatment decisions, rebiopsy may be appropriate, along with relevant/further immunohistochemistry (IHC) and potential molecular testing. [See Principles of Molecular Testing \(ME-C\).](#)

^d Repeat narrow-margin excisional biopsy is recommended if an initial partial biopsy is inadequate for diagnosis or microstaging but should not be performed if the initial specimen meets criteria for sentinel lymph node biopsy (SLNB) staging.

^e Mutational analysis for *BRAF* or multigene testing of the primary lesion is not recommended for patients with cutaneous melanoma unless required to guide adjuvant or other systemic therapy or consideration of clinical trials. [See Principles of Molecular Testing \(ME-C\).](#)

^f Dermal-based melanomas that lack epidermal involvement or regression of the epidermal/junctional component and histologically simulate cutaneous or in-transit metastasis should undergo a thorough discussion to consider a dermal primary versus metastatic process. Baseline metastatic workup with imaging (CT chest/abdomen/pelvis or PET/CT) may be warranted to exclude stage III/IV disease at the outset.

^g Although dermal mitotic rate is no longer included in the determination of T1 staging in the AJCC Cancer Staging Manual, Eighth Edition (2017), it remains an important prognostic factor across all thickness categories and should be included in the pathology assessment of melanoma biopsies and surgical excisions.

^h For histologically positive margins on the biopsy or wide excision specimen, describe whether in situ or invasive melanoma is present at the peripheral and/or deep margins. For histologically negative margins on the wide excision specimen, International Collaboration on Cancer Reporting (ICCR) and College of American Pathologists (CAP) guidelines do not require reporting of the microscopically measured distances between tumor and labeled lateral or deep margins. This measurement should not generally impact clinical decision-making.

ⁱ Microsatellitosis represents microscopically identified lymphatic metastasis and confers an increased risk of recurrence. Microsatellites are found discontinuous from the primary tumor (adjacent or deep). The AJCC Cancer Staging Manual, Eighth Edition (2017) does not define microsatellitosis according to tumor nest dimension or distance from the primary tumor. It classifies cases with microsatellites, clinical satellites, or in-transit metastases as N1c, N2c, or N3c based on the number of tumor-involved regional lymph nodes (0, 1, or ≥2, respectively).

^j For patients with microsatellitosis in the biopsy specimen (and no clinical evidence of nodal/distant disease), see [ME-4](#) for further workup and treatment.


^k At times it may be difficult to distinguish whether invasive melanoma is present within a lymphatic channel or represents a microsatellite. In this instance, IHC using a specific lymphatic marker such as D2-40 may assist in distinction.

^l In patients with pure desmoplastic melanoma (>90% of invasive melanoma associated with prominent stromal fibrosis), SLNB positivity is less common compared to mixed desmoplastic/nondesmoplastic and conventional melanoma subtypes. Variability across studies in the rate of SLNB positivity in desmoplastic melanoma may be due to lack of standardized criteria for defining pure desmoplastic melanoma, histopathologic reproducibility, and/or reporting. In the setting of these conflicting reports, the role of SLNB in patients with pure desmoplastic melanoma remains controversial.

^m Pathology reporting of extensive versus focal neurotropism (ie, involving only a single nerve vs. multiple nerves and/or size of involved nerves) may help guide clinical decision-making.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



[See other footnotes on ME-2A](#)

ⁿ If a patient's risk of a positive sentinel lymph node (SLN) is <5%, NCCN does not recommend SLNB. This would include clinical stage IA, T1a melanoma (Breslow depth of <0.8 mm, nonulcerated) without other adverse features, unless there is significant uncertainty about the adequacy of microstaging (due to positive deep margins or limited sampling of a larger lesion). If a patient's risk of a positive SLNB is 5%–10%, NCCN recommends discussing and considering SLNB. This would include clinical stage IB, T1b melanoma (Breslow depth <0.8 mm with ulceration or 0.8–1 mm with or without ulceration), or T1a lesions with Breslow depth ≥0.5 mm and other adverse features (age ≤42 years, head/neck location, lymphovascular invasion, and/or mitotic index ≥2/mm²), with additive increased risk when multiple adverse features are present (Shannon AB, et al. J Am Acad Dermatol 2023;88:52-59). Readily available, no-cost risk calculators (eg, melanomarisks.org.au; https://www.mskcc.org/nomograms/melanoma/sentinel_lymph_node_metastasis) may aid clinicians in discussion of risk versus benefit of SLNB in these scenarios.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

**FOOTNOTES FOR WORKUP AND PRIMARY TREATMENT**

^e Mutational analysis for *BRAF* or multigene testing of the primary lesion is not recommended for patients with cutaneous melanoma unless required to guide adjuvant or other systemic therapy or consideration of clinical trials. [See Principles of Molecular Testing \(ME-C\).](#)

^l In patients with pure desmoplastic melanoma (>90% of invasive melanoma associated with prominent stromal fibrosis), SLNB positivity is less common compared to mixed desmoplastic/nondesmoplastic and conventional melanoma subtypes. Variability across studies in the rate of SLNB positivity in desmoplastic melanoma may be due to lack of standardized criteria for defining pure desmoplastic melanoma, histopathologic reproducibility, and/or reporting. In the setting of these conflicting reports, the role of SLNB in patients with pure desmoplastic melanoma remains controversial.

^o Currently, there is insufficient evidence to support incorporation of current GEP tests into melanoma care. The use of GEP according to specific AJCC-8 melanoma stage (before or after SLNB) requires further prospective investigation in large, contemporary data sets of unselected patients. Prognostic GEP tests to differentiate melanomas at low versus high risk for metastasis should not replace pathologic staging procedures and are not recommended outside of the context of a clinical study or trial. Moreover, since there is a low probability of metastasis in stage I melanoma and a high proportion of false-positive results using these tests, GEP testing should not guide clinical decision-making in this subgroup. On an individual basis, the likelihood of a positive SLNB may be informed by the use of multivariable nomograms/risk calculators. Ongoing prospective investigation will further inform the use of GEP tests for SLNB risk prediction. [See Principles of Molecular Testing \(ME-C\).](#)

^p [See Principles of Imaging–Workup \(ME-D\).](#)

^q Nodal basin ultrasound (US) is not a substitute for SLNB. Consider nodal basin US prior to SLNB for patients with melanoma with an equivocal regional lymph node physical exam. Abnormal or suspicious findings on nodal basin US should be confirmed histologically, whenever possible. Negative nodal basin US is not a substitute for biopsy of clinically suspicious lymph nodes.

^r Decision not to perform SLNB may be based on significant patient comorbidities, patient preference, or other factors (such as advanced age and/or poor functional status).

^s SLNB is an important staging tool. While SLNB itself has not been shown to improve disease-specific survival (DSS), it is associated with improved regional nodal disease control (Crystal JS, et al. JAMA Surg 2022;157:835-842). A positive SLNB would upstage a patient to stage III. Adjuvant therapy has been shown to mainly improve relapse-free survival (RFS) (over overall survival [OS]) in selected patients with high-risk stage III disease.

^t [See Principles of Surgical Margins for Wide Excision of Primary Melanoma \(ME-E\).](#)

^u For patients with microsatellitosis in the wide excision specimen, see [ME-4](#) for further workup and treatment.

^v SLNs should be evaluated with serial sectioning and IHC.

^w [See Principles of Sentinel Lymph Node Biopsy \(SLNB\) \(ME-F\).](#)


Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 3.2023

Melanoma: Cutaneous



[See additional footnotes on ME-3A](#)

^x Microsatellitosis, when present in the initial biopsy or wide excision specimen, defines at least N1c and at least stage IIIB disease. Although less well-studied than other stage III patient populations, SLN status does have prognostic significance in patients with microsatellitosis, with a positive SLN upstaging a patient to at least N2c, stage IIC. SLNB should be considered in patients with microsatellitosis, especially if it will alter management decisions.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

**FOOTNOTES FOR STAGE IB (T2A) OR II (T2B OR HIGHER)**

^e Mutational analysis for *BRAF* or multigene testing of the primary lesion is not recommended for patients with cutaneous melanoma unless required to guide adjuvant or other systemic therapy or consideration of clinical trials. [See Principles of Molecular Testing \(ME-C\)](#).

^f In patients with pure desmoplastic melanoma (>90% of invasive melanoma associated with prominent stromal fibrosis), SLNB positivity is less common compared to mixed desmoplastic/nondesmoplastic and conventional melanoma subtypes. Variability across studies in the rate of SLNB positivity in desmoplastic melanoma may be due to lack of standardized criteria for defining pure desmoplastic melanoma, histopathologic reproducibility, and/or reporting. In the setting of these conflicting reports, the role of SLNB in patients with pure desmoplastic melanoma remains controversial.

^g Currently, there is insufficient evidence to support incorporation of current GEP tests into melanoma care. The use of GEP according to specific AJCC-8 melanoma stage (before or after SLNB) requires further prospective investigation in large, contemporary data sets of unselected patients. Prognostic GEP tests to differentiate melanomas at low versus high risk for metastasis should not replace pathologic staging procedures and are not recommended outside of the context of a clinical study or trial. Moreover, since there is a low probability of metastasis in stage I melanoma and a high proportion of false-positive results using these tests, GEP testing should not guide clinical decision-making in this subgroup. On an individual basis, the likelihood of a positive SLNB may be informed by the use of multivariable nomograms/risk calculators. Ongoing prospective investigation will further inform the use of GEP tests for SLNB risk prediction. [See Principles of Molecular Testing \(ME-C\)](#).

^p [See Principles of Imaging–Workup \(ME-D\)](#).

^q Nodal basin US is not a substitute for SLNB. Consider nodal basin US prior to SLNB for patients with melanoma with an equivocal regional lymph node physical exam. Abnormal or suspicious findings on nodal basin US should be confirmed histologically, whenever possible. Negative nodal basin US is not a substitute for biopsy of clinically suspicious lymph nodes.

^r Decision not to perform SLNB may be based on significant patient comorbidities, patient preference, or other factors (such as advanced patient age and/or poor functional status).

^s SLNB is an important staging tool. While SLNB itself has not been shown to improve DSS, it is associated with improved regional nodal disease control (Crystal JS, et al. *JAMA Surg* 2022;157:835-842). A positive SLNB would upstage a patient to stage III. Adjuvant therapy has been shown to mainly improve RFS (over OS) in selected patients with high-risk stage III disease.

^t [See Principles of Surgical Margins for Wide Excision of Primary Melanoma \(ME-E\)](#).

^u For patients with microsatellitosis in the wide excision specimen, see [ME-4](#) for further workup and treatment.

^v SLNs should be evaluated with serial sectioning and IHC.

^w [See Principles of Sentinel Lymph Node Biopsy \(SLNB\) \(ME-F\)](#).

^y For stage IIB/IIC patients being considered for adjuvant therapy, pretreatment imaging is appropriate.


^z Pathologic staging (with SLNB) is strongly recommended for stage IIB and IIC melanoma prior to consideration of adjuvant pembrolizumab or nivolumab—to enhance risk/benefit patient discussions and optimize local/regional disease control.

^{aa} Adjuvant pembrolizumab and nivolumab are active in reducing relapse events for resected stage IIB and IIC melanoma. However, longer follow-up is needed to evaluate the impact of adjuvant pembrolizumab or nivolumab on OS. Clinicians considering adjuvant pembrolizumab or nivolumab therapy for stages IIB or IIC disease should have a detailed discussion with the patient to weigh the pros and cons of treatment benefit versus toxicity. Factors to be considered include patient's age, performance status, personal/family history of autoimmune disease, and tolerance for risk of lifelong immunotoxicities.

^{bb} Consider RT to site of resected primary tumor in selected high-risk patients based on desmoplastic histology and/or neurotropism. [See Principles of Radiation \(ME-H\)](#).

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.




Note: All recommendations are category 2A unless otherwise indicated.
 Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

**FOOTNOTES FOR MICROSCOPIC SATELLITES**

- ⁱ Microsatellitosis represents microscopically identified lymphatic metastasis and confers an increased risk of recurrence. Microsatellites are found discontinuous from the primary tumor (adjacent or deep). The AJCC Cancer Staging Manual, Eighth Edition (2017) does not define microsatellitosis according to tumor nest dimension or distance from the primary tumor. It classifies cases with microsatellites, clinical satellites, or in-transit metastases as N1c, N2c, or N3c based on the number of tumor-involved regional lymph nodes (0, 1, or ≥2, respectively).
- ^k At times it may be difficult to distinguish whether invasive melanoma is present within a lymphatic channel or represents a microsatellite. In this instance, IHC using a specific lymphatic marker such as D2-40 may assist in distinction.
- ^p [See Principles of Imaging–Workup \(ME-D\).](#)
- ^q Nodal basin US is not a substitute for SLNB. Consider nodal basin US prior to SLNB for patients with melanoma with an equivocal regional lymph node physical exam. Abnormal or suspicious findings on nodal basin US should be confirmed histologically, whenever possible. Negative nodal basin US is not a substitute for biopsy of clinically suspicious lymph nodes.
- ^r Decision not to perform SLNB may be based on significant patient comorbidities, patient preference, or other factors (such as advanced patient age and/or poor functional status).
- ^t [See Principles of Surgical Margins for Wide Excision of Primary Melanoma \(ME-E\).](#)
- ^v SLNs should be evaluated with serial sectioning and IHC.
- ^w [See Principles of Sentinel Lymph Node Biopsy \(SLNB\) \(ME-F\).](#)
- ^x Microsatellitosis, when present in the initial biopsy or wide excision specimen, defines at least N1c and at least stage IIIB disease. Although less well-studied than other stage III patient populations, SLN status does have prognostic significance in patients with microsatellitosis, with a positive SLN upstaging a patient to at least N2c, stage IIIC. SLNB should be considered in patients with microsatellitosis, especially if it will alter management decisions.
- ^{cc} Primary lesion microsatellitosis with no clinical satellite, in-transit, or nodal disease.
- ^{dd} Patients with stage IIIB melanoma based on microsatellites alone demonstrate more favorable survival compared with those with a positive SLNB (Bartlett EK. J Surg Oncol 2019;119:200-207; Karakousis GC, et al. Ann Surg Oncol 2019;26:33-41). Because SLN-negative, microsatellite-positive patients were not studied in adjuvant therapy trials, the results of these trials may not be applicable to this subgroup.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



[See footnotes on ME-5A](#)

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

**FOOTNOTES FOR STAGE III (SENTINEL NODE POSITIVE)**

^p [See Principles of Imaging–Workup \(ME-D\).](#)

^{ee} For patients with a positive SLN(s), the presence of microsatellites in the initial biopsy of the primary tumor or wide excision specimen will upstage the patient to at least IIIC. The increased risk of recurrence associated with the presence of microsatellitosis should be acknowledged in any discussion about adjuvant therapy, independent of the SLN tumor burden. Follow-up of patients with microsatellitosis should be more frequent, commensurate with their increased risk of recurrence.

^{ff} For patients with clinically positive node(s), the presence of microsatellites in the initial biopsy of the primary tumor or wide excision specimen upstages patients to a minimum of stage IIIC. While this does not change the recommended workup and treatment, it is associated with higher risk of recurrence when compared to patients without microsatellitosis.

^{gg} *BRAF* mutation testing is recommended for patients with stage III melanoma for whom future *BRAF*-directed therapy may be an option. [See Principles of Molecular Testing \(ME-C\).](#) Consider broader genomic profiling if the test results might guide further treatment decisions or eligibility for participation in a clinical trial.

^{hh} For patients with a positive sentinel node, two prospective randomized phase III studies have demonstrated no improvement in melanoma-specific survival or OS in patients undergoing CLND compared to those who underwent nodal basin US surveillance, although only one study (MSLT-II) included primary melanomas on the head and neck. CLND did provide additional prognostic information as well as improvement in regional control/recurrence at the expense of increased morbidity, including wound complications and long-term lymphedema. Factors that predict non-SLN positivity include sentinel node tumor burden, number of positive nodes, and thickness/ulceration of the primary tumor.

[See Principles of Completion/Therapeutic Lymph Node Dissection \(ME-G\).](#)

ⁱⁱ Nodal US surveillance is preferred if institutional expertise is available. Alternative imaging modalities (eg, CT, MRI), are acceptable.

^{jj} For patients with a positive SLNB who do not undergo CLND, it would be appropriate for the frequency of clinical exam and US/imaging surveillance to be consistent with the two prospective randomized trials (MSLT-II and DeCOG; ie, every 4 months during the first 2 years, then every 6 months during years 3 through 5). [See Principles of Imaging \(ME-D\).](#)

^{kk} Nodal basin US/imaging surveillance may not be preferred over CLND in all cases (eg, patient preference due to the logistics of surveillance, when primary tumor histology and SLN tumor burden suggest a higher likelihood of additional region involvement, and/or when adjuvant therapy is not pursued).

^{ll} The choice of adjuvant systemic treatment versus observation should take into consideration the patient's risk of melanoma recurrence and the risk of treatment toxicity. [See Systemic Therapy Considerations \(ME-I\).](#)

^{mm} In patients with very-low-risk stage IIIA disease (non-ulcerated primary ≤ 2 mm thickness, SLN metastasis < 1 mm), the toxicity of adjuvant therapy may outweigh the benefit.

ⁿⁿ Nivolumab has shown a clinically significant improvement in RFS compared to high-dose ipilimumab but comparable OS at 48 months of follow-up. Pembrolizumab has shown a clinically significant improvement in RFS compared to placebo, but its impact on OS has not yet been reported.

^{oo} Adjuvant dabrafenib/trametinib and pembrolizumab are category 1 options for patients with AJCC 7th Edition stage IIIA with SLN metastasis > 1 mm or stage IIIB/C disease. Adjuvant nivolumab is a category 1 option for patients with AJCC 7th Edition stage IIIB/C disease.

^{pp} Randomized clinical trials testing adjuvant anti-PD-1 therapy included patients with sentinel node-positive disease at higher risk of recurrence: those with ulcerated primary (ie, nivolumab, pembrolizumab) or an SLN metastasis > 1 mm (pembrolizumab).

^{qq} All patients in the clinical trials studying adjuvant anti-PD-1 or adjuvant dabrafenib/trametinib were required to undergo CLND prior to randomization. In the setting of two prospective trials demonstrating that CLND has no impact on DSS or OS, it is unclear whether CLND should be a factor in the decision to use either adjuvant therapy in sentinel node-positive patients.

^{rr} The randomized clinical trial testing adjuvant dabrafenib/trametinib combination therapy for patients with *BRAF* V600E/K mutation included patients with sentinel node-positive disease at higher risk of recurrence: those with ulcerated primary and/or SLN metastasis > 1 mm.

^{ss} Other *BRAF*/*MEK* inhibitor combinations can be considered in the event of unacceptable toxicities to dabrafenib/trametinib or based on side effect profiles.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.




**CLINICAL/
PATHOLOGIC
STAGE**

WORKUP

PRIMARY TREATMENT

ADJUVANT TREATMENT



[For footnotes see ME-6A](#)

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

**FOOTNOTES FOR STAGE III (CLINICALLY NODE POSITIVE)**

^p [See Principles of Imaging–Workup \(ME-D\).](#)

^t [See Principles of Surgical Margins for Wide Excision of Primary Melanoma \(ME-E\).](#)

^{ff} For patients with clinically positive node(s), the presence of microsatellites in the initial biopsy of the primary tumor or wide excision specimen upstages patients to at least stage IIIC. While this does not change the recommended workup and treatment, it is associated with higher risk of recurrence when compared to patients without microsatellitosis.

^{gg} *BRAF* mutation testing is recommended for patients with stage III melanoma for whom future *BRAF*-directed therapy may be an option. [See Principles of Molecular Testing \(ME-C\).](#) Consider broader genomic profiling if the test results might guide further treatment decisions or eligibility for participation in a clinical trial.

^{ll} The choice of adjuvant systemic treatment versus observation should take into consideration the patient's risk of melanoma recurrence and the risk of treatment toxicity. [See Systemic Therapy Considerations \(ME-I\).](#)

ⁿⁿ Nivolumab has shown a clinically significant improvement in RFS compared to high-dose ipilimumab but comparable OS at 48 months of follow-up. Pembrolizumab has shown a clinically significant improvement in RFS compared to placebo, but its impact on OS has not yet been reported.

^{ss} Other *BRAF*/*MEK* inhibitor combinations can be considered in the event of unacceptable toxicities to dabrafenib/trametinib or based on side effect profiles.

^{tt} Patients with extensive clinically evident nodal or in-transit disease are at high risk for metastatic progression and have increased risks of perioperative morbidity. Multiple clinical trials have investigated neoadjuvant therapy, including single/combo checkpoint inhibitors, *BRAF*/*MEK* inhibitors, and intralesional therapies either alone or in combination with checkpoint inhibitors (see references below).

Clinical trials have also been designed to study pathologic response after neoadjuvant treatment and its effect on RFS. A randomized phase 2 trial of 313 patients (naïve to prior immunotherapy) showed event-free survival (EFS) at 2 years of 72% (95% confidence interval [CI], 64 to 80) for neoadjuvant pembrolizumab for 3 cycles followed by surgery and adjuvant pembrolizumab compared with 49% (95% CI, 41 to 59) in the up-front surgery and adjuvant therapy group. At present, there is no consensus regarding the recommended agents to use, duration of neoadjuvant therapy, extent of subsequent surgery, or how pathologic response to neoadjuvant therapy might impact the choice of adjuvant therapy outside the context of a prospective study.

- Amaria RN, et al. *Nature* 2022;611:155-160.
- Amaria RN, et al. *Nat Med* 2018;24:1649-1654.
- Patel SP, et al. *N Engl J Med* 2023; 388:813-823.
- Blank CU, et al. *J Clin Oncol* 2020;38(15 suppl):10002.
- Blank CU, et al. *Nat Med* 2018;24:1655-1661.
- Rozeman EA, et al. *Lancet Oncol* 2019;20:948-960.
- Amaria RN, et al. *Lancet Oncol* 2018;19:181-193.
- Long GV, et al. *Lancet Oncol* 2019;20:961-971.
- Dummer R, et al. *Nat Med* 2021;27:1789-1796.

^{uu} Prospective trials supporting the systemic therapy options on [MELSYS \(1 of 7\)](#) as neoadjuvant therapy are ongoing. Patients should be monitored for best response. The choice of neoadjuvant therapy may be influenced by prior systemic therapy, including when and what type of prior therapies were administered.

^{vv} Tumors that were locally advanced and unresectable that have become resectable should be considered for surgical resection. For patients with unresectable nodal disease, consider treatment with systemic therapy followed by resection, or treat as stage IV.

^{ww} Adjuvant nodal basin RT is associated with reduced lymph node field recurrence but has shown no improvement in RFS or OS. Its benefits must be weighed against potential toxicities such as lymphedema (limb) or oropharyngeal complications. The impact of these potential toxicities should be considered in the context of available systemic adjuvant treatment options.

^{xx} [See Principles of Radiation Therapy for Melanoma \(ME-H\).](#)


Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 3.2023

Melanoma: Cutaneous



[See footnotes on ME-7A](#)

Note: All recommendations are category 2A unless otherwise indicated.
 Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

**FOOTNOTES FOR STAGE III (CLINICAL SATELLITE/IN-TRANSIT)**

^p [See Principles of Imaging–Workup \(ME-D\).](#)

^{ll} The choice of adjuvant systemic treatment versus observation should take into consideration the patient's risk of melanoma recurrence and the risk of treatment toxicity. [See Systemic Therapy Considerations \(ME-I\).](#)

^{gg} *BRAF* mutation testing is recommended for patients with stage III melanoma for whom future *BRAF*-directed therapy may be an option. [See Principles of Molecular Testing \(ME-C\).](#) Consider broader genomic profiling if the test results might guide further treatment decisions or eligibility for participation in a clinical trial.

^{ss} Other *BRAF*/*MEK* inhibitor combinations can be considered in the event of unacceptable toxicities to dabrafenib/trametinib or based on side effect profiles.

^{xx} [See Principles of Radiation Therapy for Melanoma \(ME-H\).](#)

^{yy} Lymphatic metastases can be characterized as clinically, radiologically, or pathologically detectable satellite metastases (dermal and/or subcutaneous intralymphatic metastases occurring within 2 cm of from the primary melanoma), or in-transit metastases (identified between 2 cm from the primary melanoma and the regional nodal basin). The 2-cm cutoff is consistent with AJCC staging definitions., but satellite and in-transit lymphatic metastases are biologically and prognostically similar.

^{zz} There are no clinical data to support wider surgical margins for satellite/in-transit metastasis; clear histologic margins should be achieved. Consider sentinel node biopsy for resectable clinical satellite/in-transit disease if it will change treatment options (category 2B). [See Principles of Sentinel Lymph Node Biopsy \(SLNB\) \(ME-F\).](#)

^{aaa} [See Systemic Therapy for Metastatic or Unresectable Disease \(MELSYS 1 of 7\).](#)

^{bbb} For low-volume in-transit disease, the high risk of toxicities associated with certain combination regimens may outweigh the benefit.

^{ccc} For patients who have previously received systemic therapy for cutaneous melanoma (either as active treatment or adjuvant therapy), selection of systemic therapy regimen should be informed by response to prior systemic therapies. For patients who experienced progression of melanoma during or shortly after a prior therapy, consider agents of a different class. For patients who experience disease control (CR, PR, or SD) on a prior systemic therapy, and have no residual toxicity, but subsequently experienced disease progression/relapse >3 months after treatment discontinuation, systemic therapy with the same agent or same class of agents may be considered.

^{ddd} T-VEC was associated with a response rate (lasting ≥6 months) of 16% in highly selected patients with unresectable metastatic melanoma. Efficacy was noted in AJCC 7th Edition stage IIIB and IIIC disease, and was more likely to be seen in patients who were treatment naive.

^{eee} These options have been preference stratified as "Preferred Regimens."

^{fff} These options have been preference stratified as "Useful In Certain Circumstances."

^{ggg} Definitive or palliative radiation therapy RT can be considered for unresectable melanoma, depending on the goal of treatment. Definitive RT has the intent of durable irradiated tumor control. Palliative RT has the intent of relieving symptoms caused by tumor.

^{hhh} [See Principles of Imaging–Treatment Response Assessment \(ME-D 3 of 5\).](#)

ⁱⁱⁱ CheckMate 238 is a phase III randomized study to evaluate adjuvant nivolumab versus ipilimumab after complete resection in patients with stage IIIB/c or stage IV melanoma. The study included 155 patients with in-transit melanoma only. Nivolumab showed a clinically significant improvement in RFS compared to high-dose ipilimumab. OS results were not reported for the subjects with in-transit disease only. Pembrolizumab has shown a clinically significant improvement in RFS compared to placebo, but its impact on OS has not yet been reported. The NCCN Panel agrees that it is appropriate to extend the indication for adjuvant anti-PD-1 therapy to patients with clinical or macroscopic satellite/in-transit disease and who are at significant risk of recurrence.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



**CLINICAL/
PATHOLOGIC
STAGE**

WORKUP

Stage IV
metastatic



- Biopsy to confirm^{jjj}
- Lactate dehydrogenase (LDH)
- Imaging^p for baseline staging and to evaluate specific signs and symptoms




[See Treatment for Oligometastatic or Widely Disseminated Disease \(ME-16\)](#)

^p [See Principles of Imaging–Workup \(ME-D\).](#)

^{jjj} Initial presentation with stage IV disease or clinical recurrence should be confirmed pathologically whenever possible or if clinically indicated. Biopsy techniques may include core (preferred), FNA, incisional/partial, or excisional. Tissue is always preferred over cytology for mutational analysis. Obtain tissue to ascertain alterations in *BRAF*, and in the appropriate clinical setting, *KIT* from either biopsy of the metastasis (preferred) or archival material if the patient is being considered for targeted therapy. Consider broader genomic profiling if the test results might guide future treatment decisions or eligibility for participation in a clinical trial. [See Principles of Biopsy and Pathology \(ME-B\)](#) and [See Principles of Molecular Testing \(ME-C\)](#).

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



^{jjj} Initial presentation with stage IV disease or clinical recurrence should be confirmed pathologically whenever possible or if clinically indicated. Biopsy techniques may include core (preferred), FNA, incisional/partial, or excisional. Tissue is always preferred over cytology for mutational analysis. Obtain tissue to ascertain alterations in *BRAF*, and in the appropriate clinical setting, *KIT* from either biopsy of the metastasis (preferred) or archival material if the patient is being considered for targeted therapy. Consider broader genomic profiling if the test results might guide future treatment decisions or eligibility for participation in a clinical trial.

[See Principles of Biopsy and Pathology \(ME-B\)](#) and [See Principles of Molecular Testing \(ME-C\)](#).

^{kkk} [See Common Follow-up Recommendations for All Patients \(ME-11\)](#).

^{lll} [See Principles of Imaging-Follow-up \(ME-D\)](#).

^{mmm} True scar recurrence (persistent disease) at the primary tumor wide excision site is defined by the presence of in situ and/or radial growth phase abutting the surgical scar.

ⁿⁿⁿ Local satellite/in-transit metastasis lacks in situ or radial growth phase, and is defined by intralymphatic deep dermal or subcutaneous fat recurrence within the melanoma scar or satellite metastasis adjacent to the melanoma scar. Satellite and in-transit metastases are biologically and prognostically similar.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.




CLINICAL/ PATHOLOGIC STAGE

FOLLOW-UP

RECURRENCE^{mmm}

Stage IIB–IV NED →

- See Common Follow-up Recommendations for All Patients^{kkk}
- H&P (with emphasis on nodes and skin)
 - ▶ every 3–6 mo for 2 y, then
 - ▶ every 3–12 mo for 3 y, then
 - ▶ annually as clinically indicated
- Routine blood tests are not recommended
- Imaging^{lll} as indicated to investigate specific signs or symptoms
- Consider imaging^{lll} every 3–12 months for 2 years, then every 6–12 months for another 3 years^{ooo} (unless otherwise mandated by clinical trial participation) to screen for recurrence or metastatic disease (category 2B)
- Routine imaging to screen for asymptomatic recurrence or metastatic disease is not recommended after 3–5 years, depending on risk of relapse



^{jjj} Initial presentation with stage IV disease or clinical recurrence should be confirmed pathologically whenever possible or if clinically indicated. Biopsy techniques may include core (preferred), FNA, incisional/partial, or excisional. Tissue is always preferred over cytology for mutational analysis. Obtain tissue to ascertain alterations in *BRAF*, and in the appropriate clinical setting, *KIT* from either biopsy of the metastasis (preferred) or archival material if the patient is being considered for targeted therapy. Consider broader genomic profiling if the test results might guide future treatment decisions or eligibility for participation in a clinical trial.

[See Principles of Biopsy and Pathology \(ME-B\)](#) and [See Principles of Molecular Testing \(ME-C\)](#).

^{kkk} [See Common Follow-up Recommendations for All Patients \(ME-11\)](#).

^{lll} [See Principles of Imaging–Follow-up \(ME-D\)](#).

^{mmm} True scar recurrence (persistent disease) at the primary tumor wide excision site is defined by the presence of in situ and/or radial growth phase abutting the surgical scar.

ⁿⁿⁿ Local satellite/in-transit metastasis lacks in situ or radial growth phase, and is defined by intralymphatic deep dermal or subcutaneous fat recurrence within the melanoma scar or satellite metastasis adjacent to the melanoma scar. Satellite and in-transit metastases are biologically and prognostically similar.

^{ooo} The duration and frequency of follow-up and intensity of cross-sectional imaging should be based on the conditional probability of recurrence at any point in time after initial treatment. Follow-up recommendations listed here are for surveillance for recurrence in patients with no clinical evidence of disease.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

**COMMON FOLLOW-UP RECOMMENDATIONS FOR ALL PATIENTS**

- H&P (with emphasis on nodes and skin) is recommended at least annually, depending on stage.
 - ▶ Pre-diagnostic clinical modalities (ie, dermoscopy, total-body photography and sequential digital dermoscopy), noninvasive imaging and other technologies (eg, reflectance confocal microscopy, electrical impedance spectroscopy) may aid in surveillance for new primary melanoma, particularly in patients with high mole count and/or presence of clinically atypical nevi.
 - ▶ For melanocytic neoplasms that are clinically/dermoscopically suspicious for melanoma, pre-diagnostic noninvasive patch testing may also be helpful to guide biopsy decisions.
- Provide patient education in regular skin and lymph node self-examination.
- Clinicians are encouraged to recommend avoidance of behaviors that may increase the risk of future (new primary) melanomas. This includes patient education in principles of sun safety, including sun avoidance during peak hours, use of sun-protective clothing/hat/eyewear, and regular application of broad-spectrum sunscreen to exposed skin when outdoors, particularly in individuals with sun sensitivity/light complexion.
- In patients with an equivocal lymph node exam, short-term follow-up and/or additional imaging (ultrasound [US; preferred] or CT) should be considered, with imaging-directed biopsy as warranted.
- Follow-up schedule is influenced by risk of recurrence and new primary melanoma, which depends on patient/family history of melanoma, mole count, and/or presence of atypical moles/dysplastic nevi.
- Clinical and family history can identify patients in whom multigene testing might indicate an increased genetic risk for cutaneous and uveal melanoma, astrocytoma, mesothelioma, and cancers of the breast, pancreas, and kidney. This information can guide recommendations for surveillance and early detection in appropriate patients and their relatives.
 - ▶ Consider genetic counseling referral for *p16/CDKN2A* mutation testing in the presence of 3 or more invasive cutaneous melanomas, or a mix of invasive melanoma, pancreatic cancer, and/or astrocytoma diagnoses in an individual or family.
 - ▶ Multigene panel testing that includes *CDKN2A* is recommended for patients with invasive cutaneous melanoma who have a first-degree relative diagnosed with pancreatic cancer ([see NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic](#)).
 - ▶ Testing for other genes that can harbor melanoma-predisposing mutations ([see Risk Factors for Development of Single or Multiple Primary Melanomas ME-A 1 of 2](#)) may be warranted.

Note: All recommendations are category 2A unless otherwise indicated.


Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



WORKUP

TREATMENT OF RECURRENCE

ADJUVANT TREATMENT



^w [See Principles of Sentinel Lymph Node Biopsy \(SLNB\) \(ME-F\)](#).

^{jjj} Initial presentation with stage IV disease or clinical recurrence should be confirmed pathologically whenever possible or if clinically indicated. Biopsy techniques may include core (preferred), FNA, incisional/partial, or excisional. Tissue is always preferred over cytology for mutational analysis. Obtain tissue to ascertain alterations in *BRAF*, and in the appropriate clinical setting, *KIT* from either biopsy of the metastasis (preferred) or archival material if the patient is being considered for targeted therapy. Consider broader genomic profiling if the test results might guide future treatment decisions or eligibility for participation in a clinical trial. [See Principles of Biopsy and Pathology \(ME-B\)](#) and [See Principles of Molecular Testing \(ME-C\)](#).


^{mmm} True scar recurrence (persistent disease) at the primary tumor wide excision site is defined by the presence of in situ and/or radial growth phase abutting the surgical scar.

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 3.2023

Melanoma: Cutaneous



[See ME-13A for footnotes](#)

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

**FOOTNOTES FOR LOCAL SATELLITE/IN-TRANSIT RECURRENCE**

^p See [Principles of Imaging–Workup \(ME-D\)](#).

^{ll} The choice of adjuvant systemic treatment versus observation should take into consideration the patient's risk of melanoma recurrence and the risk of treatment toxicity. See [Systemic Therapy Considerations \(ME-I\)](#).

^{ss} Other BRAF/MEK inhibitor combinations can be considered in the event of unacceptable toxicities to dabrafenib/trametinib or based on side effect profiles.

^{xx} See [Principles of Radiation Therapy for Melanoma \(ME-H\)](#).

^{zz} There are no clinical data to support wider surgical margins for satellite/ in-transit metastasis; clear histologic margins should be achieved. Consider sentinel node biopsy for resectable clinical satellite/in-transit disease if it will change treatment options (category 2B). See [Principles of Sentinel Lymph Node Biopsy \(SLNB\) \(ME-F\)](#).

^{aaa} See [Systemic Therapy for Metastatic or Unresectable Disease \(MELSYS 1 of 7\)](#).

^{bbb} For low-volume in-transit disease, the high risk of toxicities associated with certain combination regimens may outweigh the benefit.

^{ccc} For patients who have previously received systemic therapy for cutaneous melanoma (either as active treatment or adjuvant therapy), selection of systemic therapy regimen should be informed by response to prior systemic therapies. For patients who experienced progression of melanoma during or shortly after a prior therapy, consider agents of a different class. For patients who experience disease control (CR, PR, or SD) on a prior systemic therapy, and have no residual toxicity, but subsequently experienced disease progression/relapse >3 months after treatment discontinuation, systemic therapy with the same agent or same class of agents may be considered.

^{ddd} T-VEC was associated with a response rate (lasting ≥6 months) of 16% in highly selected patients with unresectable metastatic melanoma. Efficacy was noted in AJCC 7th Edition stage IIIB and IIIC disease, and was more likely to be seen in patients who were treatment naive.

^{eee} This option has been preference stratified as "Preferred Regimens."

^{fff} These options have been preference stratified as "Useful In Certain Circumstances."

⁹⁹⁹ Definitive or palliative RT can be considered for unresectable melanoma, depending on the goal of treatment. Definitive RT has the intent of durable irradiated tumor control. Palliative RT has the intent of relieving symptoms caused by tumor.

^{hhh} See [Principles of Imaging–Treatment Response Assessment \(ME-D 3 of 5\)](#).

ⁱⁱⁱ CheckMate 238 is a phase III randomized study to evaluate adjuvant nivolumab versus ipilimumab after complete resection in patients with stage IIIb/c or stage IV melanoma. The study included 155 patients with in-transit melanoma only. Nivolumab showed a clinically significant improvement in RFS compared to high-dose ipilimumab. OS results were not reported for the subjects with in-transit disease only. Pembrolizumab has shown a clinically significant improvement in RFS compared to placebo, but its impact on OS has not yet been reported. The NCCN Panel agrees that it is appropriate to extend the indication for adjuvant anti-PD-1 therapy to patients with clinical or macroscopic satellite/intransit disease and who are at significant risk of recurrence.

^{jjj} Initial presentation with stage IV disease or clinical recurrence should be confirmed pathologically whenever possible or if clinically indicated. Biopsy techniques may include core (preferred), FNA, incisional/partial, or excisional. Tissue is always preferred over cytology for mutational analysis. Obtain tissue to ascertain alterations in *BRAF*, and in the appropriate clinical setting, *KIT* from either biopsy of the metastasis (preferred) or archival material if the patient is being considered for targeted therapy. Consider broader genomic profiling if the test results might guide future treatment decisions or eligibility for participation in a clinical trial. See [Principles of Biopsy and Pathology \(ME-B\)](#) and [Principles of Molecular Testing \(ME-C\)](#).

ⁿⁿⁿ Local satellite/in-transit metastasis lacks in situ or radial growth phase and is defined by intralymphatic deep dermal or subcutaneous fat recurrence within the melanoma scar or satellite metastasis adjacent to the melanoma scar. Satellite and in-transit metastases are biologically and prognostically similar.

^{ppp} In an EORTC prospective randomized trial of adjuvant high-dose ipilimumab at 10 mg/kg (ipi10) versus placebo, ipi10 conferred improved RFS and OS, but was associated with a high incidence of adverse events, including 1% drug-related mortality. However, there were no patients with resected in-transit disease in the adjuvant trial, and therefore the use of adjuvant ipilimumab in this setting is based on extrapolation. In situations where adjuvant ipilimumab may be an option (eg, patients who progress during anti-PD-1 therapy with resectable disease), the recommended dose is 3 mg/kg.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



WORKUP

- Nodal recurrence** →
- Biopsy to confirm^{jjj}
 - Imaging^p to assess extent of disease and to evaluate specific signs or symptoms
 - *BRAF* mutation testing if not previously performed^{jjj}

Disease limited to nodal recurrence

Systemic disease →

No previous lymph node dissection

Unresectable^{uu,vv,qqq}

Previous lymph node dissection

Resectable

TREATMENT OF RECURRENCE^{hhh}

Excise recurrence and perform TLND^{rrr} or Neoadjuvant therapy, preferably in the context of a clinical trial^{tt,uu}

[See Unresectable pathway on \(ME-15\)](#)

[See Treatment of Recurrence \(ME-15\)](#)

ADJUVANT TREATMENT

- Systemic therapy options^{ll,sss}:
- Preferred regimens
 - Nivolumab (category 1)ⁿⁿ
 - Pembrolizumab (category 1)ⁿⁿ
 - Dabrafenib/trametinib^{ss} for patients with *BRAF* V600-activating mutation (category 1)
 - Useful in certain circumstances
 - Ipilimumab^{ttt} if prior exposure to anti-PD-1 therapy
- and/or
Locoregional therapy option:
- Consider RT to nodal basin in selected high-risk patients based on location, size, and number of involved nodes, gross and/or histologic extracapsular extension^{ww,xx} (category 2B)
- or
Observation^{ll}

[Follow-up \(See ME-10\)](#)

[Distant Metastatic Disease \(See ME-16\)](#)

[See footnotes on 14A](#)

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

**FOOTNOTES FOR NODAL RECURRENCE**

^p [See Principles of Imaging–Workup \(ME-D\).](#)

^{ll} The choice of adjuvant systemic treatment versus observation should take into consideration the patient's risk of melanoma recurrence and the risk of treatment toxicity. [See Systemic Therapy Considerations \(ME-I\).](#)

ⁿⁿ Nivolumab has shown a clinically significant improvement in RFS compared to high-dose ipilimumab but comparable OS at 48 months of follow-up. Pembrolizumab has shown a clinically significant improvement in RFS compared to placebo, but its impact on OS has not yet been reported.

^{ss} Other BRAF/MEK inhibitor combinations can be considered in the event of unacceptable toxicities to dabrafenib/trametinib or based on side effect profiles.

^{tt} Patients with extensive clinically evident nodal or in-transit disease are at high risk for metastatic progression and have increased risks of perioperative morbidity. Multiple clinical trials have investigated neoadjuvant therapy, including single/combination checkpoint inhibitors, BRAF/MEK inhibitors, and intralesional therapies either alone or in combination with checkpoint inhibitors (see references below). Clinical trials have also been designed to study pathologic response after neoadjuvant treatment and its effect on RFS. A randomized phase 2 trial of 313 patients (naïve to prior immunotherapy) showed event-free survival (EFS) at 2 years of 72% (95% confidence interval [CI], 64 to 80) for neoadjuvant pembrolizumab for 3 cycles followed by surgery and adjuvant pembrolizumab compared with 49% (95% CI, 41 to 59) in the up-front surgery and adjuvant therapy group. At present, there is no consensus regarding the recommended agents to use, duration of neoadjuvant therapy, extent of subsequent surgery, or how pathologic response to neoadjuvant therapy might impact the choice of adjuvant therapy outside the context of a prospective study.

- Amaria RN, et al. *Nature* 2022;611:155-160.
- Amaria RN, et al. *Nat Med* 2018;24:1649-1654.
- Patel SP, et al. *N Engl J Med* 2023; 388:813-823.
- Blank CU, et al. *J Clin Oncol* 2020;38(15 suppl):10002.
- Blank CU, et al. *Nat Med* 2018;24:1655-1661.
- Rozeman EA, et al. *Lancet Oncol* 2019;20:948-960.
- Amaria RN, et al. *Lancet Oncol* 2018;19:181-193.
- Long GV, et al. *Lancet Oncol* 2019;20:961-971.
- Dummer R, et al. *Nat Med* 2021;27:1789-1796.

^{uu} Prospective trials supporting the systemic therapy options on [MELSYS 1 of 8](#) as neoadjuvant therapy are ongoing. Patients should be monitored for best response. The choice of neoadjuvant therapy may be influenced by prior systemic therapy, including when and what type of prior therapies were administered

^{vv} Tumors that were locally advanced and unresectable that have become resectable should be considered for surgical resection. For patients with unresectable nodal disease, consider treatment with systemic therapy followed by resection, or treat as stage IV.

^{ww} Adjuvant nodal basin RT is associated with reduced lymph node field recurrence but has shown no improvement in RFS or OS. Its benefits must be weighed against potential toxicities such as lymphedema (limb) or oropharyngeal complications. The impact of these potential toxicities should be considered in the context of available systemic adjuvant treatment options.

^{xx} [See Principles of Radiation Therapy for Melanoma \(ME-H\).](#)

^{hhh} [See Principles of Imaging--Treatment Response Assessment \(ME-D 3 of 5\).](#)

^{jjj} Initial presentation with stage IV disease or clinical recurrence should be confirmed pathologically whenever possible or if clinically indicated. Biopsy techniques may include core (preferred), FNA, incisional/partial, or excisional. Tissue is always preferred over cytology for mutational analysis. Obtain tissue to ascertain alterations in *BRAF*, and in the appropriate clinical setting, *KIT* from either biopsy of the metastasis (preferred) or archival material if the patient is being considered for targeted therapy. Consider broader genomic profiling if the test results might guide future treatment decisions or eligibility for participation in a clinical trial. [See Principles of Biopsy and Pathology \(ME-B\)](#) and [See Principles of Molecular Testing \(ME-C\).](#)

^{qqq} Disease is defined as technically unresectable (ie, involvement of a major neurovascular structure) or clinically unresectable (ie, remote nodal disease), where surgery alone would have minimal clinical benefit.


^{rrr} [See Principles of Completion/Therapeutic Lymph Node Dissection \(ME-G\).](#)

^{sss} For patients who have previously received systemic therapy for cutaneous melanoma (either as active treatment or adjuvant therapy), selection of adjuvant treatment regimen should be informed by response to prior systemic therapies. For patients who experienced progression of melanoma during or shortly after a prior therapy, consider adjuvant agents of a different class. For patients who experience disease control (CR, PR, or SD) on a prior systemic therapy, and have no residual toxicity, but subsequently experienced disease progression/relapse >3 months after treatment discontinuation, adjuvant treatment with the same agent or same class of agents may be considered.

^{ttt} In an EORTC prospective randomized trial of adjuvant high-dose ipilimumab at 10 mg/kg (ipi10) versus placebo, ipi10 conferred improved RFS and OS, but was associated with a high incidence of adverse events, including 1% drug-related mortality. In a subsequent Intergroup randomized trial of adjuvant ipilimumab 3 mg/kg (ipi3) versus ipi10 versus high-dose interferon, the incidence of treatment-related adverse events ≥ grade 3 was 37% with ipi3 versus 58% with ipi10. The trial noted a statistically significant OS advantage for ipi3 versus interferon, but a trend for OS advantage of ipi10 over interferon was not statistically significant. In situations where adjuvant ipilimumab may be an option (eg, patients who progress during anti-PD-1 therapy with resectable disease), the recommended dose is 3 mg/kg.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



[See footnotes on ME-15A and ME-15B](#)

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

**FOOTNOTES FOR DISEASE LIMITED TO NODAL RECURRENCE**

^{ll} The choice of adjuvant systemic treatment versus observation should take into consideration the patient's risk of melanoma recurrence and the risk of treatment toxicity. [See Systemic Therapy Considerations \(ME-I\)](#).

ⁿⁿ Nivolumab has shown a clinically significant improvement in RFS compared to high-dose ipilimumab, but comparable OS at 48 months of follow-up. Pembrolizumab has shown a clinically significant improvement in RFS compared to placebo, but its impact on OS has not yet been reported.

^{ss} Other BRAF/MEK inhibitor combinations can be considered in the event of unacceptable toxicities to dabrafenib/trametinib or based on side effect profiles.

^{tt} Patients with extensive clinically evident nodal or in-transit disease are at high risk for metastatic progression and have increased risks of perioperative morbidity. Multiple clinical trials have investigated neoadjuvant therapy, including single/combo checkpoint inhibitors, BRAF/MEK inhibitors, and intralesional therapies either alone or in combination with checkpoint inhibitors (see references below).

Clinical trials have also been designed to study pathologic response after neoadjuvant treatment and its effect on RFS. A randomized phase 2 trial of 313 patients (naïve to prior immunotherapy) showed event-free survival (EFS) at 2 years of 72% (95% confidence interval [CI], 64 to 80) for neoadjuvant pembrolizumab for 3 cycles followed by surgery and adjuvant pembrolizumab compared with 49% (95% CI, 41 to 59) in the up-front surgery and adjuvant therapy group. At present, there is no consensus regarding the recommended agents to use, duration of neoadjuvant therapy, extent of subsequent surgery, or how pathologic response to neoadjuvant therapy might impact the choice of adjuvant therapy outside the context of a prospective study.

- Amaria RN, et al. *Nature* 2022;611:155-160.
- Amaria RN, et al. *Nat Med* 2018;24:1649-1654.
- Patel SP, et al. *N Engl J Med* 2023; 388:813-823.
- Blank CU, et al. *J Clin Oncol* 2020;38(15 suppl):10002.
- Blank CU, et al. *Nat Med* 2018;24:1655-1661.
- Rozeman EA, et al. *Lancet Oncol* 2019;20:948-960.
- Amaria RN, et al. *Lancet Oncol* 2018;19:181-193.
- Long GV, et al. *Lancet Oncol* 2019;20:961-971.
- Dummer R, et al. *Nat Med* 2021;27:1789-1796.

^{uu} Prospective trials supporting the systemic therapy options on [MELSYS 1 of 7](#) as neoadjuvant therapy are ongoing. Patients should be monitored for best response. The choice of neoadjuvant therapy may be influenced by prior systemic therapy, including when and what type of prior therapies were administered.

^{vv} Tumors that were locally advanced and unresectable that have become resectable should be considered for surgical resection. For patients with unresectable nodal disease, consider treatment with systemic therapy followed by resection, or treat as stage IV.

^{ww} Adjuvant nodal basin RT is associated with reduced lymph node field recurrence but has shown no improvement in RFS or OS. Its benefits must be weighed against potential toxicities such as lymphedema (limb) or oropharyngeal complications. The impact of these potential toxicities should be considered in the context of available systemic adjuvant treatment options.

^{xx} [See Principles of Radiation Therapy for Melanoma \(ME-H\)](#).

^{aaa} [See Systemic Therapy for Metastatic or Unresectable Disease \(MELSYS 1 of 8\)](#).

^{ddd} T-VEC was associated with a response rate (lasting ≥6 months) of 16% in highly selected patients with unresectable metastatic melanoma. Efficacy was noted in AJCC 7th Edition stage IIIB and IIIC disease, and was more likely seen in patients who were treatment naïve.

^{fff} These options have been preference stratified as "Useful In Certain Circumstances."

^{hhh} [See Principles of Imaging--Treatment Response Assessment \(ME-D 3 of 5\)](#).

^{jjj} Initial presentation with stage IV disease or clinical recurrence should be confirmed pathologically whenever possible or if clinically indicated. Biopsy techniques may include core (preferred), FNA, incisional/partial, or excisional. Tissue is always preferred over cytology for mutational analysis. Obtain tissue to ascertain alterations in *BRAF*, and in the appropriate clinical setting, *KIT* from either biopsy of the metastasis (preferred) or archival material if the patient is being considered for targeted therapy. Consider broader genomic profiling if the test results might guide future treatment decisions or eligibility for participation in a clinical trial. [See Principles of Biopsy and Pathology \(ME-B\)](#) and [See Principles of Molecular Testing \(ME-C\)](#).

^{qqq} Disease is defined as technically unresectable (ie, involvement of a major neurovascular structure) or clinically unresectable (ie, remote nodal disease), where surgery alone would have minimal clinical benefit.

^{rrr} [See Principles of Completion/Therapeutic Lymph Node Dissection \(ME-G\)](#).

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



FOOTNOTES FOR DISEASE LIMITED TO NODAL RECURRENCE (CONTINUED)

^{sss} For patients who have previously received systemic therapy for cutaneous melanoma (either as active treatment or adjuvant therapy), selection of adjuvant treatment regimen should be informed by response to prior systemic therapies. For patients who experienced progression of melanoma during or shortly after a prior therapy, consider adjuvant agents of a different class. For patients who experience disease control (CR, PR, or SD) on a prior systemic therapy, and have no residual toxicity, but subsequently experienced disease progression/relapse >3 months after treatment discontinuation, adjuvant treatment with the same agent or same class of agents may be considered.

^{ttt} In an EORTC prospective randomized trial of adjuvant high-dose ipilimumab at 10 mg/kg (ipi10) versus placebo, ipi10 conferred improved RFS and OS, but was associated with a high incidence of adverse events, including 1% drug-related mortality. In a subsequent Intergroup randomized trial of adjuvant ipilimumab 3 mg/kg (ipi3) versus ipi10 versus high-dose interferon, the incidence of treatment-related adverse events \geq grade 3 was 37% with ipi3 versus 58% with ipi10. The trial noted a statistically significant OS advantage for ipi3 versus interferon, but a trend for OS advantage of ipi10 over interferon was not statistically significant. In situations where adjuvant ipilimumab may be an option (eg, patients who progress during anti-PD-1 therapy with resectable disease), the recommended dose is 3 mg/kg.

Note: All recommendations are category 2A unless otherwise indicated.


Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



NCCN Guidelines Version 3.2023 Melanoma: Cutaneous

WORKUP

TREATMENT OF METASTATIC DISEASE



[See footnotes on ME-16A](#)

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

**FOOTNOTES FOR TREATMENT OF METASTATIC DISEASE**

^p [See Principles of Imaging–Workup \(ME-D\).](#)

^{ll} The choice of adjuvant systemic treatment versus observation should take into consideration the patient's risk of melanoma recurrence and the risk of treatment toxicity. [See Systemic Therapy Considerations \(ME-I\).](#)

^{xx} [See Principles of Radiation Therapy for Melanoma \(ME-H\).](#)

^{aaa} [See Systemic Therapy for Metastatic or Unresectable Disease \(MELSYS 1 of 7\).](#)

^{fff} These options have been preference stratified as "Useful In Certain Circumstances."

^{hhh} [See Principles of Imaging–Treatment Response Assessment \(ME-D 3 of 5\).](#)

^{jjj} Initial presentation with stage IV disease or clinical recurrence should be confirmed pathologically whenever possible or if clinically indicated. Biopsy techniques may include core (preferred), FNA, incisional/partial, or excisional. Tissue is always preferred over cytology for mutational analysis. Obtain tissue to ascertain alterations in *BRAF*, and in the appropriate clinical setting, *KIT* from either biopsy of the metastasis (preferred) or archival material if the patient is being considered for targeted therapy. Consider broader genomic profiling if the test results might guide future treatment decisions or eligibility for participation in a clinical trial. [See Principles of Biopsy and Pathology \(ME-B\)](#) and [See Principles of Molecular Testing \(ME-C\)](#).

^{sss} For patients who have previously received systemic therapy for cutaneous melanoma (either as active treatment or adjuvant therapy), selection of adjuvant treatment regimen should be informed by response to prior systemic therapies. For patients who experienced progression of melanoma during or shortly after a prior therapy, consider adjuvant agents of a different class. For patients who experience disease control (CR, PR, or SD) on a prior systemic therapy, and have no residual toxicity, but subsequently experienced disease progression/relapse >3 months after treatment discontinuation, adjuvant treatment with the same agent or same class of agents may be considered.

^{uuu} [See Principles of Brain Metastases Management \(ME-K\).](#)

^{vvv} Ipilimumab is included as an adjuvant treatment option for patients with resected stage IV disease who have prior exposure to anti-PD-1 agents based on extrapolation of data demonstrating its efficacy as adjuvant treatment for resected stage III disease and demonstrated efficacy for unresectable stage IV disease. In an EORTC prospective randomized trial of adjuvant high-dose ipilimumab at 10 mg/kg (ipi10) versus placebo, ipi10 conferred improved RFS and OS, but was associated with a high incidence of adverse events, including 1% drug-related mortality. In a subsequent Intergroup randomized trial of adjuvant ipilimumab 3 mg/kg (ipi3) versus ipi10 versus high-dose interferon, the incidence of treatment-related adverse events ≥ grade 3 was 37% with ipi3 versus 58% with ipi10. The trial noted a statistically significant OS advantage for ipi3 versus interferon, but a trend for OS advantage of ipi10 over interferon was not statistically significant. In situations where adjuvant ipilimumab may be an option (eg, patients who progress during anti-PD-1 therapy with resectable disease), the recommended dose is 3 mg/kg.

^{www} T-VEC has shown a response rate (lasting ≥6 months) of 16% in highly selected patients with AJCC 7th Edition stage IV–M1a disease (skin, subcutaneous, and/or remote nodes).

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



SYSTEMIC THERAPY FOR METASTATIC OR UNRESECTABLE DISEASE^{a,b,c}

FIRST-LINE THERAPY^d

Metastatic or
unresectable
disease

- Preferred regimens
 - ▶ Combination checkpoint blockade (preferred)
 - ◇ Nivolumab/ipilimumab (category 1)^{e,f,g,h}
 - ◇ Nivolumab and relatlimab-rmbw (category 1)^e
 - ▶ Anti-PD-1 monotherapy^{e,f,i}
 - ◇ Pembrolizumab (category 1)
 - ◇ Nivolumab (category 1)
- Other recommended regimens
 - ▶ Combination targeted therapy if *BRAF* V600-activating mutation^{j,k,l,m,n}
 - ◇ Dabrafenib/trametinib (category 1)
 - ◇ Vemurafenib/cobimetinib (category 1)
 - ◇ Encorafenib/binimetinib (category 1)
 - ▶ Pembrolizumab/low-dose ipilimumab^o (category 2B)

Disease
progression,
intolerance,
and/or
projected risk
of progression
with
BRAF-targeted
therapy

SECOND-LINE OR SUBSEQUENT THERAPY^p

- Systemic therapy
 - ▶ Preferred regimens
 - ◇ Anti-PD-1 monotherapy^{e,f}
 - Pembrolizumab
 - Nivolumab
 - ◇ Nivolumab/ipilimumab^{e,f,g}
 - ◇ Nivolumab and relatlimab-rmbw^q
 - ◇ Pembrolizumab/low-dose ipilimumab for progression following anti-PD-1 therapy^{e,f}
 - ◇ Combination targeted therapy with *BRAF* V600-activating mutation^{k,l,m}
 - Dabrafenib/trametinib
 - Vemurafenib/cobimetinib
 - Encorafenib/binimetinib
 - ▶ Other recommended regimens
 - ◇ Ipilimumab^e
 - ◇ High-dose IL-2^r
 - ▶ Useful in certain circumstances
 - ◇ For activating mutations of *KIT*
 - KIT inhibitor therapy (eg, imatinib, dasatinib, nilotinib, ripretinib)
 - ◇ For *ROS1* fusions
 - Crizotinib, entrectinib
 - ◇ For *NTRK* fusions
 - Larotrectinib, entrectinib
 - ◇ For *BRAF* fusions and non-V600 mutations^s
 - Trametinib
 - ◇ For *NRAS*-mutated tumors (for progression following immune checkpoint inhibitor therapy)
 - Binimetinib^t (category 2B)
 - ◇ Combination therapy
 - Pembrolizumab/lenvatinib^u
 - Ipilimumab^e/intralesional T-VEC (category 2B)
 - ◇ Combination *BRAF*/MEK + PD(L)-1 checkpoint inhibitors (eg, dabrafenib/trametinib + pembrolizumab or vemurafenib/cobimetinib + atezolizumab)
 - ◇ Cytotoxic agents^v
- Consider best supportive care for poor performance status ([See NCCN Guidelines for Palliative Care](#))

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

[See footnotes on next page](#)

**FOOTNOTES FOR SYSTEMIC THERAPY FOR METASTATIC OR UNRESECTABLE DISEASE**

^a [See Principles of Imaging --Treatment Response Assessment \(ME-D\).](#)

^b [See Systemic Therapy Considerations \(ME-I\).](#)

^c The order of listed systemic therapies in a given section does not reflect order of preference. The choice of a treatment is based on evaluation of the individual patient to include patient characteristics, disease presentation, health system resources/experience, and patient preference.

^d Considerations for using combination nivolumab/ipilimumab or nivolumab and relatlimab-rmbw versus PD-1 monotherapy include: patient willingness to take on a higher risk of treatment-related toxicities (immune-related adverse events [irAEs]); absence of comorbidities or autoimmune processes that would elevate the risk of irAEs; and patient social support and preparedness to work with medical team to handle toxicities.

^e [See NCCN Guidelines for Management of Immunotherapy-Related Toxicities](#) for proactive monitoring and management of toxicities in patients undergoing treatment with immune checkpoint inhibitors.

^f Testing for tumor PD-L1 should not guide clinical decision-making. The utility of this biomarker requires further investigation.

^g Nivolumab/ipilimumab combination therapy is associated with improved overall response rate (ORR), PFS, and OS compared with single-agent ipilimumab, at the expense of significantly increased toxicity in previously untreated patients with unresectable stage III or IV melanoma. While that study was not powered to compare nivolumab plus ipilimumab and nivolumab alone, improved OS with the combination support a meaningful survival benefit of the combination compared with nivolumab monotherapy.

^h Nivolumab/ipilimumab has demonstrated clinically meaningful intracranial activity.

ⁱ Appropriateness of single agent depends on patient fitness/frailty, comorbidities, low-volume disease, autoimmune disease history, and other factors.

^j Positive VE1 IHC results are sufficient for starting targeted therapy in patients who are symptomatic or have rapidly progressing disease. Confirmatory *BRAF* molecular testing is encouraged. [See Principles of Molecular Testing \(ME-C\).](#)

^k [See Management of Toxicities Associated with Targeted Therapy \(ME-J\).](#)

^l In previously untreated patients with unresectable AJCC 7th Edition stage IIIC or stage IV disease, *BRAF*/MEK inhibitor combination therapy was associated with improved response rate, PFS, and OS compared to *BRAF* inhibitor monotherapy.

^m If *BRAF*/MEK inhibitor combination therapy is contraindicated, *BRAF* inhibitor monotherapy is an option, especially in patients who are not appropriate candidates for checkpoint immunotherapy.

ⁿ High-volume symptomatic disease *BRAF*+ patients may benefit from *BRAF*/MEK inhibition, as opposed to combination immunotherapy. Otherwise ipilimumab/nivolumab is preferred first-line over *BRAF*/MEK therapy due to OS benefit.

^o Dosing used in KEYNOTE-029: Pembrolizumab 2 mg/kg IV plus ipilimumab 1 mg/kg IV every 3 weeks (Q3W) for four doses, followed by pembrolizumab 2 mg/kg Q3W for up to 2 years or disease progression, intolerable toxicity, withdrawal of consent, or investigator decision.

^p For patients who experience progression of melanoma during or shortly after adjuvant or first-line therapy, consider second-line agents if not used first line and if from a different class. For patients who progressed on single-agent anti-PD-1 checkpoint immunotherapy, anti-PD-1/ipilimumab or *BRAF*/MEK inhibitor combination therapy or ipilimumab monotherapy are reasonable treatment options. For patients who experience disease control (CR, PR, or SD) and have no residual toxicity, but subsequently experience disease progression/relapse >3 months after treatment discontinuation, re-induction with the same agent or same class of agents may be considered.

^q The combination nivolumab and relatlimab-rmbw is associated with higher progression-free survival (PFS) but more frequent and more severe toxicity than nivolumab alone.

^r High-dose IL-2 should not be used for patients with inadequate organ reserve, poor performance status, or untreated or active brain metastases. For patients with small brain metastases and without significant peritumoral edema, IL-2 therapy may be considered (category 2B). Therapy should be restricted to an institution with medical staff experienced in the administration and management of these regimens.

^s Case reports and preclinical data have suggested that *BRAF* + MEK inhibition may be an option for certain non-V600 *BRAF* mutations, including *BRAF* L597 mutations.

^t In patients who were previously untreated or whose disease progressed despite immunotherapy, binimetinib was associated with a response rate of 15%, and demonstrated a modest improvement in PFS with no improvement in OS compared with single-agent dacarbazine.

^u For patients with confirmed progression or unresectable or metastatic melanoma after treatment with an anti-PD-1-/PD-L1–based therapy, including in combination with anti-CTLA-4 for ≥2 doses.

^v [For cytotoxic therapy recommendations, see \(MELSYS 3 of 7\).](#)

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

References**Continued****MELSYS
1A OF 7**



OTHER SYSTEMIC THERAPIES^b

Cytotoxic Therapy for Metastatic Disease (useful in certain circumstances)

- In general, immunotherapy and targeted therapy are preferred for treatment of unresectable or distant metastatic disease.
- For patients who are not eligible for any of the recommended immunotherapy or targeted therapy options (due to progression on prior therapy, unacceptable toxicity, or comorbidities), cytotoxic therapy can be considered on a case-by-case basis, and is therefore considered useful in certain circumstances.
- The literature is not directive regarding the specific chemotherapeutic agent(s), and none of these regimens offers superior outcomes, or has been shown to improve OS in a randomized phase III trial setting. However, the literature does provide evidence that some patients experience tumor regression (usually temporary) after cytotoxic therapy.
- Cytotoxic agents that have been used alone or in combination include (but are not limited to): dacarbazine, temozolomide, paclitaxel, albumin-bound paclitaxel, carboplatin/paclitaxel, and cisplatin/vinblastine/dacarbazine (CVD) (category 2B for CVD).

^b [See Systemic Therapy Considerations \(ME-I\).](#)

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

[References](#)

[Continued](#)

MELSYS
2 OF 7

**SYSTEMIC THERAPY FOR METASTATIC OR UNRESECTABLE DISEASE**
REFERENCES**Immunotherapy****Pembrolizumab**

- Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. *Lancet Oncol* 2015;16:908-918.
- Hamid O, Puzanov I, Dummer R, et al. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. *Eur J Cancer* 2017;86:37-45.
- Robert C, Schachter J, Long GV, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. *N Engl J Med* 2015;372:2521-2532.
- Schachter J, Ribas A, Long GV, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). *Lancet* 2017;390:1853-1862.
- Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. *Lancet* 2014;384:1109-1117.
- Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. *N Engl J Med* 2013;369:134-144.
- Ribas A, Hamid O, Daud A, et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. *JAMA* 2016;315:1600-1609.
- Hamid O, Robert C, Daud A, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. *Ann Oncol* 2019;30:582-588.
- Kluger HM, Chiang V, Mahajan A, et al. Long-term survival of patients with melanoma with active brain metastases treated with pembrolizumab on a phase II trial. *J Clin Oncol* 2019;37:52-60.

Nivolumab

- Weber JS, D'Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. *Lancet Oncol* 2015;16:375-384.
- Larkin J, Minor D, D'Angelo S, et al. Overall survival in patients with advanced melanoma who received nivolumab versus investigator's choice chemotherapy in CheckMate 037: A randomized, controlled, open-label phase III trial. *J Clin Oncol* 2018;36:383-390.
- Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. *N Engl J Med* 2015;372:320-330.
- Ascierto PA, Long GV, Robert C, et al. Survival outcomes in patients with previously untreated BRAF wild-type advanced melanoma treated with nivolumab therapy: Three-year follow-up of a randomized phase 3 trial. *JAMA Oncol* 2019;5:187-194.

Ipilimumab

- Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. *Lancet Oncol* 2012;13:459-465.
- Weber JS, Kahler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. *J Clin Oncol* 2012;30:2691-2697.
- Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. *N Engl J Med* 2010;363:711-723.
- Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. *N Engl J Med* 2011;364:2517-2526.
- Maio M, Grob JJ, Aamdal S, et al. Five-year survival rates for treatment-naïve patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial. *J Clin Oncol* 2015;33:1191-1196.
- Ascierto PA, Del Vecchio M, Robert C, et al. Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. *Lancet Oncol* 2017;18:611-622.

Note: All recommendations are category 2A unless otherwise indicated.**Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.**[Continued](#)

**SYSTEMIC THERAPY FOR METASTATIC OR UNRESECTABLE DISEASE**
REFERENCES**Immunotherapy (continued)****Nivolumab/Ipilimumab**

- Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. *N Engl J Med* 2015;373:23-34.
- Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. *N Engl J Med* 2017;377:1345-1356.
- Hodi FS, Chiarion-Sileni V, Gonzalez R, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. *Lancet Oncol* 2018;19:1480-1492.
- Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. *N Engl J Med* 2019;381:1535-1546.
- Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. *N Engl J Med* 2015;372:2006-2017.
- Hodi FS, Chesney J, Pavlick AC, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. *Lancet Oncol* 2016;17:1558-1568.
- Long GV, Atkinson V, Lo S, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. *Lancet Oncol* 2018;19:672-681.
- Tawbi HA, Forsyth PA, Hodi FS, et al. Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. *Lancet Oncol* 2021;22:1692-1704.
- Wolchok, JT, Chiarion-Sileni V, Gonzalez R, et al. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. *J Clin Oncol* 2022;40:127-137.

Pembrolizumab/Low-dose ipilimumab

- Carlino MS, Menzies AM, Atkinson V, et al. Long-term follow-up of standard-dose pembrolizumab plus reduced-dose ipilimumab in patients with advanced melanoma: KEYNOTE-029 Part 1B. *Clin Cancer Res* 2020;26:5086-5091.
- Olson D, Luke JJ, Poklepovic AS, et al. Significant antitumor activity for low-dose ipilimumab (IPI) with pembrolizumab (PEMBRO) immediately following progression on PD1 Ab in melanoma (MEL) in a phase II trial. *J Clin Oncol* 2020;38(15_suppl): Abstract 10004.

Ipilimumab/intralesional T-VEC

- Chesney J, Puzanov I, Collichio F, et al. Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma. *J Clin Oncol* 2018;10;36:1658-1667.

Nivolumab and relatlimab-rmbw fixed-dose

- Tawbi HA, Schadendorf D, Lipson EJ, et al. Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma. *N Engl J Med*. 2022;386:24-34.

Note: All recommendations are category 2A unless otherwise indicated.**Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.**[Continued](#)**MELSYS**
4 OF 7

**OTHER SYSTEMIC THERAPIES
REFERENCES****Targeted Therapy (combination therapy)****Dabrafenib/Trametinib**

- Long GV, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. *Lancet* 2015;386:444-451.
- Long GV, Flaherty KT, Stroyakovskiy D, et al. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. *Ann Oncol* 2017;28:1631-1639.
- Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. *N Engl J Med* 2015;372:30-39.
- Davies MA, Saiag P, Robert C, et al. Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. *Lancet Oncol* 2017;18:863-873.

Vemurafenib/Cobimetinib

- Larkin J, Ascierto PA, Dreno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. *N Engl J Med* 2014;371:1867-1876.
- Ascierto PA, McArthur GA, Dreno B, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. *Lancet Oncol* 2016;17:1248-1260.
- Ribas A, Gonzalez R, Pavlick A, et al. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. *Lancet Oncol* 2014;15:954-965.
- Daud A, Weber JS, Sosman JA, et al. Updated overall survival (OS) results for BRF113220, a phase I-II study of dabrafenib alone versus combined dabrafenib and trametinib in patients with BRAF V600 metastatic melanoma (MM). *ASCO Meeting Abstracts* 2015;33:9036.

Vemurafenib/Cobimetinib + Atezolizumab

- Gutzmer R, Stroyakovskiy D, Gogas H, et al. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF V600 mutation-positive melanoma (IMspire150): primary analysis of the randomized, double-blind, placebo-controlled, phase 3 trial. *Lancet* 2020;395:1835-1844.
- Ascierto PA, Robert C, Lewis KD, et al. Time to central nervous system (CNS) metastases (mets) with atezolizumab (A) or placebo (P) combined with cobimetinib (C) + vemurafenib (V) in the phase III IMspire150 study. *J Clin Oncol* 2020;38(15_suppl):Abstract 10023.

Encorafenib/Binimetinib

- Dummer R, Ascierto PA, Gogas HJ, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. *Lancet Oncol* 2018;19:603-615.
- Dummer R, Ascierto PA, Gogas HJ, et al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol* 2018;19:1315-1327.

Pembrolizumab/Lenvatinib

- Arance A, de la Cruz Merino L, Petrella T, et al. Lenvatinib plus pembrolizumab for patients with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor: Updated findings of LEAP-004. Presented at: American Society of Clinical Oncology (ASCO) June 4-8 2021 Virtual Meeting.

Note: All recommendations are category 2A unless otherwise indicated.**Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.**[Continued](#)**MELSYS
5 OF 7**

**OTHER SYSTEMIC THERAPIES - REFERENCES****Targeted Therapy (single-agent therapy)****Vemurafenib**

- Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. *N Engl J Med* 2012;366:707-714.
- McArthur GA, Chapman PB, Robert C, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. *Lancet Oncol* 2014;15:323-332.
- Chapman PB, Robert C, Larkin J, et al. Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. *Ann Oncol* 2017;28:2581-2587.
- McArthur GA, Maio M, Arance A, et al. Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study. *Ann Oncol* 2017;28:634-641.

Dabrafenib

- Long GV, Trefzer U, Davies MA, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. *Lancet Oncol* 2012;13:1087-1095.
- Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. *Lancet* 2012;380:358-365.

Imatinib for tumors with activating mutations of *KIT*

- Hodi FS, Corless CL, Giobbie-Hurder A, et al. Imatinib for melanomas harboring mutationally activated or amplified *KIT* arising on mucosal, acral, and chronically sun-damaged skin. *J Clin Oncol* 2013;31:3182-3190.
- Carvajal RD, Antonescu CR, Wolchok, JD, et al. *KIT* as a therapeutic target in metastatic melanoma. *JAMA* 2011;395:2327-2334.

Larotrectinib for *NTRK* gene fusion-positive tumors

- Drilon A, Laetsch TW, Kummar W, et al. Efficacy of larotrectinib in *TRK* fusion-positive cancers in adults and children. *N Engl J Med* 2018;378:731-739.

Entrectinib for *NTRK* gene fusion-positive tumors

- Drilon A, Siena S, Ou SI, et al. Safety and antitumor activity of the multitargeted Pan-*TRK*, *ROS1*, and *ALK* inhibitor entrectinib: Combined results from two phase I trials (ALKA-372-001 and STARTRK-1). *Cancer Discov* 2017;7:400-409.
- Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic *NTRK* fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. *Lancet Oncol* 2020;21:271-282.

Binimetinib for *NRAS*-mutated tumors

- Dummer R, Schadendorf D, Ascierto PA, et al. Binimetinib versus dacarbazine in patients with advanced *NRAS*-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol* 2017;18:435-445.

High-dose *IL-2*

- Buchbinder EI, Dutcher JP, Daniels GA, et al. Therapy with high-dose Interleukin-2 (HD *IL-2*) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition. *J Immunother Cancer* 2019;7:49.
- Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. *JAMA* 1994;271:907-913.
- Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. *J Clin Oncol* 1999;17:2105-2116.
- Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. *Cancer J Sci Am* 2000;6 Suppl 1:S11-14.
- Smith FO, Downey SG, Klapper JA, et al. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. *Clin Cancer Res* 2008;14:5610-5618.

Note: All recommendations are category 2A unless otherwise indicated.**Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.**[Continued](#)

**OTHER SYSTEMIC THERAPIES - REFERENCES****Cytotoxic Regimens for Metastatic Disease****Dacarbazine**

- Serrone L, Zeuli M, Sega FM, et al. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. *J Exp Clin Cancer Res* 2000;19:21-34.

Temozolomide

- Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. *J Clin Oncol* 2000;18:158-166.

Paclitaxel

- Wiernik PH and Einzig AI. Taxol in malignant melanoma. *J Natl Cancer Inst Monogr* 1993;15:185-187.

Albumin-bound paclitaxel

- Hersh EM, O'Day SJ, Ribas A, et al. A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naïve patients with metastatic melanoma. *Cancer* 2010;116:155-163.
- Kottschade LA, Suman VJ, Amatruda T, et al. A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage iv melanoma: a north central cancer treatment group study, N057E(1). *Cancer* 2011;117:1704-1710.

Paclitaxel/carboplatin

- Rao RD, Holtan SG, Ingle JN, et al. Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma. *Cancer* 2006;106:375-382.
- Agarwala SS, Keilholz U, Hogg D, et al. Randomized phase III study of paclitaxel plus carboplatin with or without sorafenib as second-line treatment in patients with advanced melanoma. *J Clin Oncol* 2007;25(18_suppl):Abstract 8510.
- Hauschild A, Agarwala SS, Trefzer U, et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. *J Clin Oncol* 2009;27:2823-2830.
- Flaherty KT, Lee SJ, Schuchter LM, et al. Final results of E2603: A double-blind, randomized phase III trial comparing carboplatin (C)/paclitaxel (P) with or without sorafenib (S) in metastatic melanoma. *J Clin Oncol* 2010;28(15_suppl):Abstract 8511.

Cisplatin/vinblastine/dacarbazine (CVD)

- Bajetta E, Del Vecchio M, Nova P, et al. Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanoma. *Ann Oncol* 2006;17:571-577.
- Legha SS, Ring S, Bedikian A, et al. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. *Ann Oncol* 1996;7:827-835.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

**RISK FACTORS FOR DEVELOPMENT OF SINGLE OR MULTIPLE PRIMARY MELANOMAS^a**

- **Male sex¹**
- **>50 years**
- **Phenotypic predisposition**
 - ▶ **Atypical moles/dysplastic nevi²**
 - ▶ **Increased mole count (particularly large nevi)³**
 - ▶ **Sun-phenotype/tendency to sunburn³**
 - ▶ **Red hair-blue eyes/Fitzpatrick skin type I/pheomelanin-predominant phenotype³**
- **Personal medical history/comorbidities**
 - ▶ **Multiple and/or blistering sunburns^{3,4}**
 - ▶ **Precancer/cancers,^{5,6} especially:**
 - ◇ **Actinic keratosis/non-melanoma (keratinocyte) skin cancer (eg, basal cell and squamous cell carcinomas)³**
 - ◇ **Childhood cancer⁷**
 - ▶ **Immunosuppression/immune perturbation related to:**
 - ◇ **Solid organ transplantation^{3,8,9}**
 - ◇ **Hematopoietic cell transplantation (HCT)⁹**
 - ◇ **Human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS)¹⁰**
 - ▶ **Rare genodermatoses**
 - ◇ **Xeroderma pigmentosum¹¹**
- **Genetic predisposition**
 - ▶ **Presence of germline mutations or polymorphisms predisposing to melanoma (eg, *CDKN2a*, *CDK4*, *MC1R*, *BAP1* [especially for uveal melanoma], *TERT*, *MITF*, *PTEN*, and potential other genes).^{3,12-14}**
 - ▶ **Family history of cutaneous melanoma (especially if multiple); pancreatic, renal, and/or breast cancer; astrocytoma; uveal melanoma; and/or mesothelioma.^{3,15}**
 - ▶ **Also see [NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal](#) and [NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic](#)**
- **Environmental factors**
 - ▶ **Tanning bed use^{3,16,17}**
 - ▶ **Residence in sunnier climate/latitude nearer to equator¹⁸**
 - ▶ **Intermittent, intense sun exposure (for truncal/extremity melanomas)³**
 - ▶ **Chronic sun exposure (for head/neck/arm melanomas)**

^a Risk factors for development of single or multiple primary melanomas, including subsequent primaries after index diagnosis. This list does not include risk factors for melanoma recurrence or progression, as those are covered elsewhere in the algorithm.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

[References](#)

ME-A
1 OF 2



RISK FACTORS FOR DEVELOPMENT OF SINGLE OR MULTIPLE PRIMARY MELANOMAS

REFERENCES

- ¹ Siegel RL, Miller KD, Fuchs BS, et al. Cancer Statistics, 2021. *CA Cancer J Clin* 2021;71:7-33.
- ² Rigel DS, Rivers JK, Kopf AW, et al. Dysplastic nevi. Markers for increased risk for melanoma. *Cancer* 1989;63:386-389.
- ³ Chen ST, Geller AC, Tsao H. Update on the epidemiology of melanoma. *Curr Dermatol Rep* 2013;2:24-34.
- ⁴ Wu S, Han J, Laden F, Qureshi AA. Long-term ultraviolet flux, other potential risk factors, and skin cancer risk: a cohort study. *Cancer Epidemiol Biomarkers Prev* 2014;23:1080-1089.
- ⁵ Lam CJ, Curtis RE, Dores GM, et al. Risk factors for melanoma among survivors of non-Hodgkin lymphoma. *J Clin Oncol* 2015;33:3096-3104.
- ⁶ Olsen CM, Lane SW, Green AC. Increased risk of melanoma in patients with chronic lymphocytic leukaemia: systematic review and meta-analysis of cohort studies. *Melanoma Res* 2016;26:188-194.
- ⁷ Pappo AS, Armstrong GT, Liu W, et al. Melanoma as a subsequent neoplasm in adult survivors of childhood cancer: a report from the childhood cancer survivor study. *Pediatr Blood Cancer* 2013;60:461-466.
- ⁸ Robbins HA, Clarke CA, Arron ST, et al. Melanoma risk and survival among organ transplant recipients. *J Invest Dermatol* 2015;135:2657-2665.
- ⁹ Omland SH, Gniadecki R, Haedersdal M, et al. Skin cancer risk in hematopoietic stem-cell transplant recipients compared with background population and renal transplant recipients: a population-based cohort study. *JAMA Dermatol* 2015:1-7.
- ¹⁰ Olsen CM, Knight LL, Green AC. Risk of melanoma in people with HIV/AIDS in the pre- and post-HAART eras: a systematic review and meta-analysis of cohort studies. *PLoS One* 2014;9:e95096.
- ¹¹ Kraemer KH, Lee MM, Scotto J. Xeroderma pigmentosum. Cutaneous, ocular, and neurologic abnormalities in 830 published cases. *Arch Dermatol* 1987;123:241-250.
- ¹² Bubien V, Bonnet F, Brouste V, et al. High cumulative risks of cancer in patients with PTEN hamartoma tumour syndrome. *J Med Genet* 2013;50:255-263.
- ¹³ Tan MH, Mester JL, Ngeow J, et al. Lifetime cancer risks in individuals with germline PTEN mutations. *Clin Cancer Res* 2012;18:400-407.
- ¹⁴ Leachman SA, Lucero OM, Sampson JE, et al. Identification, genetic testing, and management of hereditary melanoma. *Cancer Metastasis Rev* 2017;36:77-90.
- ¹⁵ Chen T, Hemminki K, Kharazmi E, et al. Multiple primary (even in situ) melanomas in a patient pose significant risk to family members. *Eur J Cancer* 2014;50:2659-2667.
- ¹⁶ Lazovich D, Vogel RI, Berwick M, et al. Indoor tanning and risk of melanoma: a case-control study in a highly exposed population. *Cancer Epidemiol Biomarkers Prev* 2010;19:1557-1568.
- ¹⁷ Cust AE, Armstrong BK, Goumas C, et al. Sunbed use during adolescence and early adulthood is associated with increased risk of early-onset melanoma. *Int J Cancer* 2011;128:2425-2435.
- ¹⁸ Richards TB, Johnson CJ, Tatalovich Z, et al. Association between cutaneous melanoma incidence rates among white US residents and county-level estimates of solar ultraviolet exposure. *J Am Acad Dermatol* 2011;65:S50-57.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



PRINCIPLES OF BIOPSY OF A SUSPICIOUS PIGMENTED LESION¹

- **Excisional/complete biopsy (elliptical, punch, or saucerization/deep shave removal) with 1- to 3-mm margins is preferred. Avoid wider margins to permit accurate subsequent lymphatic mapping.**
- **The orientation of an elliptical/fusiform excisional biopsy should be planned with definitive wide local excision in mind (eg, longitudinally [axially] and parallel to the underlying lymphatics on the extremities).**
- **Full-thickness incisional or punch biopsy of clinically thickest or most atypical portion of lesion is acceptable and may be preferred in certain anatomic areas (eg, palm/sole, digit, face, ear) or for very large lesions. Multiple "scouting" biopsies may help guide management for very large lesions. Superficial/tangential shave biopsy may compromise pathologic diagnosis and complete assessment of Breslow thickness, but is acceptable when the index of suspicion is low. However, a broad shave biopsy may be optimal for histologic assessment for melanoma in situ (MIS), lentigo maligna (LM) type (ie, melanoma on skin with high cumulative sun damage [CSD]).**
- **Appropriate biopsy of the nail matrix should be performed for suspected subungual melanoma and requires expertise in biopsy of the nail apparatus.**
- **Repeat narrow-margin excisional biopsy is recommended if an initial partial biopsy is inadequate for diagnosis or microstaging but should not be performed if the initial specimen meets criteria for SLNB.**

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued](#)

**ME-B
1 OF 3**



PRINCIPLES OF PATHOLOGY FOR PRIMARY MELANOMA^{a,b,1-5}

- The biopsy should be reported by a pathologist experienced in melanocytic neoplasms. Appropriate immunohistochemical stains may aid in histopathologic diagnosis.
- Consider the use of molecular testing for histologically equivocal lesions, as well as expert dermatopathology review.^c
- Minimal elements to be reported should include factors that inform pathologic T stage: Breslow thickness (reported to the nearest 0.1 mm), ulceration (present or absent).
- Microsatellites should be reported if observed on either initial biopsy or subsequent wide excision.^{d,e}
- Margin status should be reported on all biopsies and excisions.^f
- Synoptic reporting containing the following information is strongly recommended for optimal patient care:¹
 - ▶ Presence of macroscopic satellite lesions in the gross tumor specimen, if clinically evident.
 - ▶ Dermal mitotic rate per mm² ^g
 - ▶ Lymphovascular/angiolymphatic invasion^e
 - ▶ Histologic subtype (if desmoplastic, specify pure or mixed^h)
 - ◊ Notation of LM/high CSD subtype may affect surgical or other treatment approaches.
 - ▶ Regression (if extensive [$>75\%$] or extending beneath measured Breslow thickness)
 - ▶ Neurotropism (including peri-tumoral or intratumoral)/perineural invasionⁱ
- If there is a residual invasive melanoma in the wide excision specimen, the pathologist should incorporate elements of the initial biopsy and wide excision (ie, thickest tumor depth, ulceration) to arrive at a final pathologic T stage.

[See Footnotes on ME-B \(2A of 3\)](#)

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

[References](#)

**FOOTNOTES FOR [ME-B \(2 OF 3\)](#)**

- ^a International Collaboration on Cancer Reporting (ICCR, 11/2019) core histopathologic elements for biopsy and wide excision specimens include: macroscopic satellites (in the gross specimen), surgical margin/tissue edges (involved/uninvolved), Breslow thickness, ulceration, mitotic count, microsatellites, lymphovascular invasion, neurotropism, and desmoplastic melanoma component (“pure” [$>90\%$ desmoplastic] vs. “mixed” [desmoplastic/nondesmoplastic]).²
- ^b College of American Pathologists (CAP, 04/2020) histopathologic elements required for accreditation purposes in the wide excision specimen include: macroscopic satellite nodules, histologic subtype, thickness, ulceration, microsatellites, margins (deep/peripheral - positive or negative for invasive or in situ melanoma), mitotic rate, lymphovascular invasion, neurotropism, and regression.⁵
- ^c [See Principles of Molecular Testing \(ME-C\)](#).
- ^d Microsatellitosis represents microscopically identified lymphatic metastasis and confers an increased risk of recurrence. Microsatellites are found discontinuous from the primary tumor (adjacent or deep). The AJCC Cancer Staging Manual, Eighth Edition (2017)³ does not define microsatellitosis according to tumor nest dimension or distance from the primary tumor. It classifies cases with microsatellites, clinical satellites, or in-transit metastases as N1c, N2c, or N3c based on the number of tumor-involved regional lymph nodes (0, 1, or ≥ 2 , respectively).
- ^e At times it may be difficult to distinguish whether invasive melanoma is present within a lymphatic channel or represents a microsatellite. In this instance, the use of IHC for a specific lymphatic marker such as D2–40 may assist in differentiating lymphovascular invasion from microsatellites.
- ^f For histologically positive margins on the biopsy or wide excision specimen, describe whether in situ or invasive melanoma is present at the peripheral and/or deep margins. For histologically negative margins on the wide excision specimen, ICCR and CAP guidelines do not require reporting the microscopically measured distances between tumor and labeled lateral or deep margins, and this measurement should not generally impact clinical decision-making.^{2,5}
- ^g Dermal mitotic rate should be determined using the “hot spot” technique and expressed as number of mitoses per square millimeter. Although dermal mitotic rate is no longer included in the determination of T1 staging in the AJCC Cancer Staging Manual, Eighth Edition (2017),³ it remains an important prognostic factor across all thickness categories and should be included in the pathology assessment of melanoma biopsies and surgical excisions.
- ^h In patients with pure desmoplastic melanoma ($>90\%$ of invasive melanoma associated with prominent stromal fibrosis), SLN positivity is less common compared to mixed desmoplastic/nondesmoplastic and conventional melanoma subtypes. Variability across studies in the rate of SLN positivity in desmoplastic melanoma may be due to lack of standardized criteria for defining pure desmoplastic melanoma, histopathologic reproducibility, and/or reporting. In the setting of these conflicting reports, the role of SLNB in patients with pure desmoplastic melanoma remains controversial.
- ⁱ Pathology reporting of extensive versus focal neurotropism (ie, involving only a single nerve vs. multiple nerves and/or size of involved nerves) may help guide clinical decision-making.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



REFERENCES FOR PRINCIPLES OF PATHOLOGY FOR PRIMARY MELANOMA

- ¹ Swetter SM, Tsao H, Bichakjian CK, et al. Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol 2019;80:208-250.
- ² Scolyer R, Balamurgan T, Busam K, et al. Invasive Melanoma, Histopathology Reporting Guide, 2nd Edition. Sydney, Australia: International Collaboration on Cancer Reporting; 2019. Available at: <http://www.iccr-cancer.org/datasets/published-datasets/skin/invasive-melanoma>.
- ³ Amin MB, Edge S, Greene F, et al., eds. AJCC Cancer Staging Manual (ed 8th). New York: Springer International Publishing; 2017.
- ⁴ Shon W, Frishberg DP, Gershenwald J, et al. Protocol for the examination of biopsy specimens from patients with melanoma of the skin, version 4.2.0.0. College of American Pathologists (CAP) 2019. Available at: <https://documents.cap.org/protocols/cp-skin-melanoma-biopsy-20-4200.pdf>.
- ⁵ Shon W, Frishberg DP, Gershenwald J, et al. Protocol for the examination of excision specimens from patients with melanoma of the skin, version 4.2.0.0. College of American Pathologists (CAP) 2020. Available at: <https://documents.cap.org/protocols/cp-skin-melanoma-excision-20-4200.pdf>.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

**PRINCIPLES OF MOLECULAR TESTING****Molecular Technologies for Cutaneous Melanoma Diagnosis and Prognostication**

- **Diagnostic testing for indeterminate melanocytic neoplasms following histopathology**
 - ▶ Melanocytic neoplasms of uncertain biologic potential present a unique challenge to pathologists and treating clinicians. Ancillary tests to differentiate benign from malignant melanocytic neoplasms include immunohistochemistry (IHC) and molecular testing via comparative genomic hybridization (CGH), fluorescence in situ hybridization (FISH), gene expression profiling (GEP), single-nucleotide polymorphism (SNP) array, and next-generation sequencing (NGS). These tests may facilitate a more definitive diagnosis and guide therapy in cases that are diagnostically uncertain or controversial by histopathology. Ancillary tests should be used as adjuncts to clinical and expert dermatopathologic examination and therefore be interpreted within the context of these findings.¹⁻³
- **Prognostic testing**
 - ▶ Despite commercially available GEP tests being marketed to risk stratify cutaneous melanomas,⁴⁻¹¹ current GEP platforms do not provide clinically actionable prognostic information when combined or compared with known clinicopathologic factors (eg, sex, age, primary tumor location, thickness, ulceration, mitotic rate, lymphovascular invasion, microsatellites, and/or SLNB status) or multivariable nomograms/risk calculators.¹²⁻¹⁴ Furthermore, the clinical utility of these tests to inform treatment recommendations and predict patient outcomes has not been established.
 - ▶ Various studies of prognostic GEP tests suggest their role as an independent predictor of worse outcome. However, GEP is not superior to Breslow thickness, ulceration, or SLN status and it remains unclear whether available GEP tests are reliably predictive of outcome across the risk spectrum of cutaneous melanoma.^{9,14-20} Validation studies on prospectively collected, independent cohorts (similar to those performed in breast cancer) are necessary to define the clinical utility of molecular prognostic GEP testing as an adjunct to AJCC staging or as part of the multidisciplinary decision-making process to guide surveillance imaging, SLNB, and adjuvant therapy.²¹
 - ▶ Existing and emerging GEP tests and other molecular techniques (ie, circulating tumor DNA tests) should be prospectively compared to determine their clinical utility, including with no-cost, contemporary, multivariable SLNB risk prediction models (eg, [melanomarisks.org.au](https://www.melanomarisks.org.au) or https://www.mskcc.org/nomograms/melanoma/sentinel_lymph_node_metastasis).²²⁻³⁰
- **Somatic mutation testing**
 - ▶ A number of somatic genetic alterations have been identified in cutaneous melanoma, a few of which are targetable driver mutations that have proven useful to guide treatment decisions and/or clinical trial eligibility.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

Continued

ME-C
1 OF 8

**PRINCIPLES OF MOLECULAR TESTING****Molecular Technologies for Cutaneous Melanoma Diagnosis and Prognostication** (continued)• **Specific mutations (*BRAF*, *NRAS*, *KIT*) and implications**▶ ***BRAF* (B-Raf proto-oncogene) mutations:**

- ◇ ***BRAF* is a serine threonine kinase that activates the mitogen-activated kinase pathway. Mutations in this gene lead to unrestrained cell growth and proliferation.**
- ◇ **Some clinical features are associated with a higher frequency of *BRAF* mutations (eg, intermittent sun-exposed skin, younger age, trunk location), but these should not be used either as a proxy for these mutations or to decide testing.³¹**
- ◇ ***BRAF* mutations are most commonly found in the 600th codon (V600), most frequently V600E (80%) but also including V600K (15%) and V600R/M/D/G (5%).³²**
 - ***BRAF* V600 mutations are associated with sensitivity to *BRAF* inhibitors. Available evidence suggests that *BRAF* inhibitors should not be used in patients without activating mutations in *BRAF*.³³**
 - ***BRAF* V600 mutations are also associated with sensitivity to MEK inhibitors.³⁴**
 - **Clinical trials have shown that the combination of *BRAF* and MEK inhibitors are superior to either agent alone in patients with *BRAF* V600 mutations.³⁵**
 - **Extensive clinical trial data have shown that compared with *BRAF* V600E, patients with *BRAF* V600K-mutated metastatic melanoma may have slightly lower response/benefit when treated with *BRAF* ± MEK inhibitors. Less frequent mutations affecting codon 600 (including V600R/M/D/G) also may benefit from these therapies.^{36,37}**
- ◇ ***BRAF* mutations outside of the 600th codon (*BRAF* non-V600 mutations) and *BRAF* fusions are also found in approximately 5% of melanomas.**
 - **Mutations in codons near V600 in exon 15 (specifically *BRAF* L597 and *BRAF* K601) have shown response to MEK inhibitors and *BRAF* and MEK inhibitor combinations.^{38,39}**
 - **Fusions in *BRAF* have also shown responses to MEK inhibitors and non-specific RAF inhibitors (eg, sorafenib).^{40,41}**
 - **Mutations in other codons in exon 11 or exon 15 have not demonstrated response to either *BRAF* or MEK inhibitors.**

▶ ***KIT* (proto-oncogene c-*KIT*) mutations**

- ◇ ***KIT* is a receptor tyrosine kinase that promotes cell growth and proliferation.**
- ◇ ***KIT* mutations are present in 10%–15% of melanomas of mucosal (most frequently vulvovaginal primaries, but also anorectal and sinonasal) and acral (ie, non–hair-bearing surfaces of palms and soles, nailbeds) origin. They are also present on 2%–3% of chronically sun-exposed skin, but extremely rarely on skin with intermittent sun exposure. Thus, clinical features can guide the decision whether to perform *KIT* mutation testing.⁴²**
- ◇ ***KIT* mutations may occur in multiple “hotspots” across the gene and differ in their sensitivity to *KIT* inhibitor therapy (eg, imatinib, sunitinib, nilotinib).⁴³⁻⁴⁶**
 - ***KIT* exon 11 and exon 13 mutations (eg, W557R, V559D, L576P, K642E) appear to have a high level of sensitivity to *KIT* inhibition.**
 - ***KIT* exon 17 mutations (eg, D816H) appear to have minimal or no sensitivity to *KIT* inhibitors.**
 - ***KIT* amplifications appear to have minimal or no sensitivity to *KIT* inhibitors.**

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

Continued

ME-C
2 OF 8

**PRINCIPLES OF MOLECULAR TESTING****Molecular Technologies for Cutaneous Melanoma Diagnosis and Prognostication (continued)**

- **Specific mutations (*BRAF*, *NRAS*, *KIT*) and implications (continued)**
 - ▶ ***NRAS* (*NRAS* proto-oncogene) mutations**
 - ◊ ***NRAS* is a GTPase that activates mitogen-activated protein kinase signaling and other signaling pathways, leading to cell growth and proliferation.⁴⁷**
 - ◊ ***NRAS* mutations appear to correlate with poor survival in localized and advanced melanoma.⁴⁸**
 - ◊ ***NRAS* mutations are present in approximately 15% of melanomas in skin with chronic and intermittent sun exposure, acral surfaces, and mucosal surfaces.³¹**
 - ◊ **MEK inhibitors may produce responses in a minority of patients with *NRAS* mutations.⁴⁹**
 - ◊ **Given the low probability of overlapping targetable mutations (including *BRAF* and *KIT* mutations), the presence of an *NRAS* mutation may identify patients who will not benefit from additional molecular testing.**
- **Other uncommon genetic drivers detected by NGS panel**
 - ▶ **Fusions in *NTRK1*, *NTRK2*, and *NTRK3* occur uncommonly (<1%) across subtypes of melanoma.⁵⁰**
 - ▶ **Fusions in *ALK* and *ROS1*, more common in lung cancer, occur uncommonly (<1% incidence) across subtypes of melanoma.⁵¹**
 - ▶ **Fusion-directed therapy for *NTRK*, *ROS1*, *ALK*, or *BRAF* fusions**
 - ◊ **Case reports or limited clinical trial data have suggested activity (larotrectinib or entrectinib for *NTRK* fusions, crizotinib or entrectinib for *ROS1* fusions, or trametinib for *BRAF* fusions, and crizotinib for *ALK* fusions.)^{52,53}**
- **Methods of mutation testing**
 - ▶ **IHC is a technique to selectively visualize antigens (proteins) in tissue section by using antibodies that bind to those specific antigens. IHC may be used to screen for both *BRAF* V600E and c-KIT. This is an indirect test that detects the mutated protein.**
 - ◊ ***BRAF* VE1 (V600E) IHC test may be used as a rapid screening test for assessment of *BRAF* status in melanoma and for potential start of *BRAF* inhibitor treatment regimen. The sensitivity and specificity of the VE1 antibody are reported at 89.2% and 96.2%, respectively, with the positive and negative predictive values at 97.1% and 86.2%, respectively. Confirmatory *BRAF* molecular testing is encouraged, particularly in the setting of a negative IHC result.^{54,55}**
 - ◊ **Due to the wide range of different *KIT* mutations and lack of widespread use of *KIT* IHC testing, confirmatory c-KIT molecular testing is encouraged to avoid false positives or negatives.⁵⁶**
 - ▶ **NGS, also known as high-throughput sequencing, describes a number of different sequencing technologies that allow sequencing of DNA and RNA much more quickly and cheaply than the previously used Sanger sequencing. Single-gene or small multigene panels are also used in some cases to test either one gene (*BRAF*) or a limited number of genes.**
 - ◊ **Molecular testing may be performed on tumor tissue, or if not available, on peripheral blood (liquid biopsy). Given the possibility of a false negative, a negative liquid biopsy should prompt tissue testing.**

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

Continued

ME-C
3 OF 8

**PRINCIPLES OF MOLECULAR TESTING****Molecular Technologies for Cutaneous Melanoma Diagnosis and Prognostication** (continued)• **Indications for genetic testing**

- ▶ The panel does not recommend *BRAF* or NGS testing for resected stage I–II cutaneous melanoma unless it will inform clinical trial participation.
- ▶ *BRAF* mutation testing is recommended for patients with stage III at high risk for recurrence for whom future *BRAF*-directed therapy may be an option.
- ▶ For initial presentation with stage IV disease or clinical recurrence, obtain tissue to ascertain alterations in *BRAF*, and in the appropriate clinical setting, *KIT* from either biopsy of the metastasis (preferred) or archival material if the patient is being considered for targeted therapy. Broader genomic profiling (eg, larger NGS panels, *BRAF* non-V600 mutations) is recommended if feasible, especially if the test results might guide future treatment decisions or eligibility for participation in a clinical trial.
- ▶ If *BRAF* single-gene testing was the initial test performed, and is negative, clinicians should strongly consider larger NGS panels to identify other potential genetic targets (eg, *KIT*, *BRAF* non-V600).

• **Biomarkers with potential utility for immune therapy**▶ **PD-L1 (Programmed Death-Ligand 1)**

- ◊ The utility of this biomarker requires further investigation.
- ◊ PD-L1 is a co-regulatory molecule that can be expressed by tumor cells and tumor-infiltrating macrophages, and inhibit T-cell–mediated anti-tumor responses. PD-1, a receptor on T cells, binds to PD-L1, thus inhibiting T-cell activation.⁵⁷
- ◊ IHC for PD-L1 may help identify patients more likely to respond to immune checkpoint inhibitors.
 - Various antibody clones have been developed for IHC analysis of PD-L1 expression, and while several have shown relative equivalence, others have not.
 - Interpretation of PD-L1 IHC is typically focused on the proportion of tumor cells expressing membranous staining at any level and therefore is a continuous variable.
 - The threshold to define a clinically relevant elevated level of PD-L1 expression is dependent on the antibody and platform deployed, which may be unique to each checkpoint inhibitor therapy. The existence of multiple different assays for PD-L1 has raised concern among both pathologists and oncologists.⁵⁸
 - High PD-L1 expression (>5%) may be a marker for equivalent outcomes with nivolumab monotherapy versus combination ipilimumab and nivolumab in patients with unresectable or metastatic melanoma. Low PD-L1 expression may be a marker for worse outcome with nivolumab monotherapy compared to ipilimumab/nivolumab combination. Even in these scenarios (ie, very high or very low PD-L1 expression), the routine use of PD-L1 expression for treatment decisions is not recommended.⁵⁹
 - Testing for tumor PD-L1 should not guide clinical decision-making.⁵⁹

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

Continued**ME-C**
4 OF 8

**PRINCIPLES OF MOLECULAR TESTING****Molecular Technologies for Cutaneous Melanoma Diagnosis and Prognostication** (continued)• **Biomarkers with potential utility for immune therapy** (continued)▶ **Somatic mutation burden**

- ◊ The total number of mutations present in a tumor (mutation burden) appears to correlate with response to immune checkpoint inhibitors (both with combination ipilimumab and nivolumab, and single-agent anti-PD-1 agents) in melanoma and other cancers^{60,61}
- ◊ The mechanism of this effect may relate to increasing numbers of mutations producing increasing neoantigens, proteins that appear foreign to the immune system.⁶²
- ◊ While whole-exome sequencing is the only way to definitively quantify mutation burden, studies have shown that mutation burden assessed by targeted NGS strongly correlates with results from whole-exome sequencing assays, and shows similar correlation with immune checkpoint inhibitor responses.⁶³⁻⁶⁵
- ◊ The use of mutation burden to guide treatment decisions remains investigational at this time.

• **Reasons for retesting metastatic tissue**

- ▶ *BRAF* and *KIT* mutations appear to be early genetic driver events in melanoma.⁶⁶ Repeat molecular testing upon recurrence or metastasis is likely to be of low yield, unless new or more comprehensive testing methods are used or a larger, more representative sample is available if there is concern for sampling error.
- ▶ Repeat testing following progression on targeted therapy (*BRAF*- or *KIT*-directed therapy) does not appear to have clinical utility, since the mechanisms of resistance are diverse and do not have prognostic or therapeutic relevance.⁶⁷
- ▶ While the V600E mutation is the most common *BRAF* mutation, other *BRAF* mutations exist that may respond equally well to *BRAF* inhibitors. Some tests have lower sensitivity/specificity or detect only particular mutations. If needed for clinical care, repeat testing using a different methodology may be warranted to detect non-V600E *BRAF* mutations, or other mutations in different genes. If the initially submitted tissue was of poor quality, a new biopsy may be required before repeat testing is ordered.

• **Molecular testing requirements**

- ▶ Use of a properly accredited laboratory (CLIA or CAP)
- ▶ Understanding which types of samples (fresh, fresh frozen, formalin-fixed paraffin-embedded) are needed for different test methodologies and are accepted by the testing laboratory
- ▶ Understanding the methodologies used and their limitations
- ▶ Understanding for each specific method the spectrum of alterations that can and cannot be tested
- ▶ Understanding whether the tumor sample was histologically reviewed and representatively sampled

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

Continued**ME-C**
5 OF 8

**PRINCIPLES OF MOLECULAR TESTING (REFERENCES)**

- 1 Emanuel PO, Andea AA, Vidal CI, et al. Evidence behind the use of molecular tests in melanocytic lesions and practice patterns of these tests by dermatopathologists. *J Cutan Pathol* 2018;45:839-846.
- 2 Vidal CI, Armbrect EA, Andea AA, et al. Appropriate use criteria in dermatopathology: Initial recommendations from the American Society of Dermatopathology. *J Cutan Pathol* 2018;45:563-580.
- 3 Alomari AK, Miedema JR, Carter MD, et al. DNA copy number changes correlate with clinical behavior in melanocytic neoplasms: proposal of an algorithmic approach. *Mod Pathol* 2020;33:1307-1317.
- 4 Eggermont AMM, Bellomo D, Arias-Mejias SM, et al. Identification of stage I/IIA melanoma patients at high risk for disease relapse using a clinicopathologic and gene expression model *Eur J Cancer* 2020;140:11-18.
- 5 Gambichler T, Tsagoudis K, Kiecker F, et al. Prognostic significance of an 11-gene RNA assay in archival tissue of cutaneous melanoma stage I-III patients *Eur J Cancer* 2021;143:11-18.
- 6 Hseuh EC, DeBloom JR, Lee JH, et al. Long-Term Outcomes in a Multicenter, Prospective Cohort Evaluating the Prognostic 31-Gene Expression Profile for Cutaneous Melanoma. *JCO Precis Oncol*. 2021;5:PO.20.00119
- 7 Gerami P, Cook RW, Wilkinson J, et al. Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma. *Clin Cancer Res* 2015;21:175-183.
- 8 Gerami P, Cook RW, Russell MC, et al. Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy. *J Am Acad Dermatol* 2015;72:780-785.
- 9 Zager JS, Gastman BR, Leachman S, et al. Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients. *BMC Cancer* 2018;18:130.
- 10 Bellomo D, Arias-Mejias SM, Ramana C, et al. Model combining tumor molecular and clinicopathologic risk factors predicts sentinel lymph node metastasis in primary cutaneous melanoma. *JCO Precis Oncol* 2020;4:319-334.
- 11 Greenhaw BN, Covington KR, Kurley SJ, et al. Molecular risk prediction in cutaneous melanoma: a meta-analysis of the 31-gene expression profile prognostic test in 1,479 patients. *J Am Acad Dermatol* 2020;83:745-753.
- 12 Grossman D, Okwundu N, Bartlett EK, et al. Prognostic gene expression profiling in cutaneous melanoma: identifying the knowledge gaps and assessing the clinical benefit. *JAMA Dermatol* 2020; 156:1004-1011.
- 13 Chan WH, Tsao H. Consensus, controversy, and conversations about gene expression profiling in melanoma. *JAMA Dermatol* 2020;156:949-951.
- 14 Kangas-Dick AW, Greenbaum, Gall, V, et al. Evaluation of a gene expression profiling assay in primary cutaneous melanoma. *Ann Surg Oncol* 2021;28:4582-4589.
- 15 Keller J, Schwartz TL, Lizalek JM, et al. Prospective validation of the prognostic 31-gene expression profiling test in primary cutaneous melanoma. *Cancer Med* 2019;8:2205-2212.
- 16 Podlipnik S, Carrera C, Boada A, et al. Early outcome of a 31-gene expression profile test in 86 AJCC stage IB-II melanoma patients. A prospective multicentre cohort study. *J Eur Acad Dermatol Venereol* 2019;33:857-862.
- 17 Sabel MS. Genomic Expression Profiling in Melanoma and the Road to Clinical Practice. *Ann Surg Oncol*. 2022;29:764-766.
- 18 Marchetti MA, Bartlett EK, Dusza SW, Bichakjian CK. Use of a prognostic gene expression profile test for T1 cutaneous melanoma: Will it help or harm patients? *J Am Acad Dermatol* 2019;80:e161-e162.
- 19 Kovarik CL, Chu EY, Adamson AS. Gene expression profile testing for thin melanoma: Evidence to support clinical use remains thin. *JAMA Dermatol* 2020;156:837-838.
- 20 Marchetti MA, Coit DG, Dusza SW, et al. Performance of gene expression profile tests for prognosis in patients with localized cutaneous melanoma: a systematic review and meta-analysis. *JAMA Dermatol* 2020;156:1-10.
- 21 Harris LN, Ismaila N, McShane LM, et al. Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. *J Clin Oncol* 2016;34:1134-1150.
- 22 Gastman BR, Gerami P, Kurley SJ, et al. Identification of patients at risk of metastasis using a prognostic 31-gene expression profile in subpopulations of melanoma patients with favorable outcomes by standard criteria. *J Am Acad Dermatol* 2019;80:149-157 e4.
- 23 Cook RW, Middlebrook B, Wilkinson J, et al. Analytic validity of DecisionDx-Melanoma, a gene expression profile test for determining metastatic risk in melanoma patients. *Diagn Pathol* 2018;13:13.
- 24 Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. *CA Cancer J Clin* 2017;67:472-492.
- 25 Lo SN, Ma J, Scolyer RA, et al. Improved Risk Prediction Calculator for Sentinel Node Positivity in Patients With Melanoma: The Melanoma Institute Australia Nomogram *J Clin Onc* 2021;38:2719-2727.

Note: All recommendations are category 2A unless otherwise indicated.**Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.****Continued****ME-C
6 OF 8**

**PRINCIPLES OF MOLECULAR TESTING
REFERENCES**

- ²⁶ Arnot SP, Han G, Fortino, et al. Utility of a 31-gene expression profile for predicting outcomes in patients with primary cutaneous melanoma referred for sentinel node biopsy. *Am J Surg* 2021;221:1195-1199.
- ²⁷ Whitman ED et al. Integrating 31-Gene Expression Profiling With Clinicopathologic Features to Optimize Cutaneous Melanoma Sentinel Lymph Node Metastasis Prediction *JCO Precis Oncol* 2021;5:1466-1479.
- ²⁸ Yousaf A. Validation of CP-GEP (Merlin Assay) for predicting sentinel lymph node metastasis in primary cutaneous melanoma patients: A U.S. cohort study. *Int J Dermatol* 2021;60:851-856.
- ²⁹ Marchetti MA et al. Utility of a Model for Predicting the Risk of Sentinel Lymph Node Metastasis in Patients With Cutaneous Melanoma. *JAMA Dermatol* 2022;158:680-683.
- ³⁰ Jarell A. et al. Optimizing treatment approaches for patients with cutaneous melanoma by integrating clinical and pathologic features with the 31-gene expression profile test *J Am Acad Dermatol* 2022;87:1312-1320.
- ³¹ Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. *N Engl J Med* 2005;353:2135-2147.
- ³² Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. *Nature* 2002;417:949-954.
- ³³ Flaherty KT, Puzanov I, Kim KB, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. *N Engl J Med* 2010;363:809-819.
- ³⁴ Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. *N Engl J Med* 2012;367:107-114.
- ³⁵ Long GV, Eroglu Z, Infante J, et al. Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma who received dabrafenib combined with trametinib. *J Clin Oncol* 2018;36:667-673.
- ³⁶ Klein O, Clements A, Menzies AM, et al. BRAF inhibitor activity in V600R metastatic melanoma. *Eur J Cancer* 2013;49:1073-1079.
- ³⁷ Menzer C, Menzies AM, Carlino MS, et al. Targeted therapy in advanced melanoma with rare BRAF mutations. *J Clin Oncol* 2019;37:3142-3151.
- ³⁸ Dahlman KB, Xia J, Hutchinson K, et al. BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. *Cancer Discov* 2012;2:791-797.
- ³⁹ Dankner M, Lajoie M, Moldoveanu D, et al. Dual MAPK inhibition is an effective therapeutic strategy for a subset of Class II BRAF mutant melanomas. *Clin Cancer Res* 2018;24:6483-6494.
- ⁴⁰ Hutchinson KE, Lipson D, Stephens PJ, et al. BRAF fusions define a distinct molecular subset of melanomas with potential sensitivity to MEK inhibition. *Clin Cancer Res* 2013;19:6696-6702.
- ⁴¹ Botton T, Yeh I, Nelson T, et al. Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy. *Pigment Cell Melanoma Res* 2013;26:845-851.
- ⁴² Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. *J Clin Oncol* 2006;24:4340-4346.
- ⁴³ Hodi FS, Corless CL, Giobbie-Hurder A, et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. *J Clin Oncol* 2013;31:3182-3190.
- ⁴⁴ Carvajal RD, Antonescu CR, Wolchok JD, et al. KIT as a therapeutic target in metastatic melanoma. *JAMA* 2011;305:2327-2334.
- ⁴⁵ Guo J, Si L, Kong Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. *J Clin Oncol* 2011;29:2904-2909.
- ⁴⁶ Guo J, Carvajal RD, Dummer R, et al. Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial. *Ann Oncol* 2017;28:1380-1387.
- ⁴⁷ Johnson DB, Smalley KS, Sosman JA. Molecular pathways: targeting NRAS in melanoma and acute myelogenous leukemia. *Clin Cancer Res* 2014;20:4186-4192.
- ⁴⁸ Devitt B, Liu W, Salemi R, et al. Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. *Pigment Cell Melanoma Res* 2011;24:666-672.
- ⁴⁹ Dummer R, Schadendorf D, Ascierto PA, et al. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol* 2017;18:435-445.
- ⁵⁰ Okamura R, Boichard A, Kato S, et al. Analysis of NTRK alterations in pan-cancer adult and pediatric malignancies: Implications for NTRK-targeted therapeutics. *JCO Precis Oncol* 2018;2018.
- ⁵¹ Cancer Genome Atlas N. Genomic classification of cutaneous melanoma. *Cell* 2015;161:1681-1696.
- ⁵² Drlon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. *N Engl J Med* 2018;378:731-739.
- ⁵³ Drlon A, Siena S, Ou SI, et al. Safety and antitumor activity of the multitargeted Pan-TRK, ROS1, and ALK inhibitor entrectinib: Combined results from two phase I trials (ALKA-372-001 and STARTRK-1). *Cancer Discov* 2017;7:400-409.

Note: All recommendations are category 2A unless otherwise indicated.**Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.****Continued****ME-C
7 OF 8**

**PRINCIPLES OF MOLECULAR TESTING
REFERENCES**

- ⁵⁴ Long GV, Wilmott JS, Capper D, et al. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma. *Am J Surg Pathol* 2013;37:61-65.
- ⁵⁵ Schirosi L, Strippoli S, Gaudio F, et al. Is immunohistochemistry of BRAF V600E useful as a screening tool and during progression disease of melanoma patients? *BMC Cancer* 2016;16:905.
- ⁵⁶ Torres-Cabala CA, Wang WL, Trent J, et al. Correlation between KIT expression and KIT mutation in melanoma: a study of 173 cases with emphasis on the acral-lentiginous/mucosal type. *Mod Pathol* 2009;22:1446-1456.
- ⁵⁷ Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. *Science* 2018;359:1350-1355.
- ⁵⁸ Udall M, Rizzo M, Kenny J, et al. PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics. *Diagn Pathol* 2018;13:12.
- ⁵⁹ Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. *N Engl J Med* 2019;381:1535-1546.
- ⁶⁰ Cristescu R, Mogg R, Ayers M, et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. *Science* 2018;362.
- ⁶¹ Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden. *N Engl J Med* 2018;378:2093-2104.
- ⁶² Gubin MM, Schreiber RD. CANCER. The odds of immunotherapy success. *Science* 2015;350:158-159.
- ⁶³ Johnson DB, Frampton GM, Rioth MJ, et al. Targeted next generation sequencing identifies markers of response to PD-1 blockade. *Cancer Immunol Res* 2016;4:959-967.
- ⁶⁴ Chalmers ZR, Connelly CF, Fabrizio D, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. *Genome Med* 2017;9:34.
- ⁶⁵ Roszik J, Haydu LE, Hess KR, et al. Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. *BMC Med* 2016;14:168.
- ⁶⁶ Shain AH, Yeh I, Kovalyshyn I, et al. The genetic evolution of melanoma from precursor lesions. *N Engl J Med* 2015;373:1926-1936.
- ⁶⁷ Johnson DB, Menzies AM, Zimmer L, et al. Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. *Eur J Cancer* 2015;51:2792-2799.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



PRINCIPLES OF IMAGING¹⁻¹⁰

Imaging modalities include:

- Nodal basin US for regional lymph node assessment^a
- Cross-sectional imaging studies that include chest/abdominal/pelvic (and neck if clinically indicated) CT with intravenous (IV) contrast and/or whole-body FDG PET/CT^b
- Brain MRI with IV contrast
- Non-uniform application of chest x-ray in surveillance and monitoring of patients with advanced melanoma across NCCN Member Institutions
- Scans should be performed with IV contrast unless contraindicated; IV contrast is not necessary for CT chest screening for lung metastases

^a Nodal US assessment for melanoma requires specific radiologic expertise. Criteria concerning for early melanoma nodal involvement include the following: hypoechoic island(s) in the cortex, asymmetrical focal cortical thickening, and peripheral vascularity, particularly when there is detectable perfusion to the area of cortical thickening. Core biopsy or FNA of suspicious lymph nodes should be directed to the atypical area(s) within the cortex identified on US.¹¹⁻¹⁵

^b Choice of modality depends on clinical circumstances. Multiple retrospective studies suggest that FDG PET/CT may be more sensitive in diagnosing distant metastases, especially in the extremities.¹⁶⁻²²

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued
References](#)

**ME-D
1 OF 5**



PRINCIPLES OF IMAGING¹⁻¹⁰

Workup (Baseline)

- **Imaging to evaluate specific signs or symptoms suggestive of possible metastases is recommended in all stages.**
- **Stage-specific recommendations for routine imaging during workup are summarized below.**
- **Stage 0, IA, IB, II**
 - ▶ **Baseline cross-sectional imaging with or without brain imaging is not recommended unless needed for surgical planning.**
 - ▶ **Stage I/II: Nodal basin US is not a substitute for SLNB. Consider nodal basin US prior to SLNB for patients with melanoma with an equivocal regional lymph node physical exam. Abnormalities or suspicious lesions on nodal basin US should be confirmed histologically. Negative nodal basin US is not a substitute for biopsy of clinically suspicious lymph nodes.**
- **Stage IIIA (sentinel node positive)**
 - ▶ **Consider cross-sectional imaging for baseline staging.**
- **Stage IIIB/C/D**
 - ▶ **Cross-sectional imaging with or without brain imaging for baseline staging.**
- **True scar recurrence (persistent disease)^c**
 - ▶ **Imaging workup should be appropriate to primary tumor characteristics and melanoma stage (see above recommendations for stage 0, IA, IB, and II).**
- **Stage IV or recurrence with distant metastatic disease**
 - ▶ **Cross-sectional and brain imaging.**
- **Local satellite/in-transit recurrence;^d nodal recurrence**
 - ▶ **Cross-sectional imaging with or without brain imaging to assess extent of disease.**

^c True scar recurrence (persistent disease) is defined by the presence of in situ and/or radial growth phase.

^d Local satellite/in-transit recurrence without in situ or radial growth phase, with intralymphatic deep dermal or subcutaneous fat recurrence within the melanoma scar or satellite metastasis adjacent to the melanoma scar. Satellite and in-transit metastases are biologically and prognostically similar.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued
References](#)

**ME-D
2 OF 5**



PRINCIPLES OF IMAGING¹⁻¹⁰

Treatment Response Assessment

- For patients rendered NED by surgery, imaging recommendations are in the *Follow-up* section ([See ME-10](#)).
- For active treatment other than complete surgical resection, assessment of response is appropriate and should include clinical examination and/or imaging (cross-sectional ± brain). For patients receiving active non-surgical treatment, imaging throughout treatment at clinically appropriate intervals is recommended in the following clinical settings:
 - ▶ Stage III (clinical satellite or in-transit^e) primary or local, satellite, and/or in-transit recurrence^d
 - ▶ Nodal recurrence in previously dissected nodal bed that is unresectable^f or incompletely resected
 - ▶ Limited (resectable) distant metastatic disease
 - ▶ Disseminated (unresectable) distant metastatic disease

^d Local satellite/in-transit recurrence without in situ or radial growth phase, with intralymphatic deep dermal or subcutaneous fat recurrence within the melanoma scar or satellite metastasis adjacent to the melanoma scar. Satellite and in-transit metastases are biologically and prognostically similar.

^e Intralymphatic metastases can be characterized as clinically or pathologically detectable satellite metastases (visible or microscopic cutaneous and/or subcutaneous metastases occurring within 2 cm of the primary melanoma) or in-transit metastases (regional cutaneous and/or subcutaneous metastases identified at a distance >2 cm from the primary melanoma). The 2-cm cutoff is consistent with AJCC staging definitions. Satellite and in-transit metastases are biologically and prognostically similar.

^f Disease can be technically unresectable (eg, involvement of a major neurovascular structure), or clinically unresectable (eg, remote nodal disease), where surgery alone would have minimal clinical benefit.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued
References](#)

**ME-D
3 OF 5**

**PRINCIPLES OF IMAGING¹⁻¹⁰****Follow-up (surveillance for recurrence in patients with NED)**

- Surveillance duration and interval should be tailored to stage and based on assessment of risk factors for recurrence. The intensity and interpretation of cross-sectional imaging should also be influenced by the potential for false positives, the desire to avoid unnecessary invasive tests or treatment, patient anxiety, the potential adverse effects of cumulative radiation exposure, and medical costs, as well as treatment options available in the event that asymptomatic recurrence is detected.
- There are limited data to suggest improved patient outcomes following imaging-detected recurrence in asymptomatic patients. One retrospective study showed improved OS in resected stage IIC–IIIC (AJCC-7) patients with asymptomatic, surveillance-detected recurrence who were treated with immune checkpoint inhibition, compared with similar treatment in those who underwent surveillance imaging but had symptomatic recurrence.¹⁷
 - ▶ In patients with an equivocal lymph node exam, short-term follow-up and/or additional imaging (US [preferred] or CT) should be considered, with imaging-directed biopsy as warranted.
 - ▶ Regional lymph node US in patients with a positive SLNB who did not undergo CLND is generally preferred, where expertise is available. It would be appropriate for the frequency of clinical exam and US surveillance to be consistent with the two prospective randomized trials (MSLT-II and DeCOG): every 4 months during the first 2 years, then every 6 months during years 3 through 5.
 - ▶ Where radiologic expertise is available, regional nodal US may be utilized in higher risk (eg, T3/T4) melanomas if SLNB is not performed or not technically feasible. Nodal basin US is not a substitute for SLNB.
- Stage 0 in situ
 - ▶ Routine imaging to screen for asymptomatic recurrence or metastatic disease is not recommended.
- Stage IA–IIA (NED)
 - ▶ Imaging (cross-sectional) as indicated to evaluate specific signs or symptoms.
 - ▶ Routine imaging (cross-sectional) to screen for asymptomatic recurrence or metastatic disease is not recommended.
- Stage IIB–IV (NED)
 - ▶ Imaging (cross-sectional ± brain) as indicated to evaluate specific signs or symptoms.
 - ▶ Consider imaging (cross-sectional ± brain) every 3–12 months for 2 years, then every 6–12 months for another 3 years (unless otherwise mandated by clinical trial participation) to screen for recurrence or metastatic disease (category 2B).
 - ◊ More frequent surveillance with brain MRI is recommended for patients with prior brain metastases.
 - ◊ Periodic brain MRI for up to 3 years may be appropriate to screen for asymptomatic brain metastases in high-risk patients who had stage IIIC or higher without prior central nervous system (CNS) metastases.
 - ◊ There is non-uniform application of chest x-ray in surveillance and monitoring of patients with advanced melanoma across NCCN Member Institutions.
 - ▶ Routine imaging to screen for asymptomatic recurrence or metastatic disease is not recommended after 3–5 years, depending on risk of relapse.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

[References](#)

**PRINCIPLES OF IMAGING
REFERENCES**

- ¹ Gold JS, Jaques DP, Busam KJ, et al. Yield and predictors of radiologic studies for identifying distant metastases in melanoma patients with a positive sentinel lymph node biopsy. *Ann Surg Oncol* 2007;14:2133-2140.
- ² Leiter U, Buettner PG, Eigentler TK, et al. Is detection of melanoma metastasis during surveillance in an early phase of development associated with a survival benefit? *Melanoma Res* 2010;20:240-246.
- ³ Mathews JD, Forsythe AV, Brady Z, et al. Cancer risk in 680,000 people exposed to computed tomography scans in childhood or adolescence: data linkage study of 11 million Australians. *BMJ* 2013;346:f2360.
- ⁴ Meyers MO, Yeh JJ, Frank J, et al. Method of detection of initial recurrence of stage II/III cutaneous melanoma: analysis of the utility of follow-up staging. *Ann Surg Oncol* 2009;16:941-947.
- ⁵ Moore Dalal K, Zhou Q, Panageas KS, et al. Methods of detection of first recurrence in patients with stage I/II primary cutaneous melanoma after sentinel lymph node biopsy. *Ann Surg Oncol* 2008;15:2206-2214.
- ⁶ Rodriguez Rivera AM, Alabbas H, Ramjaun A, Meguerditchian AN. Value of positron emission tomography scan in stage III cutaneous melanoma: a systematic review and meta-analysis. *Surg Oncol* 2014;23:11-16.
- ⁷ Podlipnik S, Carrera C, Sanchez M, et al. Performance of diagnostic tests in an intensive follow-up protocol for patients with American Joint Committee on Cancer (AJCC) stage IIB, IIC, and III localized primary melanoma: A prospective cohort study. *J Am Acad Dermatol* 2016;75:516-524.
- ⁸ Romano E, Scordo M, Dusza SW, et al. Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines. *J Clin Oncol* 2010;28:3042-3047.
- ⁹ Xing Y, Bronstein Y, Ross MI, et al. Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. *J Natl Cancer Inst* 2011;103:129-142.
- ¹⁰ Yancovitz M, Finelt N, Warycha MA, et al. Role of radiologic imaging at the time of initial diagnosis of stage T1b-T3b melanoma. *Cancer* 2007;110:1107-1114.
- ¹¹ van Akkooi ACJ, Voit CA, Verhoef C, Eggermont AMM. Potential cost-effectiveness of US-guided FNAC in melanoma patients as a primary procedure and in follow-up. *Ann Surg Oncol* 2010;17:660-662.
- ¹² Voit CA, van Akkooi ACJ, Schafer-Hesterberg G, et al. Rotterdam Criteria for sentinel node (SN) tumor burden and the accuracy of ultrasound (US)-guided fine-needle aspiration cytology (FNAC): can US-guided FNAC replace SN staging in patients with melanoma? *J Clin Oncol* 2009;27:4994-5000.
- ¹³ Voit CA, Oude CMC, Ulrich J, et al. Ultrasound of the sentinel node in melanoma patients: echo-free island is a discriminatory morphologic feature for node positivity. *Melanoma Res* 2016;26:267-271.
- ¹⁴ Faries MB, Thompson JF, Cochran AJ, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. *N Engl J Med* 2017;376:2211-2222.
- ¹⁵ Bartlett E, Lee AY, Spanheimer PM, et al. Nodal and systemic recurrence following observation of a positive sentinel lymph node in melanoma. *Br J Surg* 2020;107:1480-1488.
- ¹⁶ Schröer-Günther MA, Wolff RF, Westwood ME, et al. F-18-fluoro-2-deoxyglucose positron emission tomography (PET) and PET/computed tomography imaging in primary staging of patients with malignant melanoma: a systematic review. *Syst Rev* 2012;1:62.
- ¹⁷ Xing Y, Bronstein Y, Ross MI, et al. Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. *J Natl Cancer Inst* 2011;103:129-142.
- ¹⁸ Mohr P, Eggermont AM, Hauschild A, Buzaid A. Staging of cutaneous melanoma. *Ann Oncol* 2009;20:vi14-vi21.
- ¹⁹ Gao G, Gong B, Shen W. Meta-analysis of the additional value of integrated 18FDG PET-CT for tumor distant metastasis staging: comparison with 18FDG PET alone and CT alone. *Surg Oncol* 2013;22:195-200.
- ²⁰ Bourgeois AC, Chang TT, Fish LM, Bradley YC. Positron emission tomography/computed tomography in melanoma. *Radiol Clin North Am* 2013;51:865-879.
- ²¹ Krug B, Crott R, Lonnet M, et al. Role of PET in the initial staging of cutaneous malignant melanoma: systematic review. *Radiology* 2008;249:836-844.
- ²² Ibrahim AM, May ML, Bosse D, et al. Imaging intensity and survival outcomes in high-risk resected melanoma treated by systemic therapy at recurrence. *Ann Surg Oncol* 2020;27:3683-3691. Erratum in: Ibrahim AM, et al. *Ann Surg Oncol* 2020;27:976-977.

Note: All recommendations are category 2A unless otherwise indicated.**Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.**

**PRINCIPLES OF SURGICAL MARGINS FOR WIDE EXCISION OF PRIMARY MELANOMA**

| <u>Tumor Thickness</u> | <u>Recommended Peripheral Surgical Margins</u> ^{b,1-10} |
|------------------------|--|
| In situ ^a | 0.5–1 cm |
| ≤1.0 mm | 1 cm (category 1) |
| >1.0–2.0 mm | 1–2 cm (category 1) |
| >2.0–4.0 mm | 2 cm (category 1) |
| >4.0 mm | 2 cm (category 1) |

- There are no randomized trials to inform peripheral surgical margins or depth of wide excision for MIS. Depth of excision into the subcutaneous fat may be adequate and considered in anatomic locations where excision to fascia would cause significant morbidity.
- For invasive melanoma, wide excision involves removal of all tissue to the level of the fascia, which is typically preserved unless involved by tumor. Peripheral resection margins may be modified to accommodate individual anatomic or functional considerations. However, the safety and efficacy of narrower surgical margins have not been prospectively studied in a randomized controlled manner. Narrower than recommended margins may increase the risk for margin positivity and/or local recurrence.
- The gold standard for histologic assessment of excised melanoma is use of permanent sections. If Mohs micrographic surgery (MMS) is performed, permanent section analysis of the central debulking specimen is strongly recommended to provide complete staging information. Consider delay of complex reconstruction or wound closure until histologic margin assessment is complete.
- MMS is not recommended for primary treatment of invasive cutaneous melanoma when standard clinical margins can be obtained. It may be considered selectively for minimally invasive (T1a) melanomas in anatomically constrained areas (ie, face, ears, acral sites), along with other surgical methods that provide comprehensive histologic assessment, such as staged excision with permanent sections for dermatopathology review.^{a,11}
- With respect to disease-related outcomes, there have been no prospective comparisons of different excision methods, including conventional wide excision, MMS, and staged excision with permanent sections. All randomized controlled trials of resection margins for invasive cutaneous melanoma were performed using standard wide excision technique.¹⁻¹⁰ Of note, few included head/neck melanomas, and none included acral melanomas.
- In the setting of an adequate biopsy, digit-sparing surgery may be an option for subungual MIS and select thin tumors (<0.8 mm), although further investigation is needed.

^a For large and/or poorly defined MIS, LM/high CSD or acral lentiginous subtypes, or LM melanoma with a minimally invasive (T1a) component, surgical margins >0.5 cm may be necessary, and techniques for comprehensive histologic evaluation of margins (ie, complete circumferential peripheral and deep margin assessment) should be considered.¹²⁻¹⁷ If MMS is performed, use of frozen section melanocytic IHC stains may assist in accurate interpretation of histologic margins and has been associated with lower local recurrence rates¹⁸. For selected patients with positive margins after surgery, in whom further resection is not feasible or desirable, consider topical imiquimod (for patients with MIS/LM type) or RT.

^b Excision recommendations for invasive melanoma are based on measured clinical margins taken at the time of surgery and not gross or histologic margins, as measured by the pathologist. However, narrower peripheral histologic margins have been associated with higher rates of local recurrence for invasive melanoma, though not worse melanoma-specific survival.¹⁹⁻²² Narrow pathologic margins, particularly of the invasive component, may warrant further surgical resection.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

**PRINCIPLES OF SURGICAL MARGINS FOR WIDE EXCISION OF PRIMARY MELANOMA**
REFERENCES

- ¹ Veronesi U, Cascinelli N, Adamus J, et al. Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm. *N Engl J Med* 1988;318:1159-1162.
- ² Veronesi U, Cascinelli N. Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma. *Arch Surg* 1991;126:438-441.
- ³ Cohn-Cedermark G, Rutqvist LE, Andersson R, et al. Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8-2.0 mm. *Cancer* 2000;89:1495-1501.
- ⁴ Balch CM, Urist MM, Karakousis CP, et al. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. *Ann Surg* 1993;218:262-267; discussion 267-269.
- ⁵ Balch CM, Soong SJ, Smith T, et al. Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas. *Ann Surg Oncol* 2001;8:101-108.
- ⁶ Khayat D, Rixe O, Martin G, et al. Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick). *Cancer* 2003;97:1941-1946.
- ⁷ Thomas JM, Newton-Bishop J, A'Hern R, et al. Excision margins in high-risk malignant melanoma. *N Engl J Med* 2004;350:757-766.
- ⁸ Hayes AJ, Maynard L, Coombes G, et al. Wide versus narrow excision margins for high-risk, primary cutaneous melanomas: long-term follow-up of survival in a randomised trial. *Lancet Oncol* 2016;17:184-192.
- ⁹ Gillgren P, Drzewiecki KT, Niin M, et al. 2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: a randomised, multicentre trial. *Lancet* 2011;378:1635-1642.
- ¹⁰ Utjes D, Malmstedt J, Teras J, et al. 2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: long-term follow-up of a multicentre, randomised trial. *Lancet* 2019;394:471-477.
- ¹¹ Adelsteinsson JN, Stoj VJ, Algzlan H, et al. Limitations in the literature regarding Mohs surgery and staged excision for melanoma: A critical review of quality and data reporting. *J Am Acad Dermatol* 2021:S0190-9622:00772-00776.
- ¹² Kunishige JH, Brodland DG, Zitelli JA. Surgical margins for melanoma in situ. *J Am Acad Dermatol* 2012;66:438-444.
- ¹³ de Vries K, Greveling K, Prens LM, et al. Recurrence rate of lentigo maligna after micrographically controlled staged surgical excision. *Br J Dermatol* 2016;174:588-593.
- ¹⁴ Hanson J, Demer A, Liszewski W, et al. Improved overall survival of melanoma of the head and neck treated with Mohs micrographic surgery versus wide local excision. *J Am Acad Dermatol* 2020;82:149-155.
- ¹⁵ Cheraghlou S, Christensen SR, Agogo GO, Girardi M. Comparison of survival after Mohs micrographic surgery vs wide margin excision for early-stage invasive melanoma. *JAMA Dermatol* 2019;155:1252-1259.
- ¹⁶ Moyer JS, Rudy S, Boonstra PS, et al. Efficacy of staged excision with permanent section margin control for cutaneous head and neck melanoma. *JAMA Dermatol* 2017;153:282-288.
- ¹⁷ Liu A, Botkin A, Murray C, et al. Outcomes of staged excision with circumferential en face margin control for lentigo maligna of the head and neck. *J Cutan Med Surg* 2021;25:18-24.
- ¹⁸ Vieira C, Jennings T, Renzi Jr MA, et al. Recurrence Rate for Melanoma Excised by Mohs Micrographic Surgery Without Immunostaining. *Dermatol Surg* 2022;48:492-497
- ¹⁹ MacKenzie Ross AD, Haydu LE, Quinn MJ, et al. The association between excision margins and local recurrence in 11,290 thin (t1) primary cutaneous melanomas: a case-control study. *Ann Surg Oncol* 2016;23:1082-1089.
- ²⁰ Haydu LE, Stollman JT, Scolyer RA, et al. Minimum safe pathologic excision margins for primary cutaneous melanomas (1-2 mm in thickness): analysis of 2131 patients treated at a single center. *Ann Surg Oncol* 2016;23:1071-1081.
- ²¹ Lamboo LG, Haydu LE, Scolyer RA, et al. The optimum excision margin and regional node management for primary cutaneous T3 melanomas (2-4 mm in Thickness): a retrospective study of 1587 patients treated at a single center. *Ann Surg* 2014;260:1095-1102.
- ²² Pasquali S, Haydu LE, Scolyer RA, et al. The importance of adequate primary tumor excision margins and sentinel node biopsy in achieving optimal locoregional control for patients with thick primary melanomas. *Ann Surg* 2013;258:152-157.

Note: All recommendations are category 2A unless otherwise indicated.**Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.**

**PRINCIPLES OF SENTINEL LYMPH NODE BIOPSY (SLNB)****General Principles**

- SLNB is a surgical procedure developed to accurately stage patients with cutaneous melanoma through pathologic assessment of the regional nodal basin(s) and to provide prognostic information for patients with clinical stage I/II melanoma (no clinical or radiographic evidence of nodal disease). There are emerging data that pathologic assessment of the index node carries strong prognostic significance.¹ Discussion regarding relevant risks and benefits of SLNB should occur with the appropriate health care provider(s).
- In patients with clinical stage I/II melanoma, SLN status is a strong predictor of survival and provides improved regional nodal disease control, with or without subsequent CLND.²
- SLN status may impact future therapeutic decisions, including recommendations for active nodal basin US/imaging surveillance or CLND, adjuvant therapy, and type/frequency of clinic visits and/or surveillance imaging.
- Certain pathologic features of the primary tumor are associated with higher risk of SLN positivity, with tumor thickness being the most reliable predictor of a positive SLNB.
- NCCN makes recommendations on when to perform SLNB based on the likelihood that a patient will have a positive SLNB, taking patient factors into account regarding appropriateness of the staging procedure.
- SLNB should be discussed with all patients with clinical stage IB or II melanoma, with the following considerations:
 - ▶ For patients with a melanoma Breslow depth of <0.8 mm without ulceration (T1a) or other adverse features, the probability of a positive SLN is less than 5%. NCCN does not generally recommend SLNB for these patients unless there is significant uncertainty about the adequacy of microstaging (eg, positive deep margins or limited sampling of a larger lesion).
 - ▶ For patients with clinical stage IB, T1b melanoma (Breslow depth <0.8 mm with ulceration or 0.8–1 mm with or without ulceration), or T1a lesions with Breslow depth ≥0.5 mm and other adverse features (age ≤42 years, head/neck location, lymphovascular invasion, and/or mitotic index ≥2/mm²), the probability of a positive SLNB is 5-10%, with additive increased risk when multiple adverse features are present. NCCN recommends discussing and considering SLNB for these patients.
 - ▶ For patients with stage IB (T2a) or II (T2b and higher) melanoma, the probability of a positive SLN is generally greater than 10%. However, there are subsets of patients (non-mitogenic, or older patients) for whom the probability of a positive SLN is substantially lower.^{3,4} NCCN recommends discussing and offering SLNB for these patients.
 - ▶ Regardless of a patient's risk of a positive SLNB, if the patient is medically unfit or is unlikely to act on the information that the SLNB would provide (eg, pursue surveillance nodal basin US, undergo CLND, consider adjuvant therapy, and/or change follow-up schedules), then it is reasonable to forego SLNB.
 - ▶ Prognostic GEP testing to differentiate melanomas at low versus high risk for metastasis should not replace pathologic staging procedures. Currently available GEP tests should not be used to determine SLNB eligibility. Readily available, no-cost risk calculators (eg, [melanomarisik.org.au](https://www.mskcc.org/nomograms/melanoma/sentinel_lymph_node_metastasis); https://www.mskcc.org/nomograms/melanoma/sentinel_lymph_node_metastasis) may aid clinicians in discussion of risk versus benefit of SLNB.
- Although the accuracy of SLNB may be lower after a prior wide excision, rotational flap, or skin graft closure of a primary melanoma, it may be considered selectively in this setting, particularly for non-head and neck primary melanomas.
- In the setting of an isolated in-transit metastasis or local recurrence of a primary melanoma without clinically or radiographically evident regional nodal or distant metastases, SLNB may be considered, if it will affect the decision for adjuvant therapy.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued](#)



PRINCIPLES OF SENTINEL LYMPH NODE BIOPSY (SLNB)

Principles of Nuclear Medicine

- Patients undergo preoperative lymphoscintigraphy to identify the regional lymph basin and the individual SLNs within that basin.
- Generally, 0.5–1.0 mCi of Tc-99m radiocolloid is injected intradermally in 4 to 5 locations around the biopsy site. Dynamic and static images may be obtained.
- In selected cases, especially the head and neck and pelvic regions, single-photon emission CT (SPECT)-CT imaging may be performed as an adjunct to planar imaging to better define the anatomic location of the sentinel node(s).
- Lymphoscintigraphy may be carried out the day of surgery or the day prior. If performed the afternoon prior, a higher dose of radiocolloid should be used and the case should be performed as early as possible the following day.
- Imaging should include all potentially relevant anatomic nodal basins as well as sites outside of recognized node basins. This would include the entire limb for extremity melanomas; bilateral inguinal, axillary, and cervical nodal basin imaging for truncal melanomas; and pelvic nodal basin imaging for lower extremity and low truncal melanomas.

Principles of Surgery

- Lymphatic mapping is generally performed prior to wide local excision if performed at the same procedure. If the primary site is close to the SLNB nodal basin and interferes with gamma probe use/counts, it is acceptable to perform the primary tumor wide excision prior to SLNB.
- When used, blue dye (commonly isosulfan blue or methylene blue) is injected intradermally (not subcutaneously) with a fine-gauge needle at the site of the primary lesion.
- An incision is made in the regional lymph basin of the expected lymphatic drainage, over the site of the highest transcutaneous gamma counts, orienting the wound to be compatible with possible future CLND. Once the skin incision over the SLN has been made, limited gamma probe-directed exploration of the tissue is performed to identify SLN(s).
- Once identified and removed, the SLN is examined with the gamma probe ex vivo. Further nodal exploration and SLN are identified if their maximum gamma counts are >10% of the highest SLN count and/or are blue in color. Elevated nodal basin counts above the 10% threshold indicate the need for further nodal exploration.
- In the case of a lower-extremity melanoma with iliac nodes on the same lymphatic channel as a more proximal superficial femoral SLN, excision of the second order nodes may be omitted. However, if they are on a distinct lymphatic channel or there is uncertainty as to their drainage pattern, these SLNs should be identified and excised.
- In-transit (interval or ectopic) SLNs identified that are more proximal than the draining nodal basin should also be excised.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

[References](#)

**PRINCIPLES OF SENTINEL LYMPH NODE BIOPSY (SLNB)****Principles of Pathology**

- **SLN(s) are usually not sent for frozen section analysis, but there are certain scenarios where this may be appropriate, such as unexpected findings at the time of SLNB that would affect immediate subsequent care.**
- **SLN(s) are fixed in formaldehyde and embedded in paraffin for subsequent analysis.**
- **For histologic examination, whether for sentinel node analysis or for routine regional lymph node evaluation, the entire node should be submitted. For routine evaluation, large lymph nodes may be bisected or sliced at 2-mm intervals, whereas smaller nodes (<5 mm) may be submitted whole. SLN(s) should be analyzed via standard hematoxylin and eosin (H&E) and IHC stains such as HMB45, S100, MELAN-A, or SOX-10.⁵**
- **In cases where the histologic findings in the SLN are equivocal, comparison of cytomorphology to that of the primary tumor, additional IHC staining for PRAME (for differentiation of nodal nevi vs. melanoma metastasis), and/or consultation with an experienced dermatopathologist should be considered.⁶⁻⁸**
- **Caution should be used when calling an SLN positive based solely on IHC staining of rare, small cells that lack cytomorphologic atypia. Positive staining of rare non-melanoma cells may be seen in lymph nodes with a variety of IHC stains used to detect melanocytes. Correlation of the IHC stain with the H&E slide is recommended. Additional H&E levels and IHC stains may be useful to confirm morphologic features of melanoma.^{5,9,10}**
- **The number of positive and negative SLNs examined should be recorded. If metastases are present, the greatest dimension of tumor size (in mm, measured to the nearest 0.1 mm using an ocular micrometer), location within the lymph node, and presence of extracapsular extension should be recorded.**

References

- ¹ El Sharouni MA, Stodell MD, Ahmed T, et al. Sentinel node biopsy in patients with melanoma improves the accuracy of staging when added to clinicopathological features of the primary tumor. *Ann Oncol* 2021;32:375-383.
- ² Multicenter Selective Lymphadenectomy Trials Study Group, Crystal JS, Thompson JF, Hyngstrom J, et al. Therapeutic Value of Sentinel Lymph Node Biopsy in Patients With Melanoma: A Randomized Clinical Trial. *JAMA Surg* 2022;157:835-842.
- ³ Hanna AN, Sinnamon AJ, Roses RE, et al. Relationship between age and likelihood of lymph node metastases in patients with intermediate thickness melanoma (1.01-4.00 mm): A National Cancer Database study. *J Am Acad Dermatol* 2019;80:433-440.
- ⁴ Sinnamon AJ, Neuwirth MG, Yalamanchi P, et al. Association between patient age and lymph node positivity in thin melanoma. *JAMA Dermatol* 2017;153:866-873.
- ⁵ Scolyer R, Balamurgan T, Busam K, et al. Invasive Melanoma, Histopathology Reporting Guide, 2nd Edition. Sydney, Australia: International Collaboration on Cancer Reporting; 2019. Available at: <http://www.iccr-cancer.org/datasets/published-datasets/skin/invasive-melanoma>.
- ⁶ Lezcano C, Pulitzer M, Moy AP, et al. Immunohistochemistry for PRAME in the distinction of nodal nevi from metastatic melanoma. *Am J Surg Pathol* 2020;44:503-508.
- ⁷ Lezcano C, Jungbluth AA, Nehal KS, et al. PRAME Expression in melanocytic tumors. *Am J Surg Pathol*;2018;42:1456-1465.
- ⁸ Lezcano C, Jungbluth AA, Busam K, et al. Comparison of immunohistochemistry for PRAME with cytogenetic test results in the evaluation of challenging melanocytic tumors. *Am J Surg Pathol* 2020 Jul;44:893-900.
- ⁹ LeBlanc RE, Barton DT, Li Z, et al. Small and isolated immunohistochemistry-positive cells in melanoma sentinel lymph nodes are associated with disease-specific and recurrence-free survival comparable to that of sentinel lymph nodes negative for melanoma. *Am J Surg Pathol* 2019;43:755-765.
- ¹⁰ Scolyer RA, Gershenwald JE, Thompson JF. Isolated immunohistochemistry-positive cells without morphologic characteristics of melanoma should not result in designation as a positive sentinel lymph node according to the AJCC 8th Edition Staging System. *Am J Surg Pathol* 2019;43:1442-1444.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

**PRINCIPLES OF COMPLETION/THERAPEUTIC LYMPH NODE DISSECTION****Adequacy of Regional Lymph Node Dissection**

- An anatomically complete dissection^a of involved nodal basin is required.
- For primary melanomas of the head and neck with clinically positive lymph nodes in the parotid gland, a superficial parotidectomy with facial nerve preservation and appropriate neck dissection of the draining nodal basins is recommended.
- In the axilla, for clinically involved nodal disease, dissection of levels I–III is generally recommended.
- An inguinofemoral dissection is the anatomic dissection for clinical nodal disease in the groin. Therapeutic iliac and obturator lymph node dissection may be considered if imaging shows resectable lymphadenopathy in those areas.^b
- In the groin, the presence of clinically positive inguinofemoral nodes, ≥3 microscopically positive (subclinical) inguinofemoral nodes, or a positive Cloquet's node may increase the likelihood of occult external iliac or obturator microscopic nodal disease. However, there is no known survival benefit of prophylactic lymphadenectomy for clinically/radiographically uninvolved pelvic nodal basins. This decision should be made jointly by a multidisciplinary team, given the advances in modern imaging and adjuvant therapies.
- Clinical trials are evaluating neoadjuvant response-directed treatment after resection of the index node, using pathologic complete or near complete response to inform subsequent surgical and adjuvant decision-making.^{1,2}
- Patients who undergo axillary or inguinal/pelvic lymph node dissections should be counseled and educated about signs and symptoms of lymphedema and, if available and necessary, followed and treated by a certified lymphedema physical therapist. [\[See Lymphedema \(SLYMPH-1\) from the NCCN Guidelines for Survivorship\]](#)
 - ▶ Adjunctive measures to prevent and reduce symptomatic lymphedema (eg, at-risk extremity protection, compressive garments, massage) should be considered.
 - ▶ Patients with progressive and/or symptomatic lymphedema refractory to prior conservative adjunctive measures should be considered for referral to a specialist with experience in lymphovascular revascularization. These patients should preferably be treated in the context of a clinical trial (if available).

Footnotes

^a Anatomic boundaries of lymph node dissection should be described in operative report.

^b In patients with extensive resectable nodal disease at very high risk of recurrence after complete resection, or if resectability of nodal disease is uncertain, recommend multidisciplinary tumor board review to consider neoadjuvant systemic therapy (See ME-15), preferably in the context of a clinical trial. For patients with unresectable nodal disease, consider treatment with systemic therapy (options shown on [MELSYS 1 of 7](#)) followed by resection, or treat as stage IV ([ME-16](#)).

References

¹ Schermers B, Franke V, Rozeman EA, et al. Surgical removal of the index node marked using magnetic seed localization to assess response to neoadjuvant immunotherapy in patients with stage III melanoma. *Br J Surg* 2019;106:519-522.

² Rozeman EA, Hoefsmit EP, Reijers ILM, et al. Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma. *Nat Med* 2021;27:256-263.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

**PRINCIPLES OF RADIATION THERAPY**

General Treatment Information: Consider RT in the following situations:

- **Modalities:** Adjuvant nodal external beam RT (EBRT) should be delivered using a technique judged optimal by the treating radiation oncologist. Newer technologies, such as intensity-modulated RT (IMRT), may lower toxicity and should be considered when available and where appropriate.^{1,2} Image-guided RT (IGRT) should be used to improve accuracy of radiotherapy delivery, where clinically appropriate.

Primary Disease:

- **Definitive Therapy**

- ▶ Definitive radiation may be considered as a treatment option for MIS, LM-type (ie, high-CSD) in medically inoperable patients or those in whom surgical morbidity of complete resection would be prohibitive.³⁻⁵

- ▶ **Dosing Regimens:** Optimal doses are not well established, but potential regimens include:^a

- ◊ 64–70 Gy in 32–35 fractions over 6–7 weeks
- ◊ 50–57.5 Gy in 20–23 fractions over 4–5 weeks^{4,6}
- ◊ 35 Gy in 5 fractions over 1 week for fields <3 cm in diameter²
- ◊ 32 Gy in 4 fractions once per week⁷

- ▶ There are insufficient data to support the routine use of electronic surface brachytherapy in the management of cutaneous melanoma.

- **Adjuvant Therapy**

- ▶ Adjuvant radiation may be considered for select cases of high-risk desmoplastic melanoma based on a combination of risk factors for local recurrence.^{b,8} (category 2B)

- ▶ **Dosing Regimens:** Optimal adjuvant doses are not well established, but potential regimens include:^a

- ◊ 60–66 Gy in 30–33 fractions over 6–7 weeks^{9,10}
- ◊ 48 Gy in 20 fractions over 4 weeks¹¹
- ◊ 30 Gy in 5 fractions over 2 weeks (twice per week or every other day)¹²

^a Hypofractionated regimens may increase the risk for long-term complications.

^b Risk factors for local recurrence include location on the head or neck, extensive neurotropism, pure desmoplastic melanoma histologic subtype, close margins where re-resection is not feasible, or locally recurrent disease.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued
References](#)

**ME-H
1 OF 7**

**PRINCIPLES OF RADIATION THERAPY****Regional Disease****• Adjuvant Therapy for High-Risk Resected Regional Disease**

- ▶ Adjuvant nodal basin RT is associated with reduced lymph node field recurrence in patients at high risk for regional recurrence, but is not associated with improved RFS or OS.^{7,13,14} The benefit of RT must be weighed against potential toxicities, such as lymphedema (limb) or oropharyngeal complications. The impact of these potential toxicities should be considered in the context of newer adjuvant systemic options.
- ▶ Risk factors for regional recurrence include gross and/or histologic extracapsular extension of melanoma in clinically (macroscopic) involved node(s), ≥1 parotid node, ≥2 cervical or axillary nodes, ≥3 inguinofemoral nodes, ≥3 cm cervical or axillary node, and/or ≥4 cm inguinofemoral node.^{13,15,16}
- ▶ Dosing Regimens: Optimal regional nodal doses are not well established, but potential regimens include:^{a,17}
 - ◊ 50–66 Gy in 25–33 fractions over 5–7 weeks^{18,19}
 - ◊ 48 Gy in 20 fractions over 4 weeks¹³
 - ◊ 30 Gy in 5 fractions over 2 weeks (twice per week or every other day)¹²

• Definitive or Palliative Therapy for Regional Metastases

- ▶ Definitive or palliative intent radiation can also be considered for:
 - ◊ Unresectable nodal, satellite, or in-transit disease
 - ◊ Residual local, satellite, or in-transit disease after prior treatment
- ▶ Dosing Regimens: Optimal doses are not established, but potential regimens include^a:
 - ◊ 24–27 Gy in 3 fractions over 1–1.5 weeks^{20,21}
 - ◊ 32 Gy in 4 fractions over 4 weeks²²
 - ◊ 40 Gy in 8 fractions over 4 weeks²¹
 - ◊ 50 Gy in 20 fractions over 4 weeks²²
 - ◊ 30 Gy in 10 fractions over 2 weeks²³
 - ◊ 30 Gy in 5 fractions over 2 weeks
 - ◊ 20 Gy in 5 fractions over 1 week²³
 - ◊ 8 Gy in 1 fraction over 1 day²³

^a Hypofractionated regimens may increase the risk for long-term complications.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued](#)
[References](#)

ME-H
2 OF 7

**PRINCIPLES OF RADIATION THERAPY****Distant Metastatic Disease****• Brain Metastases**

- ▶ **Stereotactic radiosurgery (SRS) and fractionated stereotactic RT (SRT) are techniques for delivering a high dose of radiation to a specific target while delivering a minimal dose to surrounding tissues, generally in the brain and spine and in 1 to 5 sessions. IGRT should be used to improve accuracy of radiotherapy delivery, where clinically appropriate.**
- ▶ **SRS or SRT as primary treatment**
 - ◊ **Smaller tumors may be treated with maximal doses of 15–24 Gy in 1 fraction according to volume guidelines based on maximum tolerated dose results from the RTOG 90-05 dose escalation study (shown below).²⁴ Caution is recommended for lesions >3 cm, and single-fraction radiosurgery is not typically recommended for lesions >4 cm.**
 - Lesions with maximum diameter ≤20 mm receive up to 24 Gy
 - Lesions with maximum diameter 21–30 mm receive up to 18 Gy
 - Lesions with maximum diameter 31–40 mm receive up to 15 Gy
 - ◊ **Larger tumors, however, may be treated with fractionated SRT. Potential regimens include, but are not limited to:^{25,26}**
 - 24–27 Gy in 3 fractions
 - 25–35 Gy in 5 fractions
- ▶ **SRS/SRT as adjuvant treatment**
 - ◊ **Smaller cavities may be treated with single-fraction SRS maximal doses ranging from 12–20 Gy depending on cavity volume per the NCCTG N107C trial protocol.²⁷**
 - Lesions <4.2 cc receive 20 Gy
 - Lesions ≥4.2 cc to <8.0 cc receive 18 Gy
 - Lesions ≥8.0 cc to <14.4 cc receive 17 Gy
 - Lesions ≥14.4 cc to <20 cc receive 15 Gy
 - Lesions ≥20 cc to <30 cc receive 14 Gy
 - Lesions ≥30 cc to <5 cm receive 12 Gy
 - ◊ **In general, single-fraction adjuvant SRS is not recommended for cavities >5 cm.**
 - ◊ **Larger cavities, however, may be treated with fractionated SRT. Potential regimens include, but are not limited to:**
 - 24–27 Gy in 3 fractions
 - 25–35 Gy in 5 fractions
- ▶ **Palliative whole brain RT (WBRT) (See ME-16)**
 - ◊ **Only consider for palliative purposes when SRS/SRT is not feasible in patients with good performance status for whom disease has progressed (See ME-K).**
 - ◊ **The pros and cons of WBRT should be considered carefully in the context of individual patient preferences/goals of care.²⁸**
 - ◊ **WBRT can be considered if radiographic, clinical, or pathologic signs of leptomeningeal carcinomatosis are present (see LEPT-1 in the [NCCN Guidelines for Central Nervous System Cancers](#)).**
 - ◊ **Common WBRT regimens include:**
 - 30 Gy in 10 fractions over 2 weeks
 - 37.5 Gy in 15 fractions over 3 weeks
 - 20 Gy in 5 fractions over 1 week
- ▶ **Adjuvant WBRT**
 - ◊ **Adjuvant WBRT after resection or SRS/SRT is not recommended for patients with melanoma.²⁹**
 - Recent data from a randomized trial suggest that adjuvant WBRT is associated with worse cognitive decline when compared to adjuvant SRS/SRT alone.²⁷ Although local control appears superior with adjuvant WBRT, there were no differences in OS.
 - ◊ **For dosing, see Palliative WBRT section above.**
- ▶ **Also see [NCCN Guidelines for Central Nervous System Cancers](#).**

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued
References](#)

**ME-H
3 OF 7**

**PRINCIPLES OF RADIATION THERAPY****Distant Metastatic Disease (continued)****• Palliative Treatment of Symptomatic Extracranial Metastases**

▶ A variety of treatment regimens are acceptable depending on location and/or clinical indication. Higher doses and/or hypofractionated regimens may be associated with more durable palliation.^{30,31}

▶ Potential regimens include:

- ◊ 24–27 Gy in 3 fractions over 1–1.5 weeks^{20,21}
- ◊ 32 Gy in 4 fractions over 4 weeks²²
- ◊ 40 Gy in 8 fractions over 4 weeks²¹
- ◊ 50 Gy in 20 fractions over 4 weeks²²
- ◊ 30 Gy in 10 fractions over 2 weeks²³
- ◊ 30 Gy in 5 fractions over 2 weeks
- ◊ 36 Gy in 6 fractions over 2 weeks
- ◊ 20 Gy in 5 fractions over 1 week²³
- ◊ 8 Gy in 1 fraction over 1 day²³

• Ablative Treatment for Intact Extracranial Metastases

▶ Higher doses utilizing conformal techniques such as stereotactic body RT (SBRT) may offer more durable local control.³²

▶ SBRT may be considered for selected patients with oligometastasis.³²

▶ This must be weighed against potential toxicities, and strict adherence to normal tissue constraints is recommended.

▶ Spine SBRT regimens include but are not limited to:

- ◊ 16–24 Gy in 1 fraction over 1 day³¹
- ◊ 20–24 Gy in 2 fractions over 1 week³³
- ◊ 24–27 Gy in 3 fractions over 1 week³⁴
- ◊ 25–40 Gy in 5 fractions over 2 weeks

▶ SBRT regimens for other body sites include but are not limited to:

- ◊ 48–60 Gy in 3 fractions over 1 week^{32,35}
- ◊ 40–60 Gy in 4–5 fractions over 2 weeks^{32,36}
- ◊ 16–24 Gy in 1 fraction over 1 day³¹

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued](#)
[References](#)

ME-H
4 OF 7



PRINCIPLES OF RADIATION THERAPY

Managing Systemic Therapy During Radiation

- Interactions between RT and systemic therapies need to be very carefully considered as there is potential for increased toxicity, particularly when utilizing higher doses of radiation.³⁷⁻³⁹
- BRAF and/or MEK inhibitors may interact with radiation and can lead to increased CNS, pulmonary, dermatologic, and visceral toxicity.^{40,41} Consideration should be given to holding BRAF and/or MEK inhibitors ≥ 3 days before and after fractionated RT and ≥ 1 day before and after SRS (or other high-dose-per-fraction regimens).⁴²
- Several studies have explored the potential interaction between immunotherapy and RT. These studies have found no clear evidence that consistent adverse interactions exist.^{38,39,43-45}

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued](#)
[References](#)

ME-H
5 OF 7

**PRINCIPLES OF RADIATION THERAPY**
REFERENCES

- 1 Adams G, Foote M, Brown S, Burmeister B. Adjuvant external beam radiotherapy after therapeutic groin lymphadenectomy for patients with melanoma: a dosimetric comparison of three-dimensional conformal and intensity-modulated radiotherapy techniques. *Melanoma Res* 2017;27:50-56.
- 2 Mattes MD, Zhou Y, Berry SL, Barker CA. Dosimetric comparison of axilla and groin radiotherapy techniques for high-risk and locally advanced skin cancer. *Radiat Oncol J* 2016;34:145-155.
- 3 Farshad A, Burg G, Panizzon R, Dummer R. A retrospective study of 150 patients with lentigo maligna and lentigo maligna melanoma and the efficacy of radiotherapy using Grenz or soft X-rays. *Br J Dermatol* 2002;146:1042-1046.
- 4 Harwood AR. Conventional fractionated radiotherapy for 51 patients with lentigo maligna and lentigo maligna melanoma. *Int J Radiat Oncol Biol Phys* 1983;9:1019-1021.
- 5 Hedblad MA, Mallbris L. Grenz ray treatment of lentigo maligna and early lentigo maligna melanoma. *J Am Acad Dermatol* 2012;67:60-68.
- 6 Christie DR, Tiver KW. Radiotherapy for melanotic freckles. *Australas Radiol* 1996;40:331-333.
- 7 Agrawal S, Kane JM, 3rd, Guadagnolo BA, et al. The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma. *Cancer* 2009;115:5836-5844.
- 8 Rule WG, Allred JB, Pockaj BA, et al. Results of NCCTG N0275 (Alliance) - a phase II trial evaluating resection followed by adjuvant radiation therapy for patients with desmoplastic melanoma. *Cancer Med* 2016;5:1890-1896.
- 9 Guadagnolo BA, Prieto V, Weber R, et al. The role of adjuvant radiotherapy in the local management of desmoplastic melanoma. *Cancer* 2014;120:1361-1368.
- 10 Strom T, Caudell JJ, Han D, et al. Radiotherapy influences local control in patients with desmoplastic melanoma. *Cancer* 2014;120:1369-1378.
- 11 Foote MC, Burmeister B, Burmeister E, et al. Desmoplastic melanoma: the role of radiotherapy in improving local control. *ANZ J Surg* 2008;78:273-276.
- 12 Ang KK, Peters LJ, Weber RS, et al. Postoperative radiotherapy for cutaneous melanoma of the head and neck region. *Int J Radiat Oncol Biol Phys* 1994;30:795-798.
- 13 Henderson MA, Burmeister BH, Ainslie J, et al. Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial. *Lancet Oncol* 2015;16:1049-1060.
- 14 Creagan ET, Cupps RE, Ivins JC, et al. Adjuvant radiation therapy for regional nodal metastases from malignant melanoma: a randomized, prospective study. *Cancer* 1978;42:2206-2210.
- 15 Beadle BM, Guadagnolo BA, Ballo MT, et al. Radiation therapy field extent for adjuvant treatment of axillary metastases from malignant melanoma. *Int J Radiat Oncol Biol Phys* 2009;73:1376-1382.
- 16 Lee RJ, Gibbs JF, Proulx GM, et al. Nodal basin recurrence following lymph node dissection for melanoma: implications for adjuvant radiotherapy. *Int J Radiat Oncol Biol Phys* 2000;46:467-474.
- 17 Chang DT, Amdur RJ, Morris CG, Mendenhall WM. Adjuvant radiotherapy for cutaneous melanoma: comparing hypofractionation to conventional fractionation. *Int J Radiat Oncol Biol Phys* 2006;66:1051-1055.
- 18 Bibault JE, Dewas S, Mirabel X, et al. Adjuvant radiation therapy in metastatic lymph nodes from melanoma. *Radiat Oncol* 2011;6:12.
- 19 Strojanc P, Jancar B, Cemazar M, et al. Melanoma metastases to the neck nodes: role of adjuvant irradiation. *Int J Radiat Oncol Biol Phys* 2010;77:1039-1045.
- 20 Overgaard J, Gonzalez Gonzalez D, Hulshof MC, et al. Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. *European Society for Hyperthermic Oncology. Lancet* 1995;345:540-543.
- 21 Overgaard J, von der Maase H, Overgaard M. A randomized study comparing two high-dose per fraction radiation schedules in recurrent or metastatic malignant melanoma. *Int J Radiat Oncol Biol Phys* 1985;11:1837-1839.
- 22 Sause WT, Cooper JS, Rush S, et al. Fraction size in external beam radiation therapy in the treatment of melanoma. *Int J Radiat Oncol Biol Phys* 1991;20:429-432.
- 23 Huguenin PU, Kieser S, Glanzmann C, et al. Radiotherapy for metastatic carcinomas of the kidney or melanomas: an analysis using palliative end points. *Int J Radiat Oncol Biol Phys* 1998;41:401-405.
- 24 Shaw E, Scott C, Souhami L, et al. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. *Int J Radiat Oncol Biol Phys* 2000;47:291-298.
- 25 Minniti G, D'Angelillo RM, Scaringi C, et al. Fractionated stereotactic radiosurgery for patients with brain metastases. *J Neurooncol* 2014;117:295-301.
- 26 Rajakesari S, Arvold ND, Jimenez RB, et al. Local control after fractionated stereotactic radiation therapy for brain metastases. *J Neurooncol* 2014;120:339-346.

Note: All recommendations are category 2A unless otherwise indicated.**Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.**[Continued](#)

**PRINCIPLES OF RADIATION THERAPY**
REFERENCES

- 27 Brown PD, Ballman KV, Cerhan JH, et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC.3): a multicentre, randomised, controlled, phase 3 trial. *Lancet Oncol* 2017;18:1049-1060.
- 28 Mulvenna P, Nankivell M, Barton R, et al. Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial. *Lancet* 2016;388:2004-2014.
- 29 Hong AM, Fogarty GB, Dolven-Jacobsen K, et al. Adjuvant whole-brain radiation therapy compared with observation after local treatment of melanoma brain metastases: a multicenter, randomized phase III trial. *J Clin Oncol* 2019;37:3132-3141.
- 30 Olivier KR, Schild SE, Morris CG, et al. A higher radiotherapy dose is associated with more durable palliation and longer survival in patients with metastatic melanoma. *Cancer* 2007;110:1791-1795.
- 31 Gerszten PC, Burton SA, Quinn AE, et al. Radiosurgery for the treatment of spinal melanoma metastases. *Stereotact Funct Neurosurg* 2005;83:213-221.
- 32 Stinauer MA, Kavanagh BD, Schefter TE, et al. Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control. *Radiat Oncol* 2011;6:34.
- 33 Sahgal A, Roberge D, Schellenberg D, et al. The Canadian Association of Radiation Oncology scope of practice guidelines for lung, liver and spine stereotactic body radiotherapy. *Clin Oncol (R Coll Radiol)* 2012;24:629-639.
- 34 Wang XS, Rhines LD, Shiu AS, et al. Stereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: a phase 1-2 trial. *Lancet Oncol* 2012;13:395-402.
- 35 Seung SK, Curti BD, Crittenden M, et al. Phase 1 study of stereotactic body radiotherapy and interleukin-2--tumor and immunological responses. *Sci Transl Med* 2012;4:137-174.
- 36 Singh D, Chen Y, Hare MZ, et al. Local control rates with five-fraction stereotactic body radiotherapy for oligometastatic cancer to the lung. *J Thorac Dis* 2014;6:369-374.
- 37 Kroeze SG, Fritz C, Hoyer M, et al. Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: A systematic review. *Cancer Treat Rev* 2017;53:25-37.
- 38 Bang A, Wilhite TJ, Pike LRG, et al. Multicenter evaluation of the tolerability of combined treatment with PD-1 and CTLA-4 immune checkpoint inhibitors and palliative radiation therapy. *Int J Radiat Oncol Biol Phys* 2017;98:344-351.
- 39 Barker CA, Postow MA, Khan SA, et al. Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma. *Cancer Immunol Res* 2013;1:92-98.
- 40 Anker CJ, Ribas A, Grossmann AH, et al. Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma. *J Clin Oncol* 2013;31:e283-e287.
- 41 Peuvrel L, Ruellan AL, Thillays F, et al. Severe radiotherapy-induced extracutaneous toxicity under vemurafenib. *Eur J Dermatol* 2013;23:879-881.
- 42 Anker CJ, Grossmann KF, Atkins MB, et al. Avoiding severe toxicity from combined BRAF inhibitor and radiation treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG). *Int J Radiat Oncol Biol Phys* 2016;95:632-646.
- 43 Ahmed KA, Stallworth DG, Kim Y, et al. Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy. *Ann Oncol* 2016;27:434-441.
- 44 Hiniker SM, Reddy SA, Maecker HT, et al. A prospective clinical trial combining radiation therapy with systemic immunotherapy in metastatic melanoma. *Int J Radiat Oncol Biol Phys* 2016;96:578-588.
- 45 Williams NL, Wuthrick EJ, Kim H, et al. Phase 1 study of ipilimumab combined with whole brain radiation therapy or radiosurgery for melanoma patients with brain metastases. *Int J Radiat Oncol Biol Phys* 2017;99:22-30.

Note: All recommendations are category 2A unless otherwise indicated.**Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.**

**SYSTEMIC THERAPY CONSIDERATIONS****General Principles**

- Treatment decisions need to be individualized based upon patient goals and anticipated therapy tolerance. Some general principles are outlined below.
- Response and duration of benefit are influenced by burden of disease when using targeted or immune therapies.
- For patients whose tumor harbors a *BRAF* mutation and who would benefit from a more rapid response, *BRAF/MEK* inhibition may be preferred.

Considerations for Selection of Systemic Therapy for Unresectable or Metastatic Disease

- Randomized clinical trials are ongoing to compare front-line systemic targeted therapy (*BRAF/MEK*) to immune therapy with checkpoint inhibitors. Results will help define the best approach for initial therapy.
 - ▶ Considerations for deciding between anti-PD-1/ipilimumab combination versus anti-PD-1 alone
 - ◇ Both anti-PD-1 monotherapy and anti-PD-1/ipilimumab combination therapy may provide durable disease control.
 - ◇ Combination therapy is associated with higher clinical response rates, PFS and OS, and a reduced need for subsequent therapy, at the expense of more frequent and more severe immune-related adverse events (irAEs).
 - ◇ Thus, combination therapy may be preferred in patients with good performance status when appropriate clinical support is readily available ([see NCCN Guidelines for Management of Immunotherapy-Related Toxicities](#)).
 - ▶ Considerations for anti-PD-1/ipilimumab dosing and anti-PD-1 monotherapy dosing
 - ◇ The clinical response to FDA-approved anti-PD-1 dosing schedules appears similar, although comparative trials are not available. The choice of regimen may vary based on the physician's preference for patient monitoring and the patient's schedule.
 - ◇ The use of ipilimumab 3 mg/kg with nivolumab 1 mg/kg every 3 weeks for 4 doses with subsequent consideration for nivolumab monotherapy is an FDA-approved regimen.
 - ◇ The CheckMate 511 trial tested an alternative regimen of nivolumab 3 mg/kg in combination with ipilimumab 1 mg/kg x 4 doses [NIVO3 + IPI1], versus the FDA-approved regimen of nivolumab 1 mg/kg in combination with ipilimumab 3 mg/kg x 4 [NIVO1 + IPI3]; both regimens with subsequent nivolumab monotherapy. In the primary analysis of the study, the rate of grade 3–5 treatment-related irAEs was lower with the NIVO3 + IPI1 regimen. Although not designed or powered to look at efficacy, the NIVO3 + IPI1 and NIVO1 + IPI3 regimens yielded overall response rates (ORRs) of 47.2% and 52.8%, respectively; 3-year PFS rates of 38% and 43%, respectively; and 3-year OS rates of 59% and 61%, respectively.
 - ◇ Alternative dosing can be utilized for patients in whom there is increased concern regarding ability to tolerate irAEs.
 - ◇ The initial clinical trials and FDA approvals of pembrolizumab and nivolumab in 2014 used dosing based on patient weight (2 mg/kg every 3 weeks for pembrolizumab and 3 mg/kg every 2 weeks for nivolumab). Subsequently the FDA amended dosing to flat doses (200 mg or 400 mg every 3 or 6 weeks, respectively, for pembrolizumab, or 240 mg or 480 mg every 2 or 4 weeks, respectively, for nivolumab), which are safe and efficacious. However, substantial cost savings for pembrolizumab and nivolumab may be obtained by weight-based dosing, depending on patient weight and on institutional practices regarding vial sharing.
 - ▶ Considerations for selecting among the three *BRAF/MEK* inhibitor options
 - ◇ Comparative studies are not available to select between the *BRAF/MEK* combination therapy agents.
 - ◇ Toxicity may require dose/schedule modifications ([See Management of Toxicities Associated with Targeted Therapy, ME-J](#)).

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued](#)

ME-I
1 OF 4

**SYSTEMIC THERAPY CONSIDERATIONS****Considerations for Patients with CNS Disease**

- For treatment planning in patients with CNS disease, consider prioritizing systemic therapies that have been shown to have activity in CNS metastases.
- For systemic therapy in patients with asymptomatic brain metastasis not requiring corticosteroids, combination therapy with nivolumab/ipilimumab (nivolumab 1 mg/kg and ipilimumab 3 mg/kg) is preferred in comparison to anti-PD-1 monotherapy or dabrafenib plus trametinib due to superior intracranial activity.
- The treatment plan for patients with brain metastases should be coordinated with the radiation oncology team even when radiation is not initially utilized.
- For patients with symptomatic brain lesions or who require corticosteroids for symptom control, comprehensive care by a multidisciplinary team, including neurosurgery, radiation oncology, medical oncology, and palliative care, is strongly recommended.

Considerations for Adjuvant Therapy

- For adjuvant therapy of resected stage III melanoma, preferred regimens include nivolumab, pembrolizumab, and dabrafenib plus trametinib (if *BRAF* mutation-positive). Ipilimumab may be indicated in special circumstances if prior exposure to PD-1. In the adjuvant setting, improved RFS was not demonstrated with the addition of ipilimumab 1 mg/kg every 6 weeks to nivolumab 240 mg every 2 weeks versus nivolumab 480 mg every 4 weeks for up to 1 year.
- For adjuvant therapy of metastatic melanoma, principles are similar to those discussed above, with the following additional consideration: The IMMUNED study was a randomized phase 2 study of adjuvant therapy of stage IV melanoma with NED after surgery or radiation.¹ Treatment duration was up to 1 year; treatment arms were nivolumab 3 mg/kg every 2 weeks, nivolumab 1 mg/kg and ipilimumab 3 mg/kg every 3 weeks x 4, followed by nivolumab 3 mg/kg every 2 weeks, or placebo. The results showed that both active regimens significantly improved RFS. Overall survival (OS) was significantly improved for patients who received nivolumab + ipilimumab compared to placebo.

When to Stop or Switch Therapies

- **Definition of maximal clinical benefit**
 - ▶ Patients who achieve a clinical response following combination immune therapy and who have experienced irAEs (grade 3 or higher) and receive no further treatment do similarly well compared to patients who continue on to maintenance anti-PD-1 treatment.
 - ▶ The optimal duration of anti-PD-1 therapy remains unknown.
 - ▶ Most patients who achieve a complete or partial response and discontinue anti-PD-1 monotherapy after 2 years of therapy maintain the response with 2 years of follow-up.
- **Defining response and pseudoprogression**
 - ▶ Radiographic or clinically evident increase in tumor size may precede regression early in the course of immune-based therapy (pseudoprogression).
 - ▶ As the average time to response varies between 6 and 12 weeks depending upon the therapy, it is reasonable to continue immunotherapy for an additional treatment interval (6–10 weeks) in some patients with tumor growth who are tolerating therapy and doing well clinically.
 - ▶ Continued growth 16 weeks after starting immunotherapy should be considered true progression

¹ Livingstone E, et al. Lancet 2022;400:1117-1129.**Note: All recommendations are category 2A unless otherwise indicated.****Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.****Continued****ME-I
2 OF 4**

**SYSTEMIC THERAPY CONSIDERATIONS****Recommendations for Patients Who Progress on Systemic Therapy**

- ***BRAF* V600-activating mutation present:**
 - ▶ For patients who progress on immune therapy, options include the following (if not already received):
 - ◇ **BRAF/MEK inhibitor combination therapy**
 - ◇ **Combination immune therapy, options include:**
 - **Anti-PD-1/ipilimumab**
 - **T-VEC/ipilimumab therapy (for low burden of disease and injectable lesions)**
 - ◇ **Ipilimumab monotherapy (if prior progression on single-agent anti-PD-1 therapy)**
 - ◇ **Pembrolizumab/lenvatinib after progression on anti-PD(L)-1**
 - ◇ **Clinical trials**
 - ▶ For patients who progress following BRAF/MEK inhibitor combination therapy, consider the following options (if not previously received):
 - ◇ **Combination immune therapy, options include:**
 - **Anti-PD-1/ipilimumab**
 - **T-VEC/ipilimumab therapy (for low burden of disease and injectable lesions)**
 - **Pembrolizumab/lenvatinib after progression on anti-PD(L)-1**
 - ◇ **Single-agent anti-PD-1**
 - ◇ **T-VEC monotherapy (for low burden of disease and injectable lesions)**
 - ◇ **Clinical trials**
 - ▶ **Some patients who previously demonstrated a clinical benefit to BRAF/MEK inhibition may benefit from rechallenge with BRAF/MEK inhibitors after other therapies. The optimal time interval between initial treatment and retreatment with BRAF/MEK to expect further clinical benefit has not been defined.**
 - ▶ For patients who progress on BRAF/MEK inhibitor combination therapy, anti-PD-1 therapy, and ipilimumab (in combination with anti-PD-1 or sequentially), consider the following options:
 - ◇ **Clinical trials**
 - ◇ **T-VEC monotherapy (for low burden of disease and injectable lesions)**
 - ◇ **High-dose bolus IL-2**
 - ◇ **Cytotoxic chemotherapy**
 - ◇ **Best supportive care**

- ***BRAF* V600-activating mutation not present:**
 - ▶ For patients with progression on anti-PD-1 monotherapy, consider the following options (if not already received):
 - ◇ **Combination immune therapy, options include:**
 - **Clinical trials**
 - **Anti-PD-1/ipilimumab (preferred)**
 - **T-VEC/ipilimumab therapy (for low burden of disease and injectable lesions)**
 - ◇ **Ipilimumab monotherapy (if prior progression on single-agent anti-PD-1 therapy).**
 - ◇ **Pembrolizumab/lenvatinib after progression on anti-PD-1/PD-L1**
 - ▶ For patients with progression on anti-PD-1 and ipilimumab (in combination with anti-PD-1 or sequentially), consider the following options:
 - ◇ **Clinical trials**
 - ◇ **T-VEC (for low burden of disease and injectable lesions)**
 - ◇ **High-dose bolus IL-2**
 - ◇ **Cytotoxic chemotherapy**
 - ◇ **Best supportive care**

Use of High-Dose IL-2 in Select Patients

- ▶ **IL-2 may be used in patients who would be anticipated to tolerate therapy as assessed by an experienced treating physician**
- ▶ **IL-2 use should be limited to centers and providers with prior delivery of IL-2**
- ▶ **IL-2 can give durable responses in a subset of patients**
- ▶ **IL-2 activity and safety data are limited for patients who have progressed on available therapies (eg, immune checkpoint inhibitors)²**

² Buchbinder EI, et al. J Immunother Cancer 2019;7:49.**Note:** All recommendations are category 2A unless otherwise indicated.**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.**Continued****ME-I**
3 OF 4

**SYSTEMIC THERAPY CONSIDERATIONS****Use of Cytotoxic Agents for Unresectable or Distant Metastatic Disease**

- **Appropriate context for use of cytotoxic agents**
 - ▶ Cytotoxic agents may be used in patients who are not candidates for further standard, immune-based, BRAF/MEK inhibitor, or clinical trial-directed therapy and who have symptomatic cancer.
 - ▶ While response rates and toxicity differ across cytotoxic agents, the impact on OS is limited.
- **Considerations for cytotoxic agents**
 - ▶ Among the recommended cytotoxic options, combination of carboplatin and paclitaxel or single-agent temozolomide are preferred.
 - ▶ Other agents include dacarbazine, paclitaxel, albumin-bound paclitaxel, or CVD.
 - ▶ Multiagent chemotherapy has shown a marginal improvement in response rate with no difference in OS when compared with single-agent dacarbazine.

Considerations for Selection of Adjuvant Systemic Therapy

- **Deciding between systemic therapy versus observation**
 - ▶ Both targeted agents (dabrafenib/trametinib) and anti-PD-1 therapies have shown improvement in RFS (both options preferred), but the impact of early (adjuvant) versus late (at time of recurrence) treatment on OS remains undefined.
 - ▶ Thus, for high-risk patients, observation alone remains an option.
 - ▶ In patients with a low risk of recurrence (for example, stage IIIA with <1 mm of nodal tumor burden), observation is preferred; although adjuvant systemic therapy is FDA approved for these patients, they were excluded from the prospective adjuvant therapy trials.
- **Considerations for selecting among adjuvant systemic therapies**
 - ▶ Side effects from immune checkpoint inhibitor therapy tend to be longer lasting than those from BRAF/MEK inhibitor therapy, persisting after discontinuation of treatment.
 - ▶ Whereas BRAF/MEK inhibitor therapy is orally administered, immune checkpoint inhibitors are parenterally administered.
 - ▶ Patient history, including pre-existing autoimmune disease, or other conditions that would be exacerbated by toxicities associated with therapy, should be considered.
 - ▶ There is no good evidence basis for selection between adjuvant BRAF/MEK inhibitors versus immune checkpoint inhibitors, as both have similar efficacy. Some clinicians prefer immune checkpoint inhibitors based on the presumption that these provide more durable benefit, but there is no high-quality evidence to support this.
 - ▶ Due to high rates of associated toxicity, adjuvant ipilimumab monotherapy has largely been replaced by adjuvant anti-PD-1 therapy. There are very few settings in which single-agent adjuvant ipilimumab is appropriate. The rare scenario in which adjuvant ipilimumab may be appropriate would be in patients who have prior exposure to anti-PD-1 therapy, especially if the patient experienced progression or recurrence on prior anti-PD-1 therapy.
 - ▶ Ipilimumab (10 mg/kg) demonstrated an improvement in OS compared to placebo, although its toxicity precludes this from being a preferred option.
 - ▶ Ipilimumab (3 mg/kg) is the recommended dose. This regimen appears to result in a similar disease-free survival (DFS) benefit as adjuvant high-dose ipilimumab, but with fewer and less severe adverse events.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

**MANAGEMENT OF TOXICITIES ASSOCIATED WITH TARGETED THERAPY****Targeted Therapy (BRAF or combined BRAF/MEK inhibitors)****• Dermatologic:**

- ▶ Regular dermatologic evaluation and referral to a dermatologist or provider experienced in the diagnosis and management of cutaneous manifestations of targeted therapy is recommended. BRAF inhibitors are associated with cutaneous squamous cell carcinoma, extreme photosensitivity, and other dermatologic toxicities, which occur much less often with concurrent MEK inhibitors.
- ▶ Severe and life-threatening¹ skin toxicity (eg, drug-induced hypersensitivity syndrome) can occur with the use of BRAF inhibitors following immune checkpoint blockade, and requires prompt dermatologic consultation for accurate diagnosis and treatment.²
- Pyrexia: Pyrexia (defined as a temperature of ≥ 38.5 °C) is a common (~55%) side effect of combining BRAF and MEK inhibitors and occurs less frequently with BRAF inhibitor monotherapy (~20%).^a The pyrexia is episodic, with a median duration of 9 days, and onset is often 2–4 weeks following the start of therapy. Pyrexia may be associated with chills, night sweats, rash, dehydration, electrolyte abnormalities, and hypotension. Stopping or holding BRAF/MEK inhibitor combination at the onset of pyrexia will often interrupt the episode, and treatment can be resumed with full-dose BRAF/MEK inhibitors upon cessation of pyrexia and pyrexia-related symptoms. Upon re-exposure to BRAF/MEK inhibitors, repeat pyrexia events can occur, but grade >3 events are uncommon (21%). In occasional instances of prolonged or severe pyrexia not responsive to discontinuation of BRAF/MEK inhibitors, low-dose steroids (prednisone 10 mg/day) can be used. Patients with pyrexia should be advised to use antipyretics as needed and increase fluid intake.
- For more information on toxicities associated with dabrafenib with or without trametinib, vemurafenib with or without cobimetinib, or encorafenib with or without binimetinib and for the management of these toxicities, see the full prescribing information (<http://www.accessdata.fda.gov/scripts/cder/daf>).

Footnotes

^a The frequency of pyrexia and other adverse events varies between specific BRAF/MEK inhibitor combinations.

References

- ¹ Maloney NJ, Rana J, Yang JJ, et al. Clinical features of drug-induced hypersensitivity syndrome to BRAF inhibitors with and without previous immune checkpoint inhibition: a review. *Support Care Cancer* 2022;30:2839-2851.
- ² Lamiaux M, Scalbert C, Lepasant P, et al. Severe skin toxicity with organ damage under the combination of targeted therapy following immunotherapy in metastatic melanoma. *Melanoma Res* 2018;28:451-457.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.



PRINCIPLES OF BRAIN METASTASES MANAGEMENT

Selection of Initial Treatment Modality (Brain-Directed vs. Systemic)

- **Multidisciplinary evaluation (ie, neurosurgery, radiation oncology, medical oncology) prior to initiation of treatment is strongly recommended.**
- **As a general approach, patients who present with a higher burden of intracranial disease associated with symptoms will often require local management of disease. In patients with lower volume, asymptomatic brain metastases as well as those with extensive extracranial disease, an initial course of systemic therapy may be preferred. It is likely that many patients presenting with brain metastases will need both systemic therapy and local brain-directed therapy over their course of treatment.**
- **The selection of initial treatment modality depends on a combination of clinical factors. Those factors determined to be most important are included below:**
 - ▶ **The extent of intracranial disease, including factors such as the size, number, and location of metastases guides the initial treatment of brain metastases.**
 - ◊ **There are limited data supporting the efficacy of upfront systemic therapy in patients with symptomatic brain metastases,¹⁻⁶ and brain-directed therapy is generally preferred.**
 - ◊ **In patients with other high-risk clinical scenarios (eg, hemorrhage, eloquent cortex, brainstem), brain-directed therapy may be preferred over systemic therapy.**
 - ▶ **The burden of extracranial disease will affect initial treatment selection. In patients with extensive extracranial disease, prompt initiation of systemic therapy may be preferred.**
 - ▶ **The context in which the brain metastases developed should be considered when selecting initial treatment. In patients who develop brain metastases while on systemic therapy, brain-directed therapy may be preferred.**

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued](#)

**ME-K
1 OF 5**

**PRINCIPLES OF BRAIN METASTASES MANAGEMENT****Brain-Directed Therapy****• Surgery versus radiation**

- ▶ **Surgery is the preferred option for large, symptomatic lesions or single lesions in resectable areas, particularly when there is diagnostic uncertainty or when additional tissue sampling may drive future therapeutic decisions.**
 - ◊ **Postoperative radiation to the resection cavity may be considered to decrease the risk of local recurrence.⁷**
 - ◊ **Adjuvant WBRT is not recommended after resection for melanoma brain metastases.**
 - ▶ **SRS is the preferred radiation modality for melanoma brain metastases and can be delivered to multiple lesions depending on local experience and technology.**
 - ◊ **Large lesions should be treated with fractionated SRS (3–5 fractions) to decrease the risk of radionecrosis.**
 - ◊ **Adjuvant WBRT is not recommended after SRS/SRT for melanoma brain metastases.**
 - ▶ **Palliative WBRT**
 - ◊ **This is only recommended for palliative purposes when SRS/SRT is not feasible in patients with good performance status for whom disease has progressed.**
 - ◊ **WBRT delivers a lower dose of radiation to metastases in the brain and is associated with lower local control and increased risk of late neurocognitive impairment.**
 - ◊ **For patients receiving WBRT, hippocampal avoidance and memantine should be considered to reduce neurocognitive toxicity in eligible patients.⁸**
- **For a detailed discussion of radiation dosing and options, [see Principles of Radiation \(ME-H\)](#).**

• Management of symptoms

- ▶ **For patients who are symptomatic from their intracranial tumor burden, corticosteroids remain the mainstay of therapy.**
 - ◊ **Patients should be on the lowest dose possible to control symptoms with a plan to taper if intracranial disease responds to therapy.**
 - ◊ **The impact of corticosteroids on the efficacy of future or current immunotherapy should be considered and weighed against the severity of symptoms.**
- ▶ **Patients who present with seizures should be treated with standard first-line anticonvulsant drug therapy.**
 - ◊ **Close monitoring of serum levels and use of the lowest effective dose is recommended to minimize toxicity.**
 - ◊ **Prophylactic anticonvulsant drug therapy in a patient with no known seizure history is generally not recommended due to the adverse side effect profile of medical therapies.^{9,10} However, as hemorrhage is associated with increased risk of seizure, selected patients with large bleeding lesions could be considered for prophylactic anticonvulsants.**
- ▶ **For symptomatic lesions following SRS that are not responsive to corticosteroids, consider neurosurgical evaluation for both diagnosis and therapy.**
 - ◊ **If unresectable, a short course of bevacizumab may allow improvement in overall quality of life by reducing steroid dose and improving functional status.¹¹**
- ▶ **In other scenarios, bevacizumab may also be used as a means to lower steroid dose in patients who are refractory to steroid withdrawal.**
 - ◊ **If clinically feasible, allow bevacizumab washout for at least 2 weeks before surgery. [See Medical Management \(BRAIN-E 2 of 3\) from the NCCN Guidelines for Central Nervous System Cancers.](#)¹²**
 - ◊ **The risks of anti-vascular endothelial growth factor (VEGF) therapy in the setting of melanoma metastases with hemorrhage should be weighed against perceived benefit.**

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued](#)

**ME-K
2 OF 5**

**PRINCIPLES OF BRAIN METASTASES MANAGEMENT****Systemic Therapy**

- Some patients may be candidates for systemic therapy as the sole initial treatment modality, with no need for brain-directed therapy (surgery or RT) unless there is intracranial progression.
- For all patients treated with this approach, close surveillance (brain MRI every 6–8 weeks) is strongly recommended.

Patients who are most likely to be considered for systemic therapy as the sole initial treatment modality include:

- Patients with <3 cm asymptomatic brain metastases, not requiring corticosteroids, and no prior treatment with systemic therapy.
 - ▶ The clinical trial supporting this strategy utilized nivolumab/ipilimumab and found high intracranial response rates in patients with previously untreated brain metastases, which appear to be durable.
 - ◊ Systemic corticosteroids may interfere with the efficacy of nivolumab/ipilimumab and should be avoided in patients being considered for combination nivolumab/ipilimumab.
 - ▶ For patients who are not candidates for nivolumab/ipilimumab combination therapy:
 - ◊ Single-agent anti-PD-1 therapies have been shown to have only modest intracranial activity, and are not preferred as the initial treatment modality for treatment of brain metastases in most patients.
 - ◊ Consider early brain-directed therapy.
 - ◊ Consider BRAF/MEK inhibitor combination therapy in patients with *BRAF* V600-activating mutation.
- Select symptomatic patients with *BRAF*-mutated melanoma who have not been previously treated with a BRAF/MEK inhibitor.
 - ▶ BRAF/MEK inhibitors result in a high intracranial response rate; however, PFS is shorter than reported data for extracranial disease. As such, this approach may be most useful when patients also have a large burden of extracranial disease or numerous brain metastases not amenable to local therapy.
 - ▶ Patients treated with this approach are very likely to need subsequent brain-directed therapy, and should be monitored closely.
 - ▶ [See Systemic Therapy for Unresectable or Metastatic Disease \(MELSYS 1 of 8\)](#) for recommended BRAF/MEK inhibitor combinations.

Adjuvant Therapy After Resection of Brain Metastases

- Following resection of brain metastases, adjuvant radiation to the cavity may be considered.⁷
- Patients rendered NED from following resection of brain metastases may be considered for adjuvant systemic therapy.
 - ▶ There are no data to guide selection of the optimal adjuvant systemic therapy in patients rendered NED by brain directed-treatment ([See ME-16](#) for adjuvant systemic therapy options for resected stage IV disease).

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued](#)

ME-K
3 OF 5



PRINCIPLES OF BRAIN METASTASES MANAGEMENT

Integration of Systemic Therapies with Brain-Directed Therapies

- Many patients with melanoma brain metastases will require a combined modality approach. As described above, the choice and sequencing of therapy depends on a number of clinical factors.
 - ▶ For patients who are on BRAF/MEK inhibitor combination therapy and RT is determined to be appropriate, it is recommended to hold therapy 1 day before and after SRS, and at least 3 days before and after fractionated RT.¹³
 - ▶ Limited data are available, but currently there does not appear to be a concerning safety signal with the combination of RT and immune checkpoint inhibitors.
 - ▶ In select patients who are otherwise continuing to benefit from systemic therapy, local treatment for the brain metastases and continuation of the same systemic therapy can be considered.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

[Continued](#)

ME-K
4 OF 5



PRINCIPLES OF BRAIN METASTASES MANAGEMENT REFERENCES

- 1 Tawbi HA-H, Forsyth PAJ, Hodi FS, et al. Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204). *J Clin Oncol* 2019;37:9501-9501.
- 2 Tawbi HA, Forsyth PA, Hodi FS, et al. Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. *Lancet Oncol* 2021;22:1692-1704.
- 3 Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. *Lancet Oncol* 2012;13:459-465.
- 4 Long GV, Atkinson V, Lo S, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. *Lancet Oncol* 2018;19:672-681.
- 5 Dummer R, Goldinger SM, Turtzsch CP, et al. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. *Eur J Cancer* 2014;50:611-621.
- 6 Davies MA, Saiag P, Robert C, et al. Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. *Lancet Oncol* 2017;18:863-873.
- 7 Mahajan A, Ahmed S, McAleer MF, et al. Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. *Lancet Oncol* 2017;18:1040-1048.
- 8 Brown PD, Gondi V, Pugh S, et al. Hippocampal avoidance during whole-brain radiotherapy plus memantine for patients with brain metastases: Phase III Trial NRG Oncology CC001. *J Clin Oncol* 2020;38:1019-1029.
- 9 Mikkelsen T, Paleologos NA, Robinson PD, et al. The role of prophylactic anticonvulsants in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. *J Neurooncol* 2010;96:97-102.
- 10 Chen CC, Rennert RC, Olson JJ. Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Role of Prophylactic Anticonvulsants in the Treatment of Adults with Metastatic Brain Tumors. *Neurosurgery* 2019;84:E195-E197.
- 11 Glitza IC, Guha-Thakurta N, D'Souza NM, et al. Bevacizumab as an effective treatment for radiation necrosis after radiotherapy for melanoma brain metastases. *Melanoma Res* 2017;27:580-584.
- 12 Sepúlveda-Sánchez JM and Pérez-Núñez A. The ESMO-EANO clinical practice guidelines for neurological and vascular complications of primary and secondary brain tumours: a valuable tool for clinicians. *Ann Oncol* 2020;32:139-141.
- 13 Anker CJ, Grossmann KF, Atkins MB, et al. Avoiding severe toxicity from combined BRAF inhibitor and radiation treatment: Consensus guidelines from the Eastern Cooperative Oncology Group (ECOG). *Int J Radiat Oncol Biol Phys* 2016;95:632-646.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

**Table 1. American Joint Committee on Cancer (AJCC)**
Definitions for T, N, M

| T Category | Thickness | Ulceration Status |
|--|------------------|----------------------------|
| TX: Primary tumor thickness cannot be assessed (eg, diagnosis by curettage) | Not applicable | Not applicable |
| T0: No evidence of primary tumor (eg, unknown primary or completely regressed melanoma) | Not applicable | Not applicable |
| Tis (melanoma <i>in situ</i>) | Not applicable | Not applicable |
| T1 | ≤1 mm | Unknown or unspecified |
| T1a | <0.8 mm | Without ulceration |
| T1b | <0.8 mm | With ulceration |
| | 0.8–1.0 mm | With or without ulceration |
| T2 | >1.0–2.0 mm | Unknown or unspecified |
| T2a | >1.0–2.0 mm | Without ulceration |
| T2b | >1.0–2.0 mm | With ulceration |
| T3 | >2.0–4.0 mm | Unknown or unspecified |
| T3a | >2.0–4.0 mm | Without ulceration |
| T3b | >2.0–4.0 mm | With ulceration |
| T4 | >4.0 mm | Unknown or unspecified |
| T4a | >4.0 mm | Without ulceration |
| T4b | >4.0 mm | With ulceration |

[Continued](#)Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. (For complete information and data supporting the staging tables, visit www.springer.com.)

**Table 1. American Joint Committee on Cancer (AJCC)**
Definitions for T, N, M (continued)**Extent of Regional Lymph Node and/or Lymphatic Metastasis**

| N Category | Number of Tumor-Involved Regional Lymph Node | Presence of In-Transit, Satellite, and/or Microsatellite Metastases |
|-------------------|---|--|
| NX | Regional nodes not assessed (eg, SLN biopsy not performed, regional nodes previously removed for another reason) Exception: When there are no clinically detected regional metastases in a pT1 cM0 melanoma, assign cN0 instead of pNX | No |
| N0 | No regional metastases detected | No |
| N1 | One tumor-involved node or in-transit, satellite, and/or microsatellite metastases with no tumor-involved nodes | |
| N1a | One clinically occult (ie, detected by SLN biopsy) | No |
| N1b | One clinically detected | No |
| N1c | No regional lymph node disease | Yes |
| N2 | Two or three tumor-involved nodes or in-transit, satellite, and/or microsatellite metastases with one tumor-involved node | |
| N2a | Two or three clinically occult (ie, detected by SLN biopsy) | No |
| N2b | Two or three, at least one of which was clinically detected | No |
| N2c | One clinically occult or clinically detected | Yes |
| N3 | Four or more tumor-involved nodes or in-transit, satellite, and/or microsatellite metastases with two or more tumor-involved nodes, or any number of matted nodes without or with in-transit, satellite, and/or microsatellite metastases | |
| N3a | Four or more clinically occult (ie, detected by SLN biopsy) | No |
| N3b | Four or more, at least one of which was clinically detected, or presence of any number of matted nodes | No |
| N3c | Two or more clinically occult or clinically detected and/or presence of any number of matted nodes | Yes |

[Continued](#)Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. (For complete information and data supporting the staging tables, visit www.springer.com.)

**Table 1. American Joint Committee on Cancer (AJCC)**

| M Category | Anatomic Site | LDH Level |
|-------------------|--|-----------------------------|
| M0 | No evidence of distant metastasis | Not applicable |
| M1 | Evidence of distant metastasis | See below |
| M1a | Distant metastasis to skin, soft tissue including muscle, and/or nonregional lymph node | Not recorded or unspecified |
| M1a(0) | | Not elevated |
| M1a(1) | | Elevated |
| M1b | Distant metastasis to lung with or without M1a sites of disease | Not recorded or unspecified |
| M1b(0) | | Not elevated |
| M1b(1) | | Elevated |
| M1c | Distant metastasis to non-CNS visceral sites with or without M1a or M1b sites of disease | Not recorded or unspecified |
| M1c(0) | | Not elevated |
| M1c(1) | | Elevated |
| M1d | Distant metastasis to CNS with or without M1a, M1b, or M1c sites of disease | Not recorded or unspecified |
| M1d(0) | | Normal |
| M1d(1) | | Elevated |

- Serum lactate dehydrogenase (LDH)
- Suffixes for M category: (0) LDH not elevated, (1) LDH elevated.
- No suffix is used if LDH is not recorded or is unspecified.

[Continued](#)

Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. (For complete information and data supporting the staging tables, visit www.springer.com.)

**Table 2. AJCC Prognostic Stage Groups**
Clinical Staging (cTNM)*

| | T | N | M |
|------------------|------------|----------|----------|
| Stage 0 | Tis | N0 | M0 |
| Stage IA | T1a | N0 | M0 |
| Stage IB | T1b | N0 | M0 |
| | T2a | N0 | M0 |
| Stage IIA | T2b | N0 | M0 |
| | T3a | N0 | M0 |
| Stage IIB | T3b | N0 | M0 |
| | T4a | N0 | M0 |
| Stage IIC | T4b | N0 | M0 |
| Stage III | Any T, Tis | ≥N1 | M0 |
| Stage IV | Any T | Any N | M1 |

*Clinical staging includes microstaging of the primary melanoma and clinical/radiologic/biopsy evaluation for metastases. By convention, clinical staging should be used after biopsy of the primary melanoma, with clinical assessment for regional and distant metastases. Note that pathological assessment of the primary melanoma is used for both clinical and pathological classification. Diagnostic biopsies to evaluate possible regional and/or distant metastasis also are included. Note there is only one stage group for clinical Stage III melanoma.

Pathological Staging (pTNM)**

| | T | N | M |
|----------------------------|-------------------|------------------|----------|
| Stage 0[†] | Tis | N0 | M0 |
| Stage IA | T1a | N0 | M0 |
| | T1b | N0 | M0 |
| Stage IB | T2a | N0 | M0 |
| Stage IIA | T2b | N0 | M0 |
| | T3a | N0 | M0 |
| Stage IIB | T3b | N0 | M0 |
| | T4a | N0 | M0 |
| Stage IIC | T4b | N0 | M0 |
| Stage IIIA | T1a/b, T2a | N1a, N2a | M0 |
| Stage IIIB | T0 | N1b, N1c | M0 |
| | T1a/b, T2a | N1b/c, N2b | M0 |
| | T2b, T3a | N1a/b/c, N2a/b | M0 |
| Stage IIIC | T0 | N2b/c, N3b/c | M0 |
| | T1a/b, T2a/b, T3a | N2c, N3a/b/c | M0 |
| | T3b, T4a | Any N ≥ N1 | M0 |
| | T4b | N1a/b/c, N2a/b/c | M0 |
| Stage IIID | T4b | N3a/b/c | M0 |
| Stage IV | Any T, Tis | Any N | M1 |

**Pathological staging includes microstaging of the primary melanoma, including any additional staging information from the wide-excision (surgical) specimen that constitutes primary tumor surgical treatment and pathological information about the regional lymph nodes after SLN biopsy or therapeutic lymph node dissection for clinically evident regional lymph node disease.

[†]Pathological Stage 0 and pathological T1 without clinically detected regional or distant metastases (pTis/pT1 cN0 cM0) do not require pathological evaluation of lymph nodes to complete pathological staging; use cN0 to assign pathological stage.

Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the AJCC Cancer Staging Manual, Eighth Edition (2017) published by Springer International Publishing. (For complete information and data supporting the staging tables, visit www.springer.com.)

**ABBREVIATIONS**

| | | | |
|-------------|---|--------------|--|
| CLND | completion lymph node dissection | NED | no evidence of disease |
| CNS | central nervous system | NGS | next-generation sequencing |
| CR | complete response | | |
| CSD | cumulative sun damage | OS | overall survival |
| DSS | disease-specific survival | PD-1 | programmed cell death protein 1 |
| | | PD-L1 | programmed cell death ligand 1 |
| EFS | event-free survival | PFS | progression-free survival |
| | | PR | partial response |
| FDG | fluorodeoxyglucose | | |
| FNA | fine-needle aspiration | RFS | relapse-free survival |
| | | RT | radiation therapy |
| GEP | gene expression profiling | SD | stable disease |
| IGRT | image-guided radiation therapy | SLN | sentinel lymph node |
| IHC | immunohistochemistry | SLNB | sentinel lymph node biopsy |
| ILI | isolated limb infusion | SRS | stereotactic radiosurgery |
| ILP | isolated limb perfusion | SRT | stereotactic radiation therapy |
| irAE | immune-related adverse event | | |
| | | TLND | therapeutic lymph node dissection |
| LDH | lactate dehydrogenase | | |
| LM | lentigo maligna | US | ultrasound |
| | | | |
| MIS | melanoma in situ | WBRT | whole brain radiation therapy |
| MMS | Mohs micrographic surgery | | |

**NCCN Categories of Evidence and Consensus**

| | |
|--------------------|--|
| Category 1 | Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate. |
| Category 2A | Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate. |
| Category 2B | Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate. |
| Category 3 | Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate. |

All recommendations are category 2A unless otherwise indicated.

NCCN Categories of Preference

| | |
|--|---|
| Preferred intervention | Interventions that are based on superior efficacy, safety, and evidence; and, when appropriate, affordability. |
| Other recommended intervention | Other interventions that may be somewhat less efficacious, more toxic, or based on less mature data; or significantly less affordable for similar outcomes. |
| Useful in certain circumstances | Other interventions that may be used for selected patient populations (defined with recommendation). |

All recommendations are considered appropriate.



NCCN Guidelines Version 3.2023 Melanoma: Cutaneous

Discussion

Table of Contents

This discussion corresponds to the NCCN Guidelines for Melanoma: Cutaneous. The following sections were last updated on March 12, 2019: Adjuvant Systemic Therapy for Melanoma, Treatment for Unresectable Stage III or Distant Metastatic Disease (Stage IV). The rest was last updated on July 7, 2016.

| | | | |
|--|--------------|--|--------------|
| Overview | MS-2 | Adjuvant Systemic Therapy for Melanoma | MS-24 |
| Delivery of High-Quality Cancer Care | MS-3 | Brief History of Adjuvant Therapy Options for Melanoma | MS-24 |
| Clinical Presentation and Preliminary Workup | MS-4 | NCCN Recommendations for Considering Adjuvant Systemic Therapy | MS-24 |
| Biopsy: NCCN Recommendations | MS-4 | Specific Systemic Therapy Options for Adjuvant Treatment | MS-27 |
| Diagnosis, Prognostic Factors, and Clinical Staging | MS-4 | Immune Checkpoint Inhibitors | MS-28 |
| Pathology Report: NCCN Recommendations..... | MS-7 | BRAF-Targeted Therapy | MS-31 |
| Preliminary Workup: NCCN Recommendations | MS-7 | Neoadjuvant Systemic Therapy | MS-33 |
| Further Workup and Pathologic Staging | MS-8 | Treatment for Stage III In-transit Disease | MS-34 |
| Laboratory Tests and Imaging | MS-8 | Local Therapy | MS-34 |
| Sentinel Lymph Node Biopsy..... | MS-9 | Regional Therapy: Isolated Limb Perfusion and Infusion | MS-37 |
| Biopsy of Palpable Lymph Nodes | MS-14 | NCCN Recommendations..... | MS-38 |
| Full Workup and Pathologic Staging: NCCN Recommendations | MS-14 | Treatment for Unresectable Stage III or Distant Metastatic Disease (Stage IV) | MS-39 |
| Treatment of Primary Melanoma | MS-16 | Systemic Therapy for Advanced Melanoma | MS-39 |
| Wide Excision | MS-16 | Radiation Therapy for Extracranial Metastases | MS-68 |
| Alternatives to Excision: Topical Imiquimod or Radiation | MS-17 | Radiation for Brain Metastases..... | MS-68 |
| NCCN Recommendations | MS-18 | Combining Radiation with Systemic Therapy | MS-68 |
| Lymph Node Dissection | MS-18 | NCCN Recommendations for Distant Metastatic Disease..... | MS-69 |
| Completion Lymph Node Dissection After Positive SLNB..... | MS-18 | Follow-up | MS-76 |
| Therapeutic Lymph Node Dissection | MS-20 | Surveillance Modalities..... | MS-77 |
| Palliative Lymph Node Dissection..... | MS-20 | Patterns of Recurrence..... | MS-77 |
| Elective Pelvic Lymph Node Dissection | MS-20 | Risk of Developing a Second Primary Melanoma..... | MS-78 |
| Morbidity of Lymph Node Dissection..... | MS-20 | Long-Term Impact of Surveillance | MS-79 |
| Technical Aspects of Lymph Node Dissection..... | MS-20 | Patient Education | MS-79 |
| NCCN Recommendations | MS-21 | NCCN Recommendations..... | MS-80 |
| Adjuvant Radiation Therapy | MS-21 | Treatment of Recurrence | MS-82 |
| Adjuvant Radiation for Desmoplastic Neurotropic Melanoma | MS-21 | NCCN Recommendations..... | MS-82 |
| Adjuvant Radiation for Preventing Nodal Relapse..... | MS-22 | Summary | MS-83 |
| Adjuvant Radiation for Brain Metastases | MS-22 | References | MS-84 |
| NCCN Recommendations | MS-23 | | |



NCCN Guidelines Version 3.2023

Melanoma: Cutaneous

Overview

In 2016, an estimated 76,380 patients will be diagnosed with and about 10,130 patients will die of melanoma in the United States.¹ However, these figures for new cases may represent a substantial underestimate, as many superficial and in situ melanomas treated in the outpatient setting are not reported. The incidence of melanoma continues to increase dramatically, at an overall rate of 33% for men and 23% women from 2002 to 2006.² Melanoma is increasing in men more rapidly than any other malignancy, and in women more rapidly than any other malignancy except lung cancer.³ Based on data from 2009 to 2011, the lifetime risk of developing cutaneous melanoma is 1 in 34 for women and 1 in 53 for men.¹ The median age at diagnosis is 59 years. On average, an individual loses 20.4 years of potential life as a result of melanoma mortality compared to 16.6 years for all malignancies.⁴

Risk factors for melanoma include skin type, personal history of prior melanoma, multiple clinically atypical moles or dysplastic nevi, a positive family history of melanoma,⁵⁻⁸ and rarely, inherited genetic mutations. Genetic counseling could be considered for individuals with a strong family history of invasive melanoma with or without pancreatic cancer. In addition to genetic factors, environmental factors including excess sun exposure and UV-based artificial tanning contribute to the development of melanoma.⁹⁻¹¹ The interaction between genetic susceptibility and environmental exposure is illustrated in individuals with an inability to tan and fair skin that sunburns easily who have a greater risk of developing melanoma.^{12,13} However, melanoma can occur in any ethnic group and also in areas of the body without substantial sun exposure.

As with nearly all malignancies, the outcome of melanoma depends on the stage at presentation.¹⁴ In the United States, it is estimated that 84% of patients with melanoma initially present with localized disease, 9% with regional disease, and 4% with distant metastatic disease.¹⁵ In general, the

prognosis is excellent for patients who present with localized disease and primary tumors 1.0 mm or less in thickness, with 5-year survival achieved in more than 90% of patients.¹⁴ For patients with localized melanomas more than 1.0 mm in thickness, survival rates range from 50% to 90%, depending on tumor thickness, ulceration, and mitotic rate.¹⁴ The likelihood of regional nodal involvement increases with increasing tumor thickness, as well as the presence of ulceration and mitotic rate.¹⁶⁻¹⁹ When regional nodes are involved, survival rates are roughly halved. However, within stage III, 5-year survival rates range from 20% to 70%, depending primarily on the nodal tumor burden.¹⁴ Historically, long-term survival in patients with distant metastatic melanoma, taken as a whole, has been less than 10%. However, even within stage IV, some patients have a more indolent clinical course that is biologically quite distinct from most patients with advanced disease. Furthermore the impact of emerging effective systemic therapies on the survival of patients with stage IV melanoma, either at presentation or recurrence, has made long-term remission possible for a larger proportion of patients.

There is increasing appreciation of the variations in specific genetic alterations among distinct clinical subtypes of melanoma. The currently described clinical subtypes of cutaneous melanoma are: non-chronic sun damage (non-CSD): melanomas on skin without chronic sun-induced damage; CSD: melanomas on skin with chronic sun-induced damage signified by the presence of marked solar elastosis; and acral: melanomas on the soles, palms, or sub-ungual sites. Melanocytes exist outside of the skin as well, and can give rise to non-cutaneous melanomas on mucosal membranes, the uveal tract of the eye, or leptomeninges.²⁰ Mucosal melanomas most often occur in the head and neck sinuses and oral cavity, anorectum, vulva, and vagina, but can arise in any of the mucosal membranes lining the gastrointestinal and urogenital tracts.²¹



NCCN Guidelines Version 3.2023

Melanoma: Cutaneous

Different subtypes of melanoma have been found to have very different genetic profiles, some of which have different therapeutic implications. In an analysis of 102 primary melanomas, the non-CSD subtype was found to have the highest proportion of *BRAF* mutations (56%) compared to CSD, acral, and mucosal subtypes (6%, 21%, and 3%, respectively).²² On the other hand, incidence of *KIT* aberrations was 28%, 36%, and 39% in CSD, acral, and mucosal subtypes, respectively, but 0% in non-CSD subtypes. *NRAS* mutations were found in 5% to 20% of the subtypes.

By definition, the National Comprehensive Cancer Network (NCCN) practice guidelines cannot incorporate all possible clinical variations and are not intended to replace good clinical judgment or individualization of treatments. Exceptions to the rule were discussed among the panel members while developing these guidelines. A 5% rule (omitting specific recommendations for clinical scenarios that comprise less than 5% of all cases) was used to eliminate uncommon clinical occurrences or conditions from these guidelines. The NCCN Melanoma Panel strongly supports early diagnosis and appropriate treatment of melanoma, including participation in clinical trials where available.

Mucosal and uveal melanomas differ significantly from cutaneous melanoma in presentation, genetic profile, staging, response to treatment, and patterns of progression.²³⁻²⁵ Ideally, mucosal and uveal melanoma should be treated as diseases distinct from cutaneous melanoma, with care tailored to the individual. The NCCN Guidelines for Melanoma do not include recommendations for the diagnostic workup or treatment of early-stage mucosal or uveal melanoma. Guidelines for initial diagnostic workup and treatment of mucosal melanoma of the head and neck can be found in the [NCCN Guidelines for Head and Neck Cancers](#). For systemic therapy of stage IVB or IVC mucosal melanoma of the head or neck, however, the [NCCN Guidelines for Head and Neck Cancers](#) points to the NCCN Guidelines for Melanoma recommendations for systemic therapy for

metastatic or unresectable disease. The NCCN Guidelines currently do not include recommendations for initial diagnosis and treatment of early-stage uveal melanoma or anogenital mucosal melanoma.

Delivery of High-Quality Cancer Care

A key component to delivery of high-quality cancer care is discussing with patients their options for diagnostic workup, treatment, and follow-up.²⁶ The goal of these conversations should be two-fold: 1) capturing all the case-specific information that should be considered when evaluating options, and 2) ensuring that the patient understands all the potential benefits and risks associated with different clinical approaches so they can make informed decisions. Adherence to the guidelines does not mean limiting decisions about patient care exclusively to NCCN-recommended guidelines, but that all the recommended options are *discussed* with the patients. The clinical team should document the rationale for the clinical approach selected. An essential feature of high-quality care is that clinical decisions are informed by a variety of case-specific factors (eg, patient characteristics and preferences, disease characteristics, medical history), such that for some patients the best clinical approach may not be an option listed in the guidelines. The guidelines include language such as “discuss and consider” and “consider and offer” to indicate situations in which conversations with the patient are especially important because the optimal option is not clear (eg, insufficient clinical data) and/or strongly depends on case-specific factors (eg, data show that the approach is beneficial only to a subset of patients with specific features). Whereas “discuss and consider” indicates that the recommended option may be beneficial for some patients, “consider and offer” indicates that the recommended approach is likely beneficial for most patients.



NCCN Guidelines Version 3.2023

Melanoma: Cutaneous

Clinical Presentation and Preliminary Workup

Biopsy: NCCN Recommendations

Patients presenting with a suspicious pigmented lesion optimally should undergo an excisional biopsy (elliptical, punch or saucerization), preferably with 1- to 3-mm negative margins. The orientation of the excisional biopsy should always be planned with definitive treatment in mind (eg, a longitudinal orientation in the extremities, parallel to lymphatics). With the increasing use of lymphatic mapping and sentinel node biopsy, biopsies should also be planned so as not to interfere with this procedure. In this regard, wider margins for the initial diagnostic procedure should be avoided.

Excisional biopsy may be inappropriate for certain sites (including the face, palmar surface of the hand, sole of the foot, ear, distal digit, or subungual lesions) or for very large lesions. In these instances, a full-thickness incisional or punch biopsy of the clinically thickest portion of the lesion is an acceptable option. These procedures should provide accurate primary tumor microstaging, without interfering with definitive local therapy. If the initial biopsy is inadequate to make a diagnosis or to accurately microstage the tumor (based on evaluation by a dermatopathologist) for treatment planning, re-biopsy with narrow margin excision should be considered. Shave biopsy may compromise pathologic diagnosis and complete assessment of Breslow thickness. However, it is acceptable in a low suspicion setting. For example, a broad shave biopsy may help to optimize accurate diagnosis of lentigo maligna. Panelists recognized that melanomas are commonly diagnosed by shave biopsy during screening in a dermatologist office, and that any diagnosis is better than none even if microstaging may not be complete.

Diagnosis, Prognostic Factors, and Clinical Staging

In general, cutaneous melanomas are categorized as follows: localized disease with no evidence of metastases (stage I–II), regional disease

(stage III), and distant metastatic disease (stage IV). The AJCC analyzed 38,918 patients to determine factors significantly predictive of survival for patients with cutaneous melanomas.^{14,27-29} This and other studies have shown that in addition to patient-specific factors of age and gender, tumor-specific factors of Breslow tumor thickness, ulceration, and mitotic rate were found to be the three most important characteristics independently predictive of outcome by multivariate analysis.^{14,28-34}

Mitotic rate is an indicator of tumor proliferation and is measured as the number of mitoses per mm². The latest AJCC Staging Manual recommended the “hot spot” technique for calculating the mitotic rate.^{27,35} Several other studies have also confirmed the prognostic importance of mitotic rate in patients with primary cutaneous melanoma.^{28-33,36-40} In the evidence-based derivation of the 2010 AJCC staging system, mitotic rate greater than or equal to 1 per mm² was independently associated with worse disease-specific survival (DSS), especially in patients with melanoma less than or equal to 1.0 mm thick.¹⁴ As such, mitotic rate has replaced Clark level as a criterion for upstaging patients with melanomas less than or equal to 1.0 mm in thickness from IA to IB.

Reporting detection of microscopic satellites in the initial biopsy or wide excision specimen is also important for AJCC staging, as this defines at least N2c, stage IIIB disease. The 2013 College of American Pathologists have defined a microsatellite as the presence of tumor nests greater than 0.05 mm in diameter, in the reticular dermis, panniculus, or vessels beneath the principal invasive tumor but separated from it by at least 0.3 mm of normal tissue on the section in which the Breslow measurement was taken.^{41,42} It is usually not possible to detect microscopic satellites with less than a complete excisional biopsy.

The American Academy of Dermatology (AAD) Task Force recommends the inclusion of additional factors such as vertical growth phase (VGP), tumor-infiltrating lymphocytes (TIL), and regression in the report.^{43,44}



NCCN Guidelines Version 3.2023

Melanoma: Cutaneous

These factors are less consistently independently predictive of outcome.^{31,32,45,46}

The AAD also recommends that pathologists should note cases of pure desmoplastic melanoma (as opposed to the presence of desmoplasia admixed with spindle cell and/or epithelioid cells) as this may impact decisions about further diagnostics and treatment.⁴³

Some melanocytic proliferations can be diagnostically challenging. Examples include atypical melanocytic proliferation, melanocytic tumor of uncertain malignant potential, superficial melanocytic tumor of uncertain significance, atypical Spitz tumor, and atypical cellular blue nevus. These lesions are more frequently seen in younger patients, and when suspected, referral to a pathologist with expertise in atypical melanocytic lesions is recommended. In cases where melanoma is included in the differential diagnosis, the pathology report should include prognostic elements as for melanoma.

Molecular Characterization of the Primary Tumor

Comparative genomic hybridization (CGH) or fluorescence in situ hybridization (FISH) may be helpful in detecting the presence of selected gene mutations for histologically equivocal lesions. CGH is a more comprehensive technique than FISH that may offer higher sensitivity and specificity in identifying relevant copy number changes, as suggested by a small study on atypical Spitz tumors.⁴⁷

In addition to CGH and FISH, a number of diagnostic or prognostic genetic tests for melanoma are in development.⁴⁸⁻⁵² One of these commercially available gene expression profiling tests was developed to help predict the biologic behavior of atypical melanocytic lesions with indeterminate histopathology (eg, melanocytic or Spitz tumors of uncertain malignant potential).⁵⁰ Although there is a tremendous clinical need for this technology, the challenges of developing a truly discriminant test are

substantial. Even in the presence of sentinel lymph node (SLN) metastasis these indeterminate neoplasms can demonstrate a strikingly benign biologic behavior, making it exceedingly difficult to define a true positive (fully malignant lesion).⁵³⁻⁵⁸ Furthermore, as the very few events in this low-risk group tend to be late, long-term follow-up is required to validate the prognostic significance of this test.

Another currently commercially available gene expression profiling test is being marketed to supplement prognostic information derived from the primary tumor and SLNs.^{48,49} This technique was developed to discriminate patients at low risk versus high risk for metastatic disease based on the differential expression of 28 genes. The gene set was developed from a relatively high-risk training set of patients and tested in a different relatively high-risk validation set of patients. This gene expression profile has been validated as independently predictive of outcome when compared to AJCC stage or SLN status.^{48,49} This test has not been directly evaluated in the context of all known prognostic characteristics of localized melanoma.⁵⁹ Furthermore, its independent prognostic value has yet to be confirmed in a large population of patients with average- to low-risk melanoma.

Gene expression profiling for melanoma could be an enormously valuable contribution to understanding the biology of the disease. However, the difficulty of embracing gene expression profiling as an independent predictor of outcome is illustrated by the inconsistency of results across studies aimed at defining the most predictive gene sets for melanoma.^{49,51,60-62} Comparison of the gene signatures identified in these studies show minimal overlap in specific genes thought to be predictive of outcome. The identification and validation of a prognostic gene expression profile is a complicated multi-step and often multi-study process, and there are many ways in which specifics of study design and methodology can impact the end result.⁶³⁻⁶⁶ The lack of overlap in gene signatures identified



as prognostic for melanoma is likely due to substantial differences in study design and methodology. Efforts to develop gene expression profiling prognostic assays for other types of cancer have also resulted in limited or partial overlap in the “gene signature” identified by different studies.⁶⁷⁻⁷⁰

Pathology of Nodal and Regional Disease

Among patients with nodal metastases (stage III), the clinical nodal status (nonpalpable vs. palpable) and the number of metastatic nodes are the most important predictors of survival.^{71,72} The AJCC staging system has recognized this difference in prognosis among patients with pathologic stage III melanoma.¹⁴ For patients with a positive SLN, prognostic factors include number of positive nodes, tumor burden in the sentinel node, primary tumor thickness, mitotic rate and ulceration, and patient age.^{28,73-80} For patients with clinically positive nodes, prognostic factors include number of positive nodes, extranodal extension, primary tumor ulceration, and patient age.^{28,81-86}

In-transit metastasis is defined as intralymphatic tumor in skin or subcutaneous tissue more than 2 cm from the primary tumor but not beyond the nearest regional lymph node basin.⁴¹ The presence of microsatellites, clinically evident satellites, and/or regional intransit disease is all part of the biologic continuum of regional lymphatic involvement, and these are all associated with a prognosis similar to that of patients with clinically positive nodes. This is recognized in the staging system with the designation of stage IIIC.

Clinical Characterization of Metastatic Disease

Among patients with distant metastatic melanoma (stage IV), the site of metastases is the most significant predictor of outcome. The three risk categories recognized by the AJCC are skin, soft tissue, and remote nodes (M1a); visceral-pulmonary (M1b); and visceral-nonpulmonary (M1c).^{14,27} Elevated lactate dehydrogenase (LDH), likely a surrogate for overall tumor burden, is also an independent predictor of poor outcome in

patients with stage IV disease and has been incorporated into the AJCC staging system; patients with distant metastases to any site and elevated LDH are in the highest risk category (M1c).^{71,87,88} The prognosis for patients with metastatic melanoma has dramatically improved with the emergence of several effective systemic therapies associated with improved overall survival (OS) and long-term survival in some patients (See *Systemic Therapy for Advanced Melanoma*). It is unclear whether the factors prognostic for outcome will also change.

Molecular Characterization of Metastatic Disease

Several targeted therapies have been developed for patients with melanoma harboring specific mutations (See *Systemic Therapy for Advanced Melanoma*, sub-sections *BRAF-targeted Therapies* and *Other Targeted Therapies*). Patients with metastatic melanoma with activating mutations of *BRAF*, an intracellular signaling kinase in the mitogen activated protein kinase (MAPK) pathway,⁸⁹⁻⁹¹ have been shown to be likely to respond to BRAF inhibitors.⁹²⁻⁹⁵ Likewise, patients with metastatic melanoma with activating mutations in *KIT*, a receptor tyrosine kinase, have been shown to be more likely to respond to imatinib, a tyrosine kinase inhibitor, compared with patients without activating *KIT* mutations.⁹⁶⁻⁹⁸ A number of tests have been developed for detecting *BRAF* and *KIT* mutations common in metastatic melanoma. The sensitivity and accuracy of these tests vary, and improved assays are in development.⁹⁹⁻¹¹⁰ For both *BRAF* and *KIT* mutations, studies have investigated the intra- and inter-tumoral homogeneity, and found that mutation status can change during disease progression, such that recurrences or metastases may have mutations not present in the primary tumor.¹¹¹⁻¹¹⁵ Pathologists are now strongly encouraged to test for and report the presence or absence gene mutations (*BRAF*, *KIT*) that may impact treatment options in patients with metastatic melanoma.



NCCN Guidelines Version 3.2023

Melanoma: Cutaneous

Pathology Report: NCCN Recommendations

For the pathology report, the NCCN Melanoma Panel recommends at a minimum the inclusion of Breslow thickness, ulceration status, mitotic rate (#/mm²), deep and peripheral margin status (positive or negative), presence or absence of microsatellites, pure desmoplasia if present, and Clark level for nonulcerated lesions 1.0 mm or less where mitotic rate is not determined. Ideally, mitotic rate should be reported for all lesions, as it is emerging as an independent predictor of outcome. When pure desmoplastic melanoma is suspected, multidisciplinary consultation including an experienced dermatopathologist is recommended for determining staging and treatment options.

The panel agreed that recording of additional parameters identified by the AAD task force would be helpful, but not mandatory. CGH or FISH should be considered to detect the presence of selected gene mutations for histologically equivocal lesions. While there is interest in newer prognostic molecular techniques such as gene expression profiling to help differentiate benign from malignant neoplasms, or to help distinguish melanomas at low- versus high-risk for metastasis, routine (baseline) genetic testing of primary cutaneous melanomas (before or following SLN biopsy [SLNB]) is not recommended outside of a clinical study.

For stage III patients, the NCCN Melanoma Panel recommends reporting the number of positive nodes, the total number of nodes examined, and the presence or absence of extranodal tumor extension. In addition, the panel recommends recording the size and location of tumor present in a positive sentinel node.

For stage IV patients, the clinician is responsible for reporting the number and sites of metastatic disease. In addition to histologic confirmation of metastatic disease whenever possible, pathologists are now strongly encouraged to test for and report the presence or absence of gene

mutations (*BRAF*, *KIT*) that may impact treatment options in patients with metastatic melanoma. Because these inhibitors of *BRAF* or *KIT* are recommended only for patients with advanced disease, *BRAF* and *c-KIT* mutational analyses are clinically useful only for patients with advanced disease considering these molecular targeted therapies. In the absence of metastatic disease, testing of the primary cutaneous melanoma for *BRAF* mutation is not recommended.

Preliminary Workup: NCCN Recommendations

After the diagnosis of cutaneous melanoma has been confirmed, detailed personal and family history, including any personal history of prior melanoma or dysplastic nevi, should be obtained. In the physical examination of patients with invasive melanoma, physicians should pay special attention to the locoregional area and lymph node drainage basin(s) of the established melanoma. A complete dermatologic examination is recommended for all patients with newly diagnosed melanoma.

Patients can be clinically staged after histopathologic microstaging of the primary tumor, and a complete history and physical examination (H&P) as described above. Patients are staged according to the AJCC criteria. Patients with in-situ melanoma are stage 0. Patients with invasive (not in-situ) melanoma and clinically negative nodes are stage I-II. The NCCN Guidelines have further stratified clinical stage I patients into three groups based on risk of lymph node involvement.

Patients with palpable regional nodes, as well as those with in-transit disease or microsatellites are clinical stage III.

Patients with distant metastases are clinical stage IV, and should be further assigned to a substage by recording all sites of metastatic disease and the serum LDH (within normal limits or elevated).

Based on preliminary workup and clinical staging patients are stratified into one of six groups for further workup and treatment:

- Stage 0 (melanoma in situ); or stage IA or IB with thickness 0.75 mm or less, regardless of other features (eg, ulceration, mitotic rate)
- Stage IA with thickness 0.76 to 1.0 mm, with no ulceration, and mitotic rate 0 per mm²
- Stage IB with thickness 0.76 to 1.0 mm with ulceration or mitotic rate greater than or equal to 1 per mm²; or stage IB or II with thickness 1.0 mm thick, any feature (eg, with or without ulceration, any mitotic rate), and clinically negative nodes
- Stage III with clinically detected (palpable) positive nodes, microscopic satellitosis (from assessment of the primary lesion), and/or in-transit disease
- Stage IV (distant metastatic disease)

Further Workup and Pathologic Staging

Laboratory Tests and Imaging

There are several reasons to embark on a further imaging and diagnostic workup to determine the extent of disease in the melanoma patient. One is to establish a set of baseline images against which to compare future studies in a patient at risk for relapse. Another is to detect clinically occult disease that would affect immediate treatment decisions. A third reason is to define homogeneously staged patients for inclusion into clinical trials. Although patients greatly value the negative result of a cross-sectional imaging study, physicians need to be cautious about over interpreting the significance of the findings, recognizing that all tests have relatively insensitive lower limits of resolution. Finally, any test carries the very real possibility of detecting findings unrelated to the melanoma, findings that can lead to morbid invasive biopsy procedures, or at the very least

substantial patient anxiety while awaiting results of interval follow-up studies.

The yield of routine blood work and imaging studies in screening patients with clinical stage I-II melanoma for asymptomatic distant metastatic disease is very low. Screening blood tests are very insensitive, and the findings of cross-sectional imaging for patients with clinical stage I-II are often nonspecific, with frequent false-positive findings unrelated to melanoma.¹¹⁶⁻¹¹⁸

The yield of imaging studies has been more extensively evaluated in the context of patients with stage III melanoma. In patients with a positive SLN, the yield of cross-sectional imaging in detecting clinically occult distant metastatic disease ranges from 0.5% to 3.7%.¹¹⁹⁻¹²² True positive findings are most often found in patients with ulcerated thick primary tumors and a large tumor burden in their sentinel nodes. In asymptomatic patients with clinically positive nodes, the yield of routine cross-sectional imaging is a bit higher than in patients with positive sentinel nodes, reported at 4% to 16%.¹²³⁻¹²⁵ All of these series also report a significant incidence of indeterminate or false-positive radiologic findings that are unrelated to the melanoma.

These retrospective studies report minimum estimates, as it is very difficult to define a study population of truly “imaging-naïve” high-risk stage II and stage III patients. It is probable that, among the entire denominator of stage III patients, some would have been defined as stage IV based on imaging before the study cohort was assembled. Furthermore, as a substantial proportion of clinical stage III patients will ultimately develop distant metastases,¹²⁶ the inability of cross-sectional imaging studies to detect metastatic disease at diagnosis of stage III is a relatively poor predictor of future events.



NCCN Guidelines Version 3.2023

Melanoma: Cutaneous

PET scanning has attracted interest as a means of enhancing detection of subclinical metastatic disease. Most investigators have described very low yield and poor sensitivity in detecting metastatic disease in patients with clinically localized melanoma.¹²⁷⁻¹³⁰ In patients with stage III disease, PET/CT scan may be more useful. In particular, PET/CT scans can help to further characterize lesions found to be indeterminate on CT scan, and can image areas of the body not studied by the routine body CT scans (ie, arms and legs).^{131,132} A systematic review of 17 diagnostic studies documented PET sensitivity ranging from 68% to 87% and specificity ranging from 92% to 98% for stage III and IV melanoma compared to sensitivity ranging from 0% to 67% and specificity ranging from 77% to 100% for stage I and II melanoma.¹³³ Another large meta-analysis suggested that PET/CT was superior over CT in detecting distant metastases.¹³⁴ Other recent studies in patients with stage III or IV melanoma have reported similar results, and indicated that additional information provided by PET/CT may impact treatment decisions in up to 30% of patients, with the greatest impact seen in surgical management.^{132,135}

Another consideration for baseline imaging is the impact on early detection of central nervous system (CNS) metastases. Early detection and treatment of subclinical CNS metastases is important because 1) clinically symptomatic CNS metastases are associated with significant morbidity and poor survival, and 2) outcomes after treatment are markedly better in patients with lower CNS tumor burden and/or asymptomatic metastases.^{126,136-144} Although CNS recurrence is rare in patients who present with stage I-IIIB melanoma ($\leq 5\%$), patients with stage IIIC disease have an appreciable risk (11%).¹²⁶ Although the yield of baseline CNS imaging may be low, it may be useful for comparison with follow-up scans in patients at risk of CNS recurrence.

Sentinel Lymph Node Biopsy

SLNB is a minimally invasive staging procedure developed to further risk-stratify patients with clinical stage I-II melanoma according to the presence or absence of subclinical nodal metastases. Patients with positive SLNB are at higher risk of recurrence, and might be candidates for complete lymph node dissection (CLND) and/or adjuvant systemic therapy.¹⁴⁵ The utility of SLNB for staging depends on a thorough understanding of 1) the technical aspects of the procedure that lead to successful identification and pathologic examination of a sentinel node; 2) the low rate of complications associated with the procedure; 3) the likelihood of sentinel node positivity; 4) the sensitivity of the test (likelihood of false positives and false negatives); and 5) the prognostic significance of SLN status.

Techniques of Sentinel Lymph Node Biopsy

SLNB is almost always performed at the time of initial wide excision; the validity of performing this technique after definitive wide excision has not been extensively studied. There is at least a theoretical concern that the relevant draining lymphatics could have been disturbed by the wide excision, especially if rotation flaps or skin grafts were used for reconstruction, degrading the accuracy of the SLNB procedure.

The technique for SLNB consists of preoperative dynamic lymphoscintigraphy, intraoperative identification using isosulfan blue or methylene blue dye, and a gamma probe to detect radiolabeled lymph nodes.^{73,146-149} Many studies have reported high rates of successful SLN detection using this robust technique ($>95\%$).^{19,73,146-149} SPECT scanning may enhance the accuracy of this technique in anatomically challenging regions, such as the head and neck, or when a faintly visible sentinel node might be otherwise overshadowed by the intense radioactivity at the primary injection site.^{150,151}

Meticulous pathologic examination of all sentinel nodes is essential to maximize the probability of detecting all SLNs with microscopic disease. When micrometastases are not identified by routine hematoxylin and eosin (H&E) staining, serial sectioning and immunohistochemical staining (eg, with HMB-45 and/or Melan-A) has been shown to identify additional patients with positive sentinel nodes.¹⁵²⁻¹⁵⁴ As the presence of even scattered clusters of melanoma cells in a sentinel node is clinically relevant, the AJCC was unable to determine a sentinel node tumor burden too low to report as metastatic disease.^{27,155,156} On the other hand, the presence of bland or benign-appearing melanocytes should be interpreted with caution. These “nodal nevi” can masquerade as metastatic disease, when in fact long-term outcomes in patients with nodal nevi are similar to those of patients with negative SLNs.¹⁵⁷ When there is any doubt about the significance of abnormal melanocytes in a sentinel node, review by an experienced dermatopathologist is recommended.

Although the concept is simple, and the technical aspects of SLNB are very robust, with similar results reported from many centers around the world using innumerable variations of the basic technique, the successful identification and characterization of the sentinel node depends on dedicated and meticulous cooperation among nuclear medicine, surgery, and pathology.

Complications of Sentinel Lymph Node Biopsy

SLNB is associated with a low complication rate (5% in the Sunbelt Melanoma trial; 10% in MSLT-1).¹⁵⁸⁻¹⁶⁵ Two prospective randomized trials have shown that the complication rate is significantly lower with SLNB compared with completion lymph node dissection.^{158,159} The most common complications associated with SLNB are wound dehiscence and infection, seroma/hematoma, and lymphedema; other associated complications are nerve injury and thrombophlebitis, deep vein thrombosis, and hemorrhage.^{158-160,162-167} Allergic reactions to the blue dye used in SLNB

have also been reported.^{159,161,162} Risk of complications, particularly lymphedema, is higher for SLNB of the groin compared with the axilla or neck.^{158,165,168}

Rates and Predictors of Sentinel Lymph Node Positivity

Depending on a variety of factors described below, 5% to 40% of patients undergoing SLNB will be upstaged from clinical stage I-II to pathologic stage III, based on subclinical micrometastatic disease in the SLN.^{18,73,147-149,169-174} Multivariate analyses have identified factors independently predictive of a positive SLN. The correlation between increased primary tumor thickness and SLN positivity is well established.^{18,45,148,169,171,172,175-177} Due in part to the low probability of finding a positive sentinel node in patients with thin primary melanomas (≤ 1 mm), the utility of SLNB in this population is controversial and is discussed below in *SLNB in Thin (≤ 1 mm) Melanoma*.

In addition to Breslow thickness, other primary lesion characteristics (eg, Clark level, mitotic rate, ulceration, lymphovascular invasion, VGP, anatomic site, tumor infiltrating lymphocytes, regression) and patient characteristics (eg, sex, age) have been assessed for their association with SLN status in patients with primary melanomas thicker than 1 mm. For each of these factors, however, their prognostic value is unclear due to results varying between studies.¹⁷⁷⁻¹⁸² For example, results vary regarding the prognostic significance of patient age for predicting likelihood of SLN positivity, but most studies show higher risk of SLN involvement in younger patients.^{18,45,148,171,175,176,183} An AJCC database analysis of patients with cutaneous melanoma, no clinically detectable LN metastases (n = 7756), and SLNB showed that age was an independent predictor of SLN positivity, with higher rates of SLN positivity in younger patients (<20 y), but that younger patients lived longer, nonetheless.¹⁸⁴ High age (>80 y) was associated with lower rates of SLN positivity, but



NCCN Guidelines Version 3.2023

Melanoma: Cutaneous

nonetheless this group had lower survival rates. Analysis of a SEER database yielded similar results.¹⁸⁰

MSLT-1: Prospective Randomized Trial on SLNB

MSLT-I, an international, multicenter, phase III trial, was initiated in 1994 to evaluate the impact of initial management with SLNB on the DSS of patients presenting with localized melanoma. Patients were treated by wide excision, followed by either SLNB (and immediate lymphadenectomy if SLN positive) or followed by observation of the nodal basin (and lymphadenectomy upon clinical detection of nodal metastasis). The final long-term results of this trial were recently reported, and provide the best available data regarding the utility of SLNB, as described in the following sections.¹⁷³

Accuracy of Sentinel Lymph Node Biopsy

Both retrospective analyses and data from MSLT-I have been evaluated to determine the false negative rate of SLNB, or the probability of missing a positive sentinel node if present. The false-negative rate is strictly defined as the number of patients with nodal recurrences after negative SLNB (false negatives), divided by the total number of patients with nodal involvement, including false negatives and patients with a positive SLNB (true positives). Using this definition, MSLT-I and retrospective series have reported false-negative rates of up to 20%.^{73,147,149,170,173,174,182,185}

Prognostic Value of the Sentinel Node

Retrospective analyses have indicated that among patients with clinically node negative localized melanoma undergoing SLNB, the status of the sentinel node is the most important prognostic factor, both for disease progression and DSS.^{71,73,172,182,185,186} Primary tumor thickness is also an independent predictor of progression and survival;⁷¹ however, and one study has shown that the prognostic value of SLN positivity is greater for patients with tumor thickness >1 mm.¹⁸⁷ The prognostic value of SLN

status in patients with thin primary melanomas is discussed further in the next section.

Prospective data from MSLT-I confirm the prognostic value of SLN status in patients with primary tumors ≥ 1.2 mm thick; among patients screened with SLNB, DSS was significantly worse in those with versus without sentinel node involvement.¹⁷³ SLN status was also the strongest predictor of disease-free survival (DFS) by multivariate analysis.

Among patients with SLN positivity, the SLN burden (number of positive SLNs, size and location of tumor in the SLN[s]) is prognostic for recurrence and survival.⁷⁴⁻⁸⁰

Therapeutic Value of SLNB

SLNB has limited therapeutic value. Although MSLT-1 largely confirmed the known role of SLNB as a very important staging test, SLNB did not improve DSS compared with nodal basin observation, regardless of primary lesion thickness. SLNB did improve DFS by 7% and 10% for patients with intermediate thickness (1.2–3.5 mm) or thick (>3.5 mm) primary lesions, respectively. Improvements in DFS were due in large part to the higher rate of nodal relapse in the nodal basin observation group.

In a prespecified retrospective subset analysis of patients who developed nodal metastases from intermediate-thickness (1.2–3.5 mm) melanoma, MSLT-I confirmed a survival advantage to those with microscopic versus macroscopic disease at the time of detection and removal (10-year DSS for those detected by SLNB versus nodal basin observation: 62% vs. 41.5%, $P = .006$). A similar survival advantage was not seen in patients with thick (>3.5 mm) melanomas and positive nodes.

In summary, although SLNB improved survival for the subgroup of patients having both intermediate thickness primary lesions and lymph node involvement, the study population as a whole did not benefit because



SLNB did not improve survival in other subgroups (patients with thick primary lesions and/or who did not develop lymph node metastasis).

The therapeutic value of SLNB for patients with thin melanomas (1.2 mm or less) was not specifically addressed in the MSLT-I trial.

Utility of SLNB in Patients with Unusual Presentations

SLNB in Thin (≤ 1 mm) Melanoma

Among patients with thin melanoma selected for SLNB, rates of SLN positivity are low, around 5% in most studies (Table 1). Primary tumor thickness is the single factor that most consistently predicts SLN positivity (Table 2), in large part because other high-risk features such as ulceration and high mitotic rate are seen so infrequently. A review by Andtbacka and Gershenwald¹⁸⁸ reported an overall SLN metastasis rate of 2.7% in patients with melanoma thinner than 0.75 mm. In patients with melanoma 0.75 to 1.0 mm thick, 6.2% of patients selected to undergo SLNB were found to have a positive SLN.

Other than thickness, individual studies have inconsistently identified additional factors to be predictive of a positive SLN among patients with

thin melanoma.¹⁸⁸ These include Clark level, mitotic rate, ulceration, lymphovascular invasion, VGP, and TIL.^{16,17,19,45,71,186,189-198} For thin melanomas the significance of tumor regression as a predictor is controversial, though most studies have reported no association.^{17,191,192,195,199}

One multi-institutional review of 1250 patients with thin melanomas (≤ 1 mm) found that less than 5% of melanomas thinner than 0.75 mm had positive SLNs regardless of Clark level and ulceration status.¹⁹⁰

However, another review found that for patients with thin melanomas and at least one risk factor (ulceration, Clark level IV, nodular growth, mitosis, regression, or age ≤ 40 years), the SLN positivity rate was as high as 18%.²⁰⁰

In patients with thin melanoma the prognostic value of SLNB results is unclear. A number of studies have associated SLN positivity with worse disease-free or melanoma-specific survival in patients with thin primary melanomas,^{186,191,201} while others have reported no association.^{192,193}

Table 1. Rate of Positive SLN in Thin Melanomas (≤1 mm)

| Study | Total Patients | Positive SLN | |
|-----------------------------------|----------------|--------------|-------------|
| | N | n | % |
| Staius Muller 2001 ¹⁴⁷ | 104 | 7 | 6.7% |
| Rousseau 2003 ¹⁴⁸ | 388 | 16 | 4.1% |
| Bleicher 2003 ²⁰² | 272 | 8 | 2.9% |
| Olah 2003 ¹⁴⁹ | 89 | 12 | 13% |
| Oliveira 2003 ¹⁶ | 77 | 6 | 7.8% |
| Borgognoni 2004 ¹⁷⁰ | 114 | 2 | 1.8% |
| Stitzenberg 2004 ¹⁹⁵ | 146 | 6 | 4.1% |
| Sondak 2004 ¹⁸ | 42 | 4 | 9.5% |
| Puleo 2005 ¹⁹⁶ | 409 | 20 | 4.9% |
| Kruper 2006 ¹⁷¹ | 251 | 13 | 5.2% |
| Ranieri 2006 ¹⁹¹ | 184 | 12 | 6.5% |
| Cascinelli 2006 ¹⁷² | 145 | 6 | 4.1% |
| Nowecki 2006 ¹⁷⁴ | 260 | 17 | 6.5% |
| Wong 2006 ¹⁹² | 223 | 8 | 3.6% |
| Wright 2008 ¹⁸⁶ | 631 | 31 | 5.0% |
| Murali 2012 ¹⁹³ | 432 | 29 | 6.7% |
| Mozzillo 2013 ²⁰¹ | 492 | 24 | 4.9% |
| Venna 2013 ¹⁸⁹ | 450 | 34 | 7.6% |
| Cooper 2013 ²⁰³ | 189 | 3 | 1.6% |
| Total | 4898 | 258 | 5.3% |

SLN, sentinel lymph node

Table 2. Effect of Thickness on Rate of Positive SLN in Thin Melanomas (≤1 mm)

| Study | Primary Tumor Thickness | | | |
|-------------------------------|-------------------------|-------------|---------------------|-------------|
| | <0.75 mm | | 0.75–1.0 mm | |
| | Positive SLN | | Positive SLN | |
| | n/N | % | n/N | % |
| Bleicher 2003 ²⁰² | 2/118 | 1.7% | 6/154 | 3.9% |
| Kesmodel 2005 ¹⁹ | 1/91 ^a | 1.1% | 8/90 ^a | 8.9% |
| Puleo 2005 ¹⁹⁶ | | | 20/409 | 4.9% |
| Ranieri 2006 ¹⁹¹ | 2/86 | 2.3% | 10/98 | 10.2% |
| Wong 2006 ¹⁹² | 0/73 | 0% | 8/150 | 5.3% |
| Wright 2008 ¹⁸⁶ | 16/372 | 4.3% | 15/259 | 5.8% |
| Vermeeren 2010 ²⁰⁴ | 0/39 ^b | 0% | 5/39 ^b | 12.8% |
| Murali 2012 ¹⁹³ | 3/113 | 2.7% | 26/290 | 9.0% |
| Venna 2013 ¹⁸⁹ | 7/170 ^c | 4.1% | 27/280 ^c | 9.6% |
| Total | 31/1062 | 2.9% | 125/1769 | 7.1% |

SLN, sentinel lymph node

^a Subgroups were primary tumor thickness <0.76 mm, 0.76–1.0 mm; all had VGP^b Subgroups were primary tumor thickness ≤0.75 mm, 0.76–1.0 mm^c Subgroups were primary tumor thickness <0.8 mm, ≥0.8 mm**SLNB in Desmoplastic Melanoma**

Although estimates vary across studies, rates of SLN positivity tend to be lower with pure desmoplastic melanoma compared with mixed desmoplastic or other types of melanoma.²⁰⁵⁻²¹⁴ Moreover, several studies have shown that among patients with desmoplastic melanoma, SLN positivity does not consistently correlate with DSS.^{209,211,214} Variability in results may be due in part to lack of standardized criteria for defining pure desmoplastic melanoma.²¹⁵⁻²¹⁸ Assignment may vary between pathologists and across institutions. In the setting of these conflicting reports, the role of SLNB in patients with pure desmoplastic melanoma remains controversial.



Biopsy of Palpable Lymph Nodes

Fine-needle aspiration (FNA), with or without ultrasound guidance, has been shown to have high sensitivity and specificity for detecting melanoma in enlarged lymph nodes (detected clinically or by imaging).²¹⁹⁻²²¹

Full Workup and Pathologic Staging: NCCN Recommendations

Practices among the NCCN Member Institutions vary greatly with respect to the appropriate workup of a melanoma patient. In the absence of compelling data beyond the retrospective series cited above, for the most part, recommendation for the appropriate extent of workup is based on non-uniform consensus within the panel.

Stage 0, I, and II

Workup

The panel stressed the importance of a careful physical examination of the primary site, the regional lymphatic pathways and lymph node basin, and the remainder of the skin. Although nodal basin ultrasound is not a substitute for SLNB, the procedure should be considered for patients with an equivocal regional lymph node physical exam prior to SLNB.

Abnormalities or suspicious lesions on nodal basin ultrasound should be confirmed histologically.

Routine cross-sectional imaging (CT, PET/CT, or MRI) is not recommended for these patients. Despite the very low yield of cross-sectional imaging, there was increasing disagreement about what consensus-based recommendations should be made for clinically node negative patients at the higher risk end of the spectrum. There was uniform consensus that imaging studies were indicated to investigate specific signs or symptoms. Routine blood tests are not recommended for patients with melanoma in situ or stage I and II disease.

Sentinel Lymph Node Biopsy

The NCCN Melanoma Panel does not recommend SLNB for patients with in situ melanoma (stage 0). The panel discussed at length the lower limit of probability of sentinel node positivity that should prompt a discussion of SLNB for stage I melanoma. According to data discussed above, Breslow thickness is the main factor associated with SLN positivity.

In general, the panel does not recommend SLNB for stage IA or IB lesions that are very thin (≤ 0.75 mm) unless there is considerable uncertainty about the adequacy of microstaging. Conventional risk factors such as ulceration, high mitotic rate, and lymphovascular invasion are very uncommon in melanomas 0.75 mm thick or less. In the rare event that a conventional high-risk feature is present, the decision about SLNB should be left to the patient and the treating physician. For patients with stage IA melanomas that are 0.76 to 1.0 mm thick without ulceration, and with mitotic rate 0 per mm^2 , SLNB should be considered in the appropriate clinical context.

SLNB should generally be discussed and offered for patients with higher-risk stage IB (>1 mm thick or 0.76–1.0 mm thick with ulceration or mitotic rate ≥ 1 per mm^2) or stage II melanoma.

Any discussion of the SLNB procedure in patients with stage I or II melanoma should reflect what is known about the prognostic value of SLNB on various clinical endpoints, its defined accuracy and false negative rate, the potential morbidity of the procedure, and what (if anything) will be done differently once the SLN status is known.

Meticulous pathologic examination of all sentinel nodes is mandatory. When micrometastases are not identified by routine H&E staining, serial sectioning and immunohistochemical staining should be performed. There is no sentinel node tumor burden too low to report as metastatic disease, including even scattered clusters of melanoma cells. On the other hand,



the presence of bland or benign-appearing melanocytes should be interpreted with caution. When any doubt is present, review by an experienced dermatopathologist is recommended.

In patients who otherwise would be candidates for SLNB, the decision to not perform SLNB may be based on significant patient comorbidities or individual patient preference. There is controversy regarding the diagnostic criteria for, the probability of a positive sentinel node in, and the prognostic significance of the sentinel node in pure desmoplastic melanoma. Clinicians may consider forgoing SLNB on confirmed pure desmoplastic melanoma. Multidisciplinary consultation including a dermatopathologist is recommended for determining staging and treatment options.

The validity of SLNB in accurately staging patients after prior wide excision is unknown. As such, wide excision before planned SLNB is discouraged, although patients may be considered for the procedure on an individual basis if they present for that discussion after initial wide excision.

The panel discussed the appropriate management of clinically negative lymph nodes in patients at risk for regional metastases, in the event that SLNB is unavailable. Based on the results of three prospective randomized trials, the panel does not recommend routine elective lymph node dissection for this group. Wide excision alone or referral to a center where lymphatic mapping is available are both acceptable options in this situation. While nodal basin ultrasound surveillance would seem to be another reasonable option in this setting, its value has not been defined in prospective studies.

Stage III Workup

Stage III Sentinel Node Positive

Most panel members acknowledged the low yield of screening CT or PET/CT scans in patients with a positive SLN. Based on the results of the

studies reported in the literature and the absence of conclusive data, there was consensus that cross-sectional imaging could be considered at baseline for staging (category 2B) or to assess specific signs or symptoms (category 2A).

Stage III with Clinically Positive Node(s)

For patients presenting with clinical stage III disease who have clinically positive node(s), all panel members believe it is appropriate to confirm the suspicion of regional metastatic disease, preferably with FNA, or with core, incisional, or excisional biopsy of the clinically enlarged lymph node. If FNA is non-diagnostic in the setting of high clinical suspicion, excisional biopsy, planned with therapeutic lymph node dissection (TLND) in mind, is appropriate. Clearly, in patients without an antecedent history of melanoma, this would have been the initial diagnostic test. At a minimum, a pelvic CT scan is recommended in the setting of inguinofemoral lymphadenopathy to rule out associated pelvic or retroperitoneal lymphadenopathy. Most of the panel also endorsed baseline cross-sectional imaging for staging purposes and to evaluate specific signs or symptoms.

Stage III In-transit

For the small group of patients presenting with stage III microsatellitosis or in-transit disease, the workup outlined above for clinical stage III nodal disease, including histologic confirmation of the in-transit metastasis, and cross-sectional imaging, is appropriate.

SLNB may be considered for patients with resectable solitary in-transit stage III disease (category 2B recommendation). However, while SLNB may be a useful staging tool, its impact on the OS of these patients remains unclear. Likewise for patients with microsatellitosis, while SLN positivity would upstage the disease to N3, stage IIIC, its significance in treatment decisions has not been clearly defined.



NCCN Guidelines Version 3.2023

Melanoma: Cutaneous

Since patients with stage IIIC have an appreciable risk of symptomatic CNS recurrence, and symptomatic CNS metastasis are associated with significant morbidity and poor survival, baseline CNS imaging should be considered in these high-risk patients.

Stage IV Workup

For patients presenting with stage IV distant metastatic disease, all panel members agree it is appropriate to confirm the suspicion of metastatic disease with either FNA or core, incisional, or excisional biopsy of the metastases. Genetic analyses (eg, *BRAF* or *KIT* mutation status) are appropriate for patients being considered for treatment with targeted therapy, or if mutational status is relevant to eligibility for participation in a clinical trial. To ensure that adequate metastatic material is available for mutational analysis, biopsy (core, excisional, or incisional) is preferred if initial therapy is to be systemic and archival tissue is not available. However, the panel also recognized that brain metastases are typically treated without histologic confirmation.

Panelists encourage baseline chest/abdominal/pelvic CT with or without PET/CT in patients with stage IV melanoma. Because patients with metastatic melanoma have a high incidence of brain metastases, brain MRI or CT scan with contrast should be performed at presentation with stage IV disease. Brain MRI is also recommended if patients have even minimal symptoms or physical findings suggestive of CNS involvement, or if results of imaging would affect decisions about treatment.

Although LDH is not a sensitive marker for detecting metastatic disease, the panel recognizes its prognostic value. It is recommended that serum LDH be obtained at diagnosis of stage IV disease. Other blood work may be done at the discretion of the treating physician.

Treatment of Primary Melanoma

Wide Excision

Surgical excision is the primary treatment for melanoma. Several prospective randomized trials have been conducted in an effort to define optimal surgical margins for primary melanoma (Table 3).

In an international prospective study carried out by WHO, 612 patients with primary melanomas not thicker than 2.0 mm were randomized to wide excision with 1 cm or ≥ 3 cm margins.^{222,223} At a median follow-up of 90 months, local recurrence, DFS and OS rates were similar in both groups. Similarly, Swedish and French randomized trials confirmed that survival was not compromised by narrower margins in melanomas thinner than 2 mm.^{224,225}

A multicenter European trial randomized 936 patients with melanoma thicker than 2.0 mm to wide excision with 2 or 4 cm margins.²²⁶ The 5-year OS rate was similar in the two groups. This is in keeping with previous trials that found no survival benefits with margins wider than 2 cm for thicker lesions.^{227,228} A systematic review and meta-analysis of the first three trials shown in Table 3 reported that surgical excision margins of at least 1 cm and no more than 2 cm are adequate.²²⁹

A recent update on the UK-based prospective trial of 1- versus 3-cm margins in patients with melanomas greater than 2 mm thick showed that at a median follow-up of 8.8 years, wider margin was associated with statistically significantly improved melanoma-specific survival (see Table 3 footnote).²³⁰ OS was not significantly different between the treatment groups. Although this is the only prospective trial that has shown a wider margin to be associated with a survival advantage, this is not practice-changing finding. The current recommendations are for 2-cm margins in this population, and this trial did not demonstrate superiority of 3-cm over 2-cm margins.



Recent large retrospective analyses are generally supportive of the margin recommendations that were based on prospective randomized trials.²³¹⁻²³⁶

Table 3. Studies That Evaluated Surgical Margins of Wide Excision of Melanoma

| Study | Year | N | Follow-up (years) | Thickness (mm) | Margin (cm) | LR | OS |
|---------------------------|------|-----|-------------------|----------------|-------------|----|-----------------|
| WHO ^{222,223} | 1991 | 612 | 8 | ≤2 | 1 vs. ≥3 | NS | NS |
| Sweden ²²⁴ | 2000 | 989 | 11 | >0.8–2.0 | 2 vs. 5 | NS | NS |
| Intergroup ²²⁷ | 2001 | 468 | 10 | 1–4 | 2 vs. 4 | NS | NS |
| France ²²⁵ | 2003 | 326 | 16 | ≤2 | 2 vs. 5 | NS | NS |
| UK ^{230,237} | 2016 | 900 | 8.8 | >2 | 1 vs. 3 | NS | NS ^a |
| Sweden ²²⁶ | 2011 | 936 | 6.7 | >2 | 2 vs. 4 | NS | NS |

LR, local recurrence; OS, overall survival; NS, non-significant

^a Analysis after a median follow-up of 5.7 years showed no significant difference in overall survival or melanoma-specific survival, but analysis after a median follow-up of 8.8 years showed significantly better melanoma-specific survival for patients with 3-cm vs. 1-cm excision margins (unadjusted HR, 1.24; 95% CI, 1.01–1.53; $P = .041$) but no significant improvement in overall survival (unadjusted HR, 1.14; 95% CI, 0.96–1.36; $P = .14$).

Management of lentigo maligna and in situ melanoma may present unique problems because of the characteristic, yet unpredictable, subclinical extension of atypical junctional melanocytic hyperplasia, which may extend several centimeters beyond the visible margins.²³⁸⁻²⁴⁰ In a prospective study of 1,120 patients with melanoma in situ treated by Mohs surgery, 9-mm surgical margins resulted in removal of 99% of melanomas while 6-mm margins removed 86%.²⁴¹ Retrospective analyses have also shown that >5 mm margins are often needed for complete histologic clearance of melanoma in situ, particularly for the lentigo maligna subtype.^{240,242-244} Mohs micrographic surgery or staged excision with or without immunohistochemical staining aimed at complete surgical excision

with meticulous margin control have demonstrated high local control rates in lentigo maligna.²⁴⁵⁻²⁴⁷

Alternatives to Excision: Topical Imiquimod or Radiation

Although surgical excision remains the standard of care for in situ melanoma, it is sometimes not feasible due to comorbidity or cosmetically sensitive tumor location. Topical imiquimod has emerged as a treatment option, especially for lentigo maligna.²⁴⁸⁻²⁶⁴ Topical imiquimod was associated with high rates of clinical and histologic clearance (70%–100%) and low recurrence rates (0%–4%) in most studies, whether used as first-line treatment (as monotherapy or prior to excision) or second-line treatment for incompletely excised lentigo maligna, or adjuvant therapy for lesions excised with narrow margins. However, long-term, comparative studies are still needed.

Radiotherapy has also been used selectively for lentigo maligna. In a systematic review of retrospective studies reporting outcomes for patients with lentigo maligna treated with definitive primary RT, there were 18 recurrences in a total of 349 assessable patients (5%), after a median follow-up of 3 years, and disease progressed to lentigo maligna melanoma in 5 cases (1.4%).²⁶⁵ There were 8 in-field recurrences (5 lentigo maligna, 3 lentigo maligna melanoma) out of 171 assessable patients (4.7%), and 5 marginal recurrences out of 123 assessable patients (4.1%). The retrospective studies used a variety of radiation protocols, including superficial RT and Grenz rays, but there were no clear trends to indicate the optimal approach. Another large retrospective study (not included in the aforementioned meta-analysis) tested Grenz ray radiation in a mixed population of patients with lentigo maligna and early lentigo maligna melanoma.²⁶⁶ Complete clearance without relapse was observed in 83% of 350 patients who received RT as primary therapy, and in 90% of 71 patients who received RT after partial excision.



Since tumor border delineation for lentigo maligna is smaller on clinical exam than with Wood lamp or digital epiluminescence microscopy, collaboration with a dermatologist who can perform these procedures is necessary to help prevent these marginal failures.²⁶⁷

NCCN Recommendations

The clinical/surgical margins discussed below refer to those taken at the time of surgery and do not necessarily correlate with gross pathologic/histologic margins measured by pathologists.

For in situ melanoma, a measured margin of 0.5 to 1 cm around the visible lesion should be obtained. For large in situ lentigo maligna melanoma, surgical margins greater than 0.5 cm may be necessary to achieve histologically negative margins. In the absence of prospective clinical trials testing margins for standard excision, this margin range is recommended based on panel consensus, data from retrospective studies, and results from the large prospective study described above that showed that increasing Mohs microsurgery margins from 6 mm to 9 mm significantly improved the rate of complete histologic clearance. More exhaustive histologic assessment of margins such as staged excision for lentigo maligna melanoma should be considered. For selected patients with positive margins after optimal surgery, topical imiquimod or RT can be considered as non-standard options (category 2B).

For melanomas 1.0 mm or less, wide excision with a 1-cm margin is recommended (category 1). Wide excision with a 1- to 2-cm margin is recommended for melanomas measuring 1.01 to 2 mm in thickness (category 1). For melanomas measuring more than 2 mm in thickness, wide excision with 2-cm margins is recommended (category 1). Surgical margins may be modified to accommodate individual anatomic or cosmetic considerations. The panel recognized that 1- to 2-cm margins might be

acceptable in anatomically difficult areas where a full 2-cm margin would be difficult to achieve.

Lymph Node Dissection

Completion Lymph Node Dissection After Positive SLNB

Traditionally, all patients with a positive SLNB have been advised to proceed to CLND. This is in part an extension of the observation that, in historical prospective trials, among patients with a positive node, survival was better in those patients where the node was removed when clinically occult by elective lymph node dissection rather than when clinically apparent by TLND.²⁶⁸ There are a number of other theoretical reasons for recommending CLND to this patient population. These include the known probability of residual positive non-SLNs (NSLNs), the prognostic value of additional positive NSLNs, improved regional nodal basin control after CLND, the lower morbidity of CLND rather than TLND, and the potential to improve long-term DSS by early aggressive nodal basin intervention. Arguments against CLND include the cost and morbidity of the procedure,²⁶⁹⁻²⁷⁴ and the fact that the procedure has never been demonstrated to offer clinical benefit to this group of patients, a group already defined as at increased risk of systemic disease based on the presence of their positive SLNB. Over the last 25 years, much has been learned about the natural history of patients with a positive sentinel node to inform many of the points cited above. More importantly, two pivotal prospective randomized trials have been conducted to directly address the impact of CLND on a number of these clinical endpoints.^{275,276}

Likelihood of Non-Sentinel Lymph Node Positivity

Among patients with a positive sentinel node, published studies have revealed additional positive non-sentinel nodes in approximately 20% of the CLND specimens (Table 4). Factors most predictive of additional non-sentinel node involvement include the largest size of the SLN metastasis,^{77,79,172,277-289} the number of SLNs involved,^{79,155,278,283,290} the

distribution of metastasis in the SLN (subcapsular vs. parenchymal),^{172,291,292} and primary tumor characteristics of thickness^{277,278,281,285-288,293,294} and ulceration.^{155,281,283,293,294} Several scoring systems have been developed to predict the likelihood of positive non-sentinel nodes based on SLN biopsy findings, primary tumor, and patient characteristics,^{288,295-299} although the utility of each of these systems has been debated based on subsequent analyses.^{80,281,283,300,301}

Table 4. Rates of Positive Non-Sentinel Lymph Nodes

| Study | Patients with CLND, n | Patients with Positive NSLN, n (%) |
|----------------------------------|-----------------------|------------------------------------|
| McMasters 2002 ³⁰² | 272 | 45 (16%) |
| Dewar 2004 ²⁹¹ | 146 | 24 (16%) |
| Sabel 2005 ²⁷⁸ | 221 | 34 (15%) |
| Kettlewell 2006 ³⁰³ | 105 | 34 (32%) |
| Cascinelli 2006 ¹⁷² | 176 | 33 (19%) |
| Govindarajan 2007 ²⁷⁹ | 127 | 20 (16%) |
| Gershenwald 2008 ²⁸⁸ | 343 | 48 (16%) |
| Cadili 2010 ⁷⁷ | 606 | 142 (24%) |
| Leung 2013 ²⁹³ | 329 | 79 (24%) |
| Wevers 2013 ²⁹⁵ | 130 | 30 (23%) |
| Pasquali 2014 ³⁰⁴ | 1,538 | 353 (23%) |
| Bertolli 2015 ²⁸⁵ | 146 | 23 (16%) |
| Rutkowski 2015 ²⁸⁷ | 473 | 132 (28%) |
| Kim 2015 ⁷⁹ | 111 | 13 (12%) |
| Total | 4723 | 1010 (21%) |

CLND, complete lymph node dissection; NSLN, non-sentinel lymph node

Prognostic Value of Complete Lymph Node Dissection

A number of retrospective studies have evaluated the prognostic value of NSLN involvement in patients who had a CLND after a positive SLN (no palpable lymph nodes). Compared to those without NSLN involvement detected by CLND, those with positive NSLN(s) have higher rates of recurrence^{80,273,293} and poorer DFS,³⁰⁵ melanoma-specific survival, and OS.^{80,172,287,293,304-306} In fact, in the studies that evaluated the clinical importance of NSLN positivity by multivariate analysis, it was consistently one of the most important independent predictor of DSS.^{273,293,304-306} Other factors identified to be independently associated with recurrence and survival include the number of positive NSLNs^{81,273,287} as well as the non-CLND factors of the primary tumor (site,²⁷³ Breslow thickness,^{80,287,301} and ulceration^{80,273,287}), the nodal basin involved,²⁷³ and the SLN burden (number of positive SLNs, size and location of tumor in the SLN[s]).^{77,79,80,301}

The challenge of using the probability of NSLN positivity as a rationale to proceed to CLND is that patients with a positive NSLN are at much higher risk for distant metastases. This is a population that intuitively may be much less likely to benefit from additional treatment of the regional nodal basin.

Therapeutic Value of CLND

The impact of completion lymph node dissection on regional control and survival in the setting of a positive SLN has not been clearly demonstrated. Results from a few retrospective studies in patients with positive SLNB have shown that treatment with CLND versus observation may be associated with improved recurrence-free survival, but is not significantly associated with improved OS or melanoma-specific survival.³⁰⁷⁻³⁰⁹ Two ongoing trials are designed to assess the therapeutic value of CLND for patients with positive SLNs (but no palpable nodes).



NCCN Guidelines Version 3.2023

Melanoma: Cutaneous

DeCOG-SLT is a phase III prospective randomized trial (<https://clinicaltrials.gov/ct2/show/record/NCT02434107>) in which melanoma patients with a positive SLNB were randomized to undergo immediate CLND (n = 241) or observation with nodal basin ultrasound surveillance (n = 242). At a mean follow-up of 34 months, CLND was not associated with any improvement in recurrence-free survival, distant-metastasis-free survival, or melanoma-specific survival.²⁷⁵ An interesting subset analysis in this trial suggested that CLND was not associated with clinical benefit in patients with either high or low SLN tumor burden.

MSLT-II is a much larger international prospective randomized trial in which patients with a positive SLNB were randomized to undergo either immediate completion lymph node dissection or nodal basin ultrasound surveillance (clinicaltrials.gov/show/NCT00297895). This trial, which has completed accrual, should further clarify the issue of whether CLND has an impact on outcome.

Therapeutic Lymph Node Dissection

In patients with clinically involved lymph nodes but no distant disease, TLND is associated with 5-year survival rates of 30% to 50%, depending on number of lymph nodes involved, extracapsular extension, and high-risk features of the primary tumor (Breslow thickness, ulceration, site).^{71,81,82,310-317} At present, there is no non-surgical therapy that has been shown to provide similar results (for survival).

Palliative Lymph Node Dissection

On occasion, lymph node dissection may be indicated for patients with distant metastatic disease in order to achieve regional nodal basin control.

Elective Pelvic Lymph Node Dissection

Among patients with positive inguofemoral nodes and no clinical or radiologic evidence of positive pelvic nodes, there is some controversy as

to the role of elective ileo-obturator lymph node dissection.^{310,318-321} In these patients, the probability of clinically occult positive pelvic nodes is increased when there are clinically positive inguofemoral nodes, three or more inguofemoral nodes involved, or when Cloquet's node is positive.³²²⁻³²⁷ Again, the impact of elective pelvic lymphadenectomy on survival in this specific patient cohort is unknown.³²⁸

Morbidity of Lymph Node Dissection

The value CLND for providing prognostic information and regional control must be weighed against morbidity of the procedure. Many studies have reported complication rates for between 40% to 60%,^{269,329} but others have reported lower rates, between 20% to 40%.^{158,159,271} Potential complications associated with CLND include wound dehiscence or infection, hematoma/seroma, neuropathy, lymphocele formation, and lymphedema.^{158,159,269-272,311,317,329-331} Lymphedema and neuropathy can be persistent postoperative problems.^{270-272,331} Most studies report lymphoedema rates between 20% to 30%, but some studies have reported lymphedema in up to 50% of patients.^{86,269,271,272,331} Risk factors for complications during or after lymph node dissection include obesity and increased age.^{331,332} The risk and severity of complications may depend on the location of the nodal basin undergoing lymph node dissection, with the groin being the highest risk location, especially for lymphedema.^{158,271,274,317,331}

Technical Aspects of Lymph Node Dissection

CLND consists of an anatomically thorough dissection of the involved nodal basin. The extent of lymph node dissection is often modified according to the anatomic area of lymphadenopathy. There is some controversy on how best to define an adequate lymph node dissection. One measure of the completeness of a regional lymph node dissection is the number of lymph nodes examined. There is not uniform agreement on



NCCN Guidelines Version 3.2023

Melanoma: Cutaneous

the number of lymph nodes needed to define an optimal CLND in a given lymph node basin.

It is unknown whether the extent of lymph node dissection can safely be modified according to the indication for the lymph node dissection (CLND due to positive SLN, TLND for palpable lymph node(s), palliative lymph node dissection regional control in patients with distant metastatic disease) to limit the morbidity of the procedure. A number of investigators have attempted to evaluate this issue.^{269,284,333-338}

NCCN Recommendations

If the sentinel node is negative, regional lymph node dissection is not indicated. For patients with stage III disease based on a positive SLN, a CLND of the involved nodal basin should be discussed and offered, in the context of all of the points raised above, including the probability of a positive NSLN, the prognostic value of the NSLN status, the morbidity of the procedure, and the fact that one prospective randomized controlled trial has shown no benefit in any clinically relevant endpoint. The impact of CLND on plans for adjuvant therapy or clinical trial enrollment should also be considered.

Patients presenting with clinically positive nodes without radiologic evidence of distant metastases should undergo wide excision of the primary site (if present) and CLND of the involved nodal basin. In the setting of inguinal lymphadenopathy, a pelvic dissection is recommended if the PET/CT or pelvic CT scan reveals iliac and/or obturator lymph node involvement (category 2A) or if a positive Cloquet's lymph node is found on intraoperative frozen section (category 2B). Pelvic dissection also should be considered for clinically positive inguinal-femoral nodes or if three or more inguinofemoral nodes are involved (category 2B). For primary lesions in the head and neck with clinically or microscopically positive lymph nodes in the parotid gland, a superficial parotidectomy

alone is insufficient and the panel recommends appropriate neck dissection of the draining nodal basins.³³⁹

However, the NCCN Panel felt that available retrospective evidence to date was insufficient to mandate that a specific number of nodes be required to deem a lymph node dissection adequate for any designated lymph node basin. As a measure of quality control to ensure adequacy of lymphadenectomy, the committee recommended that the operative note fully describe the anatomic boundaries of the lymph node dissection.

Adjuvant Radiation Therapy

Adjuvant Radiation for Desmoplastic Neurotropic Melanoma

Adjuvant radiation therapy (RT) is rarely necessary following adequate excision of a primary melanoma. One exception may be desmoplastic neurotropic melanoma (DNM), which tends to be locally aggressive. In a retrospective series of 128 patients with DNM (84% stage II), patients who did and did not receive adjuvant radiation had a similar incidence of local failure (7% with RT vs. 6% without) despite worse prognostic features in the radiated group (thicker tumors, deeper Clark level invasion, and narrower excision margins).²¹⁸ The authors concluded that radiation should be considered for patients with inadequate margins, which in this series occurred predominately in the head and neck region. A multicenter retrospective analysis in 277 patients with primary stage I-III desmoplastic melanoma treated with wide excision with or without SLNB showed that adjuvant RT was associated with improved local control, particularly in patients with positive excision margins or primary melanoma with Breslow thickness >4 mm or located in the head and neck region.³⁴⁰ Another retrospective study of patients with resected recurrent desmoplastic melanoma (n = 130) also showed that adjuvant RT was associated with improved local control but not distant metastasis-free survival (DMFS).³⁴¹ The association of RT with improved local control was particularly evident in those with pure desmoplastic melanoma or those with perineural



NCCN Guidelines Version 3.2023

Melanoma: Cutaneous

invasion. The utility of RT for local control of desmoplastic melanoma is further supported by the results from another single-institution retrospective analysis (n = 95) showing a trend toward improved relapse-free survival (RFS) in patients who received RT in addition to surgery.³⁴² Results from these four and one smaller retrospective study³⁴³ suggest that adjuvant RT improves local control in patients with desmoplastic melanoma, a hypothesis that is being tested in an ongoing phase III trial comparing adjuvant RT with observation following resection of neurotropic melanoma of the head and neck (NCT00975520).³⁴⁴

Adjuvant Radiation for Preventing Nodal Relapse

Radiation has a role in controlling nodal relapse in patients at risk. The largest retrospective review investigating the role of RT was performed by Agrawal et al.³⁴⁵ Six hundred fifteen patients were evaluated who met the specific criteria portending a “high risk” of regional nodal relapse, based on lymph node number, size, location, and extracapsular extension. At a median follow-up of 5 years, regional recurrence occurred in only 10% of the patients selected to receive adjuvant RT, compared to 41% of the non-radiated patients. Adjuvant radiation was associated with improved locoregional control on multivariate analysis ($P < .0001$). Of note, treatment-related morbidity was significantly increased with RT (5-year rate of 20% vs. 13%, $P = .004$), particularly lymphedema. Subsequent smaller retrospective analyses have also shown that adjuvant RT after surgery is associated with improved nodal basin control in patients with who are at high risk of regional recurrence.^{346,347} One retrospective analysis suggested that the benefit of RT for regional control may be associated with doses of at least 50 Gy.³⁴⁸ Interpretation of these results should take into consideration selection bias and many other potential forms of bias inherent in retrospective studies.

The only prospective randomized phase III trial of adjuvant nodal basin RT versus observation in patients at risk for nodal relapses recently reported

final results. This trial included 250 patients with nonmetastatic disease and palpable lymphadenopathy at diagnosis or as an isolated palpable site of relapse.³⁴⁹ Eligible patients were required to have an LDH < 1.5 times the upper limit of normal, as well as ≥ 1 parotid, ≥ 2 cervical or axillary or ≥ 3 groin positive nodes, a maximum nodal diameter ≥ 3 cm in neck, ≥ 4 cm in the axilla or groin, or nodal extracapsular extension.³⁵⁰ Patients were treated with lymphadenectomy followed by either adjuvant radiation (48 Gy in 20 fractions) to the nodal basin or observation.³⁴⁹ After a mean of follow-up of 73 months, lymph node field recurrence was significantly less frequent in the adjuvant radiation group (HR, 0.54; 95% CI, 0.33–0.89; $P = .021$) for all nodal basins.³⁴⁹ Although not primary endpoints, RFS and OS showed no statistically significant differences for patients treated with adjuvant RT versus observation. Adjuvant radiation was associated with frequent grade 2 to 4 toxicities primarily affecting the skin or subcutaneous tissue, but also including pain, nerve damage, and joint adverse events (AEs).

Various fractionation schemes for postoperative adjuvant radiation have been evaluated in retrospective studies.^{340,351–355} Hypofractionated radiotherapy appears to be equally as effective as standard fractionation. These studies have shown moderate toxicity associated with adjuvant RT. While some doses/schedules may be better tolerated, prospective analyses are needed to establish the optimal regimen.

Adjuvant Radiation for Brain Metastases

Adjuvant radiation is also used after surgery for melanoma brain metastases. Prospective randomized trials have compared adjuvant whole-brain radiation therapy (WBRT) with observation, given after surgery or stereotactic radiosurgery (SRS) in patients with brain metastases from various types of cancer.^{356–362} All but one of these studies showed that adjuvant WBRT reduces intracranial recurrence, and some studies also show improved duration of functional independence and



reduced mortality due to intracranial progression and neurologic causes. However, these trials included very few patients with melanoma—likely less than 60 patients all together—and did not report results specifically from patients with melanoma. The largest of these prospective randomized trials included 18 patients with melanoma, and showed that adjuvant WBRT after resection or SRS reduced intracranial progression but did not lead to statistically significant improvements in OS or duration of functional independence.³⁶² A few retrospective studies have reported outcomes for patients with brain metastases from melanoma treated with adjuvant WBRT after either surgery or SRS, but data from these analyses are insufficient for evaluating the clinical value of adjuvant WBRT for patients with melanoma.^{363,364} Further study in a prospective randomized trial setting is needed to assess the impact of WBRT on melanoma brain metastases, especially in the context of emerging data supporting the use of systemic therapy in patients with melanoma brain metastases.

There are no good prospective randomized trials testing adjuvant SRS following surgery for patients with brain metastases from melanoma, but SRS is being increasingly used in an effort to reduce the risk of neurocognitive toxicities associated with WBRT.

NCCN Recommendations

Most patients with in situ or early-stage melanoma will be cured by primary excision alone. However, patients with desmoplastic melanomas, especially those with extensive neurotropism, are at high risk for local recurrence, especially if margins are suboptimal. Adjuvant radiation following surgery may be considered to improve local control.

Adjuvant RT may be considered for select patients with clinically positive nodes and features predicting a high risk of nodal basin relapse. The NCCN Panel discussed at length the value of adjuvant RT in patients at high risk of recurrence. Panelists agreed that high-level evidence indicates

that adjuvant RT is useful in delaying or preventing nodal relapse. However, some institutions argued that the increased incidence of late RT-related toxicity could potentially outweigh the benefit of reducing nodal basin recurrence. This, coupled with the statistically insignificant trend towards worse OS in the RT arm resulted in substantial heterogeneity of opinion among panel members as to the role of adjuvant nodal basin RT. Patient characteristics that suggest potential use of radiation are those used as entry criteria in the phase III trial described above.³⁵⁰ The use of adjuvant RT for these patients is a category 2B recommendation, reflecting nonuniform panel consensus on its value. Careful patient selection based on location, size, number of positive nodes, and gross (instead of histologic) extranodal extension is critical. The benefits of adjuvant RT must be weighed against the increased likelihood of long-term skin and regional toxicities that can affect quality of life. Consideration should be given to potential interactions between radiation and systemic therapy.

The current data regarding adjuvant RT, either WBRT or SRS, for resected brain metastases are insufficient to formulate a specific recommendation. Adjuvant RT should be considered for these patients on a case-by-case basis. With the advent of more effective systemic therapy, melanoma patients are living longer than in the past, and may be more susceptible to the long-term neurocognitive toxicity of WBRT.

For adjuvant therapy of recurrent disease, see *Treatment of Recurrence*.



NCCN Guidelines Version 3.2023

Melanoma: Cutaneous

Adjuvant Systemic Therapy for Melanoma

Brief History of Adjuvant Therapy Options for Melanoma

For adjuvant treatment of melanoma in patients rendered free of disease by surgery, traditional systemic therapy approaches have proven to be ineffective. Adjuvant interferon alfa (IFN alfa), particularly high-dose IFN alfa, has been widely used in patients with melanoma for many years. A large body of clinical evidence has amassed from prospective randomized trials comparing adjuvant IFN alfa with observation or control treatments now thought to be ineffective in melanoma. Results varied across trials, with some showing improvement in RFS,³⁶⁵⁻³⁷³ a few showing improvement in OS,^{367,369,370,372} but others showing no improvement in RFS or OS or effects with borderline statistical significance.^{370,371,374-381} Meta-analyses including data from a large number of trials have shown that improvements in RFS and OS are statistically significant, but small. A recent meta-analysis reported improvements in 5- and 10-year event-free survival and OS of less than 4%.³⁸²

IFN alfa has been supplanted, however, by targeted therapy and immune checkpoint inhibitor options based on results from recent and ongoing prospective randomized trials.³⁸³⁻³⁸⁷ Although trials supporting immune checkpoint inhibitor and targeted therapy as adjuvant treatment options did not compare these agents to IFN alfa, the NCCN Melanoma Panel considers these agents to be more effective and better tolerated than IFN alfa, and therefore no longer recommends IFN alfa for adjuvant treatment of cutaneous melanoma.

For several years biochemotherapy was among the listed options for adjuvant treatment of resected high-risk stage III melanoma. Inclusion of biochemotherapy as an adjuvant option was based on results from the SWOG S0008 phase 3 randomized trial showing that the combination of cisplatin, vinblastine, dacarbazine, IL-2, and IFN alfa improved RFS compared with high-dose IFN alfa-2b (median of 4.0 years vs. 1.9 years;

HR, 0.75 with 95% CI, 0.58–0.97; $P = .03$).³⁸⁸ Although the studies supporting adjuvant immune checkpoint inhibitor and targeted therapy options did not compare these newer approaches with biochemotherapy, the latter has been removed from the list of adjuvant options because it was rarely being used at NCCN Member Institutions due both to its high toxicity profile and to the emergence of more effective adjuvant therapy options.

NCCN Recommendations for Considering Adjuvant Systemic Therapy

Adjuvant treatment outside of a clinical trial is not recommended for patients with stage I/II disease, although the rationale for this recommendation varies across the NCCN Panel. There are no FDA-approved adjuvant immune checkpoint inhibitors or BRAF-targeted therapies for this group of patients. Although most of the trials to date did not include patients with stage I/II disease (Table 5), clinical trials are underway to define the role of adjuvant checkpoint inhibitors in high-risk stage II patients.^{389,390}

For patients with resected advanced melanoma, there have been a number of prospective randomized trials suggesting that immune checkpoint inhibitor and BRAF-targeted therapy are effective options for adjuvant treatment. Data from these trials are summarized in Table 5. These trials, the FDA-approved indications (Table 6), and the NCCN recommendations (Table 7) based on these trials are discussed in greater detail in the sections below. Selection of a specific adjuvant systemic therapy for patients with resected advanced melanoma depends on many factors, including risk of recurrence, potential clinical benefit, potential toxicities, patient preference, patient age, and comorbidities. Other options include participation in a clinical trial and observation.

The most important factor to consider is the risk of recurrence and/or death from disease. Stage IIIA is the lowest risk group for which the NCCN



NCCN Guidelines Version 3.2023 Melanoma: Cutaneous

Guidelines recommend considering adjuvant treatment. Several of the recent phase III randomized trials testing immune checkpoint inhibitors or BRAF-targeted therapies have included some stage IIIA patients; generally, the trials have included only those sentinel node-positive patients with a nodal metastasis at least 1 mm in diameter, as these were judged to be higher risk (Table 5). It is important to note, however, that the entry criteria for these trials were based on AJCC 7th Edition staging, and that patients with stage IIIA disease as defined by AJCC 7th Edition staging comprise a higher risk group than stage IIIA as defined by AJCC 8th Edition staging, which also incorporates Breslow thickness into stage III disease (5-year melanoma-specific survival for AJCC 7th Edition stage IIIA is 78%, compared to 93% for AJCC 8th Edition stage IIIA).³⁹¹ In patients with resected stage III disease at low risk of recurrence (eg, AJCC 8th Edition stage IIIA and/or those with SLN metastasis <1 mm), the toxicity of adjuvant therapy may outweigh the benefit and should be discussed with the patient.

Across the NCCN Panel, opinions vary regarding the strength of evidence supporting adjuvant systemic therapy (using the currently recommended options shown in Table 7) for resected stage III/IV disease. NCCN Panel Members agree that recommendations for systemic adjuvant treatment (Table 7) are supported by improvements in RFS as reported in recent and ongoing prospective randomized trials (Table 5). Some panel members believe that RFS improvement and available survival data suggest that upfront adjuvant systemic therapy is preferable, and expect that further follow-up will confirm that adjuvant treatment (with the currently recommended agents) improves DSS. Other panel members are less convinced by the available data, and would prefer to wait for longer term follow-up confirming that the observed improvement in RFS translates into improvement in OS/DSS before making a strong case for using upfront adjuvant treatment in most patients with stage III disease. The argument against routine adjuvant therapy for all patients with resected stage III

disease is that, unless the observed improvement in RFS translates into a corresponding improvement in OS/DSS, a more selective approach to the use of adjuvant therapy may be prudent, with the idea that forgoing upfront adjuvant therapy and then treating in the event of relapse may result in similar OS/DSS but lower overall risk of toxicity.

When considering whether adjuvant therapy is appropriate for a patient with regional disease limited to clinically occult nodal metastases, it is also important to note that entry criteria for all the trials in Table 5 required complete resection of all disease, including primary tumor excision with adequate margins and CLND in patients with nodal metastases detected by SLNB. However, based on results from two prospective randomized trials (MSLT-II and DeCOG) demonstrating that CLND did not improve DSS or OS in patients with clinically occult nodal disease,^{275,392} it is reasonable to consider nodal basin ultrasound surveillance in lieu of CLND. Although it is unclear whether the recommended adjuvant treatment options have similar efficacy in the absence of CLND following a positive SLNB, the NCCN Melanoma Panel thinks that CLND should not be a factor in the decision to use adjuvant therapy in patients whose nodal metastases are detected by SLNB.

Risk of toxicity is the other major consideration when deciding whether a patient with stage III disease should receive adjuvant therapy. Table 5 includes AE rates observed in each of the prospective randomized trials testing immune checkpoint inhibitors and BRAF-targeted therapies in the adjuvant setting. Although anti-PD-1 agents and BRAF/MEK inhibitor therapy are associated with lower rates of toxicity than historical adjuvant therapy options (ie, IFN alfa, biochemotherapy), grade 3–4 AEs (all cause) were observed in 25% to 41% of patients treated in adjuvant trials,³⁸⁵⁻³⁸⁷ and a small proportion of patients receiving adjuvant immune checkpoint inhibitors can develop life-long immune-related AEs (irAEs). In patients with prior exposure to anti-PD-1 therapy and for whom adjuvant

ipilimumab is an option, the decision should be informed by careful consideration of a patient's individual risk of recurrence and his/her ability to tolerate and manage toxicities. Patients selected for the adjuvant trials shown in Table 5 all had good performance status (ECOG 0 or 1), and the immunotherapy trials also excluded patients with autoimmune disease or uncontrolled infection, and those requiring systemic glucocorticoids.³⁸⁴⁻³⁸⁷ Prior to starting any adjuvant therapy, the NCCN Panel recommends

reviewing the U.S. prescribing information for each agent being considered, to ensure that contraindications are identified, and for dosing options and administration and recommendations. For monitoring and management of irAEs associated with immune checkpoint inhibitors, refer to the [NCCN Guidelines for Management of Immunotherapy-Related Toxicities](#).

Table 5. Immune Checkpoint Inhibitor and Targeted Therapy: Randomized Trial Data for Adjuvant Treatment

| Trial | | Stages Included ^a | Treatment Arms | Median Follow-up | Efficacy Analysis ^b | | | AEs ^c Any grade Grade 3–4 Grade 5 |
|--|------------------|--|--|------------------------------|---|---|--|---|
| Name and Reference | Phase Design | | | | RFS or DFS | DMFS | OS | |
| Immune Checkpoint Inhibitors | | | | | | | | |
| EORTC 18071 NCT00636168 Eggermont 2016 ³⁸⁴ | III DB RCT | IIIA >1 mm, IIIB/C no IT | HD-Ipi (n = 475) Pbo (n = 476) | 5.3 y | 5-y: 41% vs. 30% HR = 0.76 [0.64–0.89] P < .001 | 5-y: 48 vs. 39% HR = 0.76 [0.64–0.92] P = .002 | 5-y: 65% vs. 54% HR = 0.72 [0.58–0.88] P = .001 | 99% vs. 91% 54% vs. 26% 1.5 vs. 1.3% |
| CheckMate 238 NCT02388906 Weber 2017 ³⁸⁵ | III DB RCT | IIIB/C ^d IV | Nivo + Pbo (n = 453) HD-Ipi + Pbo (n = 453) | 1.6 y | 1-y: 71% vs. 61% ^e HR = 0.65 [0.51–0.83] P < .001 | 1-y: 80 vs. 73% HR = 0.73 [0.55–0.95] | NR | 97% vs. 99% 25% vs. 55% 0 vs. 0.4% |
| KEYNOTE-054 NCT02362594 Eggermont 2018 ³⁸⁶ | III DB RCT | IIIA >1 mm, IIIB/C no IT ^f | Pembro (n = 514) Pbo (n = 505) | 1.2 y | 1-y: 75% vs. 61% HR = 0.57 [0.43–0.74] P < .001 | NR ^g | NR | 93% vs. 90% 32% vs. 19% 0.2% vs. 0 |
| BRAF-Targeted Therapy | | | | | | | | |
| COMBI-AD NCT01682083 Long 2017 ³⁸⁷ | III DB RCT | IIIA >1 mm, IIIB/C ^h | Dab + Tram (n = 438) Pbo (n = 432) | 2.8 y | 3-y: 58% vs. 39% HR = 0.47 [0.39–0.58] P < .001 | NR ⁱ HR = 0.51 [0.40–0.65] Nominal P < .001 | 3-y: 86% vs. 77% HR = 0.57 [0.42–0.79] P = .0006 ^j | 97% vs. 88% 41% vs. 14% 0.2% vs. 0 |
| BRIM8 NCT01667419 Maio 2018 ³⁹³ | III DB RCT | IIC, IIIA >1 mm, IIIB/C no IT ^k | Vem (n = 250) Pbo (n = 248) | 2.5 y, 2.8 y ^l | 2-y: 62% vs. 53% HR = 0.65 [0.50–0.85] P = .0013 | 2-y: 72% vs. 65% HR = 0.70 [0.52–0.96] P = .027 | 2-y: 90% vs. 86% HR = 0.76 [0.49–1.18] P = .2165 | NR 57% vs. 15% 0.4% vs. 0 |



>1 mm, at least one lymph node with metastasis diameter >1 mm; AEs, adverse events; Dab, dabrafenib; DB, double-blind; DFS, disease-free survival; DMFS, distant metastasis-free survival; HD-ipi, high-dose ipilimumab (10 mg/kg every 3 weeks for 4 doses, then every 3 months for up to 3 years); HR, hazard ratio, with 95% CI in square brackets; IFN, interferon; ipi, ipilimumab; IT, in-transit metastases; Nivo, nivolumab; NR, not reported; OL, open-label; OS, overall survival; Pbo, placebo; Pembro, pembrolizumab; RCT, randomized controlled trial; RFS, recurrence-free survival or relapse-free survival; Tram, trametinib; vem, vemurafenib

^a Defined per AJCC 7th Edition Staging.

^b Unless otherwise noted, Kaplan-Meier method was used to determine rates of RFS, DFS, DMFS, and OS. Square brackets show 95% CI for HR.

^c Percent of patients who experienced ≥ 1 AE of any grade, grade 3–4, grade 5. Includes all AEs, regardless of causality. Note that AE rates provided in subsequent tables are lower because they are rates of AEs reported as related to study treatment.

^d Patients with stage IIIB/C were required to have clinically detectable lymph nodes (confirmed by pathology) and/or ulcerated primary lesions. This implies that patients with in-transit disease may have been included, provided that they also had ≥ 1 clinically detectable nodal metastasis and/or ulceration in the primary lesion. More than 90% of patients with stage III had either microscopic or macroscopic lymph node involvement.

^e RFS 1.5-y rate: 66% vs. 3% for nivolumab versus ipilimumab.

^f Although entry criteria excluded patients with in-transit metastases, the analysis included 6 patients with in-transit metastasis and nodal disease.

^g Distant metastasis occurred in 78 (15.2%) vs. 138 (27.3%) of patients in the pembrolizumab vs. placebo arms. Distant metastases as first type of recurrence, 18-mo rate: 17% vs. 30%, HR, 0.53; 95% 0.37–0.76.

^h Patients were required to have *BRAF* V600E or V600K mutation. Entry criteria allowed patients presenting with initial resectable lymph node recurrence after a diagnosis of stage I or II melanoma. In-transit metastases were present in 51 patients (12%) in the dab/tram arm and 36 patients (8%) in the placebo arm. Patients were required to have CLND, so it seems unlikely that any patients with intralymphatic disease alone (no nodal metastases) were admitted to the trial.

ⁱ Patients with distant metastases or death (whole study period), in dabrafenib/trametinib vs. placebo arm: 25% vs. 35%

^j Despite this low *P* value, the between-group difference was not significant because it did not cross the prespecified conservative interim boundary of $P = .000019$.

^k Patients were required to have *BRAF* V600 mutation.

^l Median follow-up for stage IIC-IIIB, stage IIIC.

Specific Systemic Therapy Options for Adjuvant Treatment

A number of prospective randomized trials have shown that immune checkpoint inhibitors and BRAF-targeted therapies are effective for unresectable stage III and stage IV melanoma,^{92-95,136,403-413} and these drugs are now FDA approved and widely used in this setting. The FDA-approved indications are summarized in Table 6. Based on their efficacy for unresectable advanced disease, many of these therapies are now the subject of ongoing prospective randomized trials to determine whether they provide clinical benefit as adjuvant treatment for resected advanced disease. Table 5 summarizes published efficacy and safety data from prospective randomized controlled trials testing some of these immune checkpoint inhibitors (ipilimumab, nivolumab, pembrolizumab) and targeted therapies (vemurafenib, dabrafenib/trametinib) for adjuvant

treatment of high-risk resected melanoma. Based on data shown in Table 5, some of these therapies have now been approved for adjuvant treatment of resected melanoma (Table 6).

Most of the trials shown in Table 5 excluded patients who had received any kind of prior systemic therapy (ie, EORTC 1807, COMBI-AD, CheckMate 238, KEYNOTE-054, BRIM8).^{384-387,393} Each of these trials included a subset stage III disease deemed sufficiently high risk to warrant adjuvant treatment, but the definitions of “high risk” stage III differed across trials. Note that for all these trials AJCC 7th edition staging was used, whereas the NCCN Guidelines have been updated to reflect AJCC 8th edition staging (Table 7). The efficacy and safety data for each of these adjuvant therapies is described in greater detail below.

Table 6. FDA-Approved Indications for Immune Checkpoint Inhibitor and BRAF/MEK Targeted Therapy in Cutaneous Melanoma

| Agent | Treatment for Metastatic or Unresectable Disease | Adjuvant Therapy |
|--|---|---|
| Immune Checkpoint Inhibitors | | |
| Ipilimumab ³⁹⁴ | Unresectable or metastatic melanoma | Cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy |
| Nivolumab ³⁹⁵ | Unresectable or metastatic melanoma | Melanoma with lymph node involvement or metastatic disease who have undergone complete resection |
| Pembrolizumab ³⁹⁶ | Unresectable or metastatic melanoma | Melanoma with involvement of lymph node(s) following complete resection |
| Nivolumab/ipilimumab ^{394,395} | Unresectable or metastatic melanoma | No FDA approval in this setting |
| BRAF Targeted Therapies | | |
| Dabrafenib ³⁹⁷ | Unresectable or metastatic melanoma with <i>BRAF</i> V600E mutation as detected by an FDA-approved test | No FDA approval in this setting |
| Vemurafenib ³⁹⁸ | Unresectable or metastatic melanoma with <i>BRAF</i> V600E mutation as detected by an FDA-approved test | No FDA approval in this setting |
| BRAF/MEK Combinations | | |
| Dabrafenib/trametinib ^{397,399} | Unresectable or metastatic melanoma with <i>BRAF</i> V600E or V600K mutations as detected by an FDA-approved test | Melanoma with <i>BRAF</i> V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection |
| Vemurafenib/cobimetinib ^{398,400} | Unresectable or metastatic melanoma with <i>BRAF</i> V600E mutation as detected by an FDA-approved test | No FDA approval in this setting |
| Encorafenib/binimetinib ^{401,402} | Unresectable or metastatic melanoma with a <i>BRAF</i> V600E or V600K mutation, as detected by an FDA-approved test | No FDA approval in this setting |

Immune Checkpoint Inhibitors

Ipilimumab

Ipilimumab, a monoclonal antibody that binds and blocks the function of the immune checkpoint receptor CTLA-4, has been shown to significantly improve progression-free survival (PFS) and OS in patients with unresectable or metastatic melanoma,^{403,404} and originally received FDA approval in 2011 for treatment of patients with metastatic melanoma. Based on its efficacy for treating metastatic disease, the phase 3 double-

blind, randomized, multicenter, international EORTC 18071 trial compared adjuvant high-dose ipilimumab (10 mg/kg) to placebo, in selected patients with completely resected stage III melanoma (Table 5).^{383,384} Eligible patients included those with AJCC 7th Edition stage IIIA disease (if N1a, at least one metastasis >1 mm), or with stage IIIB-C disease but no in-transit metastases. All patients had their primary tumor excised with adequate margins and complete regional lymphadenectomy, but none had received systemic therapy for melanoma.³⁸³ The trial demonstrated that ipilimumab improved RFS, DMFS, and OS (Table 5). Based on these results the FDA



NCCN Guidelines Version 3.2023

Melanoma: Cutaneous

approved high-dose ipilimumab as adjuvant treatment in melanoma. The FDA-approved indication includes all patient groups included in the trial, patients with stage III in-transit disease (provided they also have at least one nodal metastasis >1 mm diameter), and those who had received prior systemic therapy for melanoma.^{383,394}

Adjuvant ipilimumab was tested and FDA approved with a prolonged high-dose regimen: 10 mg/kg every 3 weeks for 4 doses, followed by 10 mg/kg every 12 weeks for up to 3 years or until documented disease recurrence or unacceptable toxicity.^{383,394} In contrast, for treatment of unresectable or metastatic disease, the recommended ipilimumab dose is lower (3 mg/kg) and the treatment duration is shorter (every three weeks for a total of 4 doses).³⁹⁴ Ipilimumab is associated with a variety of irAEs, and the frequency and severity of these toxicities have been shown to increase with dose.⁴¹⁴⁻⁴¹⁷ A meta-analysis including 1265 patients from 22 clinical trials found that the risk of developing an irAE (high grade) was three-fold higher with ipilimumab 10 mg/kg versus 3 mg/kg.⁴¹⁵

In EORTC 18071, grade 3–4 AEs were more common with ipilimumab versus placebo (Table 5).³⁸⁴ Fatal ipilimumab-related AEs occurred in 5 patients (1%), and included colitis (n = 3), myocarditis (n = 1), and multi-organ failure with Guillain-Barré syndrome (n = 1). AEs lead to discontinuation of treatment in 53% of patients who received high-dose adjuvant ipilimumab, compared with 5% of those who received placebo. An ongoing phase III randomized trial (ECOG 1609, NCT01274338) is testing whether adjuvant ipilimumab using the 3 mg/kg dosing will reduce toxicity without reducing clinical benefit. Preliminary results presented at ASCO suggest that RFS may be similar for 3 mg/kg and 10 mg/kg dosing, and that the lower dose may reduce the rate of grade 3–4 AEs.⁴¹⁸ This trial is also comparing adjuvant ipilimumab with adjuvant interferon to determine whether ipilimumab is more effective than the previous standard

of care in the adjuvant setting, but data from the IFN alfa arm have not been reported.

Anti-PD-1 Monotherapy

The programmed cell death protein 1 (anti-PD-1) antibodies interfere with ligand binding by the T-cell surface receptor PD-1, resulting in enhanced T-cell activation.^{419,420} Two PD-1–directed antibodies, nivolumab and pembrolizumab, have been tested as adjuvant treatment for resected melanoma in two phase III randomized trials (CheckMate 238 and KEYNOTE-054, respectively; Table 5).^{385,386}

The CheckMate 238 study compared adjuvant nivolumab to adjuvant ipilimumab (10 mg/kg) in select patients with resected stage IIIB/C or stage IV (Table 5). At a median 19.5 months follow-up, nivolumab was associated with a clinically meaningful and statistically significant improvement in RFS and DMFS. The percent of patients experiencing grade 3–4 AEs was 30% lower in the nivolumab versus ipilimumab arm.³⁸⁵ Further follow-up is needed to determine whether nivolumab favorably impacts OS compared to ipilimumab. Subgroup analyses also suggest that nivolumab significantly improves RFS (relative to ipilimumab) regardless of *BRAF* mutation status or PD-L1 expression status. Based on the demonstrated improvement in RFS, the FDA approved nivolumab for adjuvant treatment of resected nodal or metastatic melanoma (Table 6). Although the trial entry criteria required patients with stage IIIB/C disease (AJCC 7th Edition) to have clinically detected lymph nodes and/or ulcerated primary, the FDA-approved indication is broader, including all patients with “lymph node involvement.”

In the KEYNOTE-054 trial, pembrolizumab was compared with placebo in selected patients with resected stage III melanoma (Tables 1). At a median follow-up of 1.2 years, pembrolizumab improved RFS and reduced risk of distant metastases; OS data were not mature at the time of the initial report.³⁸⁶ Although the fraction of patients who experienced any



grade of AE was similar across arms, high-grade AEs were somewhat more common in the pembrolizumab arm. Subgroup analyses suggest that improvement in RFS with pembrolizumab (relative to placebo) is not related to PD-L1 expression or *BRAF* mutation status.

Although there are no data from prospective randomized trials directly comparing adjuvant nivolumab versus pembrolizumab, the results from CheckMate 238 and KEYNOTE-054 suggest that these agents have similar efficacy and safety in the adjuvant setting.^{385,386}

NCCN Recommendations for Adjuvant Immune Checkpoint Inhibitors

A summary of the NCCN-recommended adjuvant systemic immune checkpoint inhibitor options and category of evidence and consensus for each of these recommendations are listed in Table 7 according to clinical/pathologic stage and primary treatment. Based on the results from CheckMate 238, the NCCN Melanoma Panel agrees that nivolumab should be listed as an adjuvant postoperative treatment option for patients with stage III-IV at presentation, as well as for patients with recurrent stage III/IV disease. Whereas the NCCN Panel considers adjuvant nivolumab to be a reasonable option across a wider range of patients than were included in the CheckMate 238 trial, nivolumab is a category 1 option only in specific subgroups, based on the makeup of the study population and strength of data for specific subgroups. The NCCN Panel agreed that results from CheckMate 238 provide high-level evidence that postoperative adjuvant nivolumab provides RFS benefit to patients who present or recur with clinically node positive disease (Table 7). Because the trial excluded patients with stage IIIA disease (AJCC 7th Edition staging), the panel is less confident about the benefit of adjuvant nivolumab in patients whose nodal disease is detected by SLNB. The recommendation for adjuvant nivolumab is category 1 only for stage IIIB/C with lymph node metastases (AJCC 7th Edition), used as selection criteria in the trial. Note that definitions of the stage III substages were

significantly revised in the AJCC 8th Edition update, such that some cases that were stage IIIB/C per the AJCC 7th Edition would be reclassified as stage IIIA per the AJCC 8th Edition, and vice versa. In addition, some cases that were stage IIIC per the AJCC 7th Edition would be reclassified as stage IIID per the AJCC 8th Edition. Results of trials based on AJCC 7th Edition staging cannot be directly mapped to patients staged using the AJCC 8th Edition, and all decisions should be informed by a thorough understanding of the probability of recurrence and the risks and potential benefits of a given adjuvant therapy. Although there may have been some patients with (resectable) in-transit disease in this trial, data from these patients were not reported separately, so adjuvant nivolumab is a category 2A recommendation in patients with satellite/in-transit disease (at initial presentation or recurrence), if complete excision to clear margins is achieved. The NCCN Panel recommends referring to the FDA label for nivolumab for details on dosing and treatment administration.³⁹⁵

Based on the results of the KEYNOTE-054 trial, the NCCN Panel recommends pembrolizumab as an adjuvant therapy option for patients with stage III disease (at presentation or recurrence) (Table 7). Similar to the situation with nivolumab, the NCCN Panel considers adjuvant pembrolizumab to be a reasonable option across a wider range of stage III patients than were included in the KEYNOTE-054, but it is a category 1 option only in specific subgroups (Table 7). The NCCN Panel agreed that the results from KEYNOTE-054 support adjuvant pembrolizumab as a category 1 option for patients with clinically detected nodal metastases. For patients with clinically occult nodal disease, the category 1 recommendation is limited to the subgroup of patients included in the trial: stage IIIA with at least one nodal metastasis >1 mm or stage IIIB/C, per AJCC 7th Edition staging definitions. Patients with in-transit metastases were excluded from this trial, so adjuvant pembrolizumab is a category 2A option in this setting.



NCCN Guidelines Version 3.2023

Melanoma: Cutaneous

Although patients with stage IV disease were not included in the KEYNOTE-054 trial, the NCCN Panel included adjuvant pembrolizumab as a category 2A option for resected stage IV disease. Because all the prospective randomized trial data thus far—both in the adjuvant setting and in the treatment of unresectable or distant metastatic melanoma—indicate that pembrolizumab and nivolumab are very similar in terms of efficacy and safety, the NCCN Panel voted to recommend pembrolizumab in all the adjuvant settings where nivolumab was recommended (Table 7).

Although results from EORTC 18071 showed that adjuvant high-dose ipilimumab improved RFS, DMFS, and OS compared with placebo, results from CheckMate 238 showed that adjuvant nivolumab improved RFS compared to high-dose ipilimumab with a better safety profile (Table 5). Although, in contrast to adjuvant high-dose ipilimumab, the impact of adjuvant anti-PD-1 therapy on OS is not yet reported, the panel considered the relative difference in toxicity to be more important in the adjuvant setting. Moreover, as prospective randomized trials have shown anti-PD-1 therapy to be associated with better OS compared with ipilimumab in patients with unresectable/distant metastatic disease,^{421,422} it is reasonable to extrapolate this observation into the adjuvant setting. Although not all the trials supporting anti-PD-1 therapy and BRAF-targeted therapy as adjuvant treatment options compared these agents to ipilimumab, the NCCN Melanoma Panel considers these agents to be more effective and better tolerated than ipilimumab, and therefore no longer recommends ipilimumab for adjuvant treatment (following resection) for patients with stage III disease at presentation. Ipilimumab is *no longer* listed among the options for first-line adjuvant systemic therapy for stage III disease shown on ME-4, ME-5, and ME-7 (Table 7).

For patients with a nodal recurrence after previous exposure to an anti-PD-1 agent, repeat exposure to adjuvant nivolumab or pembrolizumab may be less effective. This is a clinical scenario where ipilimumab remains

an adjuvant treatment option (Table 7, ME-14/15). Based on similar logic, the NCCN Panel voted to include adjuvant ipilimumab as an option for patients with resected stage IV disease who have prior exposure to anti-PD-1 agents (See Table 7 and ME-16 in the algorithm). The preferred ipilimumab dose in the adjuvant setting varies across NCCN Member Institutions because, although the efficacy of ipilimumab for adjuvant treatment was demonstrated in EORTC 18071 using the high dose (10 mg/kg), the lower dose (3 mg/kg) is safer, and preliminary ECOG 1609 data presented at ASCO 2017 suggest that the lower dose may be equally effective in the adjuvant setting.⁴¹⁸ At present, this adjuvant ipilimumab dose reduction represents what the panel felt was a prudent but not yet evidence-based extrapolation of data derived from trials of its use in other settings.

BRAF-Targeted Therapy

BRAF-targeted therapy has been tested as adjuvant treatment for resected melanoma in two prospective, double-blind, randomized controlled trials, COMBI-AD and BRIM8 (Table 5).^{387,393} COMBI-AD showed that in select patients with resected stage III disease and *BRAF* V600 E/K mutation, adjuvant treatment with the BRAF/MEK inhibitor combination dabrafenib/trametinib improved RFS and reduced risk of distant metastasis, albeit with a higher risk of toxicity (as expected).³⁸⁷ OS rate was higher with dabrafenib/trametinib versus placebo, but the P value ($P = .0006$) did not meet the prespecified interim boundary (Table 5). The trial included patients with resected AJCC 7th Edition stage IIIA who had at least one lymph node metastasis >1 mm, stage IIIB, or stage IIIC. Subgroup analyses showed RFS was significantly better with dabrafenib/trametinib for patients with *BRAF* V600E, and likely also improves RFS for patients with the less common *BRAF* V600K mutation. Based on results from COMBI-AD, dabrafenib/trametinib combination therapy was FDA approved as adjuvant therapy for patients with *BRAF* V600E/K mutations. Whereas COMBI-AD entry criteria required patients



with stage IIIA (AJCC 7th Edition) to have at least one lymph node metastasis >1 mm, the FDA-approved indication was broader, including all patients with lymph node involvement and complete resection (Table 6).

BRIM8 showed that in select patients with resected AJCC 7th Edition stage IIC-III disease and *BRAF* V600 mutation, adjuvant treatment with the BRAF inhibitor vemurafenib monotherapy improved DFS and possibly DMFS compared with placebo (Table 5).³⁹³ The effect on OS was not statistically significant, but these data remain immature. Patients with stage III disease in this trial were restricted to those who had AJCC 7th Edition stage IIIA with at least one node with diameter >1 mm, or stage IIIB/C without in-transit metastases (Table 5). As expected, BRIM8 results showed that adjuvant vemurafenib was associated with higher rates of toxicity than placebo.³⁹³ Consistent with results from prospective randomized trials comparing BRAF/MEK inhibitor combination therapy with BRAF inhibitor monotherapy for the treatment of unresectable or distant metastatic disease,⁴¹¹⁻⁴¹³ safety results from BRIM8 showed that adjuvant vemurafenib was associated with an increase in hyperproliferative cutaneous AEs (16% vs. 2% for vemurafenib vs. placebo).³⁹³ This increase was not seen for dabrafenib/trametinib (vs. placebo) in the COMBI-AD trial.³⁸⁷ Given the improved efficacy/safety profile of BRAF/MEK inhibitor combination therapy compared to BRAF inhibitor monotherapy,⁴¹¹⁻⁴¹³ vemurafenib monotherapy is not FDA approved for adjuvant treatment of melanoma (Table 6).

NCCN Recommendations for BRAF-Targeted Adjuvant Therapy

Based on the results from the COMBI-AD trial, adjuvant dabrafenib/trametinib combination therapy is a recommended option for patients with resected stage III or recurrent disease and who harbor a *BRAF* V600-activating mutation (Table 7). Dabrafenib/trametinib is an adjuvant treatment option for all patients with stage III disease, even those

categories of patients that were not included in the trial. The NCCN Panel agreed that the data from the COMBI-AD trial provide high-level evidence that adjuvant dabrafenib/trametinib provide clinical benefit in patients with nodal metastases clinically detected at initial presentation or recurrence (following complete resection and CLND). However, among patients whose regional disease consists solely of clinically occult nodal metastases, the NCCN category 1 recommendation is limited to those whose extent of disease matches study entry criteria: stage IIIA with at least one nodal metastasis >1 mm or stage IIIB/C, as defined by AJCC 7th Edition staging. Although COMBI-AD did include patients with in-transit metastases, results from these patients were not reported separately, so the adjuvant dabrafenib/trametinib is a category 2A option for patients with satellite/in-transit disease (if completely excised to clear margins). As the COMBI-AD trial excluded patients with distant metastases, dabrafenib/trametinib is not a recommended adjuvant treatment option for resected stage IV disease.

Although BRIM8 showed that adjuvant vemurafenib improved RFS and lowered risk of distant metastases relative to placebo, vemurafenib is not an FDA-approved adjuvant treatment option, and is not recommended by the NCCN Panel. The risk of hyperproliferative cutaneous AEs is considered to outweigh any clinical benefit, especially in the adjuvant setting. Moreover, because trials in patients with unresectable or distant metastatic disease (and *BRAF* V600 mutations) showed that BRAF/MEK inhibitor combination therapies are equally or more effective than BRAF inhibitor monotherapy and have a better safety profile (lower risk of hyperproliferative cutaneous AEs), and because COMBI-AD showed that BRAF/MEK inhibitor combination therapy improves RFS and DMFS in the adjuvant setting (relative to placebo), dabrafenib/trametinib combination therapy is currently the BRAF-targeted adjuvant treatment of choice in melanoma.



NCCN Guidelines Version 3.2023

Melanoma: Cutaneous

Table 7: NCCN Recommended Adjuvant Systemic Therapies

| Algorithm Page(s) | Clinical/Pathologic Stage ^a | Primary Treatment | Recommended Options, ^b Category of Evidence and Consensus | | | | |
|-------------------|---|---|---|--------------------|-------------------|-------------------|-----------------------|
| | | | Obs | Ipi | Nivo | Pembro | Dab/tram ^c |
| ME-4 | Stage III (SLN+) | WLE and SLNB, followed by CLND or nodal ultrasound surveillance | 2A | NR | 1/2A ^d | 1/2A ^e | 1/2A ^e |
| ME-5 | Stage III (cN+) | WLE and CLND | 2A | NR | 1 | 1 | 1 |
| ME-6/7 | Stage III (clinical or microscopic satellite/ in-transit) | Complete surgical excision to clear margins | 2A | NR | 2A | 2A | 2A |
| ME-8/16 | Stage IV resectable | Completely resected | 2A | NR/2A ^f | 1 | 2A | NR |
| ME-12/13 | Local satellite/in-transit recurrence | Complete surgical excision to clear margins | 2A | NR | 2A | 2A | 2A |
| ME-14/15 | Nodal recurrence | Excise nodal metastasis and CLND (if incomplete/no prior CLND) | 2A | NR/1 ^f | 1 | 1 | 1 |

NR, not recommended; cN+, clinically positive nodes (no in-transit or satellite metastases); CLND, complete lymph node dissection; dab/tram, combination dabrafenib/trametinib; ipi, high-dose ipilimumab (10 mg/kg); nivo, nivolumab; NR, not recommended; Obs, observation; pembro, pembrolizumab; SLN+, regional disease is limited to clinically occult nodal metastases; SLNB, sentinel lymph node biopsy; WLE, wide local excision of primary lesion.

^a Clinical/Pathologic Stage as described in the NCCN Guideline algorithm. Stages are defined according to AJCC 8th Edition Staging definitions. All nodal metastases must be pathologically confirmed. Initial presentation with stage IV disease or clinical recurrence should be confirmed pathologically whenever possible or if clinically indicated.

^b Treatment within the context of a clinical trial is always a recommended option.

^c Dabrafenib/trametinib is recommended only in patients with a *BRAF* V600-activating mutation.

^d Category 1 for patients with AJCC 7th Edition stage IIIB/C disease.

^e Category 1 for patients with AJCC 7th Edition stage IIIA with SLN metastasis >1 mm or stage IIIB/C disease.

^f Ipilimumab recommended only if patient has prior exposure to anti-PD-1 therapy.

Neoadjuvant Systemic Therapy

Data from pilot studies and phase I/II trials have shown promising results for use of BRAF-targeted therapies and immune checkpoint inhibitors as neoadjuvant treatment for resectable stage III-IV melanoma.⁴²³⁻⁴²⁸ There are a number of ongoing trials testing neoadjuvant therapies for melanoma.⁴²⁹⁻⁴⁴³

initial trials and the number of trials currently available, the NCCN Panel recommends considering enrollment into a clinical trial of neoadjuvant systemic therapy in patients with borderline resectable lymphadenopathy or for those at very high risk of recurrence after lymphadenectomy.

NCCN Recommendations for Neoadjuvant Systemic Therapy

Currently there are insufficient data to recommend any specific agent as neoadjuvant therapy for melanoma, but given the promising results in



NCCN Guidelines Version 3.2023

Melanoma: Cutaneous

Treatment for Stage III In-transit Disease

The tumor burden, time course of appearance, and duration of in-transit disease is variable. In some patients, in-transit lesions remain confined to a region of the body for many years. This may occur in isolation or in combination with other sites of metastatic disease. A major concern in patients in which in-transit disease occurs in isolation is the high probability of subsequent development of visceral metastasis. Therapies for isolated in-transit disease can be organized as:

- 1) Local therapy: Local treatments reduce the morbidity of in-transit lesions but have a low/variable effect on the appearance of new lesions.
- 2) Regional therapy: Regional therapies treat the entire lymphatic basin and may not only eliminate visible tumors but also prevent outgrowth of new lesions in the region.
- 3) Systemic therapy: Systemic treatments have antitumor effects on existing in transit lesions and may help delay/prevent further regional or subsequent systemic recurrence.

Many different treatment options, mostly locoregional, are available to patients presenting with stage III in-transit metastases. The choice of therapy depends on the patient's health status and tumor burden, defined by the size, location, and number of tumor deposits. Since the tempo of spread of in-transit disease is not always known at presentation, it may be reasonable to start with conservative local therapies and move to regional/systemic therapy if response to local therapy is short-lived.

Local Therapy

Excision to clear margins is the mainstay of treatment for limited resectable in-transit metastasis. Although in-transit disease has a high probability of clinically occult regional nodal involvement, and a positive

sentinel node in the presence of in-transit metastasis portends a more ominous prognosis, the impact of SLNB on outcome remains unknown.⁴⁴⁴

For patients for whom resection is not feasible, prior resections have been unsuccessful, or who refuse surgery, non-surgical local approaches for treating stage III in-transit melanoma include intralesional injections, local ablation therapy, topical imiquimod, and RT.

Intralesional Injections

A variety of agents have been tested as intralesional injections for melanoma. Key results from those showing the most promise are summarized in Table 8.

Talimogene Laherparepvec

Intralesional or perilesional injection of melanoma metastases with granulocyte macrophage colony-stimulating factor (GM-CSF) has shown modest response rates or stable disease in several small clinical studies.⁴⁴⁵⁻⁴⁴⁸ These studies and others led to the development of talimogene laherparepvec (T-VEC), an agent that uses a modified herpes simplex virus to induce tumor cell lysis and to deliver localized expression of GM-CSF to injected lesions.⁴⁴⁹ A recent phase 3 trial in select patients with unresectable stage IIIB-IV melanoma randomized subjects to intralesional injection T-VEC versus subcutaneous injection of GM-CSF.⁴⁵⁰ Patients were required to have at least one cutaneous, subcutaneous, or nodal lesion or aggregation of lesions >10 mm in diameter, bidimensionally measurable disease, and limited distant metastatic disease (with specific definitions). T-VEC produced clinically significant durable response rates (DRRs) in injected tumors, and a bystander effect on some uninjected non-visceral and visceral tumors (Table 8).⁴⁵¹ At a median follow-up of 44 months (range 32–59 months), patients treated with T-VEC compared with GM-CSF showed a higher DDR (16.3% vs. 2.1%, $P < .001$) and overall response rate (ORR; 26.4% vs. 5.7%, $P < .001$; complete response in 11% vs. <1%).⁴⁵⁰



Exploratory subset analyses showed that the effect of T-VEC on response was greater for patients with less advanced disease. Patients with stage IIIB or IIIC disease had a DRR of 33% with T-VEC compared with 0% for GM-CSF. For patients with stage IV-M1a disease, the effect of T-VEC on DRR was smaller (16.0% vs. 2.3%). For patients with stage IV-M1b or -M1c disease, however, the effects of T-VEC on DRR and OS were small and not statistically significant. The effect of T-VEC on DRR was far more profound in patients with previously untreated metastatic disease (23.9% vs. 0%) than for those with previously treated metastatic disease (9.6% vs. 5.6%).

For T-VEC, common toxicities (treatment-emergent in ≥20%, any grade) were fatigue, chills, pyrexia, nausea, flu-like illness, injection-site pain, and vomiting.⁴⁵⁰ Treatment-related toxicities of grade 3–4 occurred in 11% of patients, and included injection-site reactions (eg, cellulitis, pain, peripheral edema) and systemic toxicities (fatigue, vomiting, and other flu-like symptoms).

Interleukin-2

Intralesional injection with IL-2 is supported by a number of clinical studies (Table 8). The complete response rate in IL-2 injected lesions may be as high as 70%. Although response rates are higher in cutaneous lesions, good response rates have been observed in subcutaneous lesions as well.⁴⁵² Intralesional injection of IL-2 is far less toxic than high-dose IV IL-2. Grade 1-2 adverse effects are common but manageable, and grade 3–4 toxicities are extremely rare.⁴⁵²⁻⁴⁵⁴ Intralesional IL-2 is usually associated

with an injection site inflammatory reaction with local swelling, erythema, pain, and sometimes necrosis. Common systemic effects include fever and other flu-like symptoms (chills, fatigue, nausea, and emesis, and sometimes stomach pain, diarrhea, and headache) that are usually mild and often respond to analgesics.^{452,453,455}

Less Common Intralesional Injection Agents

IFN has been used as an intralesional injection agent for treating in-transit melanoma, although there is very little published evidence to support this approach (case reports and one small retrospective study⁴⁵⁶).

Intralesional Bacillus Calmette-Guérin (BCG) has been shown to provide at least transient complete or partial responses in most injected lesions, with much higher response rates in cutaneous versus subcutaneous metastases (Table 8).⁴⁵⁷⁻⁴⁵⁹ Although initial response rates are high for injected lesions, intralesional BCG is associated with a number of significant local and occasional systemic adverse effects.⁴⁵⁸⁻⁴⁶⁰ BCG injection has been largely supplanted by other local injection options and is rarely used in clinical practice.

Rose Bengal, a photosensitizing dye, is an investigational agent in development as another method for chemoablation of melanoma metastases by intralesional injection (using PV-10, a 10% w/v Rose Bengal saline solution).^{461,462} It has similar activity to other intralesional agents, but is not currently available outside of the clinical trial setting (NCT02288897).

Table 8. Intralesional Injection

| Injection Agent | Key Published Clinical Studies | Response Rates | |
|----------------------------------|--|--|--|
| | | Injected Lesions | Uninjected Lesions |
| Talimogene laherparepvec (T-VEC) | <ul style="list-style-type: none"> Phase III trial^{450,451} | <u>≥50% decrease in size: 64%</u> | <ul style="list-style-type: none"> ≥50% decrease in size: 32% of non-visceral 15% of visceral |
| Interleukin-2 | <ul style="list-style-type: none"> >5 non-comparative studies, including several phase II trials^{452,453} and retrospective/observational analyses⁴⁶³⁻⁴⁶⁶ 2014 systematic reviews and meta-analysis⁴⁵⁴ | <u>CR: 67%–96%</u> <ul style="list-style-type: none"> 80% for dermal 73% for subcutaneous | No responses seen in two phase 2 trials |
| Bacillus Calmette-Guérin (BCG) | <ul style="list-style-type: none"> >10 prospective pilot/retrospective studies^a 1 prospective randomized study⁴⁵⁹ | <u>CR:</u> <ul style="list-style-type: none"> 90% for dermal 45% for subcutaneous | Occasional responses observed |
| Rose Bengal | <ul style="list-style-type: none"> Phase I trial⁴⁶¹ Phase II trial⁴⁶² | <u>OR: 46%–58%</u> | <u>OR: 27%</u> |

CR, complete response, defined as the percent of lesions that disappeared; NR, not reported; OR, objective response, defined as the percent of lesions showing partial or complete response.

^a Most included fewer than 30 patients. See Krown et al. 1978,⁴⁵⁸ Morton et al. 1974,⁴⁶⁷ and Table 5 in Tan et al. 1993,⁴⁵⁷ a pooled analysis of 15 studies.

Other Local Therapies

Local Ablation

The efficacy of laser ablation, primarily carbon dioxide laser ablation, for treatment of melanoma metastases, is reported in a number of non-comparative retrospective analyses (15–100 patients/study).⁴⁶⁸⁻⁴⁷⁴ Ablation can be effectively achieved with minimal toxicity,^{468,470,471,474} but this technique has largely been supplanted by more contemporary approaches.

Topical Therapy

In patients with in-transit/locally metastatic disease, case reports suggest that imiquimod monotherapy can provide partial and complete responses in patients with cutaneous metastases, but is less likely to be effective on deep dermal or subcutaneous metastases.⁴⁷⁵⁻⁴⁷⁹ Other studies have shown that imiquimod used in combination with another local therapy can

provide high rates of durable response in patients with locally metastatic melanoma.^{477,480-486}

Topical immunotherapy using diphencyprone (DPCP), also known as diphenylcyclopropenone, has been studied in patients with in-transit melanoma, either alone or in combination with other concomitant therapies. As with topical imiquimod, supporting evidence for this approach comes primarily from case studies reporting remarkable responses in some patients.⁴⁸⁷⁻⁴⁹⁴ One retrospective study included 50 patients with in-transit cutaneously metastatic melanoma treated for at least one month with DPCP.⁴⁹⁵ Complete clearance of cutaneous disease was observed in 46% of patients, and another 38% showed partial response. DPCP is not FDA approved for this indication but may be available in the context of clinical trials.



Radiation

RT may be used for selected patients with unresectable symptomatic regional recurrences for whom there are no better options. A wide variety of dose schedules has been employed. See *Palliative Radiation Therapy*.

Regional Therapy: Isolated Limb Perfusion and Infusion

For patients with regionally recurrent melanoma not suitable for local or topical therapy, regional administration of cytotoxic chemotherapy with either isolated limb perfusion (ILP) or isolated limb infusion (ILI) is designed to administer high doses to an affected extremity while avoiding toxicities associated with systemic drug exposure. These approaches also allow delivery of chemotherapy under hyperthermic conditions, suggested by some studies to improve efficacy of cytotoxic agents,⁴⁹⁶⁻⁵⁰¹ but also associated with increased toxicity.^{502,503} These approaches are limited to patients with regional metastases confined to an extremity.

ILP, the first of these techniques to be developed, was introduced in the late 1950s and has been refined and modified to improve response rates and minimize toxicities.^{504,505} Although other agents have been used for ILP, and many have yet to be tested, melphalan (L-phenylalanine mustard) is the cytotoxic agent most commonly used, often in combination with either actinomycin D or TNF- α .⁵⁰⁵⁻⁵⁰⁸ Response rates after ILP have improved as the method has been refined. A large systematic review (n = 2018 ILPs, 22 trials) found that for patients with unresectable stage IIIB-III C metastatic melanoma of the limbs, studies published between 1990 and 2008 reported a median ORR of 90% (range 64%–100%) and a median complete response rate of 58% (range, 25%–89%).⁵⁰⁷ Median complete response rate varied somewhat depending on the agents used, ranging from 47% with single-agent melphalan, 45% to 65% for melphalan/actinomycin D combination, and up to 70% with melphalan/TNF- α combination.⁵⁰⁷ These response rates are mostly derived from retrospective series, and the differences reported depend on

definitions of response often spanning decades and on patient selection factors. The reported differences in response rates may not be clinically significant. For example, a prospective randomized clinical trial directly comparing hyperthermic ILP with single-agent melphalan to combination melphalan and TNF- α did not show a significant difference in response rate.⁵⁰⁹ TNF- α is currently unavailable for use in the United States.

Disadvantages to ILP include the technical complexity and invasiveness of the procedure, which make it challenging (or contraindicated) in elderly and frail patients, and difficult to use again in the same patient in the event of recurrence or progression.⁵¹⁰ This approach should only be performed in centers with the expertise to manage both the procedure and the potential complications.

In the 1990s ILI was developed as a simpler and less invasive approach,⁵¹¹ amenable to repeated applications,⁵¹² and safe for use in elderly patients.⁵¹³ Melphalan is commonly used for ILI, often with actinomycin D.⁵¹⁴ Addition of papaverine for cutaneous vasodilation has been shown to increase response rate but also the risk of regional toxicity.^{515,516} ILI is associated with lower rates of toxicity and morbidity compared with ILP, but retrospective comparisons of response and survival with ILP versus ILI have shown varying results.^{515,517-521} An analysis of seven studies, including 576 patients, primarily with stage III disease, treated with melphalan/actinomycin D combination via ILI, showed an ORR of 73%, with complete response in 33% (range, 26%–44% across studies), partial response in 40% (33%–53%), and stable disease in 14%.⁵¹⁴ A smaller pooled analysis of two additional studies (N = 58), one a non-comparative phase II study (NCT00004250), showed similar ORRs for stage IIIB versus stage IIIC disease (48% vs. 40%), and similar 5-year survival rates (38% vs. 52%).⁵²² Complete responses were achieved in 25% of patients, partial responses in 20%.



NCCN Recommendations

Treatment in the context of a clinical trial is the preferred option for in-transit disease. For those with a single or a small number of resectable in-transit metastases, complete surgical excision with histologically negative margins is preferred, if feasible. In the patient undergoing curative resection of a solitary in-transit metastasis, SLNB can be considered (category 2B).

If a complete surgical excision to clear margins is not feasible, treatment in the context of a clinical trial is generally the preferred option. Other local, regional, or systemic therapies can be considered. If the patient has a limited number of in-transit metastases, particularly dermal lesions, which are not amenable to complete surgical excision, intralesional local injections should be considered. Patients with least one cutaneous, subcutaneous, or nodal lesion or aggregation of lesions >10 mm in diameter, may be appropriate candidates for intralesional injection with T-VEC. Intralesional injection with T-VEC is a recommended option for patients with unresectable stage III in-transit disease based on improved durable and ORR compared to injection with GM-CSF alone. If T-VEC is not available, intralesional injection with IL-2 is another option, as is injection with BCG or IFN. All of these options are category 2B recommendations.

Based on non-comparative studies, laser ablation, topical imiquimod, or RT are category 2B options that may help for palliation or to establish regional control for selected patients with unresectable in-transit disease. Topical imiquimod can be considered as an option in very low-volume cutaneous metastases.

For patients with multiple regional in-transit metastases confined to an extremity, regional chemotherapy by hyperthermic perfusion or infusion is an option. Although ILP and ILI can be technically challenging, they can

result in high initial and durable regional response rates when administered properly.

With the advent of more effective systemic therapy, this approach is increasing be considered as a first-line treatment option for regionally recurrent melanoma. See *Systemic Therapy for Advanced Melanoma* for treatment options.

Given the number of options available, clinical judgment and multidisciplinary consultation is often helpful to determine the order of therapies.



Treatment for Unresectable Stage III or Distant Metastatic Disease (Stage IV)

Systemic Therapy for Advanced Melanoma

The therapeutic landscape for metastatic melanoma is rapidly changing with the recent development of novel agents, which have demonstrated better efficacy than traditional chemotherapy. The first generation of novel targeted and immunotherapy agents (ie, vemurafenib, dabrafenib, ipilimumab) demonstrated significantly improved response rates and outcomes compared with conventional therapies. Subsequently, a number of ongoing or recently completed phase II and phase III trials testing new immunotherapies, targeted therapies, and combination regimens have yielded noteworthy results.^{93,406-413,421,422,450,523-531} Second and emerging third generations of effective agents and combination regimens are now available for treatment of advanced unresectable or metastatic melanoma.

Immune Checkpoint Inhibitors

The immune system may be capable of identifying and destroying certain malignant cells, a process called immunosurveillance. Conditions or events that compromise the immune system can lead to cancer cells escaping immunosurveillance.⁵³²⁻⁵³⁴ Once cancer cells have escaped immunosurveillance and have begun to proliferate, their genetic and phenotypic plasticity enables them to develop additional mechanisms by which the nascent tumor can evade, thwart, or even exploit the immune system.⁵³²⁻⁵³⁴ Immunotherapies are aimed at augmenting the immune response to overcome or circumvent the immune evasion mechanisms employed by cancer cells and tumors. Some of the most effective immunotherapies target immune checkpoints—often exploited by cancers to decrease immune activity. For example, activation of T helper cells upon binding to antigens on the antigen-presenting cell (APC) can be modulated by other receptor-ligand interactions between the two cells. Cytotoxic T lymphocyte antigen-4 (CTLA-4) and programmed cell death protein 1 (PD-1) are two examples of receptors on T cells that upon ligand

binding trigger a signaling cascade that inhibits T-cell activation, limiting the immune response.⁵³⁵⁻⁵³⁸ Antibodies against these receptors (eg, ipilimumab, nivolumab, pembrolizumab) prevent receptor-ligand interaction, removing the inhibition of T-cell activation and “releasing the brake” on the immune response.^{419,420,539} The importance of this science has recently been recognized by the awarding of the 2018 Nobel Prize in Medicine to James Allison and Tasuku Honjo for their research on CTLA-4 and PD-1.

Ipilimumab

Ipilimumab is a monoclonal antibody directed against the immune checkpoint receptor CTLA-4. Two phase III trials in patients with unresectable stage III or stage IV melanoma support the use of ipilimumab for advanced disease (Table 9). Results from these trials showed that ipilimumab improved response rates, response duration, PFS, and OS in patients with previously treated or previously untreated advanced disease.^{403,404} Most importantly, extended follow-up showed that ipilimumab resulted in long-term survival in approximately 20% of patients (5-year OS: 18% vs. 9% for dacarbazine),⁵⁴⁰ consistent with findings from phase II trials.^{541,542,543} Safety results from these trials showed that ipilimumab is associated with a substantial risk of irAEs, including grade 3–4 events (Table 9) and drug-related deaths (7 in CA184-002).⁴⁰³ Even higher rates of grade 3–4 irAEs were observed in patients treated with ipilimumab in CA184-024 (Table 9), possibly due to the high dose used (10 mg/kg), or due to combination therapy with dacarbazine, or both.⁴⁰⁴ Combination therapy with ipilimumab and dacarbazine therefore is not used in clinical practice, and the FDA-recommended dose of ipilimumab is 3 mg/kg rather than 10 mg/kg.³⁹⁴ Results from CA184-169, a phase III randomized double-blind trial comparing ipilimumab 10 mg/kg dosing with 3 mg/kg, showed that the higher dose improved OS but was also associated with dramatically higher rates of treatment-related AEs (Table 9).⁵⁴⁴ Immune-related AEs associated with ipilimumab and other immune



checkpoint inhibitor regimens are detailed in the *Toxicity of Immune Checkpoint Inhibitors* section.

Given that treatment options may be limited for heavily pretreated patients who have progressed after immune checkpoint inhibitor therapy, it is noteworthy that reinduction therapy with ipilimumab was administered to a small number of patients in CA180-002 who had progressed after showing initial clinical benefit (responses or stable disease lasting ≥ 3 months).

Disease control (complete response, partial response, or stable disease) was achieved upon ipilimumab reinduction in most of these patients (20/31).^{403,545} The frequency and types of ipilimumab-related irAEs seemed similar for reinduction as for initial treatment, and patients who experienced toxicities during the initial round of therapy did not necessarily experience the same irAEs upon reinduction.⁵⁴⁵

Table 9. Ipilimumab Trials in Advanced Melanoma^a

| Trial | | | Patients | | Treatment Arms | Efficacy Results ^b | | | Grade 3-4 irAEs ^c |
|---|--------------|---------------------------|--------------------------------------|--------------------------------------|-----------------------------------|-------------------------------|---|-----------------------------|------------------------------|
| Name and References | Phase Design | Median Follow-up (months) | Tx Naive | CNS Mets | | Response Rate | PFS Median (months) | OS Median (months) | |
| CA184-002 NCT00094653 ⁴⁰³ | III RDB | 21.0 | 0% ^d | 12% ^e | lpi + gp100 (n = 403) | 6% <i>P</i> = .04 | 2.8 <i>P</i> < .05 ^f | 10.0 <i>P</i> < .001 | } 10%–15% |
| | | 27.8 | | | lpi (n = 137) | 11% <i>P</i> = .001 | 2.9 <i>P</i> < .001 ^f | 10.1 <i>P</i> = .003 | |
| | | 17.2 | | | gp100 (n = 136) | 2% | 2.8 | 6.4 | |
| CA184-024 NCT00324155 ^{404,540} | III RDB | Min 36.6 | 100% | None | DTIC + ipi (n = 250) | 15% <i>P</i> = .09 | ND ^g <i>P</i> = .0006 ^f | 11.2 <i>P</i> < .001 | 38% |
| | | | | | DTIC + pbo (n = 252) | 10% | ND ^g | 9.1 | 4% |
| CA184-169 NCT01515189 ⁵⁴⁴ | III RDB | 14.5 11.2 | 44% ^d 43% ^d | 18% ^e 17% ^e | HD-ipi (n = 365) lpi (n = 362) | 15% 12% | 2.8 <i>P</i> = .16 2.8 | 15.7 <i>P</i> = .04 11.5 | 30% 14% |

CNS Mets, percent of patients with central nervous system metastases at baseline; DTIC, dacarbazine; gp100, gp100 peptide vaccine; HD-ipi, high-dose ipilimumab (10 mg/kg Q3W); ipi, standard dose ipilimumab (3 mg/kg Q3W); irAEs, immune-related adverse events; OL, open-label; pbo, placebo; R, randomized; RDB, randomized, double-blind; Response Rate, percent of patients with complete or partial response as their best overall response; Tx Naive, percent of patients with no prior treatment for unresectable or metastatic disease.

^a Unresectable stage III or stage IV melanoma.

^b Median PFS, OS, and *P* value are based on Kaplan-Meier analysis. *P* values are for comparisons with the control arm.

^c Percent of patients who experienced any type of treatment-related irAE of grade 3 or 4.

^d In CA184-002, all patients had previous treatment with chemotherapy or IL-2, but prior treatment with anti-CTLA-4 or cancer vaccine was not allowed. In CA184-169, previous systemic therapy was allowed, but patients previously treated with BRAF inhibitors or checkpoint inhibitors were excluded.

^e Patients with active CNS metastases were excluded from the trial.

^f Although median PFS was similar across arms, *P* values are based on analyses of the entire Kaplan-Meier curves, which separated at later time points.

^g In CA184-024, the true median PFS occurred before the first assessment of progression (at week 12).

***Anti-PD-1 Agents***

While anti-CTLA-4 therapy appears to interfere primarily with the feedback mechanism at the interface between T cells and antigen-presenting dendritic cells, anti-PD-1 inhibitors are thought to interfere primarily with the feedback mechanism at the interface of T cells and tumor cells.⁵⁴⁶

Pembrolizumab

Randomized trials in patients with unresectable stage III or stage IV metastatic disease have shown that pembrolizumab (monotherapy), like nivolumab, improves response and PFS compared with chemotherapy or ipilimumab (monotherapy) (Table 10).^{406,407,422,529} Keynote-002 compared pembrolizumab with investigators choice of chemotherapy in patients with unresectable stage III or stage IV melanoma who had previously progressed on ipilimumab, and if *BRAF* V600-mutation positive, also progressed on a BRAF inhibitor.⁴⁰⁶ Over 70% of patients in this trial had received two or more prior systemic therapies. Long-term follow-up (median 28 months) in the Keynote-002 trial showed that compared with chemotherapy, pembrolizumab provided higher rates and durations of response, and was associated with long-lasting improvements in PFS (Table 10).⁵²⁹ The trend toward improved OS was not statistically significant, however, even after adjustment for crossover.⁵²⁹ Both the poor OS (compared with later trials testing pembrolizumab, see Table 10) and the failure to significantly improve OS compared with chemotherapy may be partly explained by the fact that patients in Keynote-002 were heavily pretreated.^{406,529} Keynote-002 results showed that the rates of treatment-related AEs were somewhat lower with pembrolizumab compared with chemotherapy, although the only fatal treatment-related AE occurred in a patient treated with pembrolizumab, and immune-related AEs were of course largely limited to the pembrolizumab arms.⁵²⁹ Compliance, global health status, and health-related quality of life were better with pembrolizumab compared with chemotherapy.⁵⁴⁷

Results from KEYNOTE-006 showed that in patients with one or fewer prior systemic therapies for advanced disease (and no prior immune checkpoint inhibitors), pembrolizumab improved response rate, PFS, and OS compared with ipilimumab (Table 10).^{407,422} Long-term follow-up showed that whereas both pembrolizumab and ipilimumab provided extremely long-lived responses, pembrolizumab provided long-term improvement in PFS and OS compared with ipilimumab monotherapy (Table 10).^{422,548} Post-hoc sub-analyses after long-term follow-up (median of 33.9 months) showed that compared with ipilimumab, pembrolizumab was associated with improvement in long-term PFS and OS for both patients who had received one prior systemic therapy and for those previously untreated.⁵⁴⁹

Although initial reports of KEYNOTE-006 showed lower rates of treatment-related toxicities with pembrolizumab compared with ipilimumab, after long-term follow-up the cumulative rates of treatment-related toxicities were similar across treatment arms.^{407,422} Toxicity rates were higher with ipilimumab during the first 12 weeks of study treatment, but the frequency of new AEs tapered off after the completion of the ipilimumab regimen (which consisted of a maximum of 4 cycles) around 12 weeks.⁴²² Although the rate of new AEs was lower with pembrolizumab during the first 12 weeks of study, new AEs continued to develop in the pembrolizumab arm throughout the study period (beyond 12 weeks) as patients continued to receive active treatment (no pre-specified maximum treatment duration).⁴²²

Results of KEYNOTE-006 support the recommendation that pembrolizumab should be considered as first-line therapy in patients with unresectable or distant metastatic disease.

Kinetics of Response to Pembrolizumab

In clinical trials the median time to response for pembrolizumab of approximately 3 months reflects time of the first tumor response assessment (12 weeks), similar to ipilimumab and nivolumab, and similar



NCCN Guidelines Version 3.2023

Melanoma: Cutaneous

to chemotherapy.^{406,407,550,551} Long-term follow-up from several studies has shown that late responses to pembrolizumab can be observed more than a year after the start of treatment, and that initial partial responses may become complete responses with time.^{406,407,529,549,551} A pooled analysis of cohorts from KEYNOTE-001 with long-term follow-up (median 43 months) showed that 16% of patients achieved complete response, with median time to complete response of 12 months, ranging from 3 to 36 months.⁵⁵¹

Across trials long-term follow-up has shown that responses to pembrolizumab are very long-lived, with median duration ranging from 23 months (2 mg/kg Q3W arm in Keynote-002) to much longer (eg, not

reached even after 33.9 months follow-up in KEYNOTE-006).^{405,529,549,551} In contrast, median duration of response was 6.8 months for patients treated with chemotherapy in the KEYNOTE-002 trial.⁵²⁹ Pooled analysis of Keynote-001 cohorts with long-term follow-up (median 43 months) showed that although complete responses to pembrolizumab took some time to develop, they were highly durable (88% of complete responses persisting after a median follow-up time of 30 months from the first declaration of complete response; 91% DFS 24 months after complete response), even among patients who discontinued pembrolizumab.⁵⁵¹

Table 10. Pembrolizumab Trials in Advanced Melanoma^a

| Trial | | | Patients | | Treatment Arms | Efficacy Results ^c | | | Grade 3–4 Tx-Related AEs ^d |
|---|--------------|---------------------------|-------------------|-------------------------|-------------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|---------------------------------------|
| Name and References | Phase Design | Median Follow-up (months) | Tx Naive | Brain Mets ^b | | Response Rate | PFS 2-year Rate | OS 2-year Rate | |
| KEYNOTE-002 NCT01704287 ^{406,529} | II R, OL | 28 | None ^e | -- | Pembro 2 mg/kg Q3W (n = 180) | 22% <i>P</i> < .0001 ^f | 16% <i>P</i> < .0001 | 36% <i>P</i> = .117 ^f | 14% |
| | | | | | Pembro 10 mg/kg Q3W (n = 181) | 28% <i>P</i> < .0001 | 22% <i>P</i> < .0001 | 38% <i>P</i> = .011 | 16% ^g |
| | | | | | Chemo (n = 179) | 4% | <1% | 30% | 26% |
| KEYNOTE-006 NCT01866319 ^{407,422} | III R, OL | 22.9 | 34% ^h | 9% | Pembro 10 mg/kg Q2W (n = 279) | 37% <i>P</i> < .001 ⁱ | 31% <i>P</i> < .0001 ⁱ | 55% <i>P</i> = .0009 ⁱ | 17% |
| | | | | | Pembro 10 mg/kg Q3W (n = 277) | 36% <i>P</i> < .001 | 28% <i>P</i> < .0001 | 55% <i>P</i> = .0008 | 17% |
| | | | | | Ipi 3 mg/kg Q3W x 4 doses (n = 278) | 13% | 14% | 43% | 20% |

--, data not reported; AEs, adverse events; Chemo, Investigator's choice chemotherapy; Brain Mets, percent of patients with central nervous system metastases at baseline; ipi, ipilimumab; OL, open label; pembro, pembrolizumab; Q2W, every 2 weeks; Q3W, every 3 weeks; R, randomized; Tx Naive, percent of patients with no prior treatment for unresectable or metastatic disease; Tx, treatment.

^a Unresectable stage III or stage IV melanoma.

^b Patients with active CNS metastases were excluded from the trials.

^c *P* values are for comparisons with the control arm. PFS and OS 2-year rates are based on the Kaplan-Meier method.

^d Percent of patients who experienced any type of treatment-related AE of grade 3 or 4.

^e In KEYNOTE-002, all patients were previously treated with ipilimumab and progressed; patients with *BRAF* mutations were also previously treated with BRAF or MEK inhibitors, or both.

^f In KEYNOTE-002, comparison of pembrolizumab 2 mg/kg vs. 10 mg/kg arms showed no difference in overall response rate (*P* = .214) or OS (*P* = .290).

^g In KEYNOTE-002, there was 1 fatal treatment-related AE in the pembrolizumab 10 mg/kg arm.

^h In KEYNOTE-006, patients could have had up to one prior systemic therapy, but patients previously treated with checkpoint inhibitors were excluded.

ⁱ In KEYNOTE-006, comparison of the pembrolizumab Q2W and Q3W arms showed no difference in overall response rate (*P* = .82), PFS (*P* = .62), or OS (*P* = .93).



NCCN Guidelines Version 3.2023

Melanoma: Cutaneous

Nivolumab

Checkmate 037 compared nivolumab versus investigator's choice chemotherapy in patients with unresectable stage III or stage IV melanoma who had previously progressed on ipilimumab, and if *BRAF* V600-mutation positive, also progressed on a BRAF inhibitor.⁵²³ Over 70% of patients in this trial had received two or more prior systemic therapies. Results from Checkmate 037 show that nivolumab improved response rate and duration compared with chemotherapy (Table 11). However, after approximately 2 years of follow-up, the improvement in response did not translate into improved PFS or OS (Table 11).^{410,523} Safety results suggest that nivolumab may be better tolerated than chemotherapy in heavily pretreated patients with advanced disease (Table 11).^{410,523}

Two subsequent phase III clinical trials in previously untreated patients have demonstrated nivolumab efficacy in unresectable stage III or stage IV melanoma (Table 11). As expected, the response rates to nivolumab in previously untreated patients in Checkmate 066 and 067 were higher than those seen in patients with prior systemic therapy for advanced disease treated in Checkmate 037 (Table 11). Results from Checkmate 066 showed that nivolumab improved response rate, PFS, and OS compared with chemotherapy.^{526,530} The percent of grade 3–4 treatment-related AEs was initially lower with nivolumab compared to chemotherapy (12% vs. 18%),⁵²⁶ but longer follow-up showed that treatment-related AEs continued to develop in the nivolumab arm, diminishing the difference between the two arms (Table 11).⁵³⁰ It is important to point out, however, that due to shorter time to progression, patients in the chemotherapy arm had shorter treatment duration than those in the nivolumab arm. Remarkably, the survival curve suggests that nivolumab may lead to long-term survival in up to 40% of patients.⁵³⁰ Results from Checkmate 067 showed that nivolumab (monotherapy) improved response rate, PFS, and OS compared with ipilimumab (monotherapy) (Table 11).^{408,421,531} Although initial reports showed lower toxicity with nivolumab compared with

ipilimumab (grade 3–4 treatment-related AEs for nivolumab vs. ipilimumab: 16% vs. 27%),⁴⁰⁸ longer follow-up showed that treatment-related AEs continued to develop in the nivolumab arm, reducing the difference between arms (Table 11).⁵³¹ Analysis of Checkmate 067 results also showed that PFS and OS were similar for patients who discontinued nivolumab due to toxicity and patients who continued treatment.⁵³¹

The results of Checkmate 066 and 067 supported the recommendation that nivolumab should be considered as first-line therapy in patients with unresectable or metastatic disease.

Kinetics of Response to Nivolumab

Across trials the apparent median time to response for nivolumab closely reflects the time of the first response assessment (9 or 12 weeks),^{408,410,523,526,528} similar to chemotherapy, ipilimumab, and pembrolizumab.^{403,406,407} Initial analyses of Checkmate 037, 066, and 067 showed lower rates of complete response than were reported in the final analyses after longer follow-up.^{408,410,421,523,526,530,531} Similar to pembrolizumab, late complete responses to nivolumab can be seen more than a year after the start of treatment. Across trials responses to nivolumab tend to be very long-lived, with median duration ranging from 31.9 months (Checkmate 037) to much longer (eg, not reached even after 38.4 months minimum follow-up in Checkmate 066).^{409,410,421,530,531} In contrast, duration of response was much shorter in chemotherapy control arms (median 12.8 months in CheckMate 037, median 6.0 months in Checkmate 066).^{410,530} Across trials, responses to nivolumab tend to persist after discontinuation of treatment.^{409,410,523,528,530}

Table 11. Nivolumab Trials in Advanced Melanoma^a

| Trial | | Patients | | Treatment Arms | Efficacy Results ^c | | | Grade 3–4 Tx-Related AEs ^d | |
|---|--------------|------------------------------------|----------------|-----------------|--|--|---|---|--------------------|
| Name and References | Phase Design | Median Follow-up (months) | Tx Naïve | | CNS Mets ^b | Response Rate | Median PFS (months) | | Median OS (months) |
| CheckMate 037 NCT01721746 ^{410,523} | III R, OL | ~24 | 0 ^e | 20% 14% | Nivo (n = 272) Chemo (n = 133) | 27% 10% | 3.1 3.7 | NS ^f 15.7 14.4 | 14% 34% |
| CheckMate 066 NCT01721772 ^{526,530} | III RDB | 38 ^g 39 ^g | 100% | 3.6% | Nivo (n = 210) DTIC (n = 208) | 43% 14% <i>P</i> < .001 | 5.1 2.2 <i>P</i> < .001 | 37.5 11.2 <i>P</i> < .001 | 15% 18% |
| CheckMate 067 NCT01844505 408,421,531 | III RDB | 47 36 19 | 100% | 3.6% | Nivo/ipi, then nivo (n = 314) Nivo (n = 316) Ipi (n = 315) | 58% 45% 19% <i>P</i> < .0001 ^h <i>P</i> < .0001 | 11.5 6.9 2.9 <i>P</i> < .0001 ^h <i>P</i> < .0001 | NR 36.9 19.9 <i>P</i> < .0001 ^h <i>P</i> < .0001 | 59% 22% 28% |
| CheckMate 069 NCT01927419 ^{409,528} | II RDB | 25 | 100% | 3% ^g | Nivo/ipi, then nivo (n = 95) Ipi (n = 47) | 59% 11% <i>P</i> < .0001 | NR 3.0 <i>P</i> < .0001 | NR NR <i>P</i> = .26 | 54% 20% |

Chemo, Investigator's choice chemotherapy of single-agent dacarbazine or carboplatin/paclitaxel combination; CNS Mets, percent of patients with central nervous system metastases at baseline; DTIC, dacarbazine; ipi, ipilimumab; nivo, nivolumab; NR, not reached (longer follow-up needed); NS, not statistically significant; OL, open-label; R, randomized; RDB, randomized, double blind; Tx Naïve, percent of patients with no prior treatment for unresectable or distant metastatic disease.

^a Unresectable stage III or stage IV melanoma.

^b Patients with active CNS metastases were excluded from the trials. For all studies except Checkmate 067, the percentage of patients with a history of brain metastases is shown. For Checkmate 067 the percentage of patient with brain metastases at baseline is shown.

^c Response rate is the percentage of patients that achieved complete or partial response. *P* values are for comparisons with the control arm. Median PFS and OS were determined using the Kaplan-Meier method.

^d Percent of patients who experienced any type of treatment-related AE of grade 3 or 4.

^e Entry criteria for the Checkmate 037 trial stipulated that patients must have progressed on ipilimumab, and if *BRAF*-V600 mutation positive, also progressed on a *BRAF* inhibitor.

^f In the Checkmate 037 trial, PFS was not significantly different between arms (HR, 1.03; 95% CI, 0.78–1.436).

^g Median follow-up for Checkmate 066 was not reported, but minimum follow-up was 39 months in each arm.

^h In Checkmate 067, objective response rates were higher with nivolumab/ipilimumab combination versus nivolumab monotherapy: 58% (95% CI, 52.6–63.8) vs. 45% (95% CI, 39.1–50.3). Descriptive analysis suggests that nivolumab/ipilimumab combination therapy improves PFS compared with single-agent nivolumab (HR, 0.79; 95% CI, 0.65–0.97), but the trend toward improved OS did not reach statistical significance (HR, 0.84; 95% CI, 0.67–1.05).

Anti-CTLA-4/Anti-PD-1 Combination Therapy

CTLA-4 and PD-1 inhibitor combination therapies have been investigated in a number of trials in unresectable stage III or stage IV melanoma (eg,

CA209-004, Checkmate 064, Checkmate 067, Checkmate 069, Checkmate 204, NCT02731729, NCT02374242, Keynote-029).^{408,528,552-558}
Results from two randomized trials (Checkmate 067 and Checkmate 069)



demonstrated that the response rate with ipilimumab/nivolumab combination therapy was substantially higher than with ipilimumab alone (Table 11).^{408,409,421,528,531} Both trials showed that PFS was substantially better with combination therapy compared with ipilimumab monotherapy (Table 11).^{408,421,531} Checkmate 067 showed that OS was improved with combination therapy versus ipilimumab (Table 11), and these effects persisted through long-term follow-up. The 4-year survival rates in Checkmate 067 are 53% for ipilimumab/nivolumab, 46% for single-agent nivolumab, and 30% for single-agent ipilimumab.⁵³¹ In Checkmate 069, a smaller randomized phase II study, results after 25 months median follow-up showed a trend toward improved OS with combination therapy compared with ipilimumab (2-year rate: 63.8% [95% CI, 53.3–72.6] vs. 53.6% [38.1–66.8] that was not statistically significant, although at the time of analysis median OS had not been reached in either arm (Table 11).^{409,528}

Checkmate 067 included an arm of patients treated with nivolumab monotherapy, although it was not powered to compare results to patients treated with combination therapy.⁴⁰⁸ Response rate was higher with nivolumab/ipilimumab combination therapy compared with nivolumab monotherapy (58% vs. 45%), and descriptive analysis showed improved PFS (HR, 0.79; 95% CI, 0.65–0.97).⁵³¹ A similar trend in OS did not reach statistical significance (Table 11, footnote h).⁵³¹ Subset analysis suggested that patients expressing high levels of PD-L1 expression treated with nivolumab monotherapy had a similar OS and PFS to patients treated with the more toxic combination therapy (See *PD-L1 Expression*).

Checkmate 067 and 069 also showed substantially increased toxicity with immune checkpoint inhibitor combination therapy versus monotherapy (Table 11). In both trials combination therapy was associated with a much higher rate of discontinuation due to AEs.^{408,559} A pooled analysis of these trials found that among patients treated with nivolumab/ipilimumab

combination therapy, those who discontinued during the induction phase due to AEs had similar response rates, PFS, and OS as patients who did not discontinue early due to toxicity (but may have continued for other reasons).⁵⁶⁰ There are ongoing clinical trials evaluating even lower doses of ipilimumab in combinations in order to mitigate the toxicity while still maintaining the synergy of the combination.^{558,561,562}

Kinetics of Response to Combination Therapy

Combination therapy with ipilimumab and nivolumab is associated with improved response rate compared with ipilimumab monotherapy, but as for ipilimumab and nivolumab monotherapy, the apparent median times to response reflect the time to first response assessment (12 weeks).⁴⁰⁸ As for nivolumab monotherapy, late complete responses to combination therapy were seen more than a year after the start of treatment: the rate of complete response nearly doubled (increased from 11.5% to 21%) between the first primary report (median follow-up ~12 months) and the most recent analysis (median follow-up 47 months).^{408,531} As for single-agent anti-PD-1 therapy, duration of responses were also long. In CheckMate 067 the median duration of response was 50.1 months for combination therapy, and not reached for single-agent nivolumab after a minimum of 48 months follow-up.⁵³¹

Anti-PD-1 Therapy in Patient Subpopulations

BRAF Mutation Status

Subgroup analyses in the Checkmate and KEYNOTE trials showed that patients with *BRAF* mutant tumors and those with *BRAF* wild-type tumors derived clinical benefit from anti-PD-1 therapy compared with controls (single-agent ipilimumab or chemotherapy).^{406-408,421,422,523,526,529-531}

Likewise, subgroup analyses in CheckMate 067 and 069 showed improved efficacy with nivolumab/ipilimumab combination therapy compared with ipilimumab monotherapy regardless of *BRAF* mutation status.^{408,409,421,528,531}



PD-L1 Expression

To determine whether the PD-1 ligand (PD-L1) could be used to identify candidates for anti-PD-1 therapy, PD-L1 expression was assessed in tumor samples from patients in the CheckMate and KEYNOTE trials, and various expression level cutoffs were analyzed to see whether PD-L1 expression levels could be used as a biomarker to predict response to anti-PD-1 therapy.^{408,523,526,528,549,563} Across trials, response rate, PFS, and OS for anti-PD-1 therapy tend to improve with increasing PD-L1 expression.^{408,410,421,530,531,549,564} However, there were patients who experienced durable responses to anti-PD-1 therapy despite having little or no PD-L1 expression detected in their tumor samples.^{408,410,421,526,531,549,564} Analysis of data from Checkpoint 067 showed that although nivolumab efficacy appeared to improve with increasing PD-L1 expression, time-dependent ROC curves indicated that PD-L1 expression alone is an insufficient biomarker to predict OS among patients treated with nivolumab.⁵³¹ In trials comparing anti-PD-1 monotherapy to ipilimumab monotherapy, subgroup analyses by PD-L1 expression showed that while response rate, PFS, and OS are higher with anti-PD-1 monotherapy compared to ipilimumab monotherapy for most PD-L1 expression levels, these treatment-dependent differences are smaller among patients with extremely low PD-L1 expression (<1% of cells showing membrane staining).^{531,549} None of these analyses, however, were able to identify a PD-L1 expression threshold for selection of an anti-PD-1 agent versus other options.

Among patients treated with nivolumab plus ipilimumab combination therapy, response rate, PFS, and OS tend to increase with increasing PD-L1 expression level.^{531,554} Similar to the results for nivolumab monotherapy, ROC curves in Checkmate 067 showed that PD-L1 alone is insufficient for predicting OS among patients treated with nivolumab/ipilimumab combination therapy.⁵³¹ Nivolumab/ipilimumab combination improved response rate and outcomes compared with

ipilimumab monotherapy for all PD-L1 expression levels tested—including patients with very low PD-L1 expression.⁵³¹ Descriptive analyses showed that among patients with low PD-L1 expression, nivolumab/ipilimumab seems to improve outcomes relative to nivolumab monotherapy. Improvements in outcome with combination therapy versus nivolumab monotherapy were not apparent among patients with higher PD-L1 levels.⁵³¹ The apparent predictive/prognostic value of PD-L1 is limited by the expression assays and different PD-L1 thresholds across studies. At present, the expression of PD-1 should not be used to exclude patients from anti-PD-1 monotherapy, but may be helpful when choosing between anti-PD-1 monotherapy and ipilimumab/nivolumab combination therapy.

Sequence of Immune Checkpoint Inhibitors

Ongoing studies are aimed at determining the efficacy of sequential monotherapy with ipilimumab and PD-1 inhibitor. Preliminary results from a randomized phase II trial show increased toxicity but trends toward improved response rate and OS for patients treated with nivolumab followed by ipilimumab compared with patients who received these therapies in the reverse order.⁵⁵² Cross-trial comparison suggests that patients who have progressed on ipilimumab have lower response rates and poorer outcomes on anti-PD-1 agents compared with patients who have not had prior systemic therapy (Tables 10–11). Subgroup analyses of data from Keynote-001 and Keynote-006 suggest that pembrolizumab is more effective as a first-line agent than as a second-line agent, even among patients with no prior immune checkpoint inhibitor therapy.^{405,549} A retrospective analysis showed responses to pembrolizumab in patients previously treated with ipilimumab is correlated with the patient's prior response to ipilimumab (duration of PFS).⁵⁶⁵

Brain Metastases: Efficacy of Immune Checkpoint Inhibitors


Most prospective randomized trials testing immune checkpoint inhibitors in patients with melanoma and distant metastatic disease have excluded patients with active brain metastases. Although patients with



asymptomatic brain metastasis weren't excluded, for many of these studies the subgroups of patients with brain metastases were very small, and/or data from these subgroups were not reported. Table 12 summarizes the available published efficacy data from samples that included 15 or more patients with brain metastases treated with immune checkpoint inhibitors in prospective clinical trials. Of the 6 studies included in this table, four were studying patients with brain metastases only. Of these, only CA209-170 included a randomized comparison, testing combination therapy versus nivolumab monotherapy in patients with asymptomatic brain metastases.

In aggregate, these trials show that brain metastases can respond to immune checkpoint inhibitors—including ipilimumab monotherapy, anti-PD-1 monotherapy, and ipilimumab/nivolumab combination therapy. What

these data do not provide is any robust comparison of agents for treatment of brain metastases—even asymptomatic brain metastases. It is tempting to conclude that nivolumab/ipilimumab combination therapy provides better intracranial responses rates than anti-PD-1 monotherapy, and that anti-PD-1 monotherapy likely provides higher response rates and better OS than ipilimumab monotherapy. However, it is important to note that the populations tested may vary considerably across trials, and that the sample sizes are too small for meaningful statistical comparisons. Several of the trials shown in Table 12 are ongoing (ie, NCT02085070, CA209-170, CheckMate 204), and several other trials testing immune checkpoint inhibitors in patients with brain metastases are planned or ongoing (eg, NCT02460068, NCT03728465, NCT03563729, NCT03340129, NCT02681549).





NCCN Guidelines Version 3.2023

Melanoma: Cutaneous

Table 12. Checkpoint Inhibitor Efficacy in Patients with Brain Metastases: Results from Prospective Trials

| Trial | | Patients | | | | Treatment Arms | Response Rate ^a | | PFS Median (months) ^a | | OS Median (months) ^a |
|--|--------------|---------------------------|-------------------|----------------------|--------------------|--|----------------------------|---------------|----------------------------------|---------------|---------------------------------|
| Name and References | Phase Design | Median Follow-up (months) | Prior Sys Tx | Prior Local Brain Tx | Brain Met Symptoms | | Extra-cranial | Intra-cranial | Extra-cranial | Intra-cranial | |
| Ipilimumab | | | | | | | | | | | |
| CA184-042 | II | | 78% ^b | 41% | None | HD-ipi (n = 51) | 14% | 16% | 2.6 | 1.5 | 7.0 |
| NCT00623766 ¹³⁶ | OL | -- | 71% ^b | 48% | All | HD-ipi (n = 21) | 5% | 5% | 1.3 | 1.2 | 3.7 |
| CA184-169 Subset | III | 14.5 ^c | 56% ^c | -- | None | HD-ipi (n = 65) | -- | -- | -- | -- | 7.0 NS ^d |
| NCT01515189 ⁵⁴⁴ | RDB | 11.2 ^c | 57% ^c | -- | None | Ipi (n = 62) | -- | -- | -- | -- | 5.7 |
| Pembrolizumab | | | | | | | | | | | |
| NCT02085070 ^{566,567} | II | 11.6 | 70% ^e | 78% ^e | None | Pembro (n = 23) | 30% | 26% | 2 | | 17 |
| Nivolumab, Nivolumab/Ipilimumab Combination | | | | | | | | | | | |
| CheckMate 037 Subset | III | ~24 | 100% ^f | -- | None | Nivo (n = 55) | -- | -- | -- | -- | 8.7 NS ^g |
| NCT01721746 ^{410,523} | R, OL | | | -- | None | Chemo (n = 18) | -- | -- | -- | -- | 11.8 |
| CA209-170 | II, R, | 14 | Some ^h | None | None | A ⁱ : Nivo + ipi, then nivo, (n = 36) | 57% | 46% | 13.8 | NR | NR |
| NCT02374242 ⁵⁵⁷ | OL | 17 | Some ^h | None | None | B ⁱ : Nivo (n = 27) | 29% | 20% | 2.6 | 2.5 | 18.5 |
| | | 31 | Some ^h | Some ^h | Some | C ⁱ : Nivo (n = 16) | 25% | 6% | 2.6 | 2.3 | 5.1 |
| CheckMate 204 | II | 14 | 17% ^j | Some ^j | None | Nivo + ipi, then nivo (n = 94) | 50% | 55% | NR | NR | NR |
| NCT02320058 ⁵⁵⁶ | | | | | | | | | | | |

--, data not reported; Brain Met Symptoms, percent of patients with symptomatic brain metastases; Chemo, Investigator's choice chemotherapy of single-agent dacarbazine or carboplatin/paclitaxel combination; HD-ipi, high-dose ipilimumab (10 mg/kg Q3W); ipi, standard dose ipilimumab (3 mg/kg Q3W); NR, median not reached (further follow-up needed); NS, no significant difference between arms; OL, open-label; pbo, placebo; Prior Sys Tx, percent of patients with prior systemic treatment; Prior local brain tx, percent of patient with prior local treatment for brain metastases (ie, surgery or radiation); R, randomized; RDB, randomized, double-blind; Tx, treatment.

^a Response rate is the percentage of patients that achieved complete or partial response. P values are for comparisons with the control arm. Median PFS and OS were determined using the Kaplan-Meier method.

^b In CA182-042, patients with prior checkpoint inhibitor treatment were excluded.

^c For CA184-169, median follow-up and percent of patients with prior systemic therapy are based on the whole study population (not only those with CNS metastases). Previous systemic therapy was allowed, but patients previously treated with BRAF inhibitors or checkpoint inhibitors were excluded.

^d For the subset of patients with brain metastases in CA184-169, there was no significant difference in OS between treatment arms (HR, 0.71; 95% CI, 0.49–1.04).

^e In NCT02085070, some patients had previously been treated with a BRAF inhibitor (n = 4) or ipilimumab (n = 13), but patients previously treated anti-PD-1 or anti-PD-L1 agents were excluded. Patients were required to have at least one brain metastasis that was untreated or unequivocally progressing after local therapy.



^f Entry criteria for the Checkmate 037 trial stipulated that patients must have progressed on ipilimumab, and if *BRAF* V600 mutation positive, also progressed on a *BRAF* inhibitor.

^g For the subset of patients with brain metastases in Checkmate 037, there was no significant difference in OS between treatment arms (HR, 1.42; 95% CI, 0.73–2.76).

^h In CA209-170, patients were allowed to have previous systemic therapy, but patients were excluded if they had prior treatment with a checkpoint inhibitor. Patients with previous *BRAF* inhibitor treatment must have intracranial disease progression.

ⁱ In CA209-170, patients with asymptomatic brain mets, no prior local therapy for brain metastases, and no leptomeningeal disease, were randomized to receive nivo + ipi (cohort A) or nivo alone (cohort B). Patients with brain metastases that had failed local therapy, were symptomatic, and/or had leptomeningeal disease were treated with nivo alone (cohort C). All cohorts were allowed to have had prior systemic therapy.

^j In CheckMate 204, patients were required to have at least 1 brain metastasis that had not been irradiated and did not require immediate surgery or RT. The study allowed prior local therapy for up to one brain metastasis, limited to SRS or resection. Patients with previous WBRT were excluded. Patients were allowed to have prior adjuvant systemic therapy, but for advanced disease the only prior therapy allowed was IL-2 or IFN-alpha. Seventeen percent had received prior systemic therapy, but this included adjuvant therapy.

Injectable Metastases: Immune Checkpoint Inhibitors Combined with T-VEC Intralesional Injection

Several ongoing trials are testing systemic immune checkpoint inhibitor therapy in combination with T-VEC intralesional injection in patients with unresectable stage IIIB-IV melanoma who have injectable cutaneous, subcutaneous, or nodal metastases (eg, MASTERKEY-265 [NCT02263508], S1607 [NCT02965716], NCT01740297). In all of these trials patients were also allowed to have non-injectable metastases.

Reports from phase 1 trials showed promising response rates for combination treatment with T-VEC combined with ipilimumab or pembrolizumab, with no unexpected safety signals (Table 13).^{568,569}

Results from the phase 2 part of NCT01740297 showed higher response rate among patients randomized to receive T-VEC/ipilimumab combination therapy versus ipilimumab alone (Table 13).⁵⁷⁰ Time to response and response duration were indistinguishable between treatment arms.

Combination T-VEC plus ipilimumab provided greater reduction in tumor

burden not only for injected lesions, but also for some non-injected visceral tumors, suggesting that combination therapy might enhance the systemic response to ipilimumab alone. The impact of this trial on clinical practice is limited, however, both because ipilimumab is not the preferred first-line immune checkpoint inhibitor, and because the improvements in response did not translate into improvements in PFS (Table 13).⁵⁷⁰ Follow-up in this study was too short for any comment on the impact of this combination on OS. The incidence of high-grade AEs (grade ≥ 3) was similar across treatment arms, and the safety profile reflected that observed in prior studies testing T-VEC and ipilimumab as monotherapies, with no unexpected types of toxicities. MASTERKEY-265 includes a phase 3 randomized component comparing pembrolizumab/T-VEC combination therapy with pembrolizumab monotherapy. Results from MASTERKEY-265 are more likely to impact clinical practice because pembrolizumab is among the preferred first-line immune checkpoint inhibitor options.

Table 13: T-VEC Combined with Checkpoint Inhibitors^a

| Trial | | Patients | | | Treatment Arms | Efficacy Results ^c | | | Grade 3–4 Tx-Related AEs ^d |
|---|--------------|---------------------------|----------|-----------------------|-------------------------|-------------------------------|---------------------|--------------------|---------------------------------------|
| Name and References | Phase Design | Median Follow-up (months) | Tx Naive | CNS Mets ^b | | Response Rate (irRC) | Median PFS (months) | Median OS (months) | |
| MASTERKEY-265/ Keynote-034 NCT02263508 ⁵⁶⁸ | Ib, OL | 18.6 | 100% | -- | T-VEC + Pembro (n = 21) | 62% | NR | NR | 38% |
| NCT01740297 ⁵⁶⁹ | Ib, OL | 20.0 | 100% | 0% | T-VEC + Ipi (n = 19) | 50% | NR | NR | 26% |
| NCT01740297 ⁵⁷⁰ | II, R | 15.9 | 96% | -- | T-VEC + Ipi (n = 98) | 39% <i>P</i> = .002 | 8.2 <i>P</i> = .35 | -- NS ^e | 45% |
| | | 13.5 | 97% | -- | Ipi (n = 100) | 18% | 6.4 | -- | 35% |

--, data no reported; CNS Mets, percent of patients with central nervous system metastases at baseline; ipi, ipilimumab; irRC, immune-related response criteria; NR, not reached (longer follow-up needed); NS, not statistically significant; OL, open label; pembro, pembrolizumab; R, randomized; T-VEC, talimogene laherparepvec intravesicular injection; Tx Naive, percent of patients with no prior treatment for unresectable or distant metastatic disease.

^a All trials included patients with unresectable stage IIIB-IVM1c disease with injectable lesions (cutaneous, subcutaneous, or nodal).

^b Patients with active cerebral metastases were excluded from the trials.

^c Response rate is the percentage of patients that achieved complete or partial response per immune-related response criteria. *P* values are for comparisons with the control arm. Median PFS and OS were determined using the Kaplan-Meier method.

^d Percent of patients who experienced any type of treatment-related AE of grade 3 or 4.

^e Median OS was not reported, but OS was not significantly different between treatment arms (HR, 0.8; 95% CI, 0.44–1.46).

Immune Checkpoint Inhibitor Administration

The ipilimumab treatment regimen of 3 mg/kg every three weeks for four doses in patients with unresectable or distant metastatic melanoma is well supported by clinical trial data and approved by the FDA.^{394,403,404}

Furthermore, this is the dose that is approved for use in combination with PD-1 blockade when clinically indicated.

For anti-PD-1 agents, however, there are fewer data to support the optimal dose and duration of treatment. Analyses of randomized cohorts in the KEYNOTE-001 phase I trial showed that there is no clinically meaningful difference in response rate, PFS, and OS for the 3 pembrolizumab regimens tested (ie, 2 mg/kg Q3W, 10 mg/kg Q3W, 10 mg/kg Q2W).^{405,550} Results from Keynote-002 and Keynote-006 support this observation (Table 10). Dose-finding trials for nivolumab included patients with a

variety of cancer types, and sample sizes for each of the dose levels tested in melanoma patients are too small to be sure of the best dose specifically for patients with melanoma.⁵⁷¹⁻⁵⁷⁸

Table 14 summarizes the treatment dosing and duration used in the pivotal trials supporting anti-PD-1 agents for use in unresectable or metastatic melanoma, as well as the current FDA-recommended dosing. For both nivolumab and pembrolizumab, the FDA-recommended dosing no longer reflects the dosing used in the pivotal trials supporting use of these agents for unresectable or distant metastatic melanoma. Flat dosing regimens for both nivolumab and pembrolizumab were identified by pharmacokinetic models based on data on body weight, exposure, and toxicity from large populations pooled from many trials across a variety of tumor types.^{575-577,579,580}



Although the product labels for nivolumab and pembrolizumab indicate that treatment should continue until disease progression or unacceptable toxicity,^{395,396} the published trials allowed shorter or longer treatment in certain situations. As mentioned above, long-term follow-up in trials testing anti-PD-1 agents (as monotherapy or in combination with ipilimumab) have shown that responses are very durable, and often persist for years beyond treatment discontinuation.^{530,531,551,581} Evidence is accumulating that although most responses to anti-PD-1 therapy develop within 6 months,^{406,409,410,528,530,551} there is a notable fraction of responses that take a very long time to develop, and some patients may even experience progression (RECIST-defined) before responding.^{406-408,410,421,422,523,526,529-531,549,551,582} Exploratory analyses of phase II/III trials testing nivolumab (Checkmate 037, 066, 067) reported that in highly select patients who per the investigators' discretion were allowed treatment for a limited period beyond progression, subsequent reduction in tumor burden was sometimes observed.^{523,526,583} A pooled analysis of data from 8 clinical trials found that in patients receiving anti-PD-1 agents (either alone or in combination) treatment beyond RECIST-defined progression resulted in further reduction in tumor burden by 30% or more in 19% of patients, as well as improvement in OS for patients treated beyond progression versus those who discontinued treatment at the time of progression.⁵⁸⁴ Other exploratory analyses of trials have shown that early discontinuation of anti-PD-1 therapy (ie, due to AEs) does not impact clinical outcomes,^{531,560} and that responses can occur after discontinuation.⁵⁶⁰ It is unclear whether treatment beyond progression was really responsible for the positive outcomes observed. Prospective randomized trials are needed to determine the duration of anti-PD1 treatment needed to optimize clinical benefit and minimize risk of toxicity.


Table 14. Immune Checkpoint Inhibitor Treatment Regimens

| | Dosing | Treatment Duration |
|--|---|---|
| <i>Nivolumab</i> | | |
| CheckMate 066 ⁵²⁶ | 3 mg/kg Q2W | Until disease progression or unacceptable toxicity. Patients who had clinical benefit could opt for treatment beyond progression, provided they had not experienced substantial AEs. |
| CheckMate 067 ⁴⁰⁸ | | |
| CheckMate 037 ⁵²³ | | |
| FDA Prescribing information ³⁹⁵ | 240 mg Q2W or 480 mg Q4W | Until disease progression or unacceptable toxicity. |
| <i>Pembrolizumab</i> | | |
| KEYNOTE-002 ⁴⁰⁶ | 2 mg/kg or 10 mg/kg Q3W | Until disease progression or unacceptable toxicity. Patients with PD at 12-week scan could opt to continue until confirmation of PD at next scan. |
| KEYNOTE-006 ⁴⁰⁷ | 10 mg/kg Q2W or Q3W | Until disease progression, unacceptable toxicity, or 24 months. Patients with CR lasting ≥6 months could discontinue after an additional 2 treatments. |
| FDA Prescribing information ³⁹⁶ | 200 mg Q3W | Until disease progression or unacceptable toxicity. |
| <i>Ipilimumab/Nivolumab Combination</i> | | |
| CheckMate 067 ⁴⁰⁸ | 1 mg/kg nivo + 3 mg/kg ipi (same day), Q3W for 4 doses; then 3 mg/kg nivo monotherapy Q2W | Until disease progression or unacceptable toxicity. Patients who had clinical benefit could opt for treatment beyond progression, provided they had not experienced substantial AEs. |
| CheckMate 069 ⁵²⁸ | | |
| FDA Prescribing information ⁵⁸⁵ | 1 mg/kg nivo + 3 mg/kg ipi (same day), Q3W for 4 doses; then 240 mg Q2W or 480 mg Q4W | Until disease progression or unacceptable toxicity. |

CR, complete response; Ipi, ipilimumab; nivo, nivolumab; PD, progressive disease; Q2W, once every 2 weeks; Q3W, once every 3 weeks.

Toxicity of Immune Checkpoint Inhibitors

Most of the treatment-related AEs associated with immune checkpoint inhibitors are autoimmune in nature. The array of immune-related toxicities associated with immune checkpoint inhibitors (across all cancer types), as well as recommendations for management of each, can be found in the [NCCN Guidelines for Management of Immunotherapy-Related Toxicities](#). Table 15 lists types and rates for the most common toxicities seen in prospective randomized trials that compared immune checkpoint inhibitors in patients with unresectable stage III or stage IV cutaneous melanoma.

Across all three immune checkpoint inhibitor options shown in Table 15 (ipilimumab, anti-PD-1 monotherapy, ipilimumab/nivolumab combination therapy), the most common AEs were cutaneous toxicities (rash, pruritus, maculopapular rash, and vitiligo), gastrointestinal toxicities (diarrhea/colitis), and fatigue. Aside from these 3 types of toxicities, the most common high-grade toxicities observed in clinical trials are endocrinopathies (eg, hypophysitis, adrenal insufficiency, hypo- or hyperthyroidism), pancreatitis (elevated lipase and amylase), and hepatic AEs (eg, elevated ALT/AST, hepatitis).³⁹⁴ Other less common but



potentially life-threatening high-grade immune-related toxicities include nephritis, pneumonitis, and myocarditis. Management of these unusual events is summarized in the [NCCN Guidelines for Management of Immunotherapy-Related Toxicities](#). Analysis of the WHO pharmacovigilance database, including patients treated with immune checkpoint inhibitors for any indication, found that for patients treated with anti-CTLA-4, colitis caused the most AE-related deaths, whereas AE-related deaths for anti-PD-1/PD-L1 agents were most often from pneumonitis, hepatitis, and neurotoxic effects.⁵⁸⁶ AE-related deaths in patients treated with combination PD-1/CTLA-4 inhibitors were most frequently from colitis or myocarditis.⁵⁸⁶

Although there are no data from prospective randomized trials directly comparing nivolumab versus pembrolizumab, these agents appear to have similar safety profiles (Table 15). Safety results from randomized phase II-III trials showed that combination therapy with nivolumab and ipilimumab was associated with more toxicity than single-agent ipilimumab or nivolumab (Table 15).^{408,409,528,531} Ipilimumab/nivolumab combination therapy increased the total number of patients with treatment-related AEs of any grade, and notably increased the occurrence of grade 3–4 AEs (Table 15) and AEs leading to treatment discontinuation (40% for nivolumab/ipilimumab combination vs. 13% for nivolumab monotherapy, 15% for ipilimumab monotherapy).⁵³¹ Table 15 shows that many of the common toxicities were more frequent or more often high grade with combination ipilimumab plus anti-PD-1 regimens than with immune checkpoint inhibitor monotherapy. Although earlier reports suggested that anti-PD-1 monotherapy was associated with less toxicity than ipilimumab, these differences appear to be less significant with longer term follow-up (Table 15).^{407-409,422,528,531}

Kinetics of Immune-Related Toxicities

Pooled analyses of data from prospective trials testing immune checkpoint inhibitors in patients with unresectable or distant metastatic melanoma

show that time to onset and time to resolution differ across different types of AEs.^{587,588} Most skin-related AEs manifest early, but risk of developing a cutaneous AE persists throughout treatment. Among high-grade AEs, gastrointestinal and hepatic toxicities tend to take a bit longer to develop (than cutaneous AEs), followed by pulmonary, endocrine, and renal AEs. Although these trends are clear, for many irAEs the ranges of time to onset are quite broad. Although uncommon, initial irAEs have been observed up to a year following initiation of treatment. Median time to resolution is similar for most types of common high-grade AEs, on the order of months, but endocrine AEs may not resolve. Up to 20% of high-grade cutaneous AEs also appear to persist indefinitely.^{587,588} Analysis of the WHO pharmacovigilance database found that fatal AEs associated with immune checkpoint inhibitors (all indications) usually occurred within the first 2 months of treatment.⁵⁸⁶



NCCN Guidelines Version 3.2023 Melanoma: Cutaneous

Table 15. Checkpoint Immunotherapies: Treatment-Related Toxicities^a

| Study: Agent: Grade: | CheckMate 067 and 069 ^{409,531} | | | | | | KEYNOTE-006 ^{407,422} | | | |
|----------------------------|--|-------|------------------------|-----|------------------------|-------|--------------------------------|--------------------|----------------------|--------------------|
| | Ipilimumab | | Nivolumab ^b | | Ipilimumab + Nivolumab | | Ipilimumab | | Pembrolizumab | |
| | 3–4 | Any | 3–4 | Any | 3–4 | Any | 3–5 | Any | 3–5 | Any |
| All types | 20–28 | 86–94 | 22 | 86 | 54–59 | 90–96 | 20 ^c | 73–74 ^c | 12–17 ^c | 76–80 ^c |
| Diarrhea | 6–11 *** | | 3 ** | | 10 ***** | | 3 ^c **c | | 2–3 ^d **c | |
| Colitis | 2–8 * | | 1 | | 8–13 ** | | 6 * | | 3 | |
| Nausea | 1–2 ** | | 0 * | | 1–2 *** | | <1 ^c *c | | <1 ^c *c | |
| Vomiting | <1 * | | <1 * | | 1–2 ** | | 0 * | | <1 | |
| Decreased appetite | <1 * | | 0 * | | ≤1 ** | | 0 * | | 0 * | |
| Rash | ≤2 *** | | <1 ** | | 3–4 **** | | ≤1 ^c **c | | 0 ^c **c | |
| Pruritus | <1 **** | | <1 ** | | 1–2 **** | | <1 ^c ***c | | 0 ^c **c | |
| Maculopapular rash | <1 * | | 1 * | | 2–3 ** | | <1 | | <1 | |
| Vitiligo | 0 ^b *b | | <1 * | | 0 ^b * | | 0 | | 0 * | |
| Fatigue | ≤1 ***** | | 1 **** | | 4–5 **** | | 1 ^c **c | | ≤1 ^c ***c | |
| Pyrexia | <1 * | | 0 * | | 1–3 ** | | 0 | | 0 | |
| Arthralgia ^b | 0 ^b *b | | <1 ^b * | | 1 *b | | ≤1 ^c *c | | <1 ^c *c | |
| Myalgia | 0 * | | <1 * | | <1 * | | <1 | | <1 | |
| Asthenia | 1 ^b *b | | <1 * | | <1 ^b *b | | 1 * | | <1 * | |
| Headache | <1 * | | 0 * | | 1–2 * | | 0 | | 0 | |
| Dyspnea | 0 | | <1 * | | 1–2 * | | <1 | | <1 | |
| Cough | 0 * | | 1 * | | 0 * | | 0 | | 0 | |
| Abdominal pain | 1–2 * | | 0 * | | <1 * | | 0 * | | 0 | |
| Chills | 0 * | | 0 | | 0 * | | 0 | | 0 | |
| Elevated ALT | ≤2 * | | 1 | | 9–11 *** | | 1 | | <1 | |
| Elevated AST | ≤1 * | | 1 | | 6–7 *** | | 1 | | <1 | |
| Hypophysitis | 2–4 * | | <1 | | 2 * | | 1 | | <1 | |
| Hypothyroidism | 0 * | | 0 * | | <1 ** | | 0 ^c c | | <1 ^c *c | |
| Hyperthyroidism | 0 ^b | | 0 | | 1 ^b *b | | <1 | | 0 | |
| Elevated lipase | ≤4 * | | 5 * | | 10–11 ** | | -- -- | | -- -- | |
| Elevated amylase | ≤1 | | 2 * | | 2–3 * | | -- -- | | -- -- | |
| Pneumonitis | <1 | | <1 | | 1–2 * | | -- -- | | -- -- | |
| Creatinine increased | 0 | | <1 | | ≤1 | | 0 | | 0 | |



--, not reported

^a Specific AEs listed occurred in $\geq 10\%$ of patients for at least one checkpoint immunotherapy regimen. This table shows percent of patients who experienced at least one AE of any grade, grade 3–4, or grade 3–5. For the any grade column, the percent of patients affected by specific AEs (any grade) was rounded to the nearest 10%, then assigned one asterisk (*) for every 10% of patients effected. Blank indicates that $< 5\%$ of patients experienced that AE.

^b Data available from only one of two trials.

^c For KEYNOTE-006, unless otherwise noted data shown are from the first interim analysis based on median follow-up of 7.9 months. Footnote indicates data from a later report based on median 22.9 months follow-up. The later report did not include a complete AE listing.⁴²²

BRAF-Targeted Therapies

Approximately half of patients with metastatic cutaneous melanoma harbor an activating mutation of *BRAF*, an intracellular signaling kinase in the MAPK pathway.⁸⁹⁻⁹¹ Most *BRAF*-activating mutations occurring in melanomas are at residue V600 (usually V600E but occasionally V600K or other substitutions).^{90,589} *BRAF* inhibitors have been shown to have clinical activity in unresectable metastatic melanomas with *BRAF* V600 mutations. Co-administration of inhibitors of MEK, a signaling molecule downstream of *BRAF*, potentiates these effects. Efficacy and safety data from large randomized trials testing *BRAF* and MEK inhibitors have significantly impacted the recommended treatment options for patients with *BRAF*-mutation positive unresectable advanced melanoma.

BRAF Inhibitor Monotherapy

Vemurafenib and dabrafenib were developed to inhibit *BRAF* with mutations at V600.⁵⁹⁰⁻⁵⁹² For patients with previously untreated stage IV or

unresectable stage III melanoma with *BRAF* V600 mutations, phase III trials (ie, BRIM-3, BREAK-3) have shown that monotherapy with either of these agents improves response rates, PFS, and OS compared with chemotherapy (dacarbazine; Tables 17–18). For both vemurafenib (Table 16) and dabrafenib (Table 17), efficacy in patients with previously treated unresectable advanced disease, including patients who received prior ipilimumab, is supported by single-arm open-label trials (NCT00949702, BREAK-2) showing response rates, median PFS, and median OS similar to those from the phase III trials (ie, BRIM-3, BREAK-3). Phase III trial results show that time to response for *BRAF* inhibitors (median ~1.5 months) may be shorter than with chemotherapy.^{92,94,95} Responses to *BRAF* inhibitor monotherapy are relatively short lived, however, with median duration ~5 to 10 months.^{94,412,525,593-597} Likewise, PFS and OS Kaplan-Meier curves for vemurafenib and dabrafenib show little or no decline during the first few months of treatment (ie, ~1.5 months for PFS, ~3 months for OS), and then abruptly begin to decline.^{93,94}



NCCN Guidelines Version 3.2023

Melanoma: Cutaneous

Table 16. Vemurafenib Monotherapy in Advanced Melanoma^a: Key Trials

| Trial | | Median Follow-up (months) | Patients | | | Treatment Arms | Efficacy Results ^b | | | AEs by Grade ^c | | |
|--|--------------|--|-------------|----------|------------------|---------------------------------|-------------------------------|--------------------------------|--------------------------------|---------------------------|----------|----------|
| Name and References | Phase Design | | Prior BRAFi | Tx Naive | Brain Mets | | Response Rate | Median PFS (months) | Median OS (months) | 3 | 4 | 5 |
| NCT00949702 ^{a593} | II OL | 12.9 | 0 | 0 | <1% | Vem (n = 132) | 53% | 6.8 | 15.9 | 60% | 4% | <1% |
| BRIM-3 NCT01006980 ^{92,93,598} | III R, OL | 13.4; 12.5 ^d 9.2; 9.5 ^d | 0 0 | 100% | NR ^e | Vem (n = 337) DTIC (n = 338) | 48% 5% <i>P</i> < .001 | 6.9 1.6 <i>P</i> < .0001 | 13.6 9.7 <i>P</i> = .003 | 67% 33% | 7% 9% | 2% 1% |
| NCT01307397 ^{525,594} | IV OL | 32.2 | 0 | 50% | 23% ^e | Vem (n = 3222) | 36% | 5.6 | 12.1 | 53% | | 4% |

--, data not reported; *BRAF* V600E (K), percent of patients with a *BRAF* V600E (percent with *BRAF* V600K); BRAFi, BRAF inhibitor; Brain Mets, percent of patients with brain metastases at baseline; DTIC, dacarbazine; R, randomized; OL, open label; Tx Naive, percent of patients with no prior treatment for unresectable or distant metastatic disease; vem, vemurafenib.

^a Unresectable stage IIIC or stage IV melanoma; NCT00949702 included only stage IV melanoma. All patients had a *BRAF* V600 mutation. *BRAF* mutations reported were V600E (91%–92%), V600K (8%–9%) or not reported.

^b Response rate is the percentage of patients that achieved complete or partial response. *P* values are for comparisons with the control arm. Median PFS, median OS, and *P* value determined using the Kaplan-Meier method. *P* values are for comparisons with the control arm.

^c For BRIM-3 and NCT01307397, rates show percent of patients with ≥1 AE of any cause (treatment or otherwise). For NCT00949702, rates reflect percent of patients ≥1 treatment-related AE.

^d Median follow-up for OS and safety analysis; response and PFS.

^e Patients with active CNS metastases were excluded from these trials.



NCCN Guidelines Version 3.2023

Melanoma: Cutaneous

Table 17. Dabrafenib Monotherapy in Advanced Melanoma^a: Key Trials

| Trial | | | Patients | | | Treatment Arms | Efficacy Results ^b | | | Grade 3–4 AEs ^c |
|---|--------------|---------------------------|-------------|----------|------------|----------------|-------------------------------|---------------------------|-----------------------------|----------------------------|
| Name and References | Phase Design | Median Follow-up (months) | Prior BRAFi | Tx Naïve | Brain Mets | | Response Rate | Median PFS (months) | Median OS (months) | |
| BREAK-2 NCT01153763 ⁵⁹⁵ | II OL | 11.9 | 0 | 16% | 0% | Dab (n = 92) | 59% (13%) ^d | 6.3 (4.5) ^d | 13.1 (12.9) ^d | 27% |
| BREAK-3 NCT01227889 ^{94,95} | III R, OL | 15.2 | 0 | 100% | 0% | Dab (n = 187) | 50% | 5.1 <i>P</i> < .0001 | 18.2 | 53% ^e |
| | | 12.7 | 0 | | | DTIC (n = 63) | 5% | | 15.6 | |

--, data not reported; *BRAF* V600E (K), percent of patients with a *BRAF* V600E (percent with *BRAF* V600K); BRAFi, BRAF inhibitor; Brain Mets, percent of patients with brain metastases at baseline; dab, dabrafenib; DTIC, dacarbazine; R, randomized; OL, open label; Tx Naïve, percent of patients with no prior treatment for unresectable or distant metastatic disease.

^aStage IV melanoma; BREAK-3 also included unresectable stage III. All patients had a *BRAF* V600 mutation. *BRAF* mutations reported were V600E (83%–100%) or V600K (0%–17%).

^bResponse rate is the percentage of patients that achieved complete or partial response. *P* values are for comparisons with the control arm. Median PFS and OS, *P* value, and HR were determined using the Kaplan-Meier method.

^cPercent of patients who experienced any type of treatment-related AE of grade 3 or 4.

^dData shown are from patients with *BRAF* V600E (V600K) mutation.

^ePercent of patients with AEs of grade 2 or greater. Rates of adverse events of grade ≥3 were not reported.

Table 18. Encorafenib Monotherapy in Advanced Melanoma^a

| Trial | | | Patients | | | Treatment Arms | Efficacy Results ^b | | | Grade 3–4 AEs ^c |
|----------------------------|--------------------|---------------------------|-------------|----------|-----------------|----------------|-------------------------------|---------------------|--------------------|----------------------------|
| Name and References | Phase Design | Median Follow-up (months) | Prior BRAFi | Tx Naïve | Brain Mets | | Response Rate | Median PFS (months) | Median OS (months) | |
| NCT01436656 ⁵⁹⁹ | I, dose escalation | -- | 0 | -- | -- ^d | Encor (n = 25) | 60% | -- | -- | 70% |
| | | | 100% | 0 | -- ^d | Encor (n = 29) | 10% | -- | -- | |
| | I, dose expansion | -- | 0 | -- | -- ^d | Encor (n = 15) | 60% | 12.4 | NR | -- |
| | | | 100% | 0 | -- ^d | Encor (n = 18) | 22% | 1.9 | 9.07 | -- |

--, data not reported; *BRAF* V600E (K), percent of patients with a *BRAF* V600E (percent with *BRAF* V600K); BRAFi, BRAF inhibitor; Brain Mets, percent of patients with brain metastases at baseline; Encor, encorafenib; NR, not reached; Tx Naïve, percent of patients with no prior treatment for unresectable or distant metastatic disease.

^aUnresectable stage IIIB-IV melanoma. All patients had a *BRAF* V600 mutation. *BRAF* V600E was reported in 87%–94% of patients.

^bResponse rate is the percentage of patients that achieved complete or partial response. Median PFS and OS were determined using the Kaplan-Meier method.

^cPercent of patients who experienced any type of treatment-related AE of grade 3 or 4.

^dAsymptomatic/inactive brain metastases were allowed but not reported.

***BRAF/MEK Inhibitor Combination Therapy***

Despite high initial response rates, half of the patients treated with BRAF-targeted monotherapies relapse within 6 months, due to development of drug resistance.^{94,412,525,593-597} Alternate methods for targeting the MAP kinase pathway are being explored as options for overcoming resistance to BRAF inhibitor therapy. Trametinib, cobimetinib, and binimetinib are oral small-molecule inhibitors of MEK1 and MEK2, signaling molecules downstream of BRAF in the MAP kinase pathway. Results from a phase III randomized trial (NCT01245062) showed that, in patients with *BRAF*-mutated metastatic melanoma not previously treated with BRAF inhibitors, trametinib improves PFS and OS compared with chemotherapy.⁶⁰⁰ Although trametinib response rate (22%) was significantly better than chemotherapy (8%, $P = .01$), it was lower than response rates for vemurafenib (48%, 53%) and dabrafenib (50%) from phase II-III trials.^{593,92,94} Moreover, in an open-label, phase II study, trametinib failed to induce objective responses in 40 patients previously treated with a BRAF inhibitor.⁶⁰¹ Binimetinib has also been shown to provide improved response rates and PFS compared with DTIC in a phase 3 randomized trial in patients with unresectable stage IIIC or stage IV melanoma with *NRAS* Q61R/K/L mutations.⁶⁰² Nonetheless the ORR (15%) and PFS (median 2.8 months) for patients treated with binimetinib were poor compared to those for BRAF inhibitors tested in other trials.

Although MEK inhibitor monotherapy has limited utility for treating advanced metastatic melanoma, several phase III trials have now demonstrated that combination therapy with a BRAF and MEK inhibitor has better efficacy than BRAF inhibitor monotherapy for previously untreated unresectable or distant metastatic disease (Table 19).^{411-413,597,603,604} When compared with either single-agent dabrafenib or single-agent vemurafenib, BRAF/MEK inhibitor combination therapy with dabrafenib and trametinib or vemurafenib plus cobimetinib improved response rate, duration of response, PFS, and OS.^{411-413,597} A recent

phase 3 randomized trial (COLUMBUS) showed that encorafenib, a BRAF inhibitor, when combined with the MEK inhibitor binimetinib, improves PFS and OS compared with vemurafenib monotherapy.^{605,606} Patients in the COLUMBUS trial were treatment naïve or had progressed on or after previous first-line immunotherapy; no other prior therapies for locally advanced, unresectable, or metastatic melanoma were allowed. This trial also compared encorafenib/binimetinib combination therapy versus encorafenib monotherapy, but the improvements in PFS and OS did not reach statistical significance. Although across trials of patients with previously untreated metastatic disease, vemurafenib monotherapy and dabrafenib monotherapy have resulted in roughly similar response rates and PFS,^{92-95,411-413,597,598,603,604} results from the COLUMBUS trial showed that encorafenib monotherapy improved PFS and OS compared with vemurafenib monotherapy.^{605,606}

The efficacy of BRAF/MEK inhibitor combination therapy in patients with previously treated advanced melanoma is a topic of ongoing research. Results from phase I/II studies (Table 19) showed that in patients who have received previous BRAF inhibitor treatment, subsequent BRAF/MEK inhibitor combination therapy was associated with a relatively poor response rate, PFS, and OS, compared with patients who had not received prior BRAF inhibitor treatment.^{527,607-611} Likewise, although encorafenib improved response rate and PFS compared with vemurafenib in patients with no prior BRAF inhibitor treatment (Table 19), data from a phase 1 trial suggest that patients with prior dabrafenib or vemurafenib treatment still have fairly low response rates and poor PFS when treated with encorafenib (Table 18).⁵⁹⁹ However, emerging data suggest that resistance to BRAF-targeted therapy may not be as irreversible as previously thought. A subset analysis in one of these studies (NCT01072175) showed that patients who had rapidly progressed on first-line BRAF inhibitor therapy (time to progression <6 months) derived little or no clinical benefit from second-line BRAF/MEK inhibitor combination



therapy compared with patients whose resistance to first-line BRAF inhibitor monotherapy occurred at ≥ 6 months (response rate: 0% vs. 26%; median PFS: 1.8 months vs. 3.9 months, $P = .018$).⁵²⁷ One single-arm phase II study (NCT02296996) that restricted enrollment to patients who had previously progressed on BRAF-targeted therapy, and progressed on anti-CTLA-4 or anti-PD-1, and had least 12 weeks since finishing their last BRAF-targeted treatment, found that response rate was relatively high (32%) compared with other prospective studies that tested BRAF/MEK inhibitor therapy in patients who previously progressed on BRAF-targeted therapy (response rate 10%–15% in BRIM-7, NCT01072175, NCT01619774; see Table 19).^{527,610,611} Some of the patients who responded to rechallenge had previously progressed on BRAF/MEK inhibitor combination therapy.⁶¹¹ These results from NCT01072175 and NCT02296996 suggest that resistance to BRAF-targeted therapy may be reversible, at least in some patients. Identification of the best candidates for retreatment is a topic of ongoing research.

Across trials, the apparent time to response for all BRAF/MEK inhibitor combinations reflects the time to first tumor response assessment (6 weeks in BRIM-7, 8 weeks in other trials).^{413,596,605,607} Results from multiple randomized trials suggest that BRAF/MEK inhibitor combination therapy may improve duration of response compared with BRAF inhibitor monotherapy, although the magnitude of this effect varies, with increases in median duration of response ranging from 2 to 6 months.^{412,596,597,603,606}

Discussion
update in
progress



NCCN Guidelines Version 3.2023 Melanoma: Cutaneous

Table 19. BRAF/MEK Inhibitor Combination in Advanced Melanoma^a: Key Trials

| Trial | | | Patients | | | Treatment Arms | Efficacy Results ^b | | | AEs Grade 3–4 ^c |
|---|---------------------------|---------------------------|-------------------|-------------------|------------------|--|-------------------------------|------------------------------------|------------------------------------|----------------------------|
| Name and References | Phase Design | Median follow-up (months) | Prior BRAFi | Tx Naive | Brain Mets | | Response Rate | Median PFS (months) | Median OS (months) | |
| BRIM-7 ⁶⁰⁷⁻⁶⁰⁹ NCT01271803 | Ib OL, dose escalation | 26 | 0 ^d | Some ^d | NR ^e | Vem + cobimetinib (n = 63) | 87% | 13.8 | 31.2 | 78% |
| | | 8 | 100% ^d | 0 ^d | | Vem + cobimetinib (n = 66) | 15% | 2.8 | 8.5 | 47% |
| NCT02296996 ⁶¹¹ | II OL | 6.8 | 100% ^f | 0 | 68% | Dab + trametinib (n = 25) | 32% | 4.9 | NR | 8% |
| NCT01072175 ⁵²⁷ | I/II OL | 35.3 | 100% ^g | 0 | 23% | Dab + trametinib (n = 26) | 15% | 3.6 | 10.0 | 61% |
| | | 27.4 | 100% ^g | 0 | 9% | Dab + trametinib (n = 45) | 13% | 3.6 | 11.8 | 44% |
| NCT01072175 Part C ^{596,612} | II R | 66.5 | 0 | Some ^h | 4% ^e | Dab (150 mg BID) + trametinib (2 mg QD) (n = 54) | 76% <i>P</i> = .03 | 9.4 <i>P</i> < .001 | 25.0 | 67% |
| | | | 0 | | 13% ^e | Dab (150 mg BID) + trametinib (1 mg QD) (n = 54) | 50% <i>P</i> = .77 | 9.2 <i>P</i> = .006 | 22.5 | 54% |
| | | | 0 | | 7% ^e | Dab (150 mg BID) | 54% | 5.8 | 20.2 | 47% |
| NCT01619774 ⁶¹⁰ | II | 5.9 | 100% ^g | 0 | -- ^e | Dab + trametinib (n = 23) | 10% | 3.0 | 10.2 | 71% |
| COMBI-d ^{411,603} NCT01584648 | III RDB | 20 | 0 | 100% | -- ^e | Dab + trametinib (n = 211) | 69% <i>P</i> = .0014 | 11.0 <i>P</i> = .0004 | 25.1 <i>P</i> = .0107 | 48% ⁱ |
| | | 16 | 0 | | | Dab + pembrolizumab (n = 212) | 53% | 8.8 | 18.7 | 50% ⁱ |
| COMBI-v ⁴¹² NCT01597908 | III R, OL | 11 | 0 | 100% | -- ^e | Dab + trametinib (n = 352) | 64% <i>P</i> < .001 | 11.4 <i>P</i> < .001 | NR <i>P</i> = .005 | 52% |
| | | 10 | 0 | | | Vemurafenib (n = 352) | 51% | 7.3 | 17.2 | 63% |
| Co-BRIM ^{413,597,604} NCT01689519 | III RDB | 14.2; 18.5 ^j | 0 | 100% | <1% ^e | Vemurafenib + cobimetinib (n = 247) | 70% <i>P</i> < .0001 | 12.3 <i>P</i> < .0001 | 22.3 <i>P</i> = .005 | 75% |
| | | | 0 | | <1% ^e | Vemurafenib + pembrolizumab (n = 248) | 50% | 7.2 | 17.4 | 61% |
| COLUMBUS ^{605,606} NCT01909453 | III R, OL | 32.1 (PFS) 36.8 (OS) | 0 | 70% ^k | 5% ^e | Encorafenib + binimetinib (n = 192) | 64% | 14.9 <i>P</i> < .0001 ^l | 33.6 <i>P</i> < .0001 ^l | 64% |
| | | | 0 | 70% ^k | -- ^e | Encorafenib (n = 194) | 52% | 9.6 <i>P</i> = .0038 ^l | 23.5 <i>P</i> = .033 ^l | 67% |
| | | | 0 | 70% ^k | 2% ^e | Vemurafenib (n = 191) | 41% | 7.3 | 16.9 | 66% |

--, data not reported; bini, binimetinib; BRAF V600E (K), percent of patients with a BRAF V600E (percent with BRAF V600K); BRAFi, BRAF inhibitor; Brain Mets, percent of patients with brain metastases at baseline; cobimetinib; dab, dabrafenib; encor, encorafenib; NR, not reached; OL, open label; R, randomized; RDB, randomized double-blind; tram, trametinib; Tx Naive, percent of patients with no prior treatment for unresectable or distant metastatic disease; vem, vemurafenib.

^a Unresectable (AJCC 7th Edition) stage IIIC or stage IV melanoma. COLUMBUS also included patients with (AJCC 7th Edition) stage IIIB disease. All patients had a BRAF V600 mutation. BRAF mutations reported were V600E (83%–92%), V600K (4%–17%), or not reported.

^b Response rate is the percentage of patients that achieved complete or partial response. P values are for comparisons with the control arm. Median PFS and OS, P value, and HR were determined using the Kaplan-Meier method.

^c Percent of patients with grade 3–4 AEs of any cause (treatment or otherwise).



^d BRIM-7 included a cohort of patients who had recently progressed on vemurafenib (n = 66) and a cohort of patients with no prior BRAF inhibitor (n = 63). Each may have had other types of prior systemic therapy. For the latter, the number without any prior treatment was not reported.

^e Patients with active brain metastases were excluded from the trial. Treated stable brain metastases were allowed.

^f In NCT02296996, patients were required to have progressed on prior BRAF inhibitor therapy (or BRAF/MEK inhibitor combination therapy) and to have progressed on prior anti-CTLA-4 or anti-PD-1 checkpoint inhibitor therapy.

^g Johnson 2014⁵²⁷ reported results from two cohorts in NCT01072175 consisting of patients who progressed on prior BRAF inhibitor monotherapy. Patients in NCT01619774 were required to have progressed on prior BRAF inhibitor monotherapy.

^h In Part C of NCT01072175, all patients had no prior BRAF or MEK inhibitor treatment, but some had prior chemotherapy (13% vs. 28% vs. 22%) and some had prior immunotherapy (24% vs. 30% vs. 15%). The number with no prior systemic therapy was not reported.

ⁱ Based on analysis after ≥36-month follow-up for all living patients.

^j Co-BRIM median follow-up shown for response and PFS analysis; OS and safety analysis.

^k In COLUMBUS, 30% of patients in each arm had prior systemic immunotherapy, mostly IFN or interleukins. Other types of prior systemic therapy were not allowed.

^l In COLUMBUS, encorafenib/binimetinib combination therapy versus encorafenib monotherapy did not result in significantly different PFS (HR, 0.75; 95% CI, 0.56–1.00; *P* = .050) or OS (HR, 0.81; 95% CI, 0.61–1.06; *P* = .12).

BRAF-Targeted Therapies for Brain Metastases

As shown in tables 17, 18, and 20, patients with active brain metastases were excluded from prospective comparative trials testing BRAF-targeted therapies. Patients with stable asymptomatic brain metastases were sometimes allowed, but for many of these studies this subpopulation was small. Several prospective non-comparative trials have tested single-agent dabrafenib, single-agent vemurafenib, and dabrafenib/trametinib combination in patients with brain metastases (Table 20).^{594,613-616} Some of these studies included patients with symptomatic brain metastases,^{613,614,616} and some included patients whose intracranial disease had progressed after local therapy.⁶¹⁴⁻⁶¹⁶ All of the studies shown in Table 20 included patients who had prior systemic therapy for metastatic disease, but most excluded patients with prior BRAF inhibitor therapy. Results from these trials show that melanoma brain metastases can respond to BRAF inhibitor monotherapy or BRAF/MEK inhibitor combination therapy, albeit with lower response rates than for extracranial

disease. It is notable that intracranial responses were seen even among patients with prior systemic therapy for metastatic disease, symptomatic brain metastases, and intracranial progression after local therapy, as these populations tend to be difficult to treat. One of the studies in patients with symptomatic brain metastases also reported symptomatic improvement based on reduction in use of corticosteroids and increase in performance score.⁶¹³ Results from COMBI-MB suggest that among patients with brain metastases, dabrafenib/trametinib combination therapy may provide higher rates of response than single-agent BRAF inhibitor therapy. However, cross-trial comparisons in studies of patients with brain metastases are particularly difficult because there are a number of factors that may profoundly impact measured outcomes—including extent and location of intracranial disease, severity of symptoms, and number and type of prior systemic and local intracranial therapies. Prospective randomized trials are needed to determine which BRAF-directed therapy options provide the best results in patients with brain metastases.

NCCN Guidelines Version 3.2023 Melanoma: Cutaneous

Table 20. BRAF/MEK Inhibitor Efficacy in Patients with Brain Metastases: Results from Prospective Trials

| Trial | | | Patients ^a | | | | Treatment Arms | Response Rate ^b | | PFS Median (months) ^b | | OS Median (months) ^b |
|--|--------------|----------------------------|-----------------------|--|--|---------------------|--|---|---|--|---------------|--|
| Name and References | Phase Design | Median Follow-up (months) | Prior BRAFi | Prior Sys Tx | Prior local Brain Tx | Brain Met Symptoms | | Extra-cranial | Intra-cranial | Extra-cranial | Intra-cranial | |
| NCT01253564 ⁶¹³ | Pilot, OL | -- | 0 | 83% | 79% | 100% | Vem (n = 24) | 62% | 16% | 3.8 | | 5.3 |
| MO25515 Subset ^{525,594} NCT01307397 | IV, OL | 32.2 ^b | 1% ^c | 50% ^c | -- ^c | 0 | Vem (n = 753) | 24% | | 3.7 | | 7.4 |
| McArthur 2017 ⁶¹⁴ | II | 9.6 | 0 | 20% 30% | 0 100% ^d | Some ^e | 1: Vem (n = 90) 2: Vem (n = 56) | 33% 23% | 18% 18% | -- -- | 3.7 4.0 | 8.9 9.6 |
| BREAK-MB NCT01266967 ⁶¹⁵ | II OL | ≥4 ≥4 | 0 | ≥26% ^f ≥42% ^f | 0 100% ^c | 0 0 | A: Dab (n = 89) B: Dab (n = 83) | 38% (0) ^{g,h} 31% ^f (28%) ^{g,h} | 39% (7%) ^g 31% (22%) ^g | 3.8 (1.9) ^g 3.9 (3.7) ^g | | 7.7 (3.8) ^g 7.3 (5.1) ^g |
| COMBI-MB NCT02039947 ⁶¹⁶ | II, OL | 8.5 20.0 9.5 11.0 | 0 | 22% ⁱ 31% ⁱ 19% ⁱ 41% ⁱ | 0 100% ^c Some ^c Some ^c | 0 0 0 100% | A: Dab + Tram (n = 76) B: Dab + Tram (n = 16) C: Dab + Tram (n = 16) D: Dab + Tram (n = 17) | 55% 44% 75% 41% | 58% 56% 44% 59% | 5.6 7.2 4.2 5.5 | | 10.8 24.3 10.2 11.5 |

--, data not reported; Brain Met Symptoms, percent of patients with symptomatic brain metastases; OL, open-label; Prior Sys Tx, percent of patients with prior systemic treatment; Prior local brain tx, percent of patient with prior local treatment for brain metastases (ie, surgery or radiation); Tx, treatment.

^a All patients had a *BRAF* V600 mutation. *BRAF* mutations reported were V600E (83%–100%), V600K (4%–22%), or not reported.

^b Response rate is the percentage of patients that achieved complete or partial response. Median PFS and OS were determined using the Kaplan-Meier method.

^c For MO25515, the median follow-up and percent of patients with prior systemic treatment shown are for the whole patient population, not only those with brain metastases. Prior local treatment for brain metastases was allowed, but the number of patients with prior RT or surgery for brain metastases was not reported.

^d Patients with prior local treatment for brain metastases were required to have intracranial progression.

^e Trial allowed patients with symptomatic or asymptomatic brain metastases.

^f BREAK-MB included patients with up to 2 prior systemic treatments, excluding BRAF or MEK inhibitors. For cohorts A and B, respectively, 26% and 42% had prior chemotherapy, and 6% and 17% had prior immunotherapy.

^g For response, PFS, and OS from BREAK-MB, data are reported for patients with *BRAF* V600E (V600K).

^h Extracranial response was not reported for BREAK-MB. Data shown are for overall response.

ⁱ COMBI-MB included patients with up to 2 prior systemic treatments, excluding BRAF or MEK inhibitors. Prior temozolomide and adjuvant interferon were not counted as prior systemic treatments.



BRAF and MEK Inhibitor Safety

Table 21 summarizes the safety data from phase III trials comparing BRAF/MEK inhibitor combination therapy to BRAF inhibitor monotherapy. The risk of toxicity (all grade, grade 3–5) was similar for BRAF/MEK inhibitor combination therapy compared with single-agent BRAF inhibitor therapy, and BRAF inhibitor monotherapies (ie, vemurafenib, dabrafenib, encorafenib) and BRAF/MEK inhibitor combinations (ie, dabrafenib/trametinib, vemurafenib/cobimetinib, encorafenib/binimetinib), were associated with high rates of flu-like symptoms: pyrexia and chills, fatigue and asthenia, headache, various types of musculoskeletal aches and pains (eg, arthralgia, myalgia), and gastrointestinal upset (eg, diarrhea, nausea, vomiting).^{412,524,597,603,606} Whereas BRAF/MEK inhibitor combination therapy was associated with higher risk of pyrexia and diarrhea, BRAF inhibitor monotherapy was associated with higher risk of musculoskeletal complaints. Alopecia, rash, and other skin toxicities are also common across all types of BRAF-targeted therapy, but in phase III trials most of these toxicities were actually more common with BRAF inhibitor monotherapy versus BRAF/MEK inhibitor combination therapy. Hyperproliferative skin toxicities had notably higher prevalence in patients treated with BRAF inhibitor monotherapies versus BRAF/MEK inhibitor combinations, including hyperkeratosis, palmoplantar disorders, keratoacanthoma, and cutaneous squamous cell carcinoma. Due to better efficacy and a different toxicity profile, specifically lower risk for certain proliferative skin toxicities, BRAF/MEK inhibitor combination therapy is generally preferred over BRAF inhibitor monotherapy. In clinical practice across NCCN Member Institutions, the change in prescribing patterns from using BRAF inhibitor monotherapy to using BRAF/MEK inhibitor combinations has resulted in lower rates of discontinuation due to hypoproliferative skin toxicities and musculoskeletal complaints; flu-like symptoms are still very common (with BRAF/MEK inhibitor combination) but seem less likely to lead to discontinuation of treatment, especially if patients are forewarned. There are rare patients who experience certain

toxicities on BRAF/MEK inhibitor combination therapy that are thought to be attributed to MEK inhibitors (eg, deep venous thrombosis, retinal problems, concerns about immunosuppression), and in those cases discontinuation of the MEK inhibitor may be helpful. There are few data to inform selection among the BRAF/MEK inhibitor combination therapy options (ie, dabrafenib/trametinib, vemurafenib/cobimetinib, encorafenib/binimetinib), as none of the options have been directly compared.

Grade 5 toxicities were rare ($\leq 2\%$ in phase III trials) in trials testing BRAF inhibitor monotherapy or BRAF/MEK inhibitor combination therapies.^{412,593-598,603,606,607} Grade 5 AEs observed across trials included cardiovascular or cerebrovascular events (eg, brain/intracranial hemorrhage, brain ischemia, acute coronary syndrome, cardiac arrest/failure, acute myocardial infarction, pulmonary embolism), AEs related to infection (eg, pneumonia, pleural infection, sepsis), and multi-organ failure.^{412,594,596,597,603,606} It is not clear which of these grade 5 AEs were really related to treatment. In addition to those shown in Table 21, reports from multiple clinical trials have highlighted a few other rare high-grade AEs of special interest, including an assortment of ocular AEs (eg, retinopathies, blurred vision, retinal detachment, uveitis), QT prolongation, decreased ejection fraction, thrombotic events, and the development of new primary malignancies.^{92,412,525,527,603-605,607,617}

Analysis of data from the several prospective trials showed that for BRAF-targeted therapy, most AEs manifest within the first few months of therapy, although AEs continue to develop throughout treatment, albeit at a lower rate.^{525,596,604,605} There is some evidence to suggest that time to onset may be longer for BRAF/MEK inhibitor combination therapy compared with BRAF inhibitor monotherapy, at least for some types of AEs.^{604,605} In the COLUMBUS trial, median time to first occurrence of grade 3–4 toxicity was longer with encorafenib/binimetinib combination versus encorafenib or



vemurafenib monotherapy (8.4 vs. 2.8, 3.7 months).⁶⁰⁵ In Co-BRIM, some of the most common AEs had early onset in both arms (eg, pyrexia, rash, elevated creatine phosphokinase [CPK], liver function test [LFT] abnormality), whereas diarrhea was quick to develop in the cobimetinib/vemurafenib combination therapy arm, but took longer to develop in the vemurafenib monotherapy arm.⁶⁰⁴ Regardless of treatment, cutaneous squamous cell carcinoma (cSCC)/keratoacanthoma, photosensitivity, serous retinopathy, and left ventricular ejection fraction (LVEF) decline tended to have wider ranges of time to onset (and therefore longer median time to onset) than other types of AEs.⁶⁰⁴ Results from a large stage IV trial testing vemurafenib also reported that time to onset for cSCC was longer than for other types of AEs.⁵²⁵ Results from the Co-BRIM trial suggest that for these cutaneous AEs and ocular AEs, median time to onset was longer with cobimetinib/vemurafenib versus vemurafenib monotherapy.⁶⁰⁴ Time to resolution varied across different type of AEs and type of treatment, although the majority resolved within 3 months.⁶⁰⁴

Discussion
update in
progress



NCCN Guidelines Version 3.2023

Melanoma: Cutaneous

Table 21. BRAF and MEK Inhibitors: Toxicities^a

| Studies: Agent: Grade: | COMBI-d ^{b,524,603} | | COMBI-v ⁴¹² | | Co-BRIM ⁵⁹⁷ | | COLUMBUS ⁶⁰⁶ | | | | | | | | | | | |
|------------------------------|------------------------------|------------------------|------------------------|------------------------|------------------------|------------------------|-------------------------|----------------------------------|---------------------------------------|----|----|----|----|----|----|----|----|----|
| | Dab 3-5 | Dab/Tram Any 3-5 | Vem 3-5 | Dab/Tram Any 3-5 | Vem 3-5 | Vem/Cobi Any 3-5 | Vem 3-4 ^c | Encor Any 3-4 ^c | Encor/Bini Any 3-4 ^c | | | | | | | | | |
| All types | 50 | 97 | 48 | 97 | 59 | 99 | 49 | 98 | 61 | 98 | 75 | 99 | 66 | -- | 67 | -- | 64 | -- |
| General, symptomatic: | | | | | | | | | | | | | | | | | | |
| Pyrexia | 2 *** | 7 ***** | 1 ** | 4 ***** | 0 ** | 1 *** | 0 *** | 1 * | 4 ** | | | | | | | | | |
| Chills | 1 ** | 1 *** | 0 * | 1 *** | 0 * | 0 * | -- -- | -- -- | -- -- | | | | | | | | | |
| Headache | 1 *** | 1 *** | 1 ** | 1 *** | 2 ** | <1 ** | 1 ** | 3 *** | 2 *** | | | | | | | | | |
| Fatigue | 1 **** | 2 **** | 2 *** | 1 *** | 3 *** | 5 **** | 2 *** | 1 *** | 2 *** | | | | | | | | | |
| Asthenia | 1 ^b *b | <1 ^b *b | 1 ** | 1 ** | 1 ** | 2 ** | 4 ** | 3 ** | 2 ** | | | | | | | | | |
| Decreased appetite | 1 ^b *b | <1 ^b *b | 0 ** | 1 * | <1 ** | 0 ** | 1 ** | 1 ** | 0 * | | | | | | | | | |
| Peripheral edema | 1 * | 1 ** | <1 * | <1 * | <1 * | 0 * | 1 * | 0 * | 2 * | | | | | | | | | |
| Cough | 0 ** | 0 ** | 0 * | 0 ** | 0 * | 0 * | 1 * | 1 * | 1 * | | | | | | | | | |
| General, lab results: | | | | | | | | | | | | | | | | | | |
| Hypertension | 6 ** | 6 ** | 10 ** | 14 *** | 3 * | 6 ** | 3 * | 3 * | 6 * | | | | | | | | | |
| ALT increased | 1 * | 2 * | 4 ** | 3 * | 6 ** | 11 *** | 2 * | 1 * | 5 * | | | | | | | | | |
| AST increased | 1 | 3 * | 3 * | 1 * | 2 * | 9 ** | 2 * | 1 | 2 * | | | | | | | | | |
| GGT increased | -- -- | -- -- | -- -- | -- -- | 10 ** | 15 ** | 3 * | 5 * | 9 ** | | | | | | | | | |
| Blood CPK increased | -- -- | -- -- | -- -- | -- -- | <1 | 12 **** | 0 | 0 | 7 *** | | | | | | | | | |
| Blood ALP increased | -- -- | -- -- | -- -- | -- -- | 2 * | 5 ** | 1 * | 0 | 1 * | | | | | | | | | |
| Lipase increased | -- -- | -- -- | -- -- | -- -- | 1 | 3 | 1 | 1 | 2 | | | | | | | | | |
| Anaemia | -- -- | -- -- | -- -- | -- -- | 3 * | 2 ** | 3 * | 3 * | 5 ** | | | | | | | | | |
| Musculoskeletal/Pain: | | | | | | | | | | | | | | | | | | |
| Arthralgia | 0 *** | 1 *** | 4 ***** | 1 ** | 5 ***** | 2 ***** | 6 ***** | 9 **** | 1 *** | | | | | | | | | |
| Myalgia | 0 ^b *b | <1 ^b *b | 1 * | 0 ** | 2 * | <1 ** | 1 ** | 10 *** | 0 ** | | | | | | | | | |
| Pain in extremity | -- -- | -- -- | <1 * | 1 * | 2 ** | 1 * | 1 * | 1 ** | 1 * | | | | | | | | | |
| Pain | -- -- | -- -- | -- -- | -- -- | <1 | 0 | 0 | 4 * | 1 | | | | | | | | | |
| Musculoskeletal pain | -- -- | -- -- | -- -- | -- -- | <1 * | 1 | 1 * | 3 ** | 0 * | | | | | | | | | |



NCCN Guidelines Version 3.2023

Melanoma: Cutaneous

Table 21 (Continued)

| Studies: Agent: Grade: | COMBI-d ^{b,524,603} | | COMBI-v ⁴¹² | | Co-BRIM ⁵⁹⁷ | | COLUMBUS ⁶⁰⁶ | | | |
|--|------------------------------|--------------------|------------------------|------------------|------------------------|-----------------|-------------------------|--------------|--------------------------------|-----|
| | Dab 3-5 | Dab/Tram Any | Vem 3-5 | Dab/Tram Any | Vem 3-5 | Vem/Cobi Any | Vem 3-4 ^c | Encor Any | Encor/Bini 3-4 ^c | Any |
| Gastrointestinal: | | | | | | | | | | |
| Diarrhea | 1 ** | 1 *** | <1 **** | 1 *** | 1 *** | 7 ***** | 2 *** | 2 * | 3 **** | |
| Nausea | 1 *** | 1 **** | 1 **** | <1 *** | 1 *** | 1 **** | 2 *** | 4 **** | 2 **** | |
| Vomiting | 1 * | 1 *** | 1 ** | 1 *** | 1 * | 2 *** | 1 ** | 5 *** | 2 *** | |
| Constipation | 0 ^b *b | <1 ^b *b | <1 * | 0 * | 0 * | 0 * | 1 * | 0 ** | 0 ** | |
| Cutaneous: | | | | | | | | | | |
| Rash | 1 ** | 0 *** | 9 **** | 1 ** | 6 **** | 5 **** | 3 *** | 2 ** | 2 * | |
| Pruritis | 0 ^b *b | 0 ^b *b | 1 ** | 0 * | <1 ** | 1 ** | 0 * | 1 ** | 1 * | |
| Rash maculo-papular | -- -- | -- -- | -- -- | -- -- | 5 ** | 7 ** | 4 * | 1 * | 0 | |
| Rash generalized | -- -- | -- -- | -- -- | -- -- | 1 | <1 | 4 * | 1 * | 0 | |
| Alopecia | 0 *** | 1 * | <1 **** | 0 * | <1 *** | <1 ** | 0 **** | 0 ***** | 0 * | |
| Dry skin | 0 ^b *b | 0 ^b *b | <1 ** | 0 * | 0 ** | 1 ** | 0 ** | 0 *** | 0 ** | |
| Hyperkeratosis | 1 **** | 0 * | 1 ** | 0 | 2 *** | <1 * | 0 *** | 4 **** | 1 ** | |
| Keratosis pilaris | -- -- | -- -- | 0 * | 0 | 0 * | 0 | 0 ** | 0 ** | 0 | |
| Palmoplantar erythrodysesthesia syndrome | -- -- | -- -- | <1 ^d *** | 0 ^d d | <1 | 0 * | 1 * | 14 **** | 0 * | |
| Palmoplantar keratoderma | 1 ** | 1 * | 0 * | 0 | 0 * | 0 | 1 ** | 2 *** | 0 * | |
| Skin papilloma | 0 ** | 0 | 1 ** | 0 | <1 * | 0 * | 0 ** | 0 * | 0 * | |
| Photosensitivity reaction | 0 | 0 | <1 ** | 0 | 0 ** | 3 *** | 1 ** | 0 | 1 | |
| Keratoacanthoma | 1 * | 2 | -- -- | -- -- | 9 * | 1 | 3 * | 0 * | 1 | |
| cSCC | | | <1 | 0 | 13 * | 4 | 4 * | 0 | 0 | |
| Basal cell carcinoma | 1 * | 3 | -- -- | -- -- | 2 | 6 * | 1 | 1 | 0 | |

--, data not reported; ALT, alanine aminotransferase; ALP, alkaline phosphatase; AST, aspartate aminotransferase; CPK, creatinine phosphokinase; cSCC, cutaneous squamous cell carcinoma; GGT, gamma-glutamyl transferase.

^a AE rates shown are for all AEs, regardless of whether or not they were treatment related. Table includes all AEs that occurred in >20% of patients or as high grade (grade 3-4 of 3-5) in >3% of patients in any arm in any of the four trials shown. Values are percent of patients who experienced at least one AE of any grade, grade 3-4 or grade 3-5. For the any grade column, the percent of patients affected by specific AEs (any grade) was rounded to the nearest 10%, then assigned one asterisk (*) for every 10% of patients effected. Blank indicates that <5% of patients experienced that AE.

^b For AEs not reported in Long 2017,⁶⁰³ data from Long 2014⁵²⁴ are shown. COMBI-d data are from Long 2017⁶⁰³ unless otherwise noted.

^c In the COLUMBUS trial, toxicities leading to death were not recorded as CTCAE Grade 5 AEs, but instead were assigned grade 1 to 4 based on severity prior to death.

^d In COMBI-v, palmar-plantar erythrodysesthesia, plantar-palmar hyperkeratosis, and palmoplantar keratoderma were reported as a combined term "hand-foot syndrome."



NCCN Guidelines Version 3.2023

Melanoma: Cutaneous

Other Targeted Therapies: Imatinib

KIT mutations have been associated most commonly with mucosal and acral subtypes of melanoma.²² Phase II studies testing imatinib or nilotinib, inhibitors of mutated *KIT*, in patients with *KIT*-mutated or *KIT*-amplified metastatic melanomas demonstrated 17% to 30% ORR and 35% to 57% disease control rate.^{96-98,618-620} Unfortunately, most of these responses were of limited duration. These phase II studies included a significant portion of patients with non-cutaneous melanoma (29%–71% mucosal). The results show trends toward better response for patients with *KIT* mutations versus amplifications alone, and in some studies trends toward better response in mucosal melanoma compared with acral/CSD subtypes.^{97,98,618} Like BRAF inhibitors, patient selection by molecular screening is essential to identify patients who might potentially benefit; previous studies on unselected patients yielded no meaningful responses.^{621,622}

Interleukin-2

High-dose IL-2 has been used extensively to treat metastatic melanoma in first-line and second-line settings. Although ORRs are modest (<20%), those who achieve a complete response (<10%) tend to have extremely durable responses and high rates of long-term survival.⁶²³⁻⁶²⁷ Thus, although median OS is usually 11 to 12 months, approximately 10% of patients achieve long-term survival (>5 years).^{623,625-629} In one retrospective analysis of 305 patients who received IL-2 monotherapy for previously treated measurable metastatic disease, complete response was achieved in 4%, with median duration of response >176 months (range, 12 months to >253 months).⁶²³ Of the 12 patients with complete response, 10 survived at least 13 years. A retrospective comparative study found that response rate for high-dose IL-2 was higher among patients with prior ipilimumab treatment compared with patients with no prior immune checkpoint inhibitor therapy (ORR 21% vs. 12%).⁶³⁰

High-dose IL-2 is associated with significant toxicities. Safe and effective administration requires careful selection of patients, close monitoring, and adherence to administration and AE management protocols.⁶³¹ High-dose IL-2 therapy should be restricted to institutions with medical staff experienced in the administration and management of these regimens.

Cytotoxic Therapy

Common cytotoxic agents being used in patients with metastatic melanoma include dacarbazine,^{632,633} temozolomide,⁶³³ and paclitaxel with or without carboplatin.⁶³⁴⁻⁶³⁸ These have demonstrated modest response rates less than 20% in first-line and second-line settings. Although early clinical trials suggested that nab-paclitaxel may provide higher response rates (22%–26% in phase II trials among chemotherapy-naïve patients with metastatic melanoma),^{639,640} a phase III trial of patients with chemotherapy-naïve stage IV melanoma showed that nab-paclitaxel did not result in higher rates of response compared with dacarbazine (15% vs. 11%; $P = .239$).⁶⁴¹ This and other phase III randomized trials comparing chemotherapy regimens have failed to identify any regimens that provide both better response and OS relative to their counterparts.^{633-635,641,642} A randomized phase III trial in patients with chemotherapy-naïve metastatic melanoma showed that selection of combination chemotherapy regimen based on an ex-vivo sensitivity assay did not improve response rate, PFS, or OS compared with dacarbazine monotherapy, but instead resulted in much higher rates of grade 3–4 AEs (40% vs. 12%; $P < .001$).⁶⁴³

Little consensus exists regarding optimal standard chemotherapy for patients with metastatic melanoma, which most likely reflects the low level of activity of older FDA-approved agents and equivocal results from comparative phase III trials.^{642,644}



Radiation Therapy for Extracranial Metastases

Palliative Radiation Therapy for Symptomatic Extracranial Metastases

Contrary to common perception that melanoma is radio-resistant, radiation often achieves palliation of symptomatic metastatic disease, including palliation of visceral, bone, and CNS metastases.⁶⁴⁵⁻⁶⁴⁸ Clinically significant regression of radiated lesions of up to 60% has been reported in carefully selected patients.^{649,650} A variety of treatment regimens are acceptable depending on location and/or clinical indication. Higher doses and/or hypofractionated regimens may be associated with more durable palliation.^{646,648} Potential regimens with supporting citations can be found in the *Principles of Radiation Therapy for Melanoma* in the algorithm.^{647,649,651,652}

Ablative Treatment for Extracranial Metastases

Higher doses utilizing conformal techniques such as stereotactic body radiation therapy (SBRT) may offer more durable local control and freedom from regional or distant progression.⁶⁵³⁻⁶⁵⁵ SBRT may be used in selected patients with oligometastasis.⁶⁵³ This potential benefit must be weighed against potential toxicities, and strict adherence to normal tissue constraints is recommended. Examples of dosing regimens for SBRT of the spine and for other body sites, along with supporting citations, are listed in the *Principles of Radiation Therapy for Melanoma* in the algorithm.

Radiation for Brain Metastases

SRS is gaining importance in the management of CNS metastases from melanoma. Retrospective studies have shown 1-year local tumor control rates from 72% to 100% for patients with limited CNS disease, but lower rates for patients with multiple or large (>2 cm) tumors.⁶⁵⁶⁻⁶⁶¹ With the increasing use of stereotactic radiation, the value of WBRT in patients with melanoma brain metastases is increasingly unclear and controversial. Virtually all the information available about the impact of RT for melanoma

brain metastases comes from retrospective studies. It is almost impossible to separate out the impact of patient selection from the effect of treatment. Results from recent retrospective studies comparing patients who received SRS versus those who received WBRT are especially compromised by selection bias because WBRT is more likely to be used in patients with more extensive disease.^{661,662} In clinical practice, the use of SRS in patients with a limited number of small brain tumors is gaining wider acceptance because studies have demonstrated late adverse effects of WBRT on cognitive function.^{361,663-665} Prospective randomized studies are needed to determine the best approach to radiation for melanoma brain tumors.

Combining Radiation with Systemic Therapy

Some systemic therapy regimens may increase toxicity when given concurrently with radiation. A number of case studies have reported that BRAF inhibitors vemurafenib and dabrafenib have radiosensitizing effects,⁶⁶⁶⁻⁶⁷⁴ and a retrospective analysis by Hecht and colleagues⁶⁷⁵ found that 57% of 70 patients receiving concomitant therapy experienced acute or late toxicities. Case reports indicate that radiosensitization reactions can also occur in patients treated with RT and subsequent BRAF inhibition.⁶⁷²⁻⁶⁷⁴ Radiodermatitis was the most common of these toxicities, with acute events (grade ≥2) occurring in 36% of patients treated with concomitant RT plus dabrafenib or vemurafenib.⁶⁷⁵ Acute dermatitis has also been reported in patients treated with WBRT and BRAF inhibitor therapy (either concurrent or sequential).^{670,671} In the retrospective study by Hecht and colleagues,⁶⁷⁵ BRAF inhibitor therapy was associated with increased risk of acute dermatitis among patients treated with WBRT (44% vs. 8%; $P = .07$). In contrast, a retrospective study by Gaudy-Marqueste and colleagues⁶⁷⁶ found no evidence of radiodermatitis in 30 patients who received SRS and BRAF inhibitor therapy. A variety of other toxicities have been reported to be associated with RT plus BRAF inhibitor



NCCN Guidelines Version 3.2023

Melanoma: Cutaneous

treatment; those reported in more than one patient include follicular cystic proliferation (13%), hearing disorder (4%), and dysphagia (2%).

Results from retrospective studies suggest that for patients with metastatic melanoma (including brain metastases), combining checkpoint immunotherapy (ipilimumab or nivolumab) with radiation of CNS or non-CNS metastases does not significantly increase the risk of toxicity.^{139,677-683}

However, multiple retrospective studies on ipilimumab and one on nivolumab failed to show that adding checkpoint immunotherapy provided additional clinical benefit in patients receiving RT for brain metastases, at least in terms of response rates and OS.^{139,677,678,681,684} Several analyses found that concurrent or close proximity of RT and systemic therapy treatment improved response rates and OS, although results are inconsistent regarding the optimal order of administration.^{677,679,682,685}

Abscopal responses in non-irradiated tumors have been observed, but prospective trials are needed to confirm these effects because the delayed kinetics of ipilimumab response complicate interpretation of retrospective data.^{679,686-688}

NCCN Recommendations for Distant Metastatic Disease

Multidisciplinary tumor board consultation is encouraged for patients with stage IV metastatic melanoma. Treatment depends on whether disease is limited (resectable) or disseminated (unresectable) as outlined below.

Recommendations for Limited Metastatic Disease

For limited metastatic disease, options include resection, if feasible, or systemic therapy. Observation is no longer a recommended option, even for patients with very limited stage IV disease, now that there are more effective active treatment options available. Systemic treatment should be followed by repeat scans to rule out the possibility that the disease is not more widespread, and to better select patients for surgical intervention.

Following systemic therapy, patients with resectable disease should be reassessed for surgery.

If completely resected, patients with no evidence of disease (NED) can be observed or offered adjuvant treatment. The choice of adjuvant systemic treatment versus observation should take into consideration the patient's risk of melanoma recurrence and the risk of treatment toxicity. The recommended adjuvant treatment options are described in *Adjuvant Systemic Therapy for Melanoma*.

Patients with residual disease following incomplete resection for limited metastases should be treated as described below for disseminated disease.

Recommendations for Disseminated Disease

Disseminated disease can be managed by one or more of the following options, depending on the location of and extent of metastatic disease: clinical trial, systemic therapy, local treatment, or best supportive care (see the [NCCN Guidelines for Palliative Care](#)). For all systemic therapy options, consult the prescribing information for dosing recommendations. A number of options are available for systemic therapy, as described in the next two sections.

For extracranial metastases, local treatment options may include intralesional injection with T-VEC, resection, or radiation. T-VEC can be injected into nodal or distant metastases to help with disease control, but the impact on survival is not known. It may be useful for patients with very limited stage IV disease, or in combination with other treatment modalities. Symptomatic extracranial metastases can be managed with palliative resection and/or radiation. Radiation can be used for palliation of visceral, bone, and CNS metastases. Recommended techniques and dosing for different body sites, along with supporting citations, are listed in the *Principles of Radiation Therapy for Melanoma* in the algorithm.



NCCN Guidelines Version 3.2023

Melanoma: Cutaneous

For brain metastases, recommended localized treatment options and considerations for selecting systemic therapy are described in *Treatment of Patients with Brain Metastases*.

For patients considering multi-modality therapy for disseminated disease, interactions between radiation therapy and systemic therapies (eg, BRAF inhibitors, IFN alfa-2b, immune checkpoint inhibitors) need to be very carefully considered as there is potential for increased toxicity, particularly when utilizing higher doses of radiation. Because BRAF and/or MEK inhibitors may interact with radiation, consideration should be given to holding BRAF and/or MEK inhibitors ≥ 3 days before and after fractionated radiation therapy and ≥ 1 day before and after SRS (or other high-dose-per-fraction regimens).⁶⁸⁹

Except for patients rendered NED by surgery, all patients undergoing active treatment for distant metastatic disease should be regularly assessed for response or progression, both by clinical exam and imaging. Recommended imaging modalities are the same as for initial workup, as described in *General Guidelines for Imaging in Patients with Melanoma*.

Recommendations for Systemic Therapy

Recommendations for First-line Systemic Therapy

For first-line therapy of unresectable or distant metastatic disease, recommended treatment options include immune checkpoint inhibitors, BRAF-targeted therapy for patients with an activating *BRAF* V600 mutation, or clinical trial.

Immune checkpoint inhibitor options in this setting include anti-PD-1 monotherapy with pembrolizumab (category 1) or nivolumab (category 1) or nivolumab/ipilimumab combination therapy (category 1). Immune checkpoint inhibitors have been shown to be effective regardless of *BRAF* mutation status. The NCCN Panel considers all recommended immune checkpoint inhibitor options appropriate for both *BRAF* mutant and *BRAF*

wild-type metastatic disease. The use of PD-L1 as a biomarker for selection of anti-PD-1 therapy and/or nivolumab/ipilimumab combination therapy is an emerging research issue with non-uniform application among the NCCN Member Institutions (category 2B). Descriptive analyses suggest that patients with low PD-L1 expression may benefit from nivolumab/ipilimumab combination therapy relative to nivolumab monotherapy. These analyses showed that patients with high PD-L1 expression may not benefit from addition of ipilimumab to nivolumab, and would do just as well on nivolumab monotherapy, and avoid the increased risk of toxicity associated with combination therapy.

Although ipilimumab is FDA approved for treatment of unresectable or metastatic melanoma, including both treatment-naïve and previously treated disease, single-agent ipilimumab monotherapy is no longer an NCCN-recommended first-line therapy option due to the results from the CheckMate 067 phase III trial showing improved outcomes with anti-PD-1 monotherapy or nivolumab/ipilimumab combination therapy compared with ipilimumab monotherapy.

Selection between anti-PD-1 monotherapy and nivolumab/ipilimumab combination therapy should be informed by the consideration that, although combination therapy may improve PFS relative to nivolumab monotherapy, it is associated with a much higher risk of serious immune-mediated toxicities compared with nivolumab monotherapy. Treatment selection should therefore be informed by consideration of the patient's overall health, medical history, concomitant therapies, comorbidities, and compliance with proactive monitoring and management of AEs. Relative indications for combination nivolumab/ipilimumab in comparison to PD-1 monotherapy include: patient willingness to take on high risk of irAEs; absence of comorbidities or auto-immune processes that would elevate the risk of irAEs; patient social support and anticipated compliance with



NCCN Guidelines Version 3.2023

Melanoma: Cutaneous

medical team to handle toxicities; and absent/low tissue PD-L1 expression.

For patients with unresectable or distant metastatic disease harboring a *BRAF* V600-activating mutation, *BRAF*-targeted therapy first-line options include *BRAF*/MEK inhibitor combination therapy with dabrafenib/trametinib, vemurafenib/cobimetinib, or encorafenib/binimetinib. All of these regimens are category 1 options based on results from phase 3 trials in the first-line setting (ie, COMBI-d, COMBI-v, CoBRIM, COLUMBUS). Although vemurafenib and dabrafenib are FDA approved as single-agent therapy for treatment of patients with distant metastatic or unresectable melanoma with *BRAF* V600E mutation,^{397,398} these agents are almost never given without concomitant MEK inhibition. *BRAF*/MEK inhibitor combination therapy has been shown to have superior response rate, PFS, and OS compared with *BRAF* inhibitor monotherapy, as well as a similar or better toxicity profile, so the NCCN Panel recommends *BRAF* inhibitor monotherapy only in those rare cases where combination therapy is contraindicated. In such cases, *BRAF* inhibitor monotherapy remains a treatment option especially if the patient is not an appropriate candidate for immune checkpoint inhibitor therapy. Dabrafenib/trametinib, vemurafenib/cobimetinib, and encorafenib/binimetinib combination therapy regimens are FDA approved for the treatment of patients with unresectable or distant metastatic melanoma with *BRAF* V600E or V600K mutations, as detected by an FDA-approved test.^{397-401,690} The Cobas 4800 *BRAF* V600 mutation test, a test for detecting the *BRAF* V600E mutation, received FDA approval as a companion diagnostic for selecting patients for treatment with vemurafenib. The THxID *BRAF* Kit, a test for detecting *BRAF* V600E or V600K mutations, received FDA approval as a companion diagnostic for selection of patients for treatment with dabrafenib and trametinib. The NCCN Panel recommends that *BRAF* mutational status should be tested using an FDA-approved test or by a facility approved by the Clinical

Laboratory Improvement Amendments (CLIA). Positive immunohistochemistry (IHC) staining of tumor for VE1 is sufficient for starting targeted therapy in patients who are symptomatic or have rapidly progressing disease. Due to risk of false positives and false negatives, all VE1 IHC results, both positive and negative, should be confirmed by sequencing. The NCCN Panel recommends that tissue for genetic analysis be obtained from either biopsy of a current metastasis (preferred) or from archival material. The NCCN Panel considers *BRAF*/MEK inhibitor combination therapy (or single-agent *BRAF* inhibitor therapy if combination therapy is contraindicated) as appropriate treatment options for metastatic disease with any type of activating *BRAF* V600 mutation (includes V600E, V600K, V600R, V600D, and others). Although trametinib is FDA approved for single-agent use to treat patients with unresectable or metastatic melanoma with *BRAF* V600E mutation,³⁹⁹ trametinib monotherapy is no longer an NCCN-recommended treatment option due to relatively poor efficacy compared with *BRAF* inhibitor monotherapy and *BRAF*/MEK inhibitor combination therapy.

For patients with documented *BRAF* V600 mutations, selection between first-line immune checkpoint inhibitors or *BRAF*-targeted therapy can be difficult given the lack of comparative phase III clinical trials. Clinical trials are underway to address unanswered questions regarding the optimal sequencing and/or combination of these agents. The recommendation for first-line systemic therapy should be informed by the tempo of disease, the presence or absence of cancer-related symptoms, and the patient's personal history of autoimmune disease or estimated risk (based on family history) of triggering autoimmunity by immunotherapy. Given that responses to immune checkpoint inhibitors can take longer to develop, *BRAF*-targeted therapy may be preferred in cases where the disease is symptomatic or rapidly progressing or the overall health of the patient appears to be deteriorating. Other patients with asymptomatic metastatic melanoma may be good candidates for immune checkpoint inhibitor



therapy, as there may be time for a durable antitumor immune response to emerge. Safety profiles and AE management approaches differ significantly for BRAF-targeted therapy versus immune checkpoint inhibitor therapy; treatment selection should therefore be informed by consideration of the patient's overall health, medical history, concomitant therapies, comorbidities, and compliance.

When to Discontinue Treatment or Switch Systemic Therapy

Consistent with the FDA prescribing information, the NCCN Panel recommends discontinuing systemic therapy in cases of unacceptable toxicity. If there is residual disease at the time of discontinuation, it is recommended to switch to a different class of therapy. See *Guidelines for Therapy Selection in Previously Treated Patients*.

All patients undergoing systemic therapy for distant metastatic disease should be regularly assessed for response or progression, both by clinical exam and imaging. Recommended imaging modalities are the same as for initial workup, as described in *General Guidelines for Imaging in Patients with Melanoma*.

The NCCN Panel believes that a switch in systemic therapy is appropriate if there is confirmed disease progression during or after the course of systemic therapy. Additionally, for those treated with BRAF-targeted therapy who have achieved maximum clinical benefit (but not complete remission), a switch to immune checkpoint inhibitor therapy may be considered. Although there is no standard definition for maximum clinical benefit, it is commonly defined as no additional tumor regression on at least 2 consecutive scans taken at least 12 weeks apart. However, for patients on BRAF-targeted therapy with limited subsequent treatment options (ie, those who have already failed or are ineligible for immune checkpoint inhibitor therapy), it is not unreasonable to continue BRAF-targeted therapy beyond confirmation of partial response or stable disease, as changing to less effective treatments may result in disease

progression. The optimal duration to administer BRAF-targeted therapy after achieving a durable complete response, partial response, or stable disease is not known.

For patients treated with immune checkpoint inhibitors, late responses or late improvements in response may occur. Some panel members may occasionally continue immune checkpoint inhibitor treatment beyond progression, as development of response after initial progression (sometimes referred to as “pseudo-progression”) has been described. Therefore, in patients treated with immune checkpoint inhibitors it is recommended that progression be confirmed before deciding to switch to a different type of therapy. This is especially important in patients with limited options for subsequent therapy (ie, those who are *BRAF*-V600 wild-type). For patients who achieve complete response, partial response, or stable disease while on an immune checkpoint inhibitor, the optimal duration to administer therapy after achieving best clinical response remains unknown. Although exploratory analyses of prospective trials show high durability of responses long after discontinuation of immune checkpoint inhibitor therapy, there are no prospective randomized trial data comparing treatment for a defined duration versus ongoing treatment after best clinical response is achieved. Absent high-quality prospective data, there is a wide range of clinical practice.

Recommendations for Second-line or Subsequent Therapy

For patients with previously treated distant metastatic disease, data on the efficacy and safety of specific systemic therapies are in general less robust than data in the first-line setting. For a wide variety of agents there are prospective data demonstrating activity in previously treated patients, but prospective trials comparing these options are limited, and largely included patients whose previous therapies did not include the BRAF-targeted and immune checkpoint inhibitor options that are now preferred for first-line therapy. Interpretation of data from this setting is challenging because the patient population is highly heterogenous in terms of the



NCCN Guidelines Version 3.2023

Melanoma: Cutaneous

number and types of previous systemic therapies received, location and extent of metastatic disease, and speed of progression (symptomatic or not). Given the lack of high-quality data and the wide array of scenarios that present in the clinic, the NCCN Panel lists a large number of acceptable options for second-line or subsequent systemic therapy, with the general recommendation to consider therapies whose mechanism of action differs from prior lines of therapy that resulted in poor response or disease progression. The sections below first describe the rationale for including each of the options listed for second-line or subsequent systemic therapy, and then discuss recommendations for selecting among these options.

Options for Second-line or Subsequent Systemic Therapy

BRAF-Targeted Therapies and Immune Checkpoint Inhibitors

Based on the positive results from phase III trials supporting the recommended first-line therapies, the following immune checkpoint inhibitors and BRAF-targeted therapy regimens have been incorporated into the guidelines as options for second-line or subsequent systemic therapy for qualifying patients: nivolumab, pembrolizumab, nivolumab/ipilimumab combination, dabrafenib/trametinib, vemurafenib/cobimetinib, or encorafenib/binimetinib combination. Due to lack of phase III trial data in patients with previously treated metastatic disease, however, these regimens are category 2A (rather than category 1) recommended options for second-line or subsequent systemic therapy. As described in previous sections, results from phase I/II trials in patients with previously treated advanced disease support second-line or subsequent systemic therapy for some of these options (eg, vemurafenib/cobimetinib, dabrafenib/trametinib, pembrolizumab). Use of nivolumab monotherapy in previously treated patients is supported by phase III trial data in this setting (Checkmate 037), although the results were less robust than those seen in the first-line setting. As in the first-line setting, BRAF inhibitor monotherapy is only recommended in the context

of contraindications to BRAF/MEK inhibitor combination therapy; BRAF-targeted therapy (BRAF inhibitor monotherapy or BRAF/MEK inhibitor combination therapy) is only recommended for patients with *BRAF* V600-activating mutations, and there is no panel consensus on use of PD-L1 expression as a biomarker for selection of anti-PD-1 therapy (monotherapy or nivolumab/ipilimumab combination). See *Recommendations for First-line Systemic Therapy* for guidance on *BRAF* mutation testing.

Although the Checkmate 067 trial showed ipilimumab to have inferior response rate, PFS, and OS compared with nivolumab/ipilimumab combination and compared with nivolumab monotherapy, this trial included only patients with no previous systemic therapy for advanced disease. It is unclear whether the results would be the same in patients who had progressed on prior systemic therapy, particularly if previous lines of treatment included immune checkpoint inhibitors. For this reason, ipilimumab is included among the acceptable options for systemic therapy in previously treated patients. In addition, there are several prospective trials that demonstrated ipilimumab activity in patients with previously treated unresectable stage III/IV melanoma, although previous treatments did not include BRAF-targeted therapy or immune checkpoint inhibitors.

Interleukin-2

Although associated with significant risk of severe toxicity, IL-2 remains an option in the second-line or subsequent setting because it can provide long-term survival for the small percent of patients (<10%) with complete response.⁶²³⁻⁶²⁷ Due to the low response rate and high toxicity, however, IL-2 is not a preferred option as it is considered less safe and less effective than immune checkpoint inhibitors or BRAF-targeted therapy options.

T-VEC ± Ipilimumab



NCCN Guidelines Version 3.2023

Melanoma: Cutaneous

Based on the results from a randomized phase II trial showing that intralesional T-VEC improved response rate in patients treated with systemic ipilimumab,⁵⁷⁰ this combination is listed as an option for patients with injectable metastases. Because results of the trial did not demonstrate improved PFS or OS, ipilimumab/T-VEC combination therapy is a category 2B recommendation, only listed as an option for second or subsequent-line therapy (not first-line therapy), and is not a preferred option. Although anti-PD-1 therapy is generally preferred over ipilimumab, the NCCN Panel voted not to include combination therapy with T-VEC plus systemic anti-PD-1 therapy as a recommended option, both because there are insufficient randomized trial data on this specific combination, and because the effect of adding T-VEC to ipilimumab was fairly modest.

Imatinib

Activating *KIT* mutations are rare in patients with cutaneous melanoma, but for those who have them, imatinib may be helpful for disease control. Among patients with activating *KIT* mutations, fewer than half responded to imatinib, and randomized trials to assess impact on PFS and OS have not been conducted.⁹⁶⁻⁹⁸ For these reasons imatinib is not listed as a preferred agent, even for patients with qualifying mutations, but may be useful for those who are ineligible for or unresponsive to more effective therapies (ie, immune checkpoint inhibitors, BRAF-targeted therapy).

Cytotoxic Therapy

Given that randomized trials have demonstrated that immune checkpoint inhibitors and BRAF-targeted regimens are all more effective than chemotherapy, cytotoxic therapy is not among the preferred options for systemic therapy, even in previously treated patients. For those who have failed or are ineligible for more effective options, however, cytotoxic therapy may be considered. Remarkable responses to cytotoxic therapies are occasionally observed, and these approaches can help with disease control or to reduce tumor load.

Best Supportive Care

Given the number of effective options to choose from, active treatment is appropriate for most patients. Best supportive care is usually reserved for those with very poor performance status, who have experienced progression despite multiple lines of therapy, and are ineligible for the preferred systemic treatment options.

Guidelines for Therapy Selection in Previously Treated Patients

Selection of second-line or subsequent systemic therapy remains a significant challenge due to the lack of prospective randomized comparisons in this setting and the fact that much of the data are from patients whose prior therapies did not include those currently recommended as first-line options (ie, BRAF/MEK inhibitor combination, anti-PD-1 monotherapy, ipilimumab/nivolumab combination therapy). As part of an NCCN initiative to provide guidance on treatment selection considering the evidence, relative efficacy, toxicity, and other factors that play into treatment selection, the NCCN Melanoma Panel has categorized all recommended systemic therapy regimens as “preferred,” “other recommended,” or “useful under certain circumstances.” For second-line or subsequent systemic therapy for advanced disease, preference stratification is particularly challenging because preference is highly dependent upon the details of each patient’s clinical history. Many case-specific factors should be considered when selecting second-line therapy, including response and toxicities on prior therapies, rate of progression of the underlying disease (symptomatic or not), presence or absence of CNS progression, the presence of symptoms, patient physiologic reserve, and patient preference and compliance.

In general, if a patient experienced progression of melanoma during or shortly after a systemic therapy, re-challenge with the same therapy or therapy of the same class is unlikely to yield a response and is not recommended. The exception to this rule is that for patients who progressed on single-agent immune checkpoint inhibitor therapy,



NCCN Guidelines Version 3.2023

Melanoma: Cutaneous

nivolumab/ipilimumab combination therapy is a reasonable treatment option. In addition, although anti-CTLA-4 (ipilimumab) and anti-PD-1 (ie, nivolumab, pembrolizumab) agents are both immune checkpoint inhibitors, they are not considered the same class of agent because they target different molecules. Therefore, for patients who previously received ipilimumab, subsequent treatment with anti-PD-1 therapy is a recommended option, and vice versa. Given that for both immune checkpoint inhibitors and BRAF-targeted therapy there are data showing responses upon rechallenge, the NCCN Panel recommends that, for patients who experience disease control (complete response, partial response, or stable disease) and have no residual toxicity, but subsequently experience disease progression/relapse >3 months after treatment discontinuation, re-induction with the same agent or same class of agents may be considered.

Immune Checkpoint Inhibitor Administration

For all systemic therapy options, consult the prescribing information for dosing recommendations.

Treatment-related AEs occur in a high percentage of patients treated with anti-CTLA-4 or anti-PD-1 agents, and grade 3–4 related AEs occur in as many as 22% of patients receiving anti-PD-1 therapy, 20% to 30% of patients receiving ipilimumab monotherapy, and in 50% to 60% of patients receiving nivolumab/ipilimumab combination therapy. Careful selection of patients and AE monitoring and management are therefore critical to safe administration of all of these agents. Among other factors, patient selection should take into consideration age, comorbidities (eg, disease processes whose manifestations might be confused with immune-related toxicities), concomitant medications (eg, immunosuppressive therapies), and overall performance status. Patients with underlying autoimmune disorders are generally excluded from treatment with immune checkpoint inhibitors.

Close monitoring of potentially lethal irAEs in patients receiving immune checkpoint inhibitors is essential. In addition to proactive questioning of symptoms, patient and nursing education and frequent communication with the care team are essential for identifying and effectively managing irAEs. Recommendations for monitoring and management immune-related toxicities associated with immune checkpoint inhibitors are summarized in the [NCCN Guidelines for Management of Immunotherapy-Related Toxicities](#). There are two broad categories of irAE monitoring and management: one for ipilimumab-containing regimens and one for anti-PD-1 monotherapy. Clinicians need to educate themselves about the pattern of toxicities and recognition of these toxicities, as well as management strategies. Formal training programs are strongly recommended, along with careful and frequent consultation of 1) the [NCCN Guidelines for Management of Immunotherapy-Related Toxicities](#)⁶⁹¹ and the relevant package inserts³⁹⁴⁻³⁹⁶; 2) other FDA-approved materials with detailed descriptions of the signs and symptoms of irAEs associated with ipilimumab and detailed protocols for management⁶⁹²; and 3) standard institutional protocols for monitoring and managing irAEs, with multidisciplinary input among various specialists as warranted.

Prevention and Management of BRAF Inhibitor Toxicities

Fever is common in patients receiving BRAF-targeted therapy, and is often episodic, with onset often 2 to 4 weeks following the start of therapy. Pyrexia may be associated with chills, night sweats, rash, dehydration, electrolyte abnormalities, and hypotension. Pyrexia should be managed by treatment discontinuation and use of anti-pyretics such as acetaminophen and/or NSAIDs. Stopping or holding BRAF/MEK inhibitor therapy at the onset of pyrexia will often interrupt the episode. After resolution of fever and pyrexia-related symptoms, resumption of BRAF/MEK inhibitor treatment at reduced dose may be tried. Upon re-exposure, repeat pyrexia events can occur. Patients treated with BRAF-targeted therapy should



NCCN Guidelines Version 3.2023

Melanoma: Cutaneous

also be educated to report joint pain and swelling, visual changes, and cutaneous manifestations. Patients who develop skin complications should be promptly referred to a dermatologist for management and monitoring. Patients should be advised about the possibility of photosensitivity associated with these agents, and counseled to minimize UV exposure, wear UV-protective clothing, and use high-SPF sunblock.

BRAF and/or MEK inhibitors may interact with radiation and can lead to increased CNS, pulmonary, dermatologic, and visceral toxicity. Consideration should be given to holding BRAF and/or MEK inhibitors ≥ 3 days before and after fractionated RT and ≥ 1 day before and after SRS (or other high-dose per fraction regimens).

Management of Interleukin-2 Toxicities

Caution is warranted in the administration of high-dose IL-2 due to the high degree of toxicity reported. If IL-2 is considered, the NCCN Panel recommends patients to receive treatment at institutions with relevant expertise. Contraindications for IL-2 include inadequate organ reserve, poor performance status, and untreated or active brain involvement. Additionally, panelists raised concerns over potential synergistic toxicities between ipilimumab and high-dose IL-2 therapy, especially in the gastrointestinal tract.

Recommendations for Treatment of Patients with Brain Metastases

For patients with brain metastases, treatment of the CNS disease usually takes priority in an effort to delay or prevent intratumoral hemorrhage, seizures, or neurologic dysfunction. Treatment of melanoma brain metastases is based on symptoms, number of lesions present, and location of the lesions, as described in the [NCCN Guidelines for Central Nervous System Cancers](#). SRS and/or WBRT may be administered either as the primary treatment or as an adjuvant following surgical resection. Compared with WBRT, SRS may have better long-term safety and allow earlier documentation of stable CNS disease, thus allowing earlier access

to systemic agents and clinical trials that require stable CNS disease. For patients with *BRAF* mutation who present with systemic and CNS disease, BRAF or BRAF/MEK inhibitor systemic therapy is sometimes offered as first-line therapy, with radiation used as consolidation as needed. After treatment of the brain, options for management of extracranial sites are the same as for patients without brain metastases. Ipilimumab therapy is associated with the potential for long-term disease control outside the CNS.

In patients with both brain and extracranial metastases, systemic therapy may be administered during or after treatment of the CNS disease, with the exception of high-dose IL-2, which has low efficacy in patients with previously untreated brain metastases and which may worsen edema surrounding the untreated metastases. There is disagreement on the value of IL-2 therapy in patients with small brain metastases but no significant peritumoral edema; IL-2 may be considered in selected cases (category 2B). Interactions between RT and systemic therapies need to be very carefully considered as there is potential for increased toxicity, particularly with concurrent or sequential BRAF-targeted therapy and radiation.

Follow-up

In the absence of clear data, opinions vary widely regarding the appropriate follow-up of patients with melanoma. There is debate about the appropriate surveillance methods and frequency of exams or other tests. As yet, there are no data to support that pre-symptomatic detection of visceral metastasis improves patient outcomes. While the obvious immediate clinical goal for ongoing surveillance of patients with NED is for identification of relapse or a second primary melanoma, it is important to consider the long-term impact of ongoing surveillance in terms of improved survival, patient quality of life, and exposure to risks associated with some surveillance methods.⁶⁹³⁻⁶⁹⁵



NCCN Guidelines Version 3.2023

Melanoma: Cutaneous

Surveillance Modalities

Modalities that have been tested for follow-up in melanoma patients include patient self-exam or reporting of symptoms, clinical physical exam, blood tests, and various imaging modalities (eg, chest x-ray, ultrasound, CT, PET/CT, MRI). The utility of these modalities has been evaluated in retrospective and observational studies terms of the proportion of lesions (recurrences and second primary melanomas) detected by the surveillance methods employed. These studies have shown that most recurrences are detected by the patient or during physical exam in the clinic. The proportion of recurrences detected by patients varies across studies (17%–67%), as does the proportion of recurrences detected by physician's physical exams (14%–55%), but clearly both of these modalities are essential for effective surveillance during follow-up.⁶⁹⁶⁻⁷⁰² Imaging tests detected 7% to 49% of recurrences.^{126,696,698-702} Imaging methods that detected recurrences included CT scanning, lymph node ultrasound, chest x-ray, or abdominal ultrasound; detection by brain MRI or other imaging methods was rare.^{696,698,700-702} Even in prospective trials where laboratory tests were conducted regularly, detection of recurrence by blood work results was extremely rare.^{126,700}

Recurrences detected by patients or physician clinical exams are usually local, regional satellite or in-transit, or nodal, and less commonly distant.^{126,700} Recurrences detected by imaging, on the other hand, are more likely distant and nodal; local or in-transit recurrences are rarely detected by imaging.^{126,700} These findings, combined with the low percentage of recurrences identified by imaging some studies,^{696,698,701,702} suggest that imaging can be used sparingly for surveillance, especially in patients who present with early-stage melanoma who are less likely to recur with systematic disease.

Imaging Methods: Sensitivity, Selectivity, and Safety

Studies on medical imaging have reported low yield, significant false positivity (often associated with increased patient anxiety and medical costs related to further work-up), and risks of cumulative radiation exposure.^{693,694,703-709} A large meta-analysis compared ultrasound imaging, CT, PET, and PET/CT for the staging and surveillance of patients with melanoma.¹³⁴ Data from 74 studies containing 10,528 patients were included. For both staging and surveillance purposes, ultrasound was found to be associated with the highest sensitivity and specificity for lymph node metastases, while PET/CT was superior for detecting distant metastases. The safety of CT and PET/CT is a significant concern, however, because large population-based studies have shown that cumulative radiation exposure from repeated CT and nuclear imaging tests may be associated with an increased risk of cancer.^{694,695,710}

Nodal basin ultrasound has emerged as a modality for surveillance in patients who are eligible for, but do not undergo, SLNB or in whom the procedure is not technically successful or feasible. Surveillance ultrasound is often used in patients with a positive sentinel node who have elected not to undergo CLND. This approach has been demonstrated to be safe in one prospective randomized trial that compared nodal basin ultrasound surveillance to CLND in patients with a positive sentinel node.²⁷⁵ Results from a similar but much larger trial is eagerly awaited.²⁷⁶

Patterns of Recurrence

In order to design an efficient and effective follow-up schedule, the overall stage-specific risk of relapse, median time to initial relapse, and the likely location of recurrences must be understood.

Stage-specific Probability of Recurrence

The likelihood of recurrence is dependent on the stage of the primary disease at presentation. With increasing stage at first presentation, risk of



NCCN Guidelines Version 3.2023

Melanoma: Cutaneous

recurrence increases and the distribution of recurrences changes.^{126,697,700,711,712} Recurrence rates for completely excised melanoma in situ are sufficiently low that patients are considered cured following excision, with the exception that certain subtypes may recur locally (ie, lentigo maligna).^{243,244,246,713}

For patients who present with stage I-II melanoma and who are rendered free of disease after initial treatment, recurrences are distributed as follows: approximately 15% to 20% are local or in/transit, ~50% in regional lymph nodes, and 29% at distant metastatic sites.^{711,712} In patients who present with stage III melanoma, recurrences are more likely to be distant (~50%), with the remainder divided between local sites and regional lymph nodes.¹²⁶ Increasing stage III substage at initial presentation is associated with a greater proportion of distant recurrences.

Timing of Recurrence

In general, earlier stage melanoma recurs less often, but over a longer time period, while later stage melanoma recurs more often and over a shorter time period. For all stages of melanoma, the risk of recurrence generally decreases with time (from diagnosis), although it does not reach zero at any time.^{126,697,698,700,712} Studies indicate that the risk of recurrence plateaus at between 2% to 5%.^{126,697,714,715} Late recurrence (more than 10 years after diagnosis) is well documented, especially for patients initially presenting with early-stage melanoma.⁷¹⁴⁻⁷¹⁶ Data from several studies suggest that the time it takes for the risk of recurrence to reach its low plateau depends on the stage of disease at first presentation. In a retrospective study of patients who initially presented with stage I melanoma (N = 1568), 80% of the 293 recurrences developed within the first 3 years, but some recurrences (<8%) were detected 5 to 10 years after the initial treatment.⁶⁹⁷ A prospective study found that for patients with stage I or II at initial presentation, the risk of recurrence reached a low level by 4.4 years after initial diagnosis.⁷⁰⁰ For patients initially presenting

with stage III disease, the risk of recurrence reached low levels after only 2.7 years.⁷⁰⁰ A retrospective study in patients initially presenting with stage III disease calculated the time until the risk of relapse dropped to 5% or less, and found that this time shortened as the substage at presentation increased (from stage IIIA to IIIC).¹²⁶ Recurrences to distant sites occur over a longer timeframe than local or regional recurrences, and all types of recurrence (local, regional, and distant) develop more quickly in patients who had more advanced disease at initial presentation.^{126,712} Nonetheless, over 95% of observed regional nodal and distant recurrences were detected within 3 years for stage IIIA and IIIB melanoma, and within 2 years for IIIC melanoma.¹²⁶

In summary, patients who have more advanced disease at first presentation are more likely to recur, and will recur more quickly. Patients with less advanced disease at presentation are less likely to recur, and will recur more slowly, with especially long delays associated with development of recurrences at distant sites. In patients who have already had one recurrence, subsequent recurrences tend to occur at progressively shorter intervals.⁷¹²

Risk of Developing a Second Primary Melanoma

Patients cured of an initial primary melanoma are at increased risk for developing a second primary melanoma. Although rates vary, most studies have reported that ~2% to 10% of patients with first primary melanomas develop second primary melanomas.^{697,700,717-720} The risk of developing a second primary melanoma generally decreases with time from diagnosis of the first primary melanoma.⁷²¹ About one third of second primary melanomas are identified at the same time or within the first 3 months of the diagnosis of the first melanoma,⁷¹⁷ and about half are diagnosed within the first year.⁷¹⁸ For patients who have already developed 2 primary melanomas, the risk of developing a third is higher (16% by 1 year, 31% by 5 years).⁷¹⁸ Second primary melanomas are likely



NCCN Guidelines Version 3.2023

Melanoma: Cutaneous

to occur at the same body region as the original lesion,⁷²⁰ and are usually thinner than the original lesion,^{718,722} possibly due to increased clinical surveillance. The probability of developing a second primary melanoma is increased by the presence of atypical/dysplastic nevi and a positive family history of melanoma.^{718,722}

Long-Term Impact of Surveillance

It is difficult to document the effect of intensive surveillance on the outcome of patients with melanoma. A structured follow-up program could permit the earlier detection of recurrent disease at a time when it might be more amenable to potentially curative treatment. This rationale for follow-up is particularly appropriate for patients at risk for a second primary melanoma, patients who have not undergone SLNB at risk for nodal recurrence, or in those patients with a positive sentinel node who elected not to undergo completion lymphadenectomy.

Several other reasons for a structured follow-up program include provision of ongoing psychosocial support, identification of familial kindreds, screening for second non-melanoma primary malignancies, patient education, and documentation of the results of treatment.⁷²²⁻⁷²⁴

Survival after Recurrence

Earlier detection of recurrence is assumed to be beneficial because lower tumor burden and younger age are associated with improved treatment response rates and survival. However, this concept has not been proven, even with the use of more effective therapies for advanced melanoma. Prospective randomized trials are needed to assess whether surveillance improves survival, and to determine the optimal frequency and duration of follow-up surveillance. In the absence of such trials, the patterns and risk factors of survival after recurrence can help inform design of appropriate surveillance schedules.

Risk Factors for Survival After Recurrence

Survival after recurrence is generally poor, and depends on the stage of disease at first presentation, site(s) of recurrence, stage of recurrence, disease-free interval, tumor thickness, ulceration, and response to initial therapy for the recurrence.^{711,715,725-727} Survival nodal or distant metastatic recurrences also depend on the diameter of largest metastasis, number of metastases, and presence of visceral metastases.^{711,726}

Patient Quality of Life and Emotional Well-Being

An additional consideration when designing a follow-up schedule is the impact of surveillance on the patient's quality life. Whereas normal exam results can have a positive effect on a patient's emotional well-being, follow-up visits can also cause stress associated with traveling to a clinic, the exam experience, and waiting for results. A meta-analysis of 15 studies reporting on psychosocial outcomes in patients with early stage (I/II) melanoma found that although anxiety with follow-up is common, patients value reassurance, information, and psychosocial support.⁷²⁸ It was not uncommon for follow-up exams or imaging to be primarily motivated by patient request

Psychosocial support for patients not only impacts their quality of life, but may also impact clinical outcomes. Patients in one randomized study who participated in a structured psychiatric group intervention shortly after their diagnosis and initial surgical treatment showed a trend toward decreased recurrence and significantly better survival than those without the psychiatric group intervention.⁷²³ Of note, improvement in active-behavioral coping over time was correlated with improved outcomes.

Patient Education

Skin cancer preventive education should be promoted for patients with melanoma and their families.^{729,730} There is increasing evidence that regular sunscreen use may diminish the incidence of subsequent melanoma.⁷³¹ Patients can be made aware of the various resources that



discuss skin cancer prevention. A list of useful resources is provided by the National Council on Skin Cancer Prevention at

<http://www.skincancerprevention.org/resources>.

NCCN Recommendations

Follow-up recommendations described in this section are for surveillance for recurrence in patients with NED. Recommendations for assessment of disease response to therapy is described in the specific treatment sections or left to the discretion of the practitioner.

NCCN recommendations for follow-up are largely based on retrospective studies, generally well-accepted clinical practice, and panel consensus, and thus are not overly prescriptive. The panel felt that a recommendation for lifetime dermatologic surveillance for patients with melanoma at a frequency commensurate with risk is appropriate. Risk assessment should include likelihood of relapse, metastasis, or second primary melanoma or other skin cancer. Clinical discretion is recommended for determining the appropriate follow-up schedule on a case-by-case basis. The panel recommends the development of institutional protocols for follow-up, which can be consistent with the broad parameters of the guidelines despite differing between institutions due to institutional structure, resources and processes, and characteristics of the population served. As there is a lifetime increased risk of subsequent melanoma and non-melanoma skin cancers, lifelong dermatologic surveillance at a frequency consistent with risk is appropriate.

To balance cost with clinical efficacy, the follow-up schedule should depend on a variety of patient- and disease-specific factors associated with risk of recurrence, risk of second primary melanoma, and probability that the recurrence or second primary can be effectively treated. Although the optimal duration of follow-up remains controversial, it is probably not

cost effective to follow all patients intensively for metastatic disease beyond five years.

It is important to highlight that most recurrences are detected through patient-reported symptoms and physician- or patient-reported physical exam findings, rather than by imaging surveillance. The follow-up schedule should consider the utility of these different surveillance methods in different settings. Whereas physical exam and recording of symptoms should be emphasized for patients who present with stage I/II melanoma, imaging may be incorporated into the follow-up of asymptomatic patients who present with more advanced disease or have other risk factors for recurrence.

Common Recommendations for All Patients

Skin examination and surveillance at least once a year for life is recommended for all patients with melanoma, including those who are rendered NED after treatment of stage 0, in situ melanoma. Annual exams should be conducted with care, as regular clinical examination has the highest diagnostic benefit; it is the most cost-effective method for early detection of treatable disease and provides additional diagnostic benefit by enabling imaging directed by symptoms or clinical findings. Patients with risk factors associated with increased risk of subsequent primary melanomas, such as prior multiple primary melanomas, family history of melanoma, and the presence of atypical/dysplastic nevi, should be enrolled in more intensive surveillance programs, and may benefit from adjuncts such as high-resolution total body photography. Coordination among the clinical team is recommended so that the yearly exam (and any further testing) is not duplicated across specialties. Clinicians should educate all patients about regular post-treatment self-exam of their skin and of their lymph nodes if they had stage IA to IV melanoma (and are NED).



NCCN Guidelines Version 3.2023

Melanoma: Cutaneous

Regional lymph node ultrasound may be considered for patients with an equivocal lymph node physical exam, patients who were offered but did not undergo SLNB, patients in whom SLNB was indicated but was not possible or not successful, or patients with a positive SLNB who did not undergo CLND. Nodal basin ultrasound is not a substitute for SLNB or CLND.

Routine blood testing to detect recurrence is not recommended. Appropriate workup, including radiologic imaging, should be promptly obtained in the setting of concerning signs and/or symptoms of recurrence.

Follow-up schedule should be tailored by risk of recurrence, prior primary melanoma, and family history of melanoma, and includes other factors such as atypical moles, moles/dysplastic nevi, and patient/physician concern.

Specific Recommendations

Stage IA-IIA

For patients with stage IA to IIA melanoma, a comprehensive H&P with specific emphasis on the regional nodes and skin should be performed every 6 to 12 months for five years and annually thereafter as clinically indicated. The consensus of the panel is that imaging to screen for asymptomatic recurrence/metastatic disease is not useful for these patients.

Stage IIB-IV

For patients with stage IIB-IV melanoma, a comprehensive H&P should be performed every 3 to 6 months for 2 years; then every 3 to 12 months for 3 years; and annually thereafter, as clinically indicated. Surveillance interval should be tailored to substage and based on assessment of risk factors for recurrence. In the absence of meaningful data on the association of rigorous routine surveillance imaging with improved long-term outcome for

stage IIB-IIC, the recommendations remain controversial. Periodic surveillance CNS imaging for 3 years might avert some of the substantial morbidity incurred by stage IIC patients who present with symptomatic CNS recurrence. Brain MRI surveillance beyond three years, however, has low yield and therefore is less likely to be useful.

Although not recommended at baseline, in the absence of firm data, the panel acknowledged that surveillance chest x-ray, CT, brain MRI, and/or PET/CT every 3 to 12 months (unless otherwise mandated by clinical trial participation) could be considered to screen for recurrent disease at the discretion of the physician (category 2B). Because most recurrences manifest within the first 3 years (depending on stage and other risk factors), routine imaging to screen for asymptomatic recurrence is not recommended beyond 3 to 5 years.

Prior brain metastases increase risk of new brain metastases, and treatment success increases with decreasing brain tumor burden; therefore more frequent surveillance with brain MRI is recommended for these patients with prior brain metastases.

Tailoring the Follow-up Schedule: Key Considerations

The frequency of follow-up and intensity of cross-sectional imaging should be based on the conditional probability of recurrence at any point in time after the patient is rendered free of disease, as well as the options for treatment. Surveillance for patients at higher risk should be more frequent than for those at lower risk, especially for the first two years.

The intensity and interpretation of cross-sectional imaging should also be influenced by the potential for false positives, the desire to avoid unnecessary treatment, patient anxiety, the potential adverse effects of cumulative radiation exposure, and medical costs, as well as treatment options available in the event that asymptomatic recurrence is detected.



All of the available data on risk of recurrence, surveillance, and survival are based on patients treated in the era of older, generally ineffective chemotherapy, and not the current targeted therapies or checkpoint immunotherapies. Prospective analyses are necessary to determine whether the use of newer targeted therapies and immunotherapies will impact surveillance recommendations in asymptomatic high-risk patients.

Treatment of Recurrence

NCCN Recommendations

Persistent Disease or Local Scar Recurrence

The panel recognized the distinction between true local scar recurrence after inadequate initial excision (which most likely represents locally persistent disease) and local recurrence after adequate initial excision, (which likely represents dermal lymphatic disease appearing in proximity to the wide excision scar).⁷³² In the former situation, defined by the presence of in situ and/or radial growth phase, the prognosis after re-excision is related to the microstaging of the recurrence, whereas the latter scenario is prognostically similar to recurrent regional disease.

For persistent disease or true local scar recurrence after inadequate primary therapy, a biopsy is required for confirmation. Guidelines for this biopsy should be the same as for primary tumors. The workup should be similar to that of the primary tumor based on microstaging characteristics. Re-excision to appropriate margins is recommended, with or without lymphatic mapping and SLNB according to primary tumor characteristics. Adjuvant treatment should be based on pathologic stage of the recurrence, and should be similar to that of primary tumors of equivalent stage.

Local, Satellite, and/or In-Transit Recurrence

Initial clinical recurrence should be confirmed pathologically whenever possible or if clinically indicated. Pathology should be confirmed by FNA

cytology, if feasible, or core, incisional, or excisional biopsy. Local or satellite recurrences are in the deep dermis or subcutaneous fat within the melanoma scar or satellite metastasis adjacent to the melanoma scar. By definition they are recurrences after initial adequate wide excision, and lack in situ or radial growth phase. Tissue from the recurrence (preferred) or archival tissue should be assessed for mutation status if the patient is being considered for targeted therapy or enrollment in a clinical trial that includes mutation status as an eligibility criterion. Baseline imaging (CT and/or PET/CT or MRI) is recommended for staging and to evaluate specific signs or symptoms (category 2B).

Participation in a clinical trial should be considered in all cases of local, satellite, or in-transit recurrence. In the absence of extra-regional disease, complete surgical excision to clear margins is recommended whenever feasible. Lymphatic mapping with SLNB may be considered in patients with resectable in-transit disease on an individual basis (category 2B). The prognostic significance of a positive SLNB in patients with established local regional recurrence is unclear.

Options for treatment of unresectable local, satellite, or in-transit recurrences include intralesional injection with T-VEC, ILP or ILI with melphalan, or systemic therapy (as recommended for metastatic disease). The following are category 2B alternatives: intralesional injections with BCG, IFN alfa, or IL-2, topical imiquimod (for superficial dermal lesions), local ablation therapy, or RT.

After complete response to any of these modalities, options include participation in a clinical trial or observation. For those rendered free of disease by surgery, an additional adjuvant therapy option is high-dose IFN alfa (category 2B).



Regional Nodal Recurrence

For patients presenting with regional nodal recurrence, the clinical diagnosis should be confirmed by FNA (preferred) or core, incisional, or excisional biopsy. Tissue from the recurrence (preferred) or archival tissue should be assessed for mutation status if the patient is being considered for targeted therapy or enrollment in a clinical trial that includes mutation status as an eligibility criterion. Baseline imaging (CT and/or PET/CT or MRI) is recommended for staging and to evaluate specific signs or symptoms (category 2B).

For patients who have not undergone prior lymph node dissection or had an incomplete lymph node dissection, a CLND is advised. If the patient underwent a previous CLND, excision of the recurrence to negative margins is recommended if possible. After complete resection of nodal recurrence, options for adjuvant treatment include a clinical trial, observation, or, in patients who were not previously treated, high-dose or pegylated IFN alfa, high-dose ipilimumab (category 2B), or biochemotherapy (category 2B). Adjuvant radiation to the nodal basin may also be considered in selected high-risk patients based on size, location, and number of involved nodes, and/or macroscopic extranodal extension (category 2B). For patients with incompletely resected nodal recurrence, unresectable disease, or systemic disease, options include systemic therapy (preferred), clinical trial, palliative RT, intralesional injection with T-VEC, or best supportive care (see [NCCN Guidelines for Palliative Care](#)).

Distant Recurrence

For patients presenting with distant recurrence, the workup and treatment options are similar to those outlined previously for patients presenting initially with stage IV metastatic disease.

Summary

The NCCN Guidelines for Melanoma represent an effort to distill and simplify an enormous body of knowledge and experience into fairly simple management algorithms. In general, treatment recommendations for primary tumors are based on better data than the recommendations for treating recurrent disease. These guidelines are intended as a point of departure, recognizing that all clinical decisions about individual patient management must be tempered by the clinician's judgment and other factors, such as local resources and expertise as well as the individual patient's needs, wishes, and expectations. Furthermore, the NCCN Guidelines for Melanoma undergo annual revision and are continually updated as new data become available.



References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. *CA Cancer J Clin* 2016;66:7-30. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26742998>.
2. Jemal A, Saraiya M, Patel P, et al. Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992-2006. *J Am Acad Dermatol* 2011;65:S17-25 e11-13. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22018063>.
3. National Cancer Institute. Surveillance Epidemiology and End Results. 2008. Available at: <http://seer.cancer.gov/statfacts/html/melan.html#ref11>. Accessed April 18, 2014.
4. Ekwueme DU, Guy GP, Jr., Li C, et al. The health burden and economic costs of cutaneous melanoma mortality by race/ethnicity—United States, 2000 to 2006. *J Am Acad Dermatol* 2011;65:S133-143. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22018062>.
5. Naeyaert JM, Brochez L. Clinical practice. Dysplastic nevi. *N Engl J Med* 2003;349:2233-2240. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14657431>.
6. Rigel DS, Rivers JK, Kopf AW, et al. Dysplastic nevi. Markers for increased risk for melanoma. *Cancer* 1989;63:386-389. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/2910446>.
7. Evans RD, Kopf AW, Lew RA, et al. Risk factors for the development of malignant melanoma—I: Review of case-control studies. *J Dermatol Surg Oncol* 1988;14:393-408. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/3280634>.
8. Williams ML, Sagebiel RW. Melanoma risk factors and atypical moles. *West J Med* 1994;160:343-350. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8023484>.
9. Ivry GB, Ogle CA, Shim EK. Role of sun exposure in melanoma. *Dermatol Surg* 2006;32:481-492. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16681655>.
10. Colantonio S, Bracken MB, Beecker J. The association of indoor tanning and melanoma in adults: systematic review and meta-analysis. *J Am Acad Dermatol* 2014;70:847-857 e841-818. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24629998>.
11. Gordon D, Gillgren P, Eloranta S, et al. Time trends in incidence of cutaneous melanoma by detailed anatomical location and patterns of ultraviolet radiation exposure: a retrospective population-based study. *Melanoma Res* 2015;25:348-356. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26050147>.
12. Green AC, Wallingford SC, McBride P. Childhood exposure to ultraviolet radiation and harmful skin effects: epidemiological evidence. *Prog Biophys Mol Biol* 2011;107:349-355. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21907230>.
13. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. *N Engl J Med* 2004;351:998-1012. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15342808>.
14. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. *J Clin Oncol* 2009;27:6199-6206. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19917835>.
15. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. *CA Cancer J Clin* 2015;65:5-29. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25559415>.
16. Oliveira Filho RS, Ferreira LM, Biasi LJ, et al. Vertical growth phase and positive sentinel node in thin melanoma. *Braz J Med Biol Res* 2003;36:347-350. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12640499>.
17. Yonick DV, Ballo RM, Kahn E, et al. Predictors of positive sentinel lymph node in thin melanoma. *Am J Surg* 2011;201:324-327; discussion 327-328. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21367372>.



18. Sondak VK, Taylor JM, Sabel MS, et al. Mitotic rate and younger age are predictors of sentinel lymph node positivity: lessons learned from the generation of a probabilistic model. *Ann Surg Oncol* 2004;11:247-258. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14993019>.
19. Kesmodel SB, Karakousis GC, Botbyl JD, et al. Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas. *Ann Surg Oncol* 2005;12:449-458. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15864482>.
20. Kibbi N, Kluger H, Choi JN. Melanoma: Clinical Presentations. *Cancer Treat Res* 2016;167:107-129. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26601860>.
21. Mihajlovic M, Vlajkovic S, Jovanovic P, Stefanovic V. Primary mucosal melanomas: a comprehensive review. *Int J Clin Exp Pathol* 2012;5:739-753. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23071856>.
22. Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. *J Clin Oncol* 2006;24:4340-4346. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16908931>.
23. Luke JJ, Triozzi PL, McKenna KC, et al. Biology of advanced uveal melanoma and next steps for clinical therapeutics. *Pigment Cell Melanoma Res* 2015;28:135-147. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25113308>.
24. Shields CL, Kaliki S, Furuta M, et al. American Joint Committee on Cancer Classification of Uveal Melanoma (Anatomic Stage) Predicts Prognosis in 7731 Patients: The 2013 Zimmerman Lecture. *Ophthalmology* 2015;122:1180-1186. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25813452>.
25. Tacastacas JD, Bray J, Cohen YK, et al. Update on primary mucosal melanoma. *J Am Acad Dermatol* 2014;71:366-375. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24815565>.
26. Coit DG. NCCN Guidelines and quality cancer care: where have we come from, and where should we be going? *J Natl Compr Canc Netw* 2016;14:373-377. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/27059186>.
27. Edge SB, Carducci M, Byrd DR, eds. *AJCC Cancer Staging Manual* (ed 7). New York: Springer-Verlag New York, LLC; 2009.
28. Balch CM, Gershenwald JE, Soong SJ, et al. Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. *J Clin Oncol* 2010;28:2452-2459. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20368546>.
29. Thompson JF, Soong SJ, Balch CM, et al. Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. *J Clin Oncol* 2011;29:2199-2205. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21519009>.
30. Balch CM, Soong SJ, Gershenwald JE, et al. Age as a prognostic factor in patients with localized melanoma and regional metastases. *Ann Surg Oncol* 2013;20:3961-3968. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23838920>.
31. Maurichi A, Miceli R, Camerini T, et al. Prediction of survival in patients with thin melanoma: results from a multi-institution study. *J Clin Oncol* 2014;32:2479-2485. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25002727>.
32. Eriksson H, Frohm-Nilsson M, Jaras J, et al. Prognostic factors in localized invasive primary cutaneous malignant melanoma: results of a large population-based study. *Br J Dermatol* 2015;172:175-186. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24910143>.
33. In 't Hout FE, Haydu LE, Murali R, et al. Prognostic importance of the extent of ulceration in patients with clinically localized cutaneous melanoma. *Ann Surg* 2012;255:1165-1170. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22566014>.



34. Lyth J, Hansson J, Ingvar C, et al. Prognostic subclassifications of T1 cutaneous melanomas based on ulceration, tumour thickness and Clark's level of invasion: results of a population-based study from the Swedish Melanoma Register. *Br J Dermatol* 2013;168:779-786. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23066913>.
35. Piris A, Mihm MC, Jr., Duncan LM. AJCC melanoma staging update: impact on dermatopathology practice and patient management. *J Cutan Pathol* 2011;38:394-400. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21385199>.
36. Azzola MF, Shaw HM, Thompson JF, et al. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma: an analysis of 3661 patients from a single center. *Cancer* 2003;97:1488-1498. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12627514>.
37. Francken AB, Shaw HM, Thompson JF, et al. The prognostic importance of tumor mitotic rate confirmed in 1317 patients with primary cutaneous melanoma and long follow-up. *Ann Surg Oncol* 2004;11:426-433. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15070604>.
38. Gimotty PA, Elder DE, Fraker DL, et al. Identification of high-risk patients among those diagnosed with thin cutaneous melanomas. *J Clin Oncol* 2007;25:1129-1134. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17369575>.
39. Xu X, Chen L, Guerry D, et al. Lymphatic invasion is independently prognostic of metastasis in primary cutaneous melanoma. *Clin Cancer Res* 2012;18:229-237. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22096024>.
40. Barnhill RL, Katzen J, Spatz A, et al. The importance of mitotic rate as a prognostic factor for localized cutaneous melanoma. *J Cutan Pathol* 2005;32:268-273. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15769275>.
41. College of American Pathologists. Protocol for the Examination of Specimens from Patients with Melanoma of the Skin. 2013. Available at: http://www.cap.org/apps/docs/committees/cancer/cancer_protocols/2013/SkinMelanoma_13protocol_3300.pdf. Accessed April 18, 2014.
42. Harrist TJ, Rigel DS, Day CL, Jr., et al. "Microscopic satellites" are more highly associated with regional lymph node metastases than is primary melanoma thickness. *Cancer* 1984;53:2183-2187. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/6704906>.
43. Bichakjian CK, Halpern AC, Johnson TM, et al. Guidelines of care for the management of primary cutaneous melanoma. *American Academy of Dermatology. J Am Acad Dermatol* 2011;65:1032-1047. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21868127>.
44. Sober AJ, Chuang TY, Duvic M, et al. Guidelines of care for primary cutaneous melanoma. *J Am Acad Dermatol* 2001;45:579-586. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11568750>.
45. Taylor RC, Patel A, Panageas KS, et al. Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma. *J Clin Oncol* 2007;25:869-875. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17327608>.
46. Nagore E, Oliver V, Botella-Estrada R, et al. Prognostic factors in localized invasive cutaneous melanoma: high value of mitotic rate, vascular invasion and microscopic satellitosis. *Melanoma Res* 2005;15:169-177. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15917698>.
47. Raskin L, Ludgate M, Iyer RK, et al. Copy number variations and clinical outcome in atypical spitz tumors. *Am J Surg Pathol* 2011;35:243-252. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21263245>.
48. Gerami P, Cook RW, Russell MC, et al. Gene expression profiling for molecular staging of cutaneous melanoma in patients undergoing sentinel lymph node biopsy. *J Am Acad Dermatol* 2015;72:780-785 e783. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25748297>.



49. Gerami P, Cook RW, Wilkinson J, et al. Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma. *Clin Cancer Res* 2015;21:175-183. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25564571>.
50. Clarke LE, Warf BM, Flake DD, 2nd, et al. Clinical validation of a gene expression signature that differentiates benign nevi from malignant melanoma. *J Cutan Pathol* 2015;42:244-252. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25727210>.
51. Nsengimana J, Laye J, Filia A, et al. Independent replication of a melanoma subtype gene signature and evaluation of its prognostic value and biological correlates in a population cohort. *Oncotarget* 2015;6:11683-11693. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25871393>.
52. Cirenajwis H, Ekedahl H, Lauss M, et al. Molecular stratification of metastatic melanoma using gene expression profiling: Prediction of survival outcome and benefit from molecular targeted therapy. *Oncotarget* 2015;6:12297-12309. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25909218>.
53. Lallas A, Kyrgidis A, Ferrara G, et al. Atypical Spitz tumours and sentinel lymph node biopsy: a systematic review. *Lancet Oncol* 2014;15:e178-183. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24694641>.
54. Hung T, Piris A, Lobo A, et al. Sentinel lymph node metastasis is not predictive of poor outcome in patients with problematic spitzoid melanocytic tumors. *Hum Pathol* 2013;44:87-94. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22939951>.
55. Sepehr A, Chao E, Trefrey B, et al. Long-term outcome of Spitz-type melanocytic tumors. *Arch Dermatol* 2011;147:1173-1179. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21680758>.
56. Meyers MO, Yeh JJ, Deal AM, et al. Age and Breslow depth are associated with a positive sentinel lymph node in patients with cutaneous melanocytic tumors of uncertain malignant potential. *J Am Coll Surg* 2010;211:744-748. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20869269>.
57. Ghazi B, Carlson GW, Murray DR, et al. Utility of lymph node assessment for atypical spitzoid melanocytic neoplasms. *Ann Surg Oncol* 2010;17:2471-2475. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20224858>.
58. Ludgate MW, Fullen DR, Lee J, et al. The atypical Spitz tumor of uncertain biologic potential: a series of 67 patients from a single institution. *Cancer* 2009;115:631-641. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19123453>.
59. Ji AL, Bichakjian CK, Swetter SM. Molecular Profiling in Cutaneous Melanoma. *J Natl Compr Canc Netw* 2016;14:475-480. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27059194>.
60. Winnepenninckx V, Lazar V, Michiels S, et al. Gene expression profiling of primary cutaneous melanoma and clinical outcome. *J Natl Cancer Inst* 2006;98:472-482. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16595783>.
61. Brunner G, Reitz M, Heinecke A, et al. A nine-gene signature predicting clinical outcome in cutaneous melanoma. *J Cancer Res Clin Oncol* 2013;139:249-258. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23052696>.
62. Timar J, Gyorffy B, Raso E. Gene signature of the metastatic potential of cutaneous melanoma: too much for too little? *Clin Exp Metastasis* 2010;27:371-387. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20177751>.
63. Kim K, Zakharkin SO, Allison DB. Expectations, validity, and reality in gene expression profiling. *J Clin Epidemiol* 2010;63:950-959. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20579843>.



64. Zakharkin SO, Kim K, Mehta T, et al. Sources of variation in Affymetrix microarray experiments. *BMC Bioinformatics* 2005;6:214. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16124883>.
65. Bammler T, Beyer RP, Bhattacharya S, et al. Standardizing global gene expression analysis between laboratories and across platforms. *Nat Methods* 2005;2:351-356. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15846362>.
66. Shedden K, Chen W, Kuick R, et al. Comparison of seven methods for producing Affymetrix expression scores based on False Discovery Rates in disease profiling data. *BMC Bioinformatics* 2005;6:26. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15705192>.
67. Lee SC, Tan HT, Chung MC. Prognostic biomarkers for prediction of recurrence of hepatocellular carcinoma: current status and future prospects. *World J Gastroenterol* 2014;20:3112-3124. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24696598>.
68. Hornberger J, Alvarado MD, Rebecca C, et al. Clinical validity/utility, change in practice patterns, and economic implications of risk stratifiers to predict outcomes for early-stage breast cancer: a systematic review. *J Natl Cancer Inst* 2012;104:1068-1079. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22767204>.
69. Laas E, Mallon P, Duhoux FP, et al. Low concordance between gene expression Signatures in ER positive HER2 negative breast carcinoma could impair their clinical application. *PLoS One* 2016;11:e0148957. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26895349>.
70. Liu Z, Zhang XS, Zhang S. Breast tumor subgroups reveal diverse clinical prognostic power. *Sci Rep* 2014;4:4002. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24499868>.
71. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. *J Clin Oncol* 2001;19:3622-3634. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11504744>.
72. Cascinelli N, Belli F, Santinami M, et al. Sentinel lymph node biopsy in cutaneous melanoma: the WHO Melanoma Program experience. *Ann Surg Oncol* 2000;7:469-474. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10894144>.
73. Stenius Muller MG, van Leeuwen PA, de Lange-De Klerk ES, et al. The sentinel lymph node status is an important factor for predicting clinical outcome in patients with Stage I or II cutaneous melanoma. *Cancer* 2001;91:2401-2408. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11413531>.
74. van Lanschot CG, Koljenovic S, Grunhagen DJ, et al. Pigmentation in the sentinel node correlates with increased sentinel node tumor burden in melanoma patients. *Melanoma Res* 2014;24:261-266. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24608184>.
75. van der Ploeg AP, van Akkooi AC, Haydu LE, et al. The prognostic significance of sentinel node tumour burden in melanoma patients: an international, multicenter study of 1539 sentinel node-positive melanoma patients. *Eur J Cancer* 2014;50:111-120. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24074765>.
76. Egger ME, Callender GG, McMasters KM, et al. Diversity of stage III melanoma in the era of sentinel lymph node biopsy. *Ann Surg Oncol* 2013;20:956-963. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23064795>.
77. Cadili A, Scolyer RA, Brown PT, et al. Total sentinel lymph node tumor size predicts nonsentinel node metastasis and survival in patients with melanoma. *Ann Surg Oncol* 2010;17:3015-3020. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20552405>.
78. Ulmer A, Dietz K, Hodak I, et al. Quantitative measurement of melanoma spread in sentinel lymph nodes and survival. *PLoS Med* 2014;11:e1001604. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24558354>.



NCCN Guidelines Version 3.2023

Melanoma: Cutaneous

79. Kim C, Economou S, Amatruda TT, et al. Prognostic significance of microscopic tumor burden in sentinel lymph node in patients with cutaneous melanoma. *Anticancer Res* 2015;35:301-309. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25550564>.

80. Roka F, Mastan P, Binder M, et al. Prediction of non-sentinel node status and outcome in sentinel node-positive melanoma patients. *Eur J Surg Oncol* 2008;34:82-88. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17360144>.

81. Khosrotehrani K, van der Ploeg AP, Siskind V, et al. Nomograms to predict recurrence and survival in stage IIIB and IIIC melanoma after therapeutic lymphadenectomy. *Eur J Cancer* 2014;50:1301-1309. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24613127>.

82. Spillane AJ, Pasquali S, Haydu LE, Thompson JF. Patterns of recurrence and survival after lymphadenectomy in melanoma patients: clarifying the effects of timing of surgery and lymph node tumor burden. *Ann Surg Oncol* 2014;21:292-299. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24052314>.

83. Grotz TE, Huebner M, Pockaj BA, et al. Limitations of lymph node ratio, evidence-based benchmarks, and the importance of a thorough lymph node dissection in melanoma. *Ann Surg Oncol* 2013;20:4370-4377. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24046102>.

84. Wevers KP, Bastiaannet E, Poos HP, et al. Therapeutic lymph node dissection in melanoma: different prognosis for different macrometastasis sites? *Ann Surg Oncol* 2012;19:3913-3918. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22588472>.

85. Bastiaannet E, Hoekstra OS, de Jong JR, et al. Prognostic value of the standardized uptake value for (18)F-fluorodeoxyglucose in patients with stage IIIB melanoma. *Eur J Nucl Med Mol Imaging* 2012;39:1592-1598. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22801730>.

86. Allan CP, Hayes AJ, Thomas JM. Iliioinguinal lymph node dissection for palpable metastatic melanoma to the groin. *ANZ J Surg* 2008;78:982-986. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18959697>.

87. Neuman HB, Patel A, Ishill N, et al. A single-institution validation of the AJCC staging system for stage IV melanoma. *Ann Surg Oncol* 2008;15:2034-2041. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18465172>.

88. Weide B, Elsasser M, Buttner P, et al. Serum markers lactate dehydrogenase and S100B predict independently disease outcome in melanoma patients with distant metastasis. *Br J Cancer* 2012;107:422-428. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22782342>.

89. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. *Nature* 2002;417:949-954. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12068308>.

90. Long GV, Menzies AM, Nagrial AM, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. *J Clin Oncol* 2011;29:1239-1246. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21343559>.

91. Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. *Oncogene* 2007;26:3279-3290. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17496922>.

92. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. *N Engl J Med* 2011;364:2507-2516. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21639808>.

93. McArthur GA, Chapman PB, Robert C, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. *Lancet Oncol* 2014;15:323-332. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24508103>.

94. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. *Lancet* 2012;380:358-365. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22735384>.



95. Hauschild A, Grob JJ, Demidov LV, et al. An update on BREAK-3, a phase III, randomized trial: Dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM). ASCO Meeting Abstracts 2013;31:9013. Available at: http://meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/9013.

96. Guo J, Si L, Kong Y, et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 2011;29:2904-2909. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21690468>.

97. Carvajal RD, Antonescu CR, Wolchok JD, et al. KIT as a therapeutic target in metastatic melanoma. JAMA 2011;305:2327-2334. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21642685>.

98. Hodi FS, Corless CL, Giobbie-Hurder A, et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol 2013;31:3182-3190. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23775962>.

99. Chang GA, Tadepalli JS, Shao Y, et al. Sensitivity of plasma BRAFmutant and NRASmutant cell-free DNA assays to detect metastatic melanoma in patients with low RECIST scores and non-RECIST disease progression. Mol Oncol 2016;10:157-165. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26440707>.

100. Gonzalez-Cao M, Mayo-de-Las-Casas C, Molina-Vila MA, et al. BRAF mutation analysis in circulating free tumor DNA of melanoma patients treated with BRAF inhibitors. Melanoma Res 2015;25:486-495. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26366702>.

101. Marchant J, Mange A, Larrieux M, et al. Comparative evaluation of the new FDA approved THxID-BRAF test with High Resolution Melting and Sanger sequencing. BMC Cancer 2014;14:519. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25037456>.

102. Qu K, Pan Q, Zhang X, et al. Detection of BRAF V600 mutations in metastatic melanoma: comparison of the Cobas 4800 and Sanger sequencing assays. J Mol Diagn 2013;15:790-795. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23994118>.

103. Santiago-Walker A, Gagnon R, Mazumdar J, et al. Correlation of BRAF Mutation Status in Circulating-Free DNA and Tumor and Association with Clinical Outcome across Four BRAFi and MEKi Clinical Trials. Clin Cancer Res 2016;22:567-574. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26446943>.

104. Skorokhod A. Universal BRAF State Detection by the Pyrosequencing((R))-Based U-BRAF (V600) Assay. Methods Mol Biol 2015;1315:63-82. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26103892>.

105. Long E, Ilie M, Lassalle S, et al. Why and how immunohistochemistry should now be used to screen for the BRAFV600E status in metastatic melanoma? The experience of a single institution (LCEP, Nice, France). J Eur Acad Dermatol Venereol 2015;29:2436-2443. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26377147>.

106. Aung KL, Donald E, Ellison G, et al. Analytical validation of BRAF mutation testing from circulating free DNA using the amplification refractory mutation testing system. J Mol Diagn 2014;16:343-349. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24631158>.

107. Lamy PJ, Castan F, Lozano N, et al. Next-Generation Genotyping by Digital PCR to Detect and Quantify the BRAF V600E Mutation in Melanoma Biopsies. J Mol Diagn 2015;17:366-373. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25952101>.

108. Routhier CA, Mochel MC, Lynch K, et al. Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas. Hum Pathol 2013;44:2563-2570. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24071017>.



109. Ihle MA, Fassunke J, Konig K, et al. Comparison of high resolution melting analysis, pyrosequencing, next generation sequencing and immunohistochemistry to conventional Sanger sequencing for the detection of p.V600E and non-p.V600E BRAF mutations. *BMC Cancer* 2014;14:13. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24410877>.
110. Tetzlaff MT, Pattanaprichakul P, Wargo J, et al. Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma. *Hum Pathol* 2015;46:1101-1110. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26058727>.
111. Nardin C, Puzenat E, Pretet JL, et al. BRAF mutation screening in melanoma: is sentinel lymph node reliable? *Melanoma Res* 2015;25:328-334. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26020488>.
112. Saroufim M, Habib RH, Gerges R, et al. Comparing BRAF mutation status in matched primary and metastatic cutaneous melanomas: implications on optimized targeted therapy. *Exp Mol Pathol* 2014;97:315-320. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25236573>.
113. Riveiro-Falkenbach E, Villanueva CA, Garrido MC, et al. Intra- and Inter-Tumoral Homogeneity of BRAF(V600E) Mutations in Melanoma Tumors. *J Invest Dermatol* 2015;135:3078-3085. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26083553>.
114. Shain AH, Yeh I, Kovalyshyn I, et al. The Genetic Evolution of Melanoma from Precursor Lesions. *N Engl J Med* 2015;373:1926-1936. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26559571>.
115. Dai B, Cai X, Kong YY, et al. Analysis of KIT expression and gene mutation in human acral melanoma: with a comparison between primary tumors and corresponding metastases/recurrences. *Hum Pathol* 2013;44:1472-1478. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23528861>.
116. Buzaid AC, Sandler AB, Mani S, et al. Role of computed tomography in the staging of primary melanoma. *J Clin Oncol* 1993;11:638-643. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8478659>.
117. Wang TS, Johnson TM, Cascade PN, et al. Evaluation of staging chest radiographs and serum lactate dehydrogenase for localized melanoma. *J Am Acad Dermatol* 2004;51:399-405. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15337983>.
118. Yancovitz M, Finelt N, Warycha MA, et al. Role of radiologic imaging at the time of initial diagnosis of stage T1b-T3b melanoma. *Cancer* 2007;110:1107-1114. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17620286>.
119. Aloia TA, Gershenwald JE, Andtbacka RH, et al. Utility of computed tomography and magnetic resonance imaging staging before completion lymphadenectomy in patients with sentinel lymph node-positive melanoma. *J Clin Oncol* 2006;24:2858-2865. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16782925>.
120. Gold JS, Jaques DP, Busam KJ, et al. Yield and predictors of radiologic studies for identifying distant metastases in melanoma patients with a positive sentinel lymph node biopsy. *Ann Surg Oncol* 2007;14:2133-2140. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17453294>.
121. Miranda EP, Gertner M, Wall J, et al. Routine imaging of asymptomatic melanoma patients with metastasis to sentinel lymph nodes rarely identifies systemic disease. *Arch Surg* 2004;139:831-836; discussion 836-837. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15302691>.
122. Pandalai PK, Dominguez FJ, Michaelson J, Tanabe KK. Clinical value of radiographic staging in patients diagnosed with AJCC stage III melanoma. *Ann Surg Oncol* 2011;18:506-513. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20734149>.
123. Buzaid AC, Tinoco L, Ross MI, et al. Role of computed tomography in the staging of patients with local-regional metastases of melanoma. *J Clin Oncol* 1995;13:2104-2108. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7636554>.



124. Johnson TM, Fader DJ, Chang AE, et al. Computed tomography in staging of patients with melanoma metastatic to the regional nodes. *Ann Surg Oncol* 1997;4:396-402. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/9259966>.

125. Kuvshinoff BW, Kurtz C, Coit DG. Computed tomography in evaluation of patients with stage III melanoma. *Ann Surg Oncol* 1997;4:252-258. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/9142387>.

126. Romano E, Scordo M, Dusza SW, et al. Site and timing of first relapse in stage III melanoma patients: implications for follow-up guidelines. *J Clin Oncol* 2010;28:3042-3047. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/20479405>.

127. Clark PB, Soo V, Kraas J, et al. Futility of fluorodeoxyglucose F 18 positron emission tomography in initial evaluation of patients with T2 to T4 melanoma. *Arch Surg* 2006;141:284-288. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/16549694>.

128. Maubec E, Lumbroso J, Masson F, et al. F-18 fluorodeoxy-D-glucose positron emission tomography scan in the initial evaluation of patients with a primary melanoma thicker than 4 mm. *Melanoma Res* 2007;17:147-154. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/17505260>.

129. Wagner JD, Schauwecker D, Davidson D, et al. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma. *Cancer* 2005;104:570-579. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/15977211>.

130. Bikhchandani J, Wood J, Richards AT, Smith RB. No benefit in staging fluorodeoxyglucose-positron emission tomography in clinically node-negative head and neck cutaneous melanoma. *Head Neck* 2014;36:1313-1316. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/23956077>.

131. Brady MS, Akhurst T, Spanknebel K, et al. Utility of preoperative [(18)]f fluorodeoxyglucose-positron emission tomography scanning in high-risk melanoma patients. *Ann Surg Oncol* 2006;13:525-532. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/16474909>.

132. Schule SC, Eigentler TK, Garbe C, et al. Influence of (18)F-FDG PET/CT on therapy management in patients with stage III/IV malignant melanoma. *Eur J Nucl Med Mol Imaging* 2016;43:482-488. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/26384681>.

133. Schroer-Gunther MA, Wolff RF, Westwood ME, et al. F-18-fluoro-2-deoxyglucose positron emission tomography (PET) and PET/computed tomography imaging in primary staging of patients with malignant melanoma: a systematic review. *Syst Rev* 2012;1:62. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/23237499>.

134. Xing Y, Bronstein Y, Ross MI, et al. Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. *J Natl Cancer Inst* 2011;103:129-142. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21081714>.

135. Rodriguez Rivera AM, Alabbas H, Ramjaun A, Meguerditchian AN. Value of positron emission tomography scan in stage III cutaneous melanoma: a systematic review and meta-analysis. *Surg Oncol* 2014;23:11-16. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/24556310>.

136. Margolin K, Ernstoff MS, Hamid O, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. *Lancet Oncol* 2012;13:459-465. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/22456429>.

137. Sia J, Paul E, Dally M, Ruben J. Stereotactic radiosurgery for 318 brain metastases in a single Australian centre: the impact of histology and other factors. *J Clin Neurosci* 2015;22:303-307. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/25304434>.



138. Press RH, Prabhu RS, Nickleach DC, et al. Novel risk stratification score for predicting early distant brain failure and salvage whole-brain radiotherapy after stereotactic radiosurgery for brain metastases. *Cancer* 2015;121:3836-3843. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26242475>.

139. Patel KR, Shoukat S, Oliver DE, et al. Ipilimumab and Stereotactic Radiosurgery Versus Stereotactic Radiosurgery Alone for Newly Diagnosed Melanoma Brain Metastases. *Am J Clin Oncol* 2015. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26017484>.

140. Ostheimer C, Bormann C, Fiedler E, et al. Malignant melanoma brain metastases: Treatment results and prognostic factors - a single-center retrospective study. *Int J Oncol* 2015;46:2439-2448. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25891163>.

141. Minniti G, Scaringi C, Paolini S, et al. Repeated stereotactic radiosurgery for patients with progressive brain metastases. *J Neurooncol* 2016;126:91-97. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26369769>.

142. Lucas JT, Jr., Colmer HGt, White L, et al. Competing Risk Analysis of Neurologic versus Nonneurologic Death in Patients Undergoing Radiosurgical Salvage After Whole-Brain Radiation Therapy Failure: Who Actually Dies of Their Brain Metastases? *Int J Radiat Oncol Biol Phys* 2015;92:1008-1015. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26050609>.

143. Hauswald H, Stenke A, Debus J, Combs SE. Linear accelerator-based stereotactic radiosurgery in 140 brain metastases from malignant melanoma. *BMC Cancer* 2015;15:537. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26201853>.

144. Goyal S, Silk AW, Tian S, et al. Clinical Management of Multiple Melanoma Brain Metastases: A Systematic Review. *JAMA Oncol* 2015;1:668-676. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26181286>.

145. Johnson TM, Sondak VK, Bichakjian CK, Sabel MS. The role of sentinel lymph node biopsy for melanoma: evidence assessment. *J Am Acad Dermatol* 2006;54:19-27. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16384752>.

146. Bedrosian I, Faries MB, Guerry Dt, et al. Incidence of sentinel node metastasis in patients with thin primary melanoma (< or = 1 mm) with vertical growth phase. *Ann Surg Oncol* 2000;7:262-267. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10819365>.

147. Staius Muller MG, van Leeuwen PA, van Diest PJ, et al. No indication for performing sentinel node biopsy in melanoma patients with a Breslow thickness of less than 0.9 mm. *Melanoma Res* 2001;11:303-307. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11468520>.

148. Rousseau DL, Jr., Ross MI, Johnson MM, et al. Revised American Joint Committee on Cancer staging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients. *Ann Surg Oncol* 2003;10:569-574. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12794025>.

149. Olah J, Gyulai R, Korom I, et al. Tumour regression predicts higher risk of sentinel node involvement in thin cutaneous melanomas. *Br J Dermatol* 2003;149:662-663. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14511013>.

150. Jimenez-Heffernan A, Ellmann A, Sado H, et al. Results of a Prospective Multicenter International Atomic Energy Agency Sentinel Node Trial on the Value of SPECT/CT Over Planar Imaging in Various Malignancies. *J Nucl Med* 2015;56:1338-1344. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26229148>.

151. Stoffels I, Boy C, Poppel T, et al. Association between sentinel lymph node excision with or without preoperative SPECT/CT and metastatic node detection and disease-free survival in melanoma. *JAMA* 2012;308:1007-1014. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22968889>.



152. Abrahamsen HN, Hamilton-Dutoit SJ, Larsen J, Steiniche T. Sentinel lymph nodes in malignant melanoma: extended histopathologic evaluation improves diagnostic precision. *Cancer* 2004;100:1683-1691. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15073857>.

153. Gershenwald JE, Colome MI, Lee JE, et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. *J Clin Oncol* 1998;16:2253-2260. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9626228>.

154. Yu LL, Flotte TJ, Tanabe KK, et al. Detection of microscopic melanoma metastases in sentinel lymph nodes. *Cancer* 1999;86:617-627. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10440689>.

155. van Akkooi AC, de Wilt JH, Verhoef C, et al. Clinical relevance of melanoma micrometastases (<0.1 mm) in sentinel nodes: are these nodes to be considered negative? *Ann Oncol* 2006;17:1578-1585. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16968875>.

156. Scheri RP, Essner R, Turner RR, et al. Isolated tumor cells in the sentinel node affect long-term prognosis of patients with melanoma. *Ann Surg Oncol* 2007;14:2861-2866. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17882497>.

157. Gambichler T, Scholl L, Stucker M, et al. Clinical characteristics and survival data of melanoma patients with nevus cell aggregates within sentinel lymph nodes. *Am J Clin Pathol* 2013;139:566-573. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23596107>.

158. Wrightson WR, Wong SL, Edwards MJ, et al. Complications associated with sentinel lymph node biopsy for melanoma. *Ann Surg Oncol* 2003;10:676-680. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12839853>.

159. Morton DL, Cochran AJ, Thompson JF, et al. Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial. *Ann Surg* 2005;242:302-311; discussion 311-303. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16135917>.

160. van den Broek FJ, Sloots PC, de Waard JW, Roumen RM. Sentinel lymph node biopsy for cutaneous melanoma: results of 10 years' experience in two regional training hospitals in the Netherlands. *Int J Clin Oncol* 2013;18:428-434. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22402887>.

161. Neves RI, Reynolds BQ, Hazard SW, et al. Increased post-operative complications with methylene blue versus lymphazurin in sentinel lymph node biopsies for skin cancers. *J Surg Oncol* 2011;103:421-425. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21400527>.

162. Gad D, Hoiland-Carlsen PF, Bartram P, et al. Staging patients with cutaneous malignant melanoma by same-day lymphoscintigraphy and sentinel lymph node biopsy: a single-institutional experience with emphasis on recurrence. *J Surg Oncol* 2006;94:94-100. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16847917>.

163. de Vries M, Vonkeman WG, van Ginkel RJ, Hoekstra HJ. Morbidity after axillary sentinel lymph node biopsy in patients with cutaneous melanoma. *Eur J Surg Oncol* 2005;31:778-783. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15993029>.

164. Chakera AH, Drzewiecki KT, Eigtved A, Juhl BR. Sentinel node biopsy for melanoma: a study of 241 patients. *Melanoma Res* 2004;14:521-526. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15577324>.

165. Wasserberg N, Tulchinsky H, Schachter J, et al. Sentinel-lymph-node biopsy (SLNB) for melanoma is not complication-free. *Eur J Surg Oncol* 2004;30:851-856. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15336731>.

166. Voss RK, Cromwell KD, Chiang YJ, et al. The long-term risk of upper-extremity lymphedema is two-fold higher in breast cancer patients than in melanoma patients. *J Surg Oncol* 2015;112:834-840. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26477877>.



167. Read RL, Pasquali S, Haydu L, et al. Quality assurance in melanoma surgery: The evolving experience at a large tertiary referral centre. *Eur J Surg Oncol* 2015;41:830-836. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/25595509>.

168. White I, Mills JK, Diggs B, et al. Sentinel lymph node biopsy for melanoma: comparison of lymphocele rates by surgical technique. *Am Surg* 2013;79:388-392. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/23574849>.

169. Fontaine D, Parkhill W, Greer W, Walsh N. Partial regression of primary cutaneous melanoma: is there an association with sub-clinical sentinel lymph node metastasis? *Am J Dermatopathol* 2003;25:371-376. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/14501285>.

170. Borgognoni L, Urso C, Vaggelli L, et al. Sentinel node biopsy procedures with an analysis of recurrence patterns and prognosis in melanoma patients: technical advantages using computer-assisted gamma probe with adjustable collimation. *Melanoma Res* 2004;14:311-319. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/15305163>.

171. Kruper LL, Spitz FR, Czerniecki BJ, et al. Predicting sentinel node status in AJCC stage I/II primary cutaneous melanoma. *Cancer* 2006;107:2436-2445. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/17058288>.

172. Cascinelli N, Bombardieri E, Bufalino R, et al. Sentinel and nonsentinel node status in stage IB and II melanoma patients: two-step prognostic indicators of survival. *J Clin Oncol* 2006;24:4464-4471. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/16983115>.

173. Morton DL, Thompson JF, Cochran AJ, et al. Final trial report of sentinel-node biopsy versus nodal observation in melanoma. *N Engl J Med* 2014;370:599-609. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/24521106>.

174. Nowecki ZI, Rutkowski P, Nasierowska-Guttmejer A, Ruka W. Survival analysis and clinicopathological factors associated with false-negative sentinel lymph node biopsy findings in patients with cutaneous melanoma. *Ann Surg Oncol* 2006;13:1655-1663. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/17016755>.

175. Azimi F, Scolyer RA, Rumcheva P, et al. Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. *J Clin Oncol* 2012;30:2678-2683. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/22711850>.

176. Speijers MJ, Bastiaannet E, Sloot S, et al. Tumor mitotic rate added to the equation: melanoma prognostic factors changed? : a single-institution database study on the prognostic value of tumor mitotic rate for sentinel lymph node status and survival of cutaneous melanoma patients. *Ann Surg Oncol* 2015;22:2978-2987. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/25605514>.

177. Munsch C, Lauwers-Cances V, Lamant L, et al. Breslow thickness, clark index and ulceration are associated with sentinel lymph node metastasis in melanoma patients: a cohort analysis of 612 patients. *Dermatology* 2014;229:183-189. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/25171688>.

178. Morris KT, Busam KJ, Bero S, et al. Primary cutaneous melanoma with regression does not require a lower threshold for sentinel lymph node biopsy. *Ann Surg Oncol* 2008;15:316-322. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/18004626>.

179. Baker JJ, Meyers MO, Deal AM, et al. Prognostic significance of tumor mitotic rate in T2 melanoma staged with sentinel lymphadenectomy. *J Surg Oncol* 2015;111:711-715. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/25663414>.



180. Cavanaugh-Hussey MW, Mu EW, Kang S, et al. Older Age is Associated with a Higher Incidence of Melanoma Death but a Lower Incidence of Sentinel Lymph Node Metastasis in the SEER Databases (2003-2011). *Ann Surg Oncol* 2015;22:2120-2126. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25940571>.

181. Mahiques Santos L, Oliver Martinez V, Alegre de Miquel V. Sentinel lymph node status in melanoma: prognostic value in a tertiary hospital and correlation with mitotic activity. *Actas Dermosifiliogr* 2014;105:60-68. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24021663>.

182. Lima Sanchez J, Sanchez Medina M, Garcia Duque O, et al. Sentinel lymph node biopsy for cutaneous melanoma: a 6 years study. *Indian J Plast Surg* 2013;46:92-97. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23960312>.

183. Paek SC, Griffith KA, Johnson TM, et al. The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma. *Cancer* 2007;109:100-108. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17146784>.

184. Balch CM, Thompson JF, Gershenwald JE, et al. Age as a predictor of sentinel node metastasis among patients with localized melanoma: an inverse correlation of melanoma mortality and incidence of sentinel node metastasis among young and old patients. *Ann Surg Oncol* 2014;21:1075-1081. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24531700>.

185. Yamamoto M, Fisher KJ, Wong JY, et al. Sentinel lymph node biopsy is indicated for patients with thick clinically lymph node-negative melanoma. *Cancer* 2015;121:1628-1636. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25677366>.

186. Wright BE, Scheri RP, Ye X, et al. Importance of sentinel lymph node biopsy in patients with thin melanoma. *Arch Surg* 2008;143:892-899; discussion 899-900. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18794428>.

187. Freeman SR, Gibbs BB, Brodland DG, Zitelli JA. Prognostic value of sentinel lymph node biopsy compared with that of Breslow thickness: implications for informed consent in patients with invasive melanoma. *Dermatol Surg* 2013;39:1800-1812. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24299573>.

188. Andtbacka RH, Gershenwald JE. Role of sentinel lymph node biopsy in patients with thin melanoma. *J Natl Compr Canc Netw* 2009;7:308-317. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19401063>.

189. Venna SS, Thummala S, Nosrati M, et al. Analysis of sentinel lymph node positivity in patients with thin primary melanoma. *J Am Acad Dermatol* 2013;68:560-567. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23182069>.

190. Han D, Zager JS, Shyr Y, et al. Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma. *J Clin Oncol* 2013;31:4387-4393. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24190111>.

191. Ranieri JM, Wagner JD, Wenck S, et al. The prognostic importance of sentinel lymph node biopsy in thin melanoma. *Ann Surg Oncol* 2006;13:927-932. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16788753>.

192. Wong SL, Brady MS, Busam KJ, Coit DG. Results of sentinel lymph node biopsy in patients with thin melanoma. *Ann Surg Oncol* 2006;13:302-309. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16485151>.

193. Murali R, Haydu LE, Quinn MJ, et al. Sentinel lymph node biopsy in patients with thin primary cutaneous melanoma. *Ann Surg* 2012;255:128-133. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21975320>.

194. Wat H, Senthilselvan A, Salopek TG. A retrospective, multicenter analysis of the predictive value of mitotic rate for sentinel lymph node (SLN) positivity in thin melanomas. *J Am Acad Dermatol* 2016;74:94-101. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26542815>.



195. Stitzenberg KB, Groben PA, Stern SL, et al. Indications for lymphatic mapping and sentinel lymphadenectomy in patients with thin melanoma (Breslow thickness < or =1.0 mm). *Ann Surg Oncol* 2004;11:900-906. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15383424>.

196. Puleo CA, Messina JL, Riker AI, et al. Sentinel node biopsy for thin melanomas: which patients should be considered? *Cancer Control* 2005;12:230-235. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16258494>.

197. Hershko DD, Robb BW, Lowy AM, et al. Sentinel lymph node biopsy in thin melanoma patients. *J Surg Oncol* 2006;93:279-285. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16496355>.

198. Jacobs IA, Chang CK, DasGupta TK, Salti GI. Role of sentinel lymph node biopsy in patients with thin (<1 mm) primary melanoma. *Ann Surg Oncol* 2003;10:558-561. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12794023>.

199. Cecchi R, Pavesi M, Buralli L, et al. Tumour regression does not increase the risk of sentinel node involvement in thin melanomas. *Chir Ital* 2008;60:257-260. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18689175>.

200. Mitteldorf C, Bertsch HP, Jung K, et al. Sentinel node biopsy improves prognostic stratification in patients with thin (pT1) melanomas and an additional risk factor. *Ann Surg Oncol* 2014;21:2252-2258. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24652352>.

201. Mozzillo N, Pennacchioli E, Gandini S, et al. Sentinel node biopsy in thin and thick melanoma. *Ann Surg Oncol* 2013;20:2780-2786. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23720068>.

202. Bleicher RJ, Essner R, Foshag LJ, et al. Role of sentinel lymphadenectomy in thin invasive cutaneous melanomas. *J Clin Oncol* 2003;21:1326-1331. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12663722>.

203. Cooper C, Wayne JD, Damstetter EM, et al. A 10-year, single-institution analysis of clinicopathologic features and sentinel lymph node biopsy in thin melanomas. *J Am Acad Dermatol* 2013;69:693-699. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23978604>.

204. Vermeeren L, Van der Ent F, Sastrowijoto P, Hulsewe K. Sentinel lymph node biopsy in patients with thin melanoma: occurrence of nodal metastases and its prognostic value. *Eur J Dermatol* 2010;20:30-34. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19889594>.

205. Murali R, Shaw HM, Lai K, et al. Prognostic factors in cutaneous desmoplastic melanoma: a study of 252 patients. *Cancer* 2010;116:4130-4138. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20564101>.

206. Mohebbati A, Ganly I, Busam KJ, et al. The role of sentinel lymph node biopsy in the management of head and neck desmoplastic melanoma. *Ann Surg Oncol* 2012;19:4307-4313. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22766985>.

207. Han D, Zager JS, Yu D, et al. Desmoplastic melanoma: is there a role for sentinel lymph node biopsy? *Ann Surg Oncol* 2013;20:2345-2351. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23389470>.

208. Broer PN, Walker ME, Goldberg C, et al. Desmoplastic melanoma: a 12-year experience with sentinel lymph node biopsy. *Eur J Surg Oncol* 2013;39:681-685. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23522951>.

209. Gyorki DE, Busam K, Panageas K, et al. Sentinel lymph node biopsy for patients with cutaneous desmoplastic melanoma. *Ann Surg Oncol* 2003;10:403-407. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12734089>.

210. Pawlik TM, Ross MI, Prieto VG, et al. Assessment of the role of sentinel lymph node biopsy for primary cutaneous desmoplastic melanoma. *Cancer* 2006;106:900-906. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16411225>.



211. Smith VA, Lentsch EJ. Sentinel node biopsy in head and neck desmoplastic melanoma: an analysis of 244 cases. *Laryngoscope* 2012;122:116-120. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/22072330>.

212. Livestro DP, Muzikansky A, Kaine EM, et al. Biology of desmoplastic melanoma: a case-control comparison with other melanomas. *J Clin Oncol* 2005;23:6739-6746. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/16170181>.

213. Sassen S, Shaw HM, Colman MH, et al. The complex relationships between sentinel node positivity, patient age, and primary tumor desmoplasia: analysis of 2303 melanoma patients treated at a single center. *Ann Surg Oncol* 2008;15:630-637. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/18080717>.

214. Eppsteiner RW, Swick BL, Milhem MM, et al. Sentinel node biopsy for head and neck desmoplastic melanoma: not a given. *Otolaryngol Head Neck Surg* 2012;147:271-274. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/22399279>.

215. Weissinger SE, Keil P, Silvers DN, et al. A diagnostic algorithm to distinguish desmoplastic from spindle cell melanoma. *Mod Pathol* 2014;27:524-534. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/24051699>.

216. Lin MJ, Mar V, McLean C, et al. Diagnostic accuracy of malignant melanoma according to subtype. *Australas J Dermatol* 2014;55:35-42. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24283461>.

217. Jaimes N, Chen L, Dusza SW, et al. Clinical and dermoscopic characteristics of desmoplastic melanomas. *JAMA Dermatol* 2013;149:413-421. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/23325288>.

218. Chen JY, Hruby G, Scolyer RA, et al. Desmoplastic neurotropic melanoma: a clinicopathologic analysis of 128 cases. *Cancer* 2008;113:2770-2778. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/18823042>.

219. Hall BJ, Schmidt RL, Sharma RR, Layfield LJ. Fine-needle aspiration cytology for the diagnosis of metastatic melanoma: systematic review and meta-analysis. *Am J Clin Pathol* 2013;140:635-642. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/24124141>.

220. Cangiarella J, Symmans WF, Shapiro RL, et al. Aspiration biopsy and the clinical management of patients with malignant melanoma and palpable regional lymph nodes. *Cancer* 2000;90:162-166. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/10896329>.

221. Basler GC, Fader DJ, Yahanda A, et al. The utility of fine needle aspiration in the diagnosis of melanoma metastatic to lymph nodes. *J Am Acad Dermatol* 1997;36:403-408. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/9091471>.

222. Veronesi U, Cascinelli N. Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma. *Arch Surg* 1991;126:438-441. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/2009058>.

223. Veronesi U, Cascinelli N, Adamus J, et al. Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm. *N Engl J Med* 1988;318:1159-1162. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/3079582>.

224. Cohn-Cedermark G, Rutqvist LE, Andersson R, et al. Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8-2.0 mm. *Cancer* 2000;89:1495-1501. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11013363>.

225. Khayat D, Rixe O, Martin G, et al. Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick). *Cancer* 2003;97:1941-1946. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/12673721>.

226. Gillgren P, Drzewiecki KT, Niin M, et al. 2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: a randomised, multicentre trial. *Lancet* 2011;378:1635-1642. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/22027547>.



227. Balch CM, Soong SJ, Smith T, et al. Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas. *Ann Surg Oncol* 2001;8:101-108. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11258773>.

228. Balch CM, Urist MM, Karakousis CP, et al. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. *Ann Surg* 1993;218:262-267; discussion 267-269. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8373269>.

229. Haigh PI, DiFronzo LA, McCready DR. Optimal excision margins for primary cutaneous melanoma: a systematic review and meta-analysis. *Can J Surg* 2003;46:419-426. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14680348>.

230. Hayes AJ, Maynard L, Coombes G, et al. Wide versus narrow excision margins for high-risk, primary cutaneous melanomas: long-term follow-up of survival in a randomised trial. *Lancet Oncol* 2016;17:184-192. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26790922>.

231. Pasquali S, Haydu LE, Scolyer RA, et al. The importance of adequate primary tumor excision margins and sentinel node biopsy in achieving optimal locoregional control for patients with thick primary melanomas. *Ann Surg* 2013;258:152-157. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23426339>.

232. Koskivuo I, Giordano S, Verajankorva E, Vihinen P. One-cm Versus 2-cm Excision Margins for Patients With Intermediate Thickness Melanoma: A Matched-Pair Analysis. *Dermatol Surg* 2015;41:1130-1136. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26356846>.

233. Hunger RE, Angermeier S, Seyed Jafari SM, et al. A retrospective study of 1- versus 2-cm excision margins for cutaneous malignant melanomas thicker than 2 mm. *J Am Acad Dermatol* 2015;72:1054-1059. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25877659>.

234. MacKenzie Ross AD, Haydu LE, Quinn MJ, et al. The Association Between Excision Margins and Local Recurrence in 11,290 Thin (T1) Primary Cutaneous Melanomas: A Case-Control Study. *Ann Surg Oncol* 2016;23:1082-1089. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26561405>.

235. Haydu LE, Stollman JT, Scolyer RA, et al. Minimum Safe Pathologic Excision Margins for Primary Cutaneous Melanomas (1-2 mm in Thickness): Analysis of 2131 Patients Treated at a Single Center. *Ann Surg Oncol* 2016;23:1071-1081. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25956574>.

236. Doepker MP, Thompson ZJ, Fisher KJ, et al. Is a Wider Margin (2 cm vs. 1 cm) for a 1.01-2.0 mm Melanoma Necessary? *Ann Surg Oncol* 2016;23:2336-2342. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26957503>.

237. Thomas JM, Newton-Bishop J, A'Hern R, et al. Excision margins in high-risk malignant melanoma. *N Engl J Med* 2004;350:757-766. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14973217>.

238. Hazan C, Dusza SW, Delgado R, et al. Staged excision for lentigo maligna and lentigo maligna melanoma: A retrospective analysis of 117 cases. *J Am Acad Dermatol* 2008;58:142-148. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18029055>.

239. Gardner KH, Hill DE, Wright AC, et al. Upstaging From Melanoma in Situ to Invasive Melanoma on the Head and Neck After Complete Surgical Resection. *Dermatol Surg* 2015;41:1122-1125. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26356849>.

240. Felton S, Taylor RS, Srivastava D. Excision Margins for Melanoma In Situ on the Head and Neck. *Dermatol Surg* 2016;42:327-334. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26866286>.

241. Kunishige JH, Brodland DG, Zitelli JA. Surgical margins for melanoma in situ. *J Am Acad Dermatol* 2012;66:438-444. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22196979>.



242. Hilari H, Llorca D, Traves V, et al. Conventional surgery compared with slow Mohs micrographic surgery in the treatment of lentigo maligna: a retrospective study of 62 cases. *Actas Dermosifiliogr* 2012;103:614-623. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22572575>.

243. Duffy KL, Truong A, Bowen GM, et al. Adequacy of 5-mm surgical excision margins for non-lentiginous melanoma in situ. *J Am Acad Dermatol* 2014;71:835-838. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25219711>.

244. Akhtar S, Bhat W, Magdum A, Stanley PR. Surgical excision margins for melanoma in situ. *J Plast Reconstr Aesthet Surg* 2014;67:320-323. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24444795>.

245. Walling HW, Scupham RK, Bean AK, Ceilley RI. Staged excision versus Mohs micrographic surgery for lentigo maligna and lentigo maligna melanoma. *J Am Acad Dermatol* 2007;57:659-664. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17870430>.

246. de Vries K, Greveling K, Prens LM, et al. Recurrence rate of lentigo maligna after micrographically controlled staged surgical excision. *Br J Dermatol* 2016;174:588-593. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26616840>.

247. Hou JL, Reed KB, Knudson RM, et al. Five-year outcomes of wide excision and Mohs micrographic surgery for primary lentigo maligna in an academic practice cohort. *Dermatol Surg* 2015;41:211-218. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25590473>.

248. Cotter MA, McKenna JK, Bowen GM. Treatment of lentigo maligna with imiquimod before staged excision. *Dermatol Surg* 2008;34:147-151. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18093206>.

249. Naylor MF, Crowson N, Kuwahara R, et al. Treatment of lentigo maligna with topical imiquimod. *Br J Dermatol* 2003;149 Suppl 66:66-70. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14616356>.

250. Powell AM, Russell-Jones R, Barlow RJ. Topical imiquimod immunotherapy in the management of lentigo maligna. *Clin Exp Dermatol* 2004;29:15-21. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14723712>.

251. Spenny ML, Walford J, Werchniak AE, et al. Lentigo maligna (melanoma in situ) treated with imiquimod cream 5%: 12 case reports. *Cutis* 2007;79:149-152. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17388218>.

252. Buettiker UV, Yawalkar NY, Braathen LR, Hunger RE. Imiquimod treatment of lentigo maligna: an open-label study of 34 primary lesions in 32 patients. *Arch Dermatol* 2008;144:943-945. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18645150>.

253. Mahoney MH, Joseph MG, Temple C. Topical imiquimod therapy for lentigo maligna. *Ann Plast Surg* 2008;61:419-424. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18812714>.

254. Powell AM, Robson AM, Russell-Jones R, Barlow RJ. Imiquimod and lentigo maligna: a search for prognostic features in a clinicopathological study with long-term follow-up. *Br J Dermatol* 2009;160:994-998. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19222462>.

255. Ly L, Kelly JW, O'Keefe R, et al. Efficacy of imiquimod cream, 5%, for lentigo maligna after complete excision: a study of 43 patients. *Arch Dermatol* 2011;147:1191-1195. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22006136>.

256. Hyde MA, Hadley ML, Tristani-Firouzi P, et al. A randomized trial of the off-label use of imiquimod, 5%, cream with vs without tazarotene, 0.1%, gel for the treatment of lentigo maligna, followed by conservative staged excisions. *Arch Dermatol* 2012;148:592-596. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22431716>.

257. Wong JG, Toole JW, Demers AA, et al. Topical 5% imiquimod in the treatment of lentigo maligna. *J Cutan Med Surg* 2012;16:245-249. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22784516>.



258. Read T, Noonan C, David M, et al. A systematic review of non-surgical treatments for lentigo maligna. *J Eur Acad Dermatol Venereol* 2016;30:748-753. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26299846>.

259. Kai AC, Richards T, Coleman A, et al. Five-year recurrence rate of lentigo maligna after treatment with imiquimod. *Br J Dermatol* 2016;174:165-168. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26595446>.

260. Gautschi M, Oberholzer PA, Baumgartner M, et al. Prognostic markers in lentigo maligna patients treated with imiquimod cream: A long-term follow-up study. *J Am Acad Dermatol* 2016;74:81-87 e81. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26601565>.

261. Mora AN, Karia PS, Nguyen BM. A quantitative systematic review of the efficacy of imiquimod monotherapy for lentigo maligna and an analysis of factors that affect tumor clearance. *J Am Acad Dermatol* 2015;73:205-212. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26088690>.

262. Swetter SM, Chen FW, Kim DD, Egbert BM. Imiquimod 5% cream as primary or adjuvant therapy for melanoma in situ, lentigo maligna type. *J Am Acad Dermatol* 2015;72:1047-1053. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25791801>.

263. Kirtschig G, van Meurs T, van Doorn R. Twelve-week treatment of lentigo maligna with imiquimod results in a high and sustained clearance rate. *Acta Derm Venereol* 2015;95:83-85. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24696093>.

264. Alarcon I, Carrera C, Alos L, et al. In vivo reflectance confocal microscopy to monitor the response of lentigo maligna to imiquimod. *J Am Acad Dermatol* 2014;71:49-55. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24725478>.

265. Fogarty GB, Hong A, Scolyer RA, et al. Radiotherapy for lentigo maligna: a literature review and recommendations for treatment. *Br J Dermatol* 2014;170:52-58. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24032599>.

266. Hedblad MA, Mallbris L. Grenz ray treatment of lentigo maligna and early lentigo maligna melanoma. *J Am Acad Dermatol* 2012;67:60-68. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22030019>.

267. Robinson JK. Use of digital epiluminescence microscopy to help define the edge of lentigo maligna. *Arch Dermatol* 2004;140:1095-1100. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15381550>.

268. Cascinelli N, Morabito A, Santinami M, et al. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. *WHO Melanoma Programme. Lancet* 1998;351:793-796. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9519951>.

269. Matthey-Gie ML, Gie O, Deretti S, et al. Prospective Randomized Study to Compare Lymphocele and Lymphorrhea Control Following Inguinal and Axillary Therapeutic Lymph Node Dissection With or Without the Use of an Ultrasonic Scalpel. *Ann Surg Oncol* 2016;23:1716-1720. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26714939>.

270. Slagelse C, Petersen KL, Dahl JB, et al. Persistent postoperative pain and sensory changes following lymph node excision in melanoma patients: a topical review. *Melanoma Res* 2014;24:93-98. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24346167>.

271. Theodore JE, Frankel AJ, Thomas JM, et al. Assessment of morbidity following regional nodal dissection in the axilla and groin for metastatic melanoma. *ANZ J Surg* 2017;87:44-48. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27102082>.

272. Hyngstrom JR, Chiang YJ, Cromwell KD, et al. Prospective assessment of lymphedema incidence and lymphedema-associated symptoms following lymph node surgery for melanoma. *Melanoma Res* 2013;23:290-297. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23752305>.

273. Kretschmer L, Bertsch HP, Zapf A, et al. Nodal Basin Recurrence After Sentinel Lymph Node Biopsy for Melanoma: A Retrospective Multicenter Study in 2653 Patients. *Medicine (Baltimore)* 2015;94:e1433. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26356697>.



NCCN Guidelines Version 3.2023 Melanoma: Cutaneous

274. Guggenheim MM, Hug U, Jung FJ, et al. Morbidity and recurrence after completion lymph node dissection following sentinel lymph node biopsy in cutaneous malignant melanoma. *Ann Surg* 2008;247:687-693. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18362633>.
275. Leiter U, Stadler R, Mauch C, et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. *Lancet Oncol* 2016;17:757-767. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27161539>.
276. Morton DL. Overview and update of the phase III Multicenter Selective Lymphadenectomy Trials (MSLT-I and MSLT-II) in melanoma. *Clin Exp Metastasis* 2012;29:699-706. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22729520>.
277. Lee JH, Essner R, Torisu-Itakura H, et al. Factors predictive of tumor-positive nonsentinel lymph nodes after tumor-positive sentinel lymph node dissection for melanoma. *J Clin Oncol* 2004;22:3677-3684. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15365064>.
278. Sabel MS, Griffith K, Sondak VK, et al. Predictors of nonsentinel lymph node positivity in patients with a positive sentinel node for melanoma. *J Am Coll Surg* 2005;201:37-47. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15978442>.
279. Govindarajan A, Ghazarian DM, McCreedy DR, Leong WL. Histological features of melanoma sentinel lymph node metastases associated with status of the completion lymphadenectomy and rate of subsequent relapse. *Ann Surg Oncol* 2007;14:906-912. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17136471>.
280. Cadili A, McKinnon G, Wright F, et al. Validation of a scoring system to predict non-sentinel lymph node metastasis in melanoma. *J Surg Oncol* 2010;101:191-194. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20039281>.
281. Quaglino P, Ribero S, Osella-Abate S, et al. Clinico-pathologic features of primary melanoma and sentinel lymph node predictive for non-sentinel lymph node involvement and overall survival in melanoma patients: a single centre observational cohort study. *Surg Oncol* 2011;20:259-264. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21145730>.
282. Glumac N, Hocevar M, Zadnik V, Snoj M. Inguinal or inguino-iliac/obturator lymph node dissection after positive inguinal sentinel lymph node in patients with cutaneous melanoma. *Radiol Oncol* 2012;46:258-264. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23077465>.
283. Nagaraja V, Eslick GD. Is complete lymph node dissection after a positive sentinel lymph node biopsy for cutaneous melanoma always necessary? A meta-analysis. *Eur J Surg Oncol* 2013;39:669-680. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23571104>.
284. Gyorki DE, Boyle JO, Ganly I, et al. Incidence and location of positive nonsentinel lymph nodes in head and neck melanoma. *Eur J Surg Oncol* 2014;40:305-310. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24361245>.
285. Bertolli E, Macedo MP, Pinto CA, et al. Metastatic area ratio can help predict nonsentinel node positivity in melanoma patients. *Melanoma Res* 2016;26:42-45. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26397049>.
286. Kibrite A, Milot H, Douville P, et al. Predictive factors for sentinel lymph nodes and non-sentinel lymph nodes metastatic involvement: a database study of 1,041 melanoma patients. *Am J Surg* 2016;211:89-94. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26275921>.
287. Rutkowski P, Szydłowski K, Nowecki ZI, et al. The long-term results and prognostic significance of cutaneous melanoma surgery using sentinel node biopsy with triple technique. *World J Surg Oncol* 2015;13:299. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26462471>.



288. Gershenwald JE, Andtbacka RH, Prieto VG, et al. Microscopic tumor burden in sentinel lymph nodes predicts synchronous nonsentinel lymph node involvement in patients with melanoma. *J Clin Oncol* 2008;26:4296-4303. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18606982>.

289. Holtkamp LH, Wang S, Wilmott JS, et al. Detailed pathological examination of completion node dissection specimens and outcome in melanoma patients with minimal (<0.1 mm) sentinel lymph node metastases. *Ann Surg Oncol* 2015;22:2972-2977. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25990968>.

290. Elias N, Tanabe KK, Sober AJ, et al. Is completion lymphadenectomy after a positive sentinel lymph node biopsy for cutaneous melanoma always necessary? *Arch Surg* 2004;139:400-404; discussion 404-405. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15078708>.

291. Dewar DJ, Newell B, Green MA, et al. The microanatomic location of metastatic melanoma in sentinel lymph nodes predicts nonsentinel lymph node involvement. *J Clin Oncol* 2004;22:3345-3349. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15310779>.

292. Rossi CR, De Salvo GL, Bonandini E, et al. Factors predictive of nonsentinel lymph node involvement and clinical outcome in melanoma patients with metastatic sentinel lymph node. *Ann Surg Oncol* 2008;15:1202-1210. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18165880>.

293. Leung AM, Morton DL, Ozao-Choy J, et al. Staging of regional lymph nodes in melanoma: a case for including nonsentinel lymph node positivity in the American Joint Committee on Cancer staging system. *JAMA Surg* 2013;148:879-884. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23903435>.

294. Fritsch VA, Cunningham JE, Lentsch EJ. Completion Lymph Node Dissection Based on Risk of Nonsentinel Metastasis in Cutaneous Melanoma of the Head and Neck. *Otolaryngol Head Neck Surg* 2016;154:94-103. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26399717>.

295. Wevers KP, Murali R, Bastiaannet E, et al. Assessment of a new scoring system for predicting non-sentinel node positivity in sentinel node-positive melanoma patients. *Eur J Surg Oncol* 2013;39:179-184. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23137997>.

296. Feldmann R, Fink AM, Jurecka W, et al. Accuracy of the non-sentinel node risk score (N-SNORE) in patients with cutaneous melanoma and positive sentinel lymph nodes: a retrospective study. *Eur J Surg Oncol* 2014;40:73-76. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24075029>.

297. Murali R, Desilva C, Thompson JF, Scolyer RA. Non-Sentinel Node Risk Score (N-SNORE): a scoring system for accurately stratifying risk of non-sentinel node positivity in patients with cutaneous melanoma with positive sentinel lymph nodes. *J Clin Oncol* 2010;28:4441-4449. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20823419>.

298. van der Ploeg AP, van Akkooi AC, Rutkowski P, et al. Prognosis in patients with sentinel node-positive melanoma is accurately defined by the combined Rotterdam tumor load and Dewar topography criteria. *J Clin Oncol* 2011;29:2206-2214. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21519012>.

299. Starz H, Balda BR, Kramer KU, et al. A micromorphometry-based concept for routine classification of sentinel lymph node metastases and its clinical relevance for patients with melanoma. *Cancer* 2001;91:2110-2121. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11391592>.

300. Cadili A, Dabbs K, Scolyer RA, et al. Re-evaluation of a scoring system to predict nonsentinel-node metastasis and prognosis in melanoma patients. *J Am Coll Surg* 2010;211:522-525. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20729103>.

301. Egger ME, Bower MR, Czystoczon IA, et al. Comparison of sentinel lymph node micrometastatic tumor burden measurements in melanoma. *J Am Coll Surg* 2014;218:519-528. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24491245>.



302. McMasters KM, Wong SL, Edwards MJ, et al. Frequency of nonsentinel lymph node metastasis in melanoma. *Ann Surg Oncol* 2002;9:137-141. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11888869>.

303. Kettlewell S, Moyes C, Bray C, et al. Value of sentinel node status as a prognostic factor in melanoma: prospective observational study. *BMJ* 2006;332:1423. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16735303>.

304. Pasquali S, Mocellin S, Mozzillo N, et al. Nonsentinel lymph node status in patients with cutaneous melanoma: results from a multi-institution prognostic study. *J Clin Oncol* 2014;32:935-941. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24516022>.

305. Brown RE, Ross MI, Edwards MJ, et al. The prognostic significance of nonsentinel lymph node metastasis in melanoma. *Ann Surg Oncol* 2010;17:3330-3335. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20645010>.

306. Ghaferi AA, Wong SL, Johnson TM, et al. Prognostic significance of a positive nonsentinel lymph node in cutaneous melanoma. *Ann Surg Oncol* 2009;16:2978-2984. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19711133>.

307. Satzger I, Meier A, Zapf A, et al. Is there a therapeutic benefit of complete lymph node dissection in melanoma patients with low tumor burden in the sentinel node? *Melanoma Res* 2014;24:454-461. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24811213>.

308. Bamboat ZM, Konstantinidis IT, Kuk D, et al. Observation after a positive sentinel lymph node biopsy in patients with melanoma. *Ann Surg Oncol* 2014;21:3117-3123. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24833100>.

309. van der Ploeg AP, van Akkooi AC, Rutkowski P, et al. Prognosis in patients with sentinel node-positive melanoma without immediate completion lymph node dissection. *Br J Surg* 2012;99:1396-1405. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22961519>.

310. Egger ME, Brown RE, Roach BA, et al. Addition of an iliac/obturator lymph node dissection does not improve nodal recurrence or survival in melanoma. *J Am Coll Surg* 2014;219:101-108. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24726566>.

311. Strobbe LJ, Jonk A, Hart AA, et al. Positive iliac and obturator nodes in melanoma: survival and prognostic factors. *Ann Surg Oncol* 1999;6:255-262. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10340884>.

312. Kretschmer L, Neumann C, Preusser KP, Marsch WC. Superficial inguinal and radical ilioinguinal lymph node dissection in patients with palpable melanoma metastases to the groin--an analysis of survival and local recurrence. *Acta Oncol* 2001;40:72-78. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11321665>.

313. Kretschmer L, Preusser KP, Marsch WC, Neumann C. Prognostic factors of overall survival in patients with delayed lymph node dissection for cutaneous malignant melanoma. *Melanoma Res* 2000;10:483-489. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11095410>.

314. Kretschmer L, Preusser KP, Neumann C. Locoregional cutaneous metastasis in patients with therapeutic lymph node dissection for malignant melanoma: risk factors and prognostic impact. *Melanoma Res* 2002;12:499-504. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12394192>.

315. Khosrotehrani K, Dasgupta P, Byrom L, et al. Melanoma survival is superior in females across all tumour stages but is influenced by age. *Arch Dermatol Res* 2015;307:731-740. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26103951>.

316. Glover AR, Allan CP, Wilkinson MJ, et al. Outcomes of routine ilioinguinal lymph node dissection for palpable inguinal melanoma nodal metastasis. *Br J Surg* 2014;101:811-819. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24752717>.



317. van Akkooi AC, Bouwhuis MG, van Geel AN, et al. Morbidity and prognosis after therapeutic lymph node dissections for malignant melanoma. *Eur J Surg Oncol* 2007;33:102-108. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17161577>.

318. van der Ploeg IM, Kroon BB, Valdes Olmos RA, Nieweg OE. Evaluation of lymphatic drainage patterns to the groin and implications for the extent of groin dissection in melanoma patients. *Ann Surg Oncol* 2009;16:2994-2999. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19653043>.

319. Mozzillo N, Pasquali S, Santinami M, et al. Factors predictive of pelvic lymph node involvement and outcomes in melanoma patients with metastatic sentinel lymph node of the groin: A multicentre study. *Eur J Surg Oncol* 2015;41:823-829. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25800935>.

320. Pasquali S, Mocellin S, Bigolin F, et al. Pelvic lymph node status prediction in melanoma patients with inguinal lymph node metastasis. *Melanoma Res* 2014;24:462-467. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24999756>.

321. Karakousis GC, Pandit-Taskar N, Hsu M, et al. Prognostic significance of drainage to pelvic nodes at sentinel lymph node mapping in patients with extremity melanoma. *Melanoma Res* 2013;23:40-46. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23250048>.

322. Chu CK, Delman KA, Carlson GW, et al. Inguinopelvic lymphadenectomy following positive inguinal sentinel lymph node biopsy in melanoma: true frequency of synchronous pelvic metastases. *Ann Surg Oncol* 2011;18:3309-3315. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21541825>.

323. West CA, Saleh DB, Peach H. Combined clearance of pelvic and superficial nodes for clinical groin melanoma. *J Plast Reconstr Aesthet Surg* 2014;67:1711-1718. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25219338>.

324. Koh YX, Chok AY, Zheng H, et al. Cloquet's node trumps imaging modalities in the prediction of pelvic nodal involvement in patients with lower limb melanomas in Asian patients with palpable groin nodes. *Eur J Surg Oncol* 2014;40:1263-1270. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24947073>.

325. Coit DG. Extent of groin dissection for melanoma. *Surg Clin North Am* 1992;1:271-280. Available at: <http://www.surgical.theclinics.com/>.

326. Coit DG, Brennan MF. Extent of lymph node dissection in melanoma of the trunk or lower extremity. *Arch Surg* 1989;124:162-166. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/2464981>.

327. Shen P, Conforti AM, Essner R, et al. Is the node of Cloquet the sentinel node for the iliac/obturator node group? *Cancer J* 2000;6:93-97. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11069226>.

328. Mann GB, Coit DG. Does the extent of operation influence the prognosis in patients with melanoma metastatic to inguinal nodes? *Ann Surg Oncol* 1999;6:263-271. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10340885>.

329. Soderman M, Thomsen JB, Sorensen JA. Complications following inguinal and ilioinguinal lymphadenectomies: a meta-analysis. *J Plast Surg Hand Surg* 2016;50:315-320. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27146716>.

330. Bertheuil N, Sulpice L, Levi Sandri GB, et al. Inguinal lymphadenectomy for stage III melanoma: a comparative study of two surgical approaches at the onset of lymphoedema. *Eur J Surg Oncol* 2015;41:215-219. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25524886>.

331. Urist MM, Maddox WA, Kennedy JE, Balch CM. Patient risk factors and surgical morbidity after regional lymphadenectomy in 204 melanoma patients. *Cancer* 1983;51:2152-2156. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/6839303>.



332. Friedman JF, Sunkara B, Jehnsen JS, et al. Risk factors associated with lymphedema after lymph node dissection in melanoma patients. *Am J Surg* 2015;210:1178-1184; discussion 1184. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26482511>.

333. Tsutsumida A, Takahashi A, Namikawa K, et al. Frequency of level II and III axillary nodes metastases in patients with positive sentinel lymph nodes in melanoma: a multi-institutional study in Japan. *Int J Clin Oncol* 2016;21:796-800. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26759315>.

334. Gentile D, Covarelli P, Picciotto F, et al. Axillary Lymph Node Metastases of Melanoma: Management of Third-level Nodes. *In Vivo* 2016;30:141-145. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26912825>.

335. Nessim C, Law C, McConnell Y, et al. How often do level III nodes bear melanoma metastases and does it affect patient outcomes? *Ann Surg Oncol* 2013;20:2056-2064. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23370671>.

336. Dossett LA, Castner NB, Pow-Sang JM, et al. Robotic-Assisted Transperitoneal Pelvic Lymphadenectomy for Metastatic Melanoma: Early Outcomes Compared with Open Pelvic Lymphadenectomy. *J Am Coll Surg* 2016;222:702-709. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26875071>.

337. Jakub JW, Terando AM, Sarnaik A, et al. Safety and Feasibility of Minimally Invasive Inguinal Lymph Node Dissection in Patients With Melanoma (SAFE-MILND): Report of a Prospective Multi-institutional Trial. *Ann Surg* 2017;265:192-196. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28009745>.

338. Jakub JW, Terando AM, Sarnaik A, et al. Training High-Volume Melanoma Surgeons to Perform a Novel Minimally Invasive Inguinal Lymphadenectomy: Report of a Prospective Multi-Institutional Trial. *J Am Coll Surg* 2016;222:253-260. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26711792>.

339. Pathak I, O'Brien CJ, Petersen-Schaeffer K, et al. Do nodal metastases from cutaneous melanoma of the head and neck follow a clinically predictable pattern? *Head Neck* 2001;23:785-790. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11505490>.

340. Strom T, Caudell JJ, Han D, et al. Radiotherapy influences local control in patients with desmoplastic melanoma. *Cancer* 2014;120:1369-1378. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24142775>.

341. Guadagnolo BA, Prieto V, Weber R, et al. The role of adjuvant radiotherapy in the local management of desmoplastic melanoma. *Cancer* 2014;120:1361-1368. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24142803>.

342. Oliver DE, Patel KR, Switchenko J, et al. Roles of adjuvant and salvage radiotherapy for desmoplastic melanoma. *Melanoma Res* 2015. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26397051>.

343. Vongtama R, Safa A, Gallardo D, et al. Efficacy of radiation therapy in the local control of desmoplastic malignant melanoma. *Head Neck* 2003;25:423-428. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12784232>.

344. National Institutes of Health. A Randomised Trial of Post-operative Radiation Therapy Following Wide Excision of Neurotropic Melanoma of the Head and Neck (RTN2). Available at: <https://clinicaltrials.gov/ct2/show/record/NCT00975520>. Accessed January 21, 2016.

345. Agrawal S, Kane JM, 3rd, Guadagnolo BA, et al. The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high-risk, lymph node-metastatic melanoma. *Cancer* 2009;115:5836-5844. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19701906>.

346. Pinkham MB, Foote MC, Burmeister E, et al. Stage III melanoma in the axilla: patterns of regional recurrence after surgery with and without adjuvant radiation therapy. *Int J Radiat Oncol Biol Phys* 2013;86:702-708. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23773393>.



347. Strojan P, Jancar B, Cemazar M, et al. Melanoma metastases to the neck nodes: role of adjuvant irradiation. *Int J Radiat Oncol Biol Phys* 2010;77:1039-1045. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19910139>.

348. Bibault JE, Dewas S, Mirabel X, et al. Adjuvant radiation therapy in metastatic lymph nodes from melanoma. *Radiat Oncol* 2011;6:12.

Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21294913>.

349. Henderson MA, Burmeister BH, Ainslie J, et al. Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial. *Lancet Oncol* 2015;16:1049-1060. Available at:

<https://www.ncbi.nlm.nih.gov/pubmed/26206146>.

350. Burmeister BH, Henderson MA, Ainslie J, et al. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. *Lancet Oncol* 2012;13:589-597. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/22575589>.

351. Beadle BM, Guadagnolo BA, Ballo MT, et al. Radiation therapy field extent for adjuvant treatment of axillary metastases from malignant melanoma. *Int J Radiat Oncol Biol Phys* 2009;73:1376-1382. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/18774657>.

352. Chang DT, Amdur RJ, Morris CG, Mendenhall WM. Adjuvant radiotherapy for cutaneous melanoma: comparing hypofractionation to conventional fractionation. *Int J Radiat Oncol Biol Phys* 2006;66:1051-1055. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16973303>.

353. Mendenhall WM, Shaw C, Amdur RJ, et al. Surgery and adjuvant radiotherapy for cutaneous melanoma considered high-risk for local-regional recurrence. *Am J Otolaryngol* 2013;34:320-322. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/23375588>.

354. Hallemeier CL, Garces YI, Neben-Wittich MA, et al. Adjuvant hypofractionated intensity modulated radiation therapy after resection of regional lymph node metastases in patients with cutaneous malignant melanoma of the head and neck. *Pract Radiat Oncol* 2013;3:e71-77. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24674323>.

355. Conill C, Valduvico I, Domingo-Domenech J, et al. Loco-regional control after postoperative radiotherapy for patients with regional nodal metastases from melanoma. *Clin Transl Oncol* 2009;11:688-693. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19828412>.

356. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. *N Engl J Med* 1990;322:494-500. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/2405271>.

357. Vecht CJ, Haaxma-Reiche H, Noordijk EM, et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? *Ann Neurol* 1993;33:583-590. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/8498838>.

358. Mintz AH, Kestle J, Rathbone MP, et al. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. *Cancer* 1996;78:1470-1476. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/8839553>.

359. Patchell RA, Tibbs PA, Regine WF, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. *JAMA* 1998;280:1485-1489. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/9809728>.

360. Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. *JAMA* 2006;295:2483-2491. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/16757720>.



361. Chang EL, Wefel JS, Hess KR, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. *Lancet Oncol* 2009;10:1037-1044. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19801201>.

362. Kocher M, Soffiotti R, Abacioglu U, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. *J Clin Oncol* 2011;29:134-141. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21041710>.

363. Samlowski WE, Watson GA, Wang M, et al. Multimodality treatment of melanoma brain metastases incorporating stereotactic radiosurgery (SRS). *Cancer* 2007;109:1855-1862. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/17351953>.

364. Hauswald H, Dittmar JO, Habermehl D, et al. Efficacy and toxicity of whole brain radiotherapy in patients with multiple cerebral metastases from malignant melanoma. *Radiat Oncol* 2012;7:130. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/22857154>.

365. Pehamberger H, Soyer HP, Steiner A, et al. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. *J Clin Oncol* 1998;16:1425-1429. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9552047>.

366. Grob JJ, Dreno B, de la Salmoniere P, et al. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. *Lancet* 1998;351:1905-1910. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9654256>.

367. Garbe C, Radny P, Linse R, et al. Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis. *Ann Oncol* 2008;19:1195-1201. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18281266>.

368. Hansson J, Aamdal S, Bastholt L, et al. Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial. *Lancet Oncol* 2011;12:144-152. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/21256809>.

369. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. *J Clin Oncol* 1996;14:7-17. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8558223>.

370. Kirkwood JM, Manola J, Ibrahim J, et al. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. *Clin Cancer Res* 2004;10:1670-1677. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15014018>.

371. Kirkwood JM, Ibrahim JG, Sondak VK, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. *J Clin Oncol* 2000;18:2444-2458. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10856105>.

372. Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. *J Clin Oncol* 2001;19:2370-2380. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/11331315>.

373. Eggermont AM, Suci S, Santinami M, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. *Lancet* 2008;372:117-126. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/18620949>.

374. Cascinelli N, Belli F, MacKie RM, et al. Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. *Lancet* 2001;358:866-869. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11567700>.



375. Hancock BW, Wheatley K, Harris S, et al. Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. *J Clin Oncol* 2004;22:53-61. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14665609>.

376. Kleeberg UR, Suci S, Brocker EB, et al. Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. *Eur J Cancer* 2004;40:390-402. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14746858>.

377. Eggermont AM, Suci S, Rutkowski P, et al. Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB-III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: Ulceration of primary is key determinant for IFN-sensitivity. *Eur J Cancer* 2016;55:111-121. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26790144>.

378. McMasters KM, Egger ME, Edwards MJ, et al. Final Results of the Sunbelt Melanoma Trial: A Multi-Institutional Prospective Randomized Phase III Study Evaluating the Role of Adjuvant High-Dose Interferon Alfa-2b and Completion Lymph Node Dissection for Patients Staged by Sentinel Lymph Node Biopsy. *J Clin Oncol* 2016;34:1079-1086. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26858331>.

379. Agarwala SS, Lee SJ, Yip W, et al. Phase III Randomized Study of 4 Weeks of High-Dose Interferon-alpha-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697). *J Clin Oncol* 2017;35:885-892. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28135150>.

380. Creagan ET, Dalton RJ, Ahmann DL, et al. Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. *J Clin Oncol* 1995;13:2776-2783. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7595738>.

381. Eggermont AM, Suci S, Testori A, et al. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. *J Clin Oncol* 2012;30:3810-3818. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23008300>.

382. Ives NJ, Suci S, Eggermont AMM, et al. Adjuvant interferon-alpha for the treatment of high-risk melanoma: An individual patient data meta-analysis. *Eur J Cancer* 2017;82:171-183. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28692949>.

383. Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. *Lancet Oncol* 2015;16:522-530. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25840693>.

384. Eggermont AM, Chiarion-Sileni V, Grob JJ, et al. Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. *N Engl J Med* 2016;375:1845-1855. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27717298>.

385. Weber J, Mandala M, Del Vecchio M, et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. *N Engl J Med* 2017;377:1824-1835. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28891423>.

386. Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. *N Engl J Med* 2018;378:1789-1801. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29658430>.

387. Long GV, Hauschild A, Santinami M, et al. Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. *N Engl J Med* 2017;377:1813-1823. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28891408>.



388. Flaherty LE, Othus M, Atkins MB, et al. Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Children's Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. *J Clin Oncol* 2014;32:3771-3778. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25332243>.

389. ClinicalTrials.gov. Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716). Available at: <https://clinicaltrials.gov/ct2/show/NCT03553836>. Accessed Feb 26, 2019.

390. ClinicalTrials.gov. Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by Surgery. Available at: <https://clinicaltrials.gov/ct2/show/record/NCT03405155>. Accessed Feb 26, 2019.

391. Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. *CA Cancer J Clin* 2017;67:472-492. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29028110>.

392. Faries MB, Thompson JF, Cochran AJ, et al. Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma. *N Engl J Med* 2017;376:2211-2222. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28591523>.

393. Maio M, Lewis K, Demidov L, et al. Adjuvant vemurafenib in resected, BRAF(V600) mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. *Lancet Oncol* 2018;19:510-520. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29477665>.

394. E.R. Squibb & Sons, LLC. Prescribing information: YERVOY® (ipilimumab) injection, for intravenous use. 2018. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125377s0961.bl.pdf. Accessed Oct 15, 2018.

395. Bristol-Myers Squibb Company. Prescribing information: OPDIVO (nivolumab) injection, for intravenous use. 2019. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125554s0721.bl.pdf. Accessed Feb 2019.

396. Merck & Co., Inc. Prescribing information: KEYTRUDA® (pembrolizumab) injection, for intravenous use. 2019. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/125514s0401.bl.pdf. Accessed Feb 19, 2019.

397. GlaxoSmithKline. Prescribing information: TAFINLAR (dabrafenib) capsules, for oral use. 2018. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/202806s0101.bl.pdf. Accessed Oct 15, 2018.

398. Genentech, Inc. Prescribing information: ZELBORAF® (vemurafenib) tablet for oral use. 2017. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202429s0161.bl.pdf. Accessed Oct 15, 2018.

399. GlaxoSmithKline. Prescribing information: MEKINIST (trametinib) tablets, for oral use. 2018. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/204114Orig1s0091bl.pdf. Accessed Oct 15, 2018.

400. Genentech, Inc. Prescribing information: COTELLIC (cobimetinib) tablets, for oral use. 2018. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/206192s0021.bl.pdf. Accessed Oct 15, 2018.

401. Array BioPharma Inc. Prescribing information: MEKTOVI (binimetinib) tablets, for oral use. 2018. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/2104981bl.pdf. Accessed Oct 15, 2018.

402. Array BioPharma Inc. Prescribing information: BRAFTOVI (encorafenib) capsules, for oral use. 2019. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210496s0011.bl.pdf. Accessed Feb 2019.



NCCN Guidelines Version 3.2023

Melanoma: Cutaneous

403. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. *N Engl J Med* 2010;363:711-723. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20525992>.

404. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. *N Engl J Med* 2011;364:2517-2526. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21639810>.

405. Ribas A, Hamid O, Daud A, et al. Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma. *JAMA* 2016;315:1600-1609. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27092830>.

406. Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. *Lancet Oncol* 2015;16:908-918. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26115796>.

407. Robert C, Schachter J, Long GV, et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. *N Engl J Med* 2015;372:2521-2532. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25891173>.

408. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. *N Engl J Med* 2015;373:23-34. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26027431>.

409. Hodi FS, Chesney J, Pavlick AC, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. *Lancet Oncol* 2016;17:1558-1568. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27622997>.

410. Larkin J, Minor D, D'Angelo S, et al. Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. *J Clin Oncol* 2018;36:383-390. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28671856>.

411. Long GV, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. *Lancet* 2015;386:444-451. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26037941>.

412. Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. *N Engl J Med* 2015;372:30-39. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25399551>.

413. Larkin J, Ascierto PA, Dreno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. *N Engl J Med* 2014;371:1867-1876. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25265494>.

414. Feng Y, Roy A, Masson E, et al. Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma. *Clin Cancer Res* 2013;19:3977-3986. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23741070>.

415. Bertrand A, Kostine M, Barnette T, et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. *BMC Med* 2015;13:211. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26337719>.

416. Wolchok JD, Weber JS, Hamid O, et al. Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials. *Cancer Immun* 2010;10:9. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20957980>.



NCCN Guidelines Version 3.2023 Melanoma: Cutaneous

417. Wolchok JD, Neyns B, Linette G, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. *Lancet Oncol* 2010;11:155-164. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20004617>.
418. Tarhini AA, Lee SJ, Hodi FS, et al. A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk melanoma (U.S. Intergroup E1609): Preliminary safety and efficacy of the ipilimumab arms (abstract). *J Clin Oncol* 2017;35:Abstr 9500. Available at: http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.9500.
419. Woo SR, Turnis ME, Goldberg MV, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. *Cancer Res* 2012;72:917-927. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22186141>.
420. Wang C, Thudium KB, Han M, et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. *Cancer Immunol Res* 2014;2:846-856. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24872026>.
421. Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. *N Engl J Med* 2017;377:1345-1356. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28889792>.
422. Schachter J, Ribas A, Long GV, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). *Lancet* 2017;390:1853-1862. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28822576>.
423. Amaria RN, Prieto PA, Tetzlaff MT, et al. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. *Lancet Oncol* 2018;19:181-193. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29361468>.
424. Blank CU, Rozeman EA, Fanchi LF, et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. *Nat Med* 2018. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30297911>.
425. Amaria RN, Reddy SM, Tawbi HA, et al. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. *Nat Med* 2018. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30297909>.
426. Tarhini AA, Edington H, Butterfield LH, et al. Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. *PLoS One* 2014;9:e87705. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24498358>.
427. Retseck J, VanderWeele R, Lin HM, et al. Phenotypic and functional testing of circulating regulatory T cells in advanced melanoma patients treated with neoadjuvant ipilimumab. *J Immunother Cancer* 2016;4:38. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27330811>.
428. Tarhini AA, Zahoor H, Lin Y, et al. Baseline circulating IL-17 predicts toxicity while TGF-beta1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. *J Immunother Cancer* 2015;3:39. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26380086>.
429. National Institutes of Health. Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma (NeoTrio). Available at: <https://clinicaltrials.gov/ct2/show/record/NCT02858921>. Accessed June 6, 2017.
430. National Institutes of Health. ML29255 Neoadjuvant Vemurafenib and Cobimetinib Melanoma. Available at: <https://clinicaltrials.gov/ct2/show/record/NCT03005639>. Accessed June 6, 2017.



NCCN Guidelines Version 3.2023

Melanoma: Cutaneous

431. National Institutes of Health. Neoadjuvant and Adjuvant Dabrafenib and Trametinib in Patients With Clinical Stage III Melanoma (Combi-Neo). Available at: <https://clinicaltrials.gov/ct2/show/record/NCT02231775>. Accessed June 6, 2017.

432. National Institutes of Health. Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases. Available at: <https://clinicaltrials.gov/ct2/show/record/NCT02036086>. Accessed June 6, 2017.

433. National Institutes of Health. Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma. Available at: <https://clinicaltrials.gov/ct2/show/record/NCT01972347>. Accessed June 6, 2017.

434. National Institutes of Health. Neoadjuvant Vemurafenib + Cobimetinib in Melanoma: NEO-VC. Available at: <https://clinicaltrials.gov/ct2/show/record/NCT02303951>. Accessed January 25, 2016.

435. National Institutes of Health. Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma (NeoPembroMel). Available at: <https://clinicaltrials.gov/ct2/show/record/NCT02306850>. Accessed June 6, 2017.

436. National Institutes of Health. Pembrolizumab in Treating Patients With Stage III-IV High-Risk Melanoma Before and After Surgery. Available at: <https://clinicaltrials.gov/ct2/show/NCT03698019>. Accessed Oct 17, 2018.

437. National Institutes of Health. CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease. Available at: <https://clinicaltrials.gov/ct2/show/record/NCT03618641>. Accessed Oct 17, 2018.

438. National Institutes of Health. Neoadjuvant Combination Targeted and Immunotherapy for Patients With High-Risk Stage III Melanoma (NeoACTIVATE). Available at: <https://clinicaltrials.gov/ct2/show/NCT03554083>. Accessed Oct 17, 2018.

439. National Institutes of Health. Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma. Available at: <https://clinicaltrials.gov/ct2/show/record/NCT03259425>. Accessed Oct 17, 2018.

440. National Institutes of Health. Nivolumab With or Without Ipilimumab or Relatlimab Before Surgery in Treating Patients With Stage IIIB-IV Melanoma That Can Be Removed by Surgery. Available at: <https://clinicaltrials.gov/ct2/show/NCT02519322>. Accessed Oct 17, 2018.

441. National Institutes of Health. A Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced Melanoma. Available at: <https://clinicaltrials.gov/ct2/show/NCT02434354>. Accessed Oct 17, 2018.

442. National Institutes of Health. Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN- α 2b. Available at: <https://clinicaltrials.gov/ct2/show/NCT02339324>. Accessed Oct 17, 2018.

443. National Institutes of Health. Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma. Available at: <https://clinicaltrials.gov/ct2/show/NCT02211131>. Accessed Oct 17, 2018.

444. Yao KA, Hsueh EC, Essner R, et al. Is sentinel lymph node mapping indicated for isolated local and in-transit recurrent melanoma? *Ann Surg* 2003;238:743-747. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14578738>.

445. Ridolfi L, Ridolfi R. Preliminary experiences of intralesional immunotherapy in cutaneous metastatic melanoma. *Hepatogastroenterology* 2002;49:335-339. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11995445>.



NCCN Guidelines Version 3.2023 Melanoma: Cutaneous

446. Si Z, Hersey P, Coates AS. Clinical responses and lymphoid infiltrates in metastatic melanoma following treatment with intralesional GM-CSF. *Melanoma Res* 1996;6:247-255. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8819128>.

447. Nasi ML, Lieberman P, Busam KJ, et al. Intradermal injection of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with metastatic melanoma recruits dendritic cells. *Cytokines Cell Mol Ther* 1999;5:139-144. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10641571>.

448. Hoeller C, Jansen B, Heere-Ress E, et al. Perilesional injection of r-GM-CSF in patients with cutaneous melanoma metastases. *J Invest Dermatol* 2001;117:371-374. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11511318>.

449. Kaufman HL, Ruby CE, Hughes T, Slingluff CL, Jr. Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma. *J Immunother Cancer* 2014;2:11. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24971166>.

450. Andtbacka RH, Kaufman HL, Collichio F, et al. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. *J Clin Oncol* 2015;33:2780-2788. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26014293>.

451. Andtbacka RHI, Chastain M, Li A, et al. Phase 2, multicenter, randomized, open-label trial assessing efficacy and safety of talimogene laherparepvec (T-VEC) neoadjuvant treatment (tx) plus surgery vs surgery for resectable stage IIIB/C and IVM1a melanoma (MEL). *ASCO Meeting Abstracts* 2015;33:TPS9094. Available at: http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/TPS9094.

452. Weide B, Derhovanessian E, Pflugfelder A, et al. High response rate after intratumoral treatment with interleukin-2: results from a phase 2 study in 51 patients with metastasized melanoma. *Cancer* 2010;116:4139-4146. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20564107>.

453. Radny P, Caroli UM, Bauer J, et al. Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases. *Br J Cancer* 2003;89:1620-1626. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14583759>.

454. Byers BA, Temple-Oberle CF, Hurdle V, McKinnon JG. Treatment of in-transit melanoma with intra-lesional interleukin-2: a systematic review. *J Surg Oncol* 2014;110:770-775. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24996052>.

455. Temple-Oberle CF, Byers BA, Hurdle V, et al. Intra-lesional interleukin-2 therapy for in transit melanoma. *J Surg Oncol* 2014;109:327-331. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24453036>.

456. Ilic D, Spaventi S, Padovan I, et al. Local interferon therapy for melanoma patients. *Int J Dermatol* 1995;34:872-874. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8647672>.

457. Tan JK, Ho VC. Pooled analysis of the efficacy of bacille Calmette-Guerin (BCG) immunotherapy in malignant melanoma. *J Dermatol Surg Oncol* 1993;19:985-990. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8245304>.

458. Krown SE, Hilal EY, Pinsky CM, et al. Intralesional injection of the methanol extraction residue of Bacillus Calmette-Guerin (MER) into cutaneous metastases of malignant melanoma. *Cancer* 1978;42:2648-2660. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/728866>.

459. Cohen MH, Jessup JM, Felix EL, et al. Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: a randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene. *Cancer* 1978;41:2456-2463. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/657108>.

460. Mastrangelo MJ, Sulit HL, Prehn LM, et al. Intralesional BCG in the treatment of metastatic malignant melanoma. *Cancer* 1976;37:684-692. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/766947>.



461. Thompson JF, Agarwala SS, Smithers BM, et al. Phase 2 Study of Intravesicular PV-10 in Refractory Metastatic Melanoma. *Ann Surg Oncol* 2015;22:2135-2142. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/25348780>.

462. Thompson JF, Hersey P, Wachter E. Chemoablation of metastatic melanoma using intralesional Rose Bengal. *Melanoma Res* 2008;18:405-411. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18830132>.

463. Boyd KU, Wehrli BM, Temple CL. Intra-lesional interleukin-2 for the treatment of in-transit melanoma. *J Surg Oncol* 2011;104:711-717. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21744347>.

464. Garcia MS, Ono Y, Martinez SR, et al. Complete regression of subcutaneous and cutaneous metastatic melanoma with high-dose intralesional interleukin 2 in combination with topical imiquimod and retinoid cream. *Melanoma Res* 2011;21:235-243. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21464773>.

465. Weide B, Eigentler TK, Pflugfelder A, et al. Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up. *Cancer Immunol Immunother* 2011;60:487-493. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21174093>.

466. Dehesa LA, Vilar-Alejo J, Valeron-Almazan P, Carretero G. [Experience in the treatment of cutaneous in-transit melanoma metastases and satellitosis with intralesional interleukin-2]. *Actas Dermosifiliogr* 2009;100:571-585. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19715642>.

467. Morton DL, Eilber FR, Holmes EC, et al. BCG immunotherapy of malignant melanoma: summary of a seven-year experience. *Ann Surg* 1974;180:635-643. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/4412271>.

468. van Jarwaarde JA, Wessels R, Nieweg OE, et al. CO2 laser treatment for regional cutaneous malignant melanoma metastases. *Dermatol Surg* 2015;41:78-82. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/25521108>.

469. Kandamany N, Mahaffey P. Carbon dioxide laser ablation as first-line management of in-transit cutaneous malignant melanoma metastases. *Lasers Med Sci* 2009;24:411-414. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18566850>.

470. Gibson SC, Byrne DS, McKay AJ. Ten-year experience of carbon dioxide laser ablation as treatment for cutaneous recurrence of malignant melanoma. *Br J Surg* 2004;91:893-895. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15227697>.

471. Hill S, Thomas JM. Use of the carbon dioxide laser to manage cutaneous metastases from malignant melanoma. *Br J Surg* 1996;83:509-512. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8665245>.

472. Lingam MK, McKay AJ. Carbon dioxide laser ablation as an alternative treatment for cutaneous metastases from malignant melanoma. *Br J Surg* 1995;82:1346-1348. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7489160>.

473. Waters RA, Clement RM, Thomas JM. Carbon dioxide laser ablation of cutaneous metastases from malignant melanoma. *Br J Surg* 1991;78:493-494. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1903320>.

474. Hill S, Thomas JM. Treatment of cutaneous metastases from malignant melanoma using the carbon-dioxide laser. *Eur J Surg Oncol* 1993;19:173-177. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8491321>.

475. Turza K, Dengel LT, Harris RC, et al. Effectiveness of imiquimod limited to dermal melanoma metastases, with simultaneous resistance of subcutaneous metastasis. *J Cutan Pathol* 2010;37:94-98. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19602071>.



476. Bong AB, Bonnekoh B, Franke I, et al. Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma. *Dermatology* 2002;205:135-138. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12218228>.
477. Kibbi N, Ariyan S, Faries M, Choi JN. Treatment of In-Transit Melanoma With Intralesional Bacillus Calmette-Guerin (BCG) and Topical Imiquimod 5% Cream: A Report of 3 Cases. *J Immunother* 2015;38:371-375. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26448581>.
478. Heber G, Helbig D, Ponitzsch I, et al. Complete remission of cutaneous and subcutaneous melanoma metastases of the scalp with imiquimod therapy. *J Dtsch Dermatol Ges* 2009;7:534-536. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19250248>.
479. Miller AK, Dusing R, Meggison A, Aires D. Regression of internal melanoma metastases following application of topical imiquimod to overlying skin. *J Drugs Dermatol* 2011;10:302-305. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21369648>.
480. Arbiser JL, Bips M, Seidler A, et al. Combination therapy of imiquimod and gentian violet for cutaneous melanoma metastases. *J Am Acad Dermatol* 2012;67:e81-83. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22794825>.
481. Shistik G, Prakash AV, Fenske NA, Glass LF. Treatment of locally metastatic melanoma: a novel approach. *J Drugs Dermatol* 2007;6:830-832. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17763615>.
482. Li X, Naylor MF, Le H, et al. Clinical effects of in situ photoimmunotherapy on late-stage melanoma patients: a preliminary study. *Cancer Biol Ther* 2010;10:1081-1087. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20890121>.
483. Florin V, Desmedt E, Vercambre-Darras S, Mortier L. Topical treatment of cutaneous metastases of malignant melanoma using combined imiquimod and 5-fluorouracil. *Invest New Drugs* 2012;30:1641-1645. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21748297>.
484. Green DS, Bodman-Smith MD, Dalglish AG, Fischer MD. Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanoma. *Br J Dermatol* 2007;156:337-345. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17223875>.
485. Kidner TB, Morton DL, Lee DJ, et al. Combined intralesional Bacille Calmette-Guerin (BCG) and topical imiquimod for in-transit melanoma. *J Immunother* 2012;35:716-720. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23090081>.
486. Shi VY, Tran K, Patel F, et al. 100% Complete response rate in patients with cutaneous metastatic melanoma treated with intralesional interleukin (IL)-2, imiquimod, and topical retinoid combination therapy: Results of a case series. *J Am Acad Dermatol* 2015;73:645-654. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26259990>.
487. Hinz T, Ehler LK, Bieber T, Schmid-Wendtner MH. Complete remission of extensive cutaneous metastatic melanoma on the scalp under topical mono-immunotherapy with diphenylcyclopropenone. *Eur J Dermatol* 2013;23:532-533. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24002471>.
488. Kim YJ. Topical diphencyprone as an effective treatment for cutaneous metastatic melanoma. *Ann Dermatol* 2012;24:373-375. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22879730>.
489. Damian DL, Thompson JF. Topical diphencyprone immunotherapy for a large primary melanoma on an elderly leg. *Am J Clin Dermatol* 2011;12:403-404. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21967115>.
490. Martiniuk F, Damian DL, Thompson JF, et al. TH17 is involved in the remarkable regression of metastatic malignant melanoma to topical diphencyprone. *J Drugs Dermatol* 2010;9:1368-1372. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21061759>.



NCCN Guidelines Version 3.2023

Melanoma: Cutaneous

491. Damian DL, Thompson JF. Treatment of extensive cutaneous metastatic melanoma with topical diphenylproprionone. *J Am Acad Dermatol* 2007;56:869-871. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/17276544>.

492. Damian DL, Shannon KF, Saw RP, Thompson JF. Topical diphenylproprionone immunotherapy for cutaneous metastatic melanoma. *Australas J Dermatol* 2009;50:266-271. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19916970>.

493. Harland CC, Saihan EM. Regression of cutaneous metastatic malignant melanoma with topical diphenylproprionone and oral cimetidine. *Lancet* 1989;2:445. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/2569622>.

494. Trefzer U, Sterry W. Topical immunotherapy with diphenylproprionone in combination with DTIC and radiation for cutaneous metastases of melanoma. *Dermatology* 2005;211:370-371. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/16286751>.

495. Damian DL, Saw RP, Thompson JF. Topical immunotherapy with diphenylproprionone for in transit and cutaneously metastatic melanoma. *J Surg Oncol* 2014;109:308-313. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/24522938>.

496. Omlor G, Gross G, Ecker KW, et al. Optimization of isolated hyperthermic limb perfusion. *World J Surg* 1992;16:1117-1119. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/1455882>.

497. Stehlin JS, Jr., Giovanella BC, de Ipolyi PD, Anderson RF. Results of eleven years' experience with heated perfusion for melanoma of the extremities. *Cancer Res* 1979;39:2255-2257. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/445425>.

498. Ko SH, Ueno T, Yoshimoto Y, et al. Optimizing a novel regional chemotherapeutic agent against melanoma: hyperthermia-induced enhancement of temozolomide cytotoxicity. *Clin Cancer Res* 2006;12:289-297. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/16397054>.

499. Lindner P, Doubrovsky A, Kam PC, Thompson JF. Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma. *Ann Surg Oncol* 2002;9:127-136. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/11888868>.

500. Barbour AP, Thomas J, Suffolk J, et al. Isolated limb infusion for malignant melanoma: predictors of response and outcome. *Ann Surg Oncol* 2009;16:3463-3472. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/19830498>.

501. Di Filippo F, Garinei R, Giannarelli D, et al. Hyperthermic antilimbic perfusion in the treatment of locoregional spreading limb melanoma. *J Exp Clin Cancer Res* 2003;22:89-95. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/16767913>.

502. Vrouenraets BC, Eggermont AM, Hart AA, et al. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor-alpha versus toxicity after melphalan alone. *Eur J Surg Oncol* 2001;27:390-395. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/11417986>.

503. Thompson JF, Eksborg S, Kam PC, et al. Determinants of acute regional toxicity following isolated limb perfusion for melanoma. *Melanoma Res* 1996;6:267-271. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/8819130>.

504. Creech O, Jr., Ryan RF, Kremenz ET. Treatment of melanoma by isolation-perfusion technique. *J Am Med Assoc* 1959;169:339-343. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/13610669>.

505. Thompson JF, Lai DT, Ingvar C, Kam PC. Maximizing efficacy and minimizing toxicity in isolated limb perfusion for melanoma. *Melanoma Res* 1994;4 Suppl 1:45-50. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/8038596>.

506. Thompson JF, Hunt JA, Shannon KF, Kam PC. Frequency and duration of remission after isolated limb perfusion for melanoma. *Arch Surg* 1997;132:903-907. Available at:

<http://www.ncbi.nlm.nih.gov/pubmed/9267277>.



NCCN Guidelines Version 3.2023

Melanoma: Cutaneous

507. Moreno-Ramirez D, de la Cruz-Merino L, Ferrandiz L, et al. Isolated limb perfusion for malignant melanoma: systematic review on effectiveness and safety. *Oncologist* 2010;15:416-427. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20348274>.

508. Noorda EM, Vrouwenraets BC, Nieweg OE, et al. Isolated limb perfusion for unresectable melanoma of the extremities. *Arch Surg* 2004;139:1237-1242. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15545572>.

509. Cornett WR, McCall LM, Petersen RP, et al. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. *J Clin Oncol* 2006;24:4196-4201. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16943537>.

510. Kroon HM. Treatment of locally advanced melanoma by isolated limb infusion with cytotoxic drugs. *J Skin Cancer* 2011;2011:106573. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21822495>.

511. Thompson JF, Kam PC, Waugh RC, Harman CR. Isolated limb infusion with cytotoxic agents: a simple alternative to isolated limb perfusion. *Semin Surg Oncol* 1998;14:238-247. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9548607>.

512. Kroon HM, Lin DY, Kam PC, Thompson JF. Efficacy of repeat isolated limb infusion with melphalan and actinomycin D for recurrent melanoma. *Cancer* 2009;115:1932-1940. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19288571>.

513. Kroon HM, Lin DY, Kam PC, Thompson JF. Safety and efficacy of isolated limb infusion with cytotoxic drugs in elderly patients with advanced locoregional melanoma. *Ann Surg* 2009;249:1008-1013. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19474677>.

514. Kroon HM, Huismans AM, Kam PC, Thompson JF. Isolated limb infusion with melphalan and actinomycin D for melanoma: a systematic review. *J Surg Oncol* 2014;109:348-351. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24522939>.

515. Beasley GM, Caudle A, Petersen RP, et al. A multi-institutional experience of isolated limb infusion: defining response and toxicity in the US. *J Am Coll Surg* 2009;208:706-715; discussion 715-707. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19476821>.

516. Santillan AA, Delman KA, Beasley GM, et al. Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis. *Ann Surg Oncol* 2009;16:2570-2578. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19543771>.

517. Lidsky ME, Turley RS, Beasley GM, et al. Predicting disease progression after regional therapy for in-transit melanoma. *JAMA Surg* 2013;148:493-498. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23558401>.

518. Chai CY, Deneve JL, Beasley GM, et al. A multi-institutional experience of repeat regional chemotherapy for recurrent melanoma of extremities. *Ann Surg Oncol* 2012;19:1637-1643. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22143576>.

519. Raymond AK, Beasley GM, Broadwater G, et al. Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution. *J Am Coll Surg* 2011;213:306-316. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21493111>.

520. Reintgen M, Reintgen C, Nobo C, et al. Regional Therapy for Recurrent Metastatic Melanoma Confined to the Extremity: Hyperthermic Isolated Limb Perfusion vs. Isolated Limb Infusion. *Cancers (Basel)* 2010;2:43-50. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24281032>.

521. Sharma K, Beasley G, Turley R, et al. Patterns of recurrence following complete response to regional chemotherapy for in-transit melanoma. *Ann Surg Oncol* 2012;19:2563-2571. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22476748>.



522. Steinman J, Ariyan C, Rafferty B, Brady MS. Factors associated with response, survival, and limb salvage in patients undergoing isolated limb infusion. *J Surg Oncol* 2014;109:405-409. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24318953>.

523. Weber JS, D'Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. *Lancet Oncol* 2015;16:375-384. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25795410>.

524. Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. *N Engl J Med* 2014;371:1877-1888. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25265492>.

525. Larkin J, Del Vecchio M, Ascierto PA, et al. Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study. *Lancet Oncol* 2014;15:436-444. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24582505>.

526. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. *N Engl J Med* 2015;372:320-330. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25399552>.

527. Johnson DB, Flaherty KT, Weber JS, et al. Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitor. *J Clin Oncol* 2014;32:3697-3704. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25287827>.

528. Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. *N Engl J Med* 2015;372:2006-2017. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25891304>.

529. Hamid O, Puzanov I, Dummer R, et al. Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. *Eur J Cancer* 2017;86:37-45. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28961465>.

530. Ascierto PA, Long GV, Robert C, et al. Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial. *JAMA Oncol* 2018. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30422243>.

531. Hodi FS, Chiarion-Sileni V, Gonzalez R, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. *Lancet Oncol* 2018. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30361170>.

532. Finn OJ. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. *Ann Oncol* 2012;23 Suppl 8:viii6-9. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22918931>.

533. Bhatia A, Kumar Y. Cellular and molecular mechanisms in cancer immune escape: a comprehensive review. *Expert Rev Clin Immunol* 2014;10:41-62. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24325346>.

534. Vinay DS, Ryan EP, Pawelec G, et al. Immune evasion in cancer: Mechanistic basis and therapeutic strategies. *Semin Cancer Biol* 2015;35 Suppl:S185-198. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25818339>.

535. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. *J Exp Med* 1995;182:459-465. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7543139>.

536. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. *Nat Rev Cancer* 2012;12:252-264. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22437870>.



537. Huard B, Prigent P, Tournier M, et al. CD4/major histocompatibility complex class II interaction analyzed with CD4- and lymphocyte activation gene-3 (LAG-3)-Ig fusion proteins. *Eur J Immunol* 1995;25:2718-2721. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/7589152>.

538. Grosso JF, Kelleher CC, Harris TJ, et al. LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. *J Clin Invest* 2007;117:3383-3392. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17932562>.

539. Peggs KS, Quezada SA, Chambers CA, et al. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. *J Exp Med* 2009;206:1717-1725. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19581407>.

540. Maio M, Grob JJ, Aamdal S, et al. Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial. *J Clin Oncol* 2015;33:1191-1196. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25713437>.

541. Wolchok JD, Weber JS, Maio M, et al. Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. *Ann Oncol* 2013;24:2174-2180. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23666915>.

542. Lebbe C, Weber JS, Maio M, et al. Survival follow-up and ipilimumab retreatment of patients with advanced melanoma who received ipilimumab in prior phase II studies. *Ann Oncol* 2014;25:2277-2284. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25210016>.

543. Schadendorf D, Hodi FS, Robert C, et al. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma. *J Clin Oncol* 2015;33:1889-1894. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25667295>.

544. Ascierto PA, Del Vecchio M, Robert C, et al. Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. *Lancet Oncol* 2017. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28359784>.

545. Robert C, Schadendorf D, Messina M, et al. Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control. *Clin Cancer Res* 2013;19:2232-2239. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23444228>.

546. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. *Cancer Cell* 2015;27:450-461. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25858804>.

547. Schadendorf D, Dummer R, Hauschild A, et al. Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma. *Eur J Cancer* 2016;67:46-54. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27596353>.

548. Robert C, Long GV, Schachter J, et al. Long-term outcomes in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in the phase 3 KEYNOTE-006 study who completed pembrolizumab (pembro) treatment. *J Clin Oncol* 2017;35:9504-9504. Available at: http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.9504.

549. Carlino MS, Long GV, Schadendorf D, et al. Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial. *Eur J Cancer* 2018;101:236-243. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30096704>.

550. Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. *Lancet* 2014;384:1109-1117. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25034862>.



551. Robert C, Ribas A, Hamid O, et al. Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. *J Clin Oncol* 2018;36:1668-1674. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29283791>.

552. Weber JS, Gibney G, Sullivan RJ, et al. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. *Lancet Oncol* 2016;17:943-955. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27269740>.

553. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. *N Engl J Med* 2013;369:122-133. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/23724867>.

554. Callahan MK, Kluger H, Postow MA, et al. Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study. *J Clin Oncol* 2018;36:391-398. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29040030>.

555. Di Giacomo AM, Annesi D, Ascierto PA, et al. A randomized, phase III study of fotemustine versus the combination of fotemustine and ipilimumab or the combination of ipilimumab and nivolumab in patients with metastatic melanoma with brain metastasis: the NIBIT-M2 trial. *ASCO Meeting Abstracts* 2015;33:TPS9090. Available at: http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/TPS9090.

556. Tawbi HA, Forsyth PA, Algazi A, et al. Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain. *N Engl J Med* 2018;379:722-730. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30134131>.

557. Long GV, Atkinson V, Lo S, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. *Lancet Oncol* 2018;19:672-681. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29602646>.

558. Long GV, Atkinson V, Cebon JS, et al. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. *Lancet Oncol* 2017;18:1202-1210. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28729151>.

559. Hodi FS, Postow MA, Chesney JA, et al. Clinical response, progression-free survival (PFS), and safety in patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI) vs IPI monotherapy in CheckMate 069 study. *ASCO Meeting Abstracts* 2015;33:9004. Available at: http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/9004.

560. Schadendorf D, Wolchok JD, Hodi FS, et al. Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. *J Clin Oncol* 2017;0:JCO2017732289. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28841387>.

561. Olson D, Luke JJ, Hallmeyer S, et al. Phase II trial of pembrolizumab (pembro) plus 1 mg/kg ipilimumab (ipi) immediately following progression on anti-PD-1 Ab in melanoma (mel) (abstract). 2018;36:Abs 9514. Available at: http://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.9514.

562. Lebbé C, Meyer N, Mortier L, et al. Initial results from a phase IIIb/IV study evaluating two dosing regimens of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 511)(abstract). *Ann Oncol* 2018;29:LBA47. Available at: <http://dx.doi.org/10.1093/annonc/mdy424.057>.

563. Puzanov I, Dummer R, Schachter J, et al. Efficacy based on tumor PD-L1 expression in KEYNOTE-002, a randomized comparison of pembrolizumab (pembro; MK-3475) versus chemotherapy in patients (pts) with ipilimumab-refractory (IPI-R) advanced melanoma (MEL). *ASCO Meeting Abstracts* 2015;33:3012. Available at: http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/3012.



NCCN Guidelines Version 3.2023

Melanoma: Cutaneous

564. Daud AI, Wolchok JD, Robert C, et al. Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. *J Clin Oncol* 2016;34:4102-4109. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27863197>.

565. Shreders A, Joseph R, Peng C, et al. Prolonged Benefit from Ipilimumab Correlates with Improved Outcomes from Subsequent Pembrolizumab. *Cancer Immunol Res* 2016;4:569-573. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27197063>.

566. Goldberg SB, Gettinger SN, Mahajan A, et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. *Lancet Oncol* 2016;17:976-983. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27267608>.

567. Kluger HM, Chiang V, Mahajan A, et al. Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial. *J Clin Oncol* 2018;JCO1800204. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30407895>.

568. Ribas A, Dummer R, Puzanov I, et al. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. *Cell* 2017;170:1109-1119 e1110. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28886381>.

569. Puzanov I, Milhem MM, Minor D, et al. Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma. *J Clin Oncol* 2016;34:2619-2626. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27298410>.

570. Chesney J, Puzanov I, Collichio F, et al. Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. *J Clin Oncol* 2018;36:1658-1667. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28981385>.

571. Agrawal S, Feng Y, Roy A, et al. Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy. *J Immunother Cancer* 2016;4:72. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27879974>.

572. Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. *J Clin Oncol* 2014;32:1020-1030. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24590637>.

573. Weber JS, Kudchadkar RR, Yu B, et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. *J Clin Oncol* 2013;31:4311-4318. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24145345>.

574. Freeman-Keller M, Kim Y, Cronin H, et al. Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes. *Clin Cancer Res* 2016;22:886-894. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26446948>.

575. Zhao X, Suryawanshi S, Hruska M, et al. Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors. *Ann Oncol* 2017;28:2002-2008. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28520840>.

576. Long GV, Tykodi SS, Schneider JG, et al. Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer. *Ann Oncol* 2018. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30215677>.

577. Wang X, Feng Y, Bajaj G, et al. Quantitative Characterization of the Exposure-Response Relationship for Cancer Immunotherapy: A Case Study of Nivolumab in Patients With Advanced Melanoma. *CPT Pharmacometrics Syst Pharmacol* 2017;6:40-48. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28019090>.



578. Larkin J, Lao CD, Urba WJ, et al. Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials. *JAMA Oncol* 2015;1:433-440. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26181250>.

579. Freshwater T, Kondic A, Ahamadi M, et al. Evaluation of dosing strategy for pembrolizumab for oncology indications. *J Immunother Cancer* 2017;5:43. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28515943>.

580. Bajaj G, Wang X, Agrawal S, et al. Model-Based Population Pharmacokinetic Analysis of Nivolumab in Patients With Solid Tumors. *CPT Pharmacometrics Syst Pharmacol* 2017;6:58-66. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28019091>.

581. Long GV, Schachter J, Ribas A, et al. 4-year survival and outcomes after cessation of pembrolizumab (pembro) after 2-years in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in KEYNOTE-006 (abstract). *J Clin Oncol* 2018;36:abstr 9503. Available at: <https://meetinglibrary.asco.org/record/159075/abstract>.

582. Hodi FS, Hwu WJ, Kefford R, et al. Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. *J Clin Oncol* 2016;34:1510-1517. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/26951310>.

583. Long GV, Weber JS, Larkin J, et al. Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials. *JAMA Oncol* 2017;3:1511-1519. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28662232>.

584. Beaver JA, Hazarika M, Mulkey F, et al. Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis. *Lancet Oncol* 2018;19:229-239. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29361469>.

585. Bristol-Myers Squibb Company. Prescribing information: OPDIVO (nivolumab) injection, for intravenous use. 2018. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125554s0691.pdf. Accessed Nov 30, 2018.

586. Wang DY, Salem JE, Cohen JV, et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. *JAMA Oncol* 2018;4:1721-1728. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30242316>.

587. Weber JS, Hodi FS, Wolchok JD, et al. Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. *J Clin Oncol* 2017;35:785-792. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28068177>.

588. Sznol M, Ferrucci PF, Hogg D, et al. Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma. *J Clin Oncol* 2017;35:3815-3822. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28915085>.

589. Ekedahl H, Cirenajwis H, Harbst K, et al. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort. *Br J Dermatol* 2013;169:1049-1055. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23855428>.

590. Sala E, Mologni L, Truffa S, et al. BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. *Mol Cancer Res* 2008;6:751-759. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18458053>.

591. Halaban R, Zhang W, Bacchiocchi A, et al. PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. *Pigment Cell Melanoma Res* 2010;23:190-200. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20149136>.



592. Lemech C, Infante J, Arkenau HT. The potential for BRAF V600 inhibitors in advanced cutaneous melanoma: rationale and latest evidence. *Ther Adv Med Oncol* 2012;4:61-73. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22423265>.

593. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. *N Engl J Med* 2012;366:707-714. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22356324>.

594. Blank CU, Larkin J, Arance AM, et al. Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF(V600) mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis. *Eur J Cancer* 2017;79:176-184. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28501764>.

595. Ascierto PA, Minor D, Ribas A, et al. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. *J Clin Oncol* 2013;31:3205-3211. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23918947>.

596. Long GV, Eroglu Z, Infante J, et al. Long-Term Outcomes in Patients With BRAF V600-Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib. *J Clin Oncol* 2018;36:667-673. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28991513>.

597. Ascierto PA, McArthur GA, Dreno B, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. *Lancet Oncol* 2016;17:1248-1260. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27480103>.

598. Chapman PB, Robert C, Larkin J, et al. Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study. *Ann Oncol* 2017;28:2581-2587. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28961848>.

599. Delord JP, Robert C, Nyakas M, et al. Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma. *Clin Cancer Res* 2017;23:5339-5348. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28611198>.

600. Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. *N Engl J Med* 2012;367:107-114. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22663011>.

601. Kim KB, Kefford R, Pavlick AC, et al. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. *J Clin Oncol* 2013;31:482-489. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23248257>.

602. Dummer R, Schadendorf D, Ascierto PA, et al. Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol* 2017;18:435-445. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28284557>.

603. Long GV, Flaherty KT, Stroyakovskiy D, et al. Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. *Ann Oncol* 2017;28:1631-1639. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28475671>.

604. Dreno B, Ribas A, Larkin J, et al. Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study. *Ann Oncol* 2017;28:1137-1144. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28444112>.

605. Dummer R, Ascierto PA, Gogas HJ, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. *Lancet Oncol* 2018;19:603-615. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29573941>.



NCCN Guidelines Version 3.2023

Melanoma: Cutaneous

606. Dummer R, Ascierto PA, Gogas HJ, et al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol* 2018;19:1315-1327. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/30219628>.

607. Ribas A, Gonzalez R, Pavlick A, et al. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. *Lancet Oncol* 2014;15:954-965. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25037139>.

608. Pavlick AC, Ribas A, Gonzalez R, et al. Extended follow-up results of phase 1b study (BRIM7) of vemurafenib (VEM) with cobimetinib (COBI) in BRAF-mutant melanoma. *ASCO Meeting Abstracts* 2015;33:9020. Available at: http://meeting.ascopubs.org/cgi/content/abstract/33/15_suppl/9020.

609. Daud A, Pavlick AC, Ribas A, et al. Extended follow-up results of a phase 1B study (BRIM7) of cobimetinib (C) and vemurafenib (V) in BRAF-mutant melanoma (abstract). *J Clin Oncol* 2016;34:Abstr 9510. Available at: http://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.9510.

610. Chen G, McQuade JL, Panka DJ, et al. Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial. *JAMA Oncol* 2016;2:1056-1064. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27124486>.

611. Schreuer M, Jansen Y, Planken S, et al. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial. *Lancet Oncol* 2017;18:464-472. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28268064>.

612. Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. *N Engl J Med* 2012;367:1694-1703. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23020132>.

613. Dummer R, Goldinger SM, Turtzchi CP, et al. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. *Eur J Cancer* 2014;50:611-621. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24295639>.

614. McArthur GA, Maio M, Arance A, et al. Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study. *Ann Oncol* 2017;28:634-641. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27993793>.

615. Long GV, Trefzer U, Davies MA, et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. *Lancet Oncol* 2012;13:1087-1095. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23051966>.

616. Davies MA, Saiag P, Robert C, et al. Dabrafenib plus trametinib in patients with BRAF(V600)-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. *Lancet Oncol* 2017;18:863-873. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28592387>.

617. de la Cruz-Merino L, Di Guardo L, Grob JJ, et al. Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study. *J Transl Med* 2017;15:146. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28646893>.

618. Lee SJ, Kim TM, Kim YJ, et al. Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring KIT Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06). *Oncologist* 2015. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26424760>.

619. Guo J, Carvajal RD, Dummer R, et al. Efficacy and Safety of Nilotinib in Patients With KIT-Mutated Metastatic or Inoperable Melanoma: Final Results From the Global, Single-Arm, Phase II TEAM Trial. *Ann Oncol* 2017. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28327988>.



620. Delyon J, Chevret S, Jouary T, et al. STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network. *J Invest Dermatol* 2018;138:58-67. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28843487>.

621. Wyman K, Atkins MB, Prieto V, et al. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. *Cancer* 2006;106:2005-2011. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16565971>.

622. Ugurel S, Hildenbrand R, Zimpfer A, et al. Lack of clinical efficacy of imatinib in metastatic melanoma. *Br J Cancer* 2005;92:1398-1405. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15846297>.

623. Smith FO, Downey SG, Klapper JA, et al. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. *Clin Cancer Res* 2008;14:5610-5618. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18765555>.

624. Rosenberg SA, Yang JC, Topalian SL, et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. *JAMA* 1994;271:907-913. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8120958>.

625. Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. *Cancer J Sci Am* 2000;6 Suppl 1:S11-14. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10685652>.

626. Davar D, Ding F, Saul M, et al. High-dose interleukin-2 (HD IL-2) for advanced melanoma: a single center experience from the University of Pittsburgh Cancer Institute. *J Immunother Cancer* 2017;5:74. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28923120>.

627. Alva A, Daniels GA, Wong MK, et al. Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma. *Cancer Immunol Immunother* 2016;65:1533-1544. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27714434>.

628. Schwartzenuber DJ, Lawson DH, Richards JM, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. *N Engl J Med* 2011;364:2119-2127. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21631324>.

629. Dillman RO, Depriest C, McClure SE. High-dose IL2 in metastatic melanoma: better survival in patients immunized with antigens from autologous tumor cell lines. *Cancer Biother Radiopharm* 2014;29:53-57. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24380630>.

630. Buchbinder EI, Gunturi A, Perritt J, et al. A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma. *J Immunother Cancer* 2016;4:52. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/27660706>.

631. Schwartz RN, Stover L, Dutcher J. Managing toxicities of high-dose interleukin-2. *Oncology (Williston Park)* 2002;16:11-20. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/12469935>.

632. Serrone L, Zeuli M, Sega FM, Cognetti F. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. *J Exp Clin Cancer Res* 2000;19:21-34. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10840932>.

633. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. *J Clin Oncol* 2000;18:158-166. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10623706>.

634. Flaherty KT, Lee SJ, Schuchter LM, et al. Final results of E2603: a double-blind, randomized phase III trial comparing carboplatin (C)/paclitaxel (P) with or without sorafenib (S) in metastatic melanoma [abstract]. *J Clin Oncol* 2010;28(Suppl 15):8511. Available at: http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/8511.



NCCN Guidelines Version 3.2023 Melanoma: Cutaneous

635. Hauschild A, Agarwala SS, Trefzer U, et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. *J Clin Oncol* 2009;27:2823-2830. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19349552>.

636. Agarwala SS, Keilholz U, Hogg D, et al. Randomized phase III study of paclitaxel plus carboplatin with or without sorafenib as second-line treatment in patients with advanced melanoma [abstract]. *J Clin Oncol* 2007;25(Suppl 18):8510. Available at: http://meeting.ascopubs.org/cgi/content/abstract/25/18_suppl/8510.

637. Rao RD, Holtan SG, Ingle JN, et al. Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma. *Cancer* 2006;106:375-382. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16342250>.

638. Papadopoulos NE, Bedikian A, Ring S, et al. Phase I/II Study of a Cisplatin-Taxol-Dacarbazine Regimen in Metastatic Melanoma. *Am J Clin Oncol* 2009. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19506454>.

639. Hersh EM, O'Day SJ, Ribas A, et al. A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma. *Cancer* 2010;116:155-163. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19877111>.

640. Kottschade LA, Suman VJ, Amatruda T, 3rd, et al. A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group Study, N057E(1). *Cancer* 2011;117:1704-1710. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21472717>.

641. Hersh EM, Del Vecchio M, Brown MP, et al. A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naive patients with metastatic melanoma. *Ann Oncol* 2015. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26410620>.

642. Eigentler TK, Caroli UM, Radny P, Garbe C. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. *Lancet Oncol* 2003;4:748-759. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/14662431>.

643. Ugurel S, Loquai C, Terheyden P, et al. Chemosensitivity-directed therapy compared to dacarbazine in chemo-naive advanced metastatic melanoma: a multicenter randomized phase-3 DeCOG trial. *Oncotarget* 2017;8:76029-76043. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29100289>.

644. Houghton AN, Coit DG, Daud A, et al. Melanoma. *J Natl Compr Canc Netw* 2006;4:666-684. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16884669>.

645. Konefal JB, Emami B, Pilepich MV. Analysis of dose fractionation in the palliation of metastases from malignant melanoma. *Cancer* 1988;61:243-246. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/3334956>.

646. Olivier KR, Schild SE, Morris CG, et al. A higher radiotherapy dose is associated with more durable palliation and longer survival in patients with metastatic melanoma. *Cancer* 2007;110:1791-1795. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/17721993>.

647. Huguenin PU, Kieser S, Glanzmann C, et al. Radiotherapy for metastatic carcinomas of the kidney or melanomas: an analysis using palliative end points. *Int J Radiat Oncol Biol Phys* 1998;41:401-405. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9607358>.

648. Gerszten PC, Burton SA, Quinn AE, et al. Radiosurgery for the treatment of spinal melanoma metastases. *Stereotact Funct Neurosurg* 2005;83:213-221. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/16534253>.

649. Sause WT, Cooper JS, Rush S, et al. Fraction size in external beam radiation therapy in the treatment of melanoma. *Int J Radiat Oncol Biol Phys* 1991;20:429-432. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1995527>.



650. Seegenschmiedt MH, Keilholz L, Altendorf-Hofmann A, et al. Palliative radiotherapy for recurrent and metastatic malignant melanoma: prognostic factors for tumor response and long-term outcome: a 20-year experience. *Int J Radiat Oncol Biol Phys* 1999;44:607-618. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10348291>.

651. Overgaard J, Gonzalez Gonzalez D, Hulshof MC, et al. Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. *European Society for Hyperthermic Oncology. Lancet* 1995;345:540-543. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/7776772>.

652. Overgaard J, von der Maase H, Overgaard M. A randomized study comparing two high-dose per fraction radiation schedules in recurrent or metastatic malignant melanoma. *Int J Radiat Oncol Biol Phys* 1985;11:1837-1839. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/4044346>.

653. Stinauer MA, Kavanagh BD, Schefter TE, et al. Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control. *Radiat Oncol* 2011;6:34. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/21477295>.

654. Youland RS, Blanchard ML, Dronca R, et al. Role of radiotherapy in extracranial metastatic malignant melanoma in the modern era. *Clin Transl Radiat Oncol* 2017;6:25-30. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29594220>.

655. Franceschini D, Franzese C, De Rose F, et al. Role of extra cranial stereotactic body radiation therapy in the management of Stage IV melanoma. *Br J Radiol* 2017;90:20170257. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/28707533>.

656. Jahanshahi P, Nasr N, Unger K, et al. Malignant melanoma and radiotherapy: past myths, excellent local control in 146 studied lesions at Georgetown University, and improving future management. *Front Oncol* 2012;2:167. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23162795>.

657. Frakes JM, Figura ND, Ahmed KA, et al. Potential role for LINAC-based stereotactic radiosurgery for the treatment of 5 or more radioresistant melanoma brain metastases. *J Neurosurg* 2015:1-7. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26140482>.

658. Selek U, Chang EL, Hassenbusch SJ, 3rd, et al. Stereotactic radiosurgical treatment in 103 patients for 153 cerebral melanoma metastases. *Int J Radiat Oncol Biol Phys* 2004;59:1097-1106. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15234044>.

659. Bernard ME, Wegner RE, Reineman K, et al. Linear accelerator based stereotactic radiosurgery for melanoma brain metastases. *J Cancer Res Ther* 2012;8:215-221. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22842364>.

660. Rades D, Sehmisch L, Huttenlocher S, et al. Radiosurgery alone for 1-3 newly-diagnosed brain metastases from melanoma: impact of dose on treatment outcomes. *Anticancer Res* 2014;34:5079-5082. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25202094>.

661. Christ SM, Mahadevan A, Floyd SR, et al. Stereotactic radiosurgery for brain metastases from malignant melanoma. *Surg Neurol Int* 2015;6:S355-365. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26392919>.

662. Bates JE, Youn P, Usuki KY, et al. Brain metastasis from melanoma: the prognostic value of varying sites of extracranial disease. *J Neurooncol* 2015;125:411-418. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26354772>.

663. DeAngelis LM, Delattre JY, Posner JB. Radiation-induced dementia in patients cured of brain metastases. *Neurology* 1989;39:789-796. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/2725874>.

664. Nieder C, Leicht A, Motaref B, et al. Late radiation toxicity after whole brain radiotherapy: the influence of antiepileptic drugs. *Am J Clin Oncol* 1999;22:573-579. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10597741>.



665. Soffiatti R, Kocher M, Abacioglu UM, et al. A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: quality-of-life results. *J Clin Oncol* 2013;31:65-72. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23213105>.

666. Satzger I, Degen A, Asper H, et al. Serious skin toxicity with the combination of BRAF inhibitors and radiotherapy. *J Clin Oncol* 2013;31:e220-222. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23530102>.

667. Peuvrel L, Ruellan AL, Thillays F, et al. Severe radiotherapy-induced extracutaneous toxicity under vemurafenib. *Eur J Dermatol* 2013;23:879-881. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24192487>.

668. Anker CJ, Ribas A, Grossmann AH, et al. Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma. *J Clin Oncol* 2013;31:e283-287. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23650406>.

669. Merten R, Hecht M, Haderlein M, et al. Increased skin and mucosal toxicity in the combination of vemurafenib with radiation therapy. *Strahlenther Onkol* 2014;190:1169-1172. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24965480>.

670. Schulze B, Meissner M, Wolter M, et al. Unusual acute and delayed skin reactions during and after whole-brain radiotherapy in combination with the BRAF inhibitor vemurafenib. Two case reports. *Strahlenther Onkol* 2014;190:229-232. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24362499>.

671. Harding JJ, Barker CA, Carvajal RD, et al. Cutis verticis gyrata in association with vemurafenib and whole-brain radiotherapy. *J Clin Oncol* 2014;32:e54-56. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24470011>.

672. Forschner A, Zips D, Schraml C, et al. Radiation recall dermatitis and radiation pneumonitis during treatment with vemurafenib. *Melanoma Res* 2014;24:512-516. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24743051>.

673. Reigneau M, Granel-Brocard F, Geoffrois L, et al. Efflorescence of scalp cysts during vemurafenib treatment following brain radiation therapy: a radiation recall dermatitis? *Eur J Dermatol* 2013;23:544-545. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24001519>.

674. Lang N, Sterzing F, Enk AH, Hassel JC. Cutis verticis gyrata-like skin toxicity during treatment of melanoma patients with the BRAF inhibitor vemurafenib after whole-brain radiotherapy is a consequence of the development of multiple follicular cysts and milia. *Strahlenther Onkol* 2014;190:1080-1081. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24972891>.

675. Hecht M, Zimmer L, Loquai C, et al. Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients. *Ann Oncol* 2015;26:1238-1244. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25762352>.

676. Gaudy-Marqueste C, Carron R, Delsanti C, et al. On demand Gamma-Knife strategy can be safely combined with BRAF inhibitors for the treatment of melanoma brain metastases. *Ann Oncol* 2014;25:2086-2091. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25057167>.

677. Silk AW, Bassetti MF, West BT, et al. Ipilimumab and radiation therapy for melanoma brain metastases. *Cancer Med* 2013;2:899-906. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24403263>.

678. Mathew M, Tam M, Ott PA, et al. Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery. *Melanoma Res* 2013;23:191-195. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23462208>.



679. Schoenfeld JD, Mahadevan A, Floyd SR, et al. Ipilimumab and cranial radiation in metastatic melanoma patients: a case series and review. *J Immunother Cancer* 2015;3:50. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26672895>.

680. Gerber NK, Young RJ, Barker CA, et al. Ipilimumab and whole brain radiation therapy for melanoma brain metastases. *J Neurooncol* 2015;121:159-165. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25273687>.

681. Ahmed KA, Stallworth DG, Kim Y, et al. Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy. *Ann Oncol* 2016;27:434-441. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26712903>.

682. Barker CA, Postow MA, Khan SA, et al. Concurrent radiotherapy and ipilimumab immunotherapy for patients with melanoma. *Cancer Immunol Res* 2013;1:92-98. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24777500>.

683. Johnson DB, Friedman DL, Berry E, et al. Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center. *Cancer Immunol Res* 2015;3:464-469. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25649350>.

684. Knisely JP, Yu JB, Flanigan J, et al. Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. *J Neurosurg* 2012;117:227-233. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22702482>.

685. Kiess AP, Wolchok JD, Barker CA, et al. Stereotactic radiosurgery for melanoma brain metastases in patients receiving ipilimumab: safety profile and efficacy of combined treatment. *Int J Radiat Oncol Biol Phys* 2015;92:368-375. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25754629>.

686. Grimaldi AM, Simeone E, Giannarelli D, et al. Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy. *Oncoimmunology* 2014;3:e28780. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25083318>.

687. Chandra RA, Wilhite TJ, Balboni TA, et al. A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab. *Oncoimmunology* 2015;4:e1046028. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26451318>.

688. Postow MA, Callahan MK, Barker CA, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. *N Engl J Med* 2012;366:925-931. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22397654>.

689. Anker CJ, Grossmann KF, Atkins MB, et al. Avoiding Severe Toxicity From Combined BRAF Inhibitor and Radiation Treatment: Consensus Guidelines from the Eastern Cooperative Oncology Group (ECOG). *Int J Radiat Oncol Biol Phys* 2016;95:632-646. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/27131079>.

690. Array BioPharma Inc. Prescribing information: BRAFTOVI (encorafenib) capsules, for oral use. 2018. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210496lbl.pdf. Accessed Oct 15, 2018.

691. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) in partnership with the American Society of Clinical Oncology (ASCO) for Management of Immunotherapy-Related Toxicities (Version 1.2019). © 2018 National Comprehensive Cancer Network, Inc; 2018. Available at: NCCN.org. Accessed Nov 14, 2018. To view the most recent and complete version of the NCCN Guidelines®, go online to NCCN.org.

692. Bristol-Myers Squibb Company. BLA 125377 YERVOY (ipilimumab) injection, for intravenous infusion: Risk Evaluation and Mitigation Strategy (REMS). 2012. Available at: <http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM249435.pdf>. Accessed November 16, 2015.



693. Brenner DJ, Hall EJ. Computed tomography--an increasing source of radiation exposure. *N Engl J Med* 2007;357:2277-2284. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18046031>.

694. Fazel R, Krumholz HM, Wang Y, et al. Exposure to low-dose ionizing radiation from medical imaging procedures. *N Engl J Med* 2009;361:849-857. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19710483>.

695. Mathews JD, Forsythe AV, Brady Z, et al. Cancer risk in 680,000 people exposed to computed tomography scans in childhood or adolescence: data linkage study of 11 million Australians. *BMJ* 2013;346:f2360. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23694687>.

696. Basseres N, Grob JJ, Richard MA, et al. Cost-effectiveness of surveillance of stage I melanoma. A retrospective appraisal based on a 10-year experience in a dermatology department in France. *Dermatology* 1995;191:199-203. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8534937>.

697. Dicker TJ, Kavanagh GM, Herd RM, et al. A rational approach to melanoma follow-up in patients with primary cutaneous melanoma. Scottish Melanoma Group. *Br J Dermatol* 1999;140:249-254. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/10233217>.

698. Hofmann U, Szedlak M, Rittgen W, et al. Primary staging and follow-up in melanoma patients--monocenter evaluation of methods, costs and patient survival. *Br J Cancer* 2002;87:151-157. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/12107834>.

699. Baker JJ, Meyers MO, Frank J, et al. Routine restaging PET/CT and detection of initial recurrence in sentinel lymph node positive stage III melanoma. *Am J Surg* 2014;207:549-554. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/24674829>.

700. Garbe C, Paul A, Kohler-Spath H, et al. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. *J Clin Oncol* 2003;21:520-529. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/12560444>.

701. Moore Dalal K, Zhou Q, Panageas KS, et al. Methods of detection of first recurrence in patients with stage I/II primary cutaneous melanoma after sentinel lymph node biopsy. *Ann Surg Oncol* 2008;15:2206-2214. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/18512102>.

702. Meyers MO, Yeh JJ, Frank J, et al. Method of detection of initial recurrence of stage II/III cutaneous melanoma: analysis of the utility of follow-up staging. *Ann Surg Oncol* 2009;16:941-947. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19101766>.

703. Morton RL, Craig JC, Thompson JF. The role of surveillance chest X-rays in the follow-up of high-risk melanoma patients. *Ann Surg Oncol* 2009;16:571-577. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/19030934>.

704. Weiss M, Loprinzi CL, Creagan ET, et al. Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas. *JAMA* 1995;274:1703-1705. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/7474276>.

705. Brown RE, Stromberg AJ, Hagendoorn LJ, et al. Surveillance after surgical treatment of melanoma: futility of routine chest radiography. *Surgery* 2010;148:711-716; discussion 716-717. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/20800862>.

706. McGovern PM, Gross CR, Krueger RA, et al. False-positive cancer screens and health-related quality of life. *Cancer Nurs* 2004;27:347-352. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/15525861>.

707. Nelson HD, Pappas M, Cantor A, et al. Harms of Breast Cancer Screening: Systematic Review to Update the 2009 U.S. Preventive Services Task Force Recommendation. *Ann Intern Med* 2016;164:256-267. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/26756737>.

708. Bond M, Garside R, Hyde C. A crisis of visibility: The psychological consequences of false-positive screening mammograms, an interview study. *Br J Health Psychol* 2015;20:792-806. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25944747>.



NCCN Guidelines Version 3.2023

Melanoma: Cutaneous

709. Wu GX, Raz DJ, Brown L, Sun V. Psychological burden associated with lung cancer screening: a systematic review. Clin Lung Cancer 2016. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/27130469>.

710. Pearce MS, Salotti JA, Little MP, et al. Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study. Lancet 2012;380:499-505. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22681860>.

711. Soong SJ, Harrison RA, McCarthy WH, et al. Factors affecting survival following local, regional, or distant recurrence from localized melanoma. J Surg Oncol 1998;67:228-233. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/9579369>.

712. Salama AK, de Rosa N, Scheri RP, et al. Hazard-rate analysis and patterns of recurrence in early stage melanoma: moving towards a rationally designed surveillance strategy. PLoS One 2013;8:e57665. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/23516415>.

713. Joyce KM, Joyce CW, Jones DM, et al. An assessment of histological margins and recurrence of melanoma in situ. Plast Reconstr Surg Glob Open 2015;3:e301. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25750840>.

714. Osella-Abate S, Ribero S, Sanlorenzo M, et al. Risk factors related to late metastases in 1,372 melanoma patients disease free more than 10 years. Int J Cancer 2015;136:2453-2457. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25331444>.

715. Crowley NJ, Seigler HF. Late recurrence of malignant melanoma. Analysis of 168 patients. Ann Surg 1990;212:173-177. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/2375648>.

716. Yang GB, Barnholtz-Sloan JS, Chen Y, Bordeaux JS. Risk and survival of cutaneous melanoma diagnosed subsequent to a previous cancer. Arch Dermatol 2011;147:1395-1402. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22184761>.

717. Slingluff CL, Jr., Vollmer RT, Seigler HF. Multiple primary melanoma: incidence and risk factors in 283 patients. Surgery 1993;113:330-339. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8441968>.

718. Ferrone CR, Ben Porat L, Panageas KS, et al. Clinicopathological features of and risk factors for multiple primary melanomas. JAMA 2005;294:1647-1654. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16204664>.

719. Schmid-Wendtner MH, Baumert J, Wendtner CM, et al. Risk of second primary malignancies in patients with cutaneous melanoma. Br J Dermatol 2001;145:981-985. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/11899153>.

720. Youlden DR, Youl PH, Soyer HP, et al. Distribution of subsequent primary invasive melanomas following a first primary invasive or in situ melanoma Queensland, Australia, 1982-2010. JAMA Dermatol 2014;150:526-534. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/25093216>.

721. Caini S, Boniol M, Botteri E, et al. The risk of developing a second primary cancer in melanoma patients: a comprehensive review of the literature and meta-analysis. J Dermatol Sci 2014;75:3-9. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/24680127>.

722. Kang S, Barnhill RL, Mihm MC, Jr., Sober AJ. Multiple primary cutaneous melanomas. Cancer 1992;70:1911-1916. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/1525766>.

723. Fawzy FI, Fawzy NW, Hyun CS, et al. Malignant melanoma. Effects of an early structured psychiatric intervention, coping, and affective state on recurrence and survival 6 years later. Arch Gen Psychiatry 1993;50:681-689. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/8357293>.

724. Gutman M, Cnaan A, Inbar M, et al. Are malignant melanoma patients at higher risk for a second cancer? Cancer 1991;68:660-665. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/2065289>.



725. Leiter U, Buettner PG, Eigentler TK, et al. Is detection of melanoma metastasis during surveillance in an early phase of development associated with a survival benefit? *Melanoma Res* 2010;20:240-246. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/20216239>.

726. Voit C, Mayer T, Kron M, et al. Efficacy of ultrasound B-scan compared with physical examination in follow-up of melanoma patients. *Cancer* 2001;91:2409-2416. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/11413532>.

727. Murali R, Moncrieff MD, Hong J, et al. The prognostic value of tumor mitotic rate and other clinicopathologic factors in patients with locoregional recurrences of melanoma. *Ann Surg Oncol* 2010;17:2992-2999. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/20425144>.

728. Rychetnik L, McCaffery K, Morton R, Irwig L. Psychosocial aspects of post-treatment follow-up for stage I/II melanoma: a systematic review of the literature. *Psychooncology* 2013;22:721-736. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/22431448>.

729. Rhodes AR. Cutaneous melanoma and intervention strategies to reduce tumor-related mortality: what we know, what we don't know, and what we think we know that isn't so. *Dermatol Ther* 2006;19:50-69. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/16405570>.

730. Geller AC, Swetter SM, Oliveria S, et al. Reducing mortality in individuals at high risk for advanced melanoma through education and screening. *J Am Acad Dermatol* 2011;65:S87-94. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/22018072>.

731. Green AC, Williams GM, Logan V, Strutton GM. Reduced melanoma after regular sunscreen use: randomized trial follow-up. *J Clin Oncol* 2011;29:257-263. Available at: <http://www.ncbi.nlm.nih.gov/pubmed/21135266>.

732. MacCormack MA, Cohen LM, Rogers GS. Local melanoma recurrence: a clarification of terminology. *Dermatol Surg* 2004;30:1533-1538. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/15606834>.